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The first section of this dissertation describes the synthesis of a tethered macrocyclic ring system 
based on the natural product westiellamide. As expected, this system was shown to increase the 
affinity and ease of complexation to Ag(I) ions as confirmed by NMR and fluorescence Ag(I) 
titration studies. 
The second section describes the synthesis of a new series of heterocyclic inhibitors of 
the BoNT serotype A metalloprotease based on the therapeutic lead NSC 240898. Preliminary 
structure-activity relationship studies afford detailed insights into the steric and electrostatic 
properties of the pharmacophore of this molecular scaffold. Four of the newly synthesized 
inhibitors exhibited elevated inhibition against BoNT/A LC when compared to the lead agent.  
The third section describes an approach towards the total synthesis of haouamine A. A 
promising route to the marine alkaloid was established, including a highly efficient Suzuki cross-
coupling reaction, aldol condensation and aromatization reaction. Several late-stage 
intermediates were analyzed by X-ray diffraction to provide valuable information about the 
relationships between conformation and reactivity.  
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1.0  SYNTHESIS OF TETHERED  
BIS-OXAZOLINE LIGANDS FOR SILVER(I) BINDING STUDY 
1.1 INTRODUCTION 
1.1.1 Silver Recovery 
Silver has long been an important metal in industry. It finds broad applications in areas such as 
medicine, photography, electronic industry and jewelry. The recovery of silver from waste 
solutions has not only commercial importance, but also an environmental advantage. Because 
there are legal limits on silver concentrations in municipal water supplies.1 It has been estimated2 
that over 1000 tons of silver are recycled annually in the US, followed by Japan with about 500 
tons.  
The concentration of silver in photographic waste ranges from over 5 g/L to less than 1 
mg/L.3 Several traditional silver recovery methods are available (Table 1).3-4 Generally, these 
methods suffer from a high silver leaching level and low cation selectivity.  Owing to the low 
silver concentration and abundance of other cations in waste solutions, new methods are needed 
for recycling silver. 
 
 2 
Table 1 Comparison of conventional silver recovery methods 
Recovery 
Method 
Description  Advantages Disadvantages 
Electrolysis 
 
An electric current 
reduces the silver and 
plates silver metal onto 
an electrode 
Obtain >90% pure 
silver 
High capital costs, low 
removal efficiency (90%), 
requires high silver 
concentration in waste  
Ion Exchange Exchange the silver on 
an ion-exchange resin  
98 – 99.99% removal 
efficiency from dilute 
solutions  
High capital costs, low 
capacity of the resin 
Metallic 
Replacement 
Exchange silver with 
solid iron through an 
oxidation-reduction 
reaction 
Low capital costs, low 
maintenance, 99% 
removal possible with 
2 units  
High smelting and refining 
costs, monitoring required 
for replacement  
Precipitation Precipitate silver by 
Na2S 
>99% removal possible Moderate to high operation 
costs, , handling of harsh 
chemicals, messy sludge 
Reverse 
Osmosis 
A semi-permeable 
membrane separates 
large molecules from 
small ones 
Up to 90% efficiency 
on dilute waste  
High capital and operation 
costs  
 
Recently, a few new methods utilizing ligands with high affinity and selectivity towards 
silver have emerged.  Tri-isobutylphosphine sulfide (TIBPS) was found to bind to silver, forming 
a Ag(TIBPS)2NO3 complex.5 It was demonstrated that TIBPS was able to selectively extract 
silver in the presence of Cu(II), Ni(II) and Fe(III)6 (Table 2). However, in this experiment a 
nitrate counter anion was required. 
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Table 2 Extraction of silver in the presence of other metals by TIBPS 
Metal  Initial concentration in donor solution 
(mM) 
Concentration in acceptor solution after 4 h 
(mM) 
Ag(I) 12.0 7.18 
Cu(II) 107.0 0.17 
Zn(II) 88.7 0.31 
Ni(II) 78.3 0.09 
 
Another extracting method is the use of macrocyclic compounds, in particular hetero 
crown ethers. Hetero crown ethers are known to interact with soft cations better than hard ones 
due to the soft nature of the nitrogen or sulfur atoms in the ring.7 Izatt et al.8 demonstrated the 
feasibility of selective uptake of Ag(I) over Pb(II) and Tl(I) using 18-crown-6 type macrocycles 
1-1a, 1-1b and 1-2 (Figure 1). The uptake speed of the metals by the macrocycles is listed in 
Table 3. Other more commonly found transition metals were not tested for selectivity. Another 
shortcoming is that the concentration of metals used in the experiment is much higher than the 
concentration found in waste. 
Figure 1 Macrocyclic ligands for silver recovery 
O
N
O
OO
O
NHN
O
N
O
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O
NHN
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R2
1-1a, R1=H, R2=n-C8H17
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SC12H25
SC12H25O
O
1-2 1-3
 
 
Table 3 Extraction of silver (I) ion in the presence of lead(II) ion by 1-1a, 1-1b and 1-2a 
Ligand  Ag(I) flux (mol·s-1·m-2×108) Pb(II) flux (mol·s-1·m-2×108)
1-1a 1303 73 
1-1b 601 8 
1-2 1549 8 
aInitial concentration: 1 M AgNO3, 1 M Pb(NO3)2 
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Another group9 adopted polythioether 1-3 as a ligand and was able to recover the silver (I) 
in the presence of Cu(II) (Figure 1). However, this ligand class was totally inhibited by Pd(II). 
An even more appealing idea is to extract silver from sea water. The major difficulty is the 
low abundance of Ag(I) in sea water (average 0.24 ug/L10). Precipitation by a 
NaOH/FeCl2/Na2CO3 mixture has been tested11 and proved to be both cost and labor intensive. 
Another report12 suggested the use of ion-exchange resins, which may suffer from selectivity, 
capacity and durability.   
In the search for a better ligand for silver, we turned our attention to the marine metabolites, 
or more specifically, Lissoclinum cyclic peptides. 
 
1.1.2 Lissoclinum Cyclopeptides and Their Binding to Metal Ions 
Marine metabolites have received much attention in recent years due to their unprecedented 
structures and attractive biological activities.13 The genus Lissoclinum has proven itself as a rich 
source of cyclopeptide alkaloids featuring multiple oxazolines, thiazolines, oxazoles, or thiazoles 
(Figure 2). 13-14 
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Figure 2 Lissoclinum cyclopeptides 
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Since these polyheterocycles share structure features with some common macrocyclic 
ionophores, such as hetero crown ethers and porphyrins,15 it has been postulated that they might 
complex to metals, and subsequently transport them in vivo. However, so far no metal-
complexed Lissoclinum cyclopeptides have been isolated from natural sources. In contrast, quite 
a few studies regarding the complexation of synthetic Lissoclinum cyclopeptides with metals 
have been published. Wipf et al.16 reported the first example of a Lissoclinum cyclopeptide 
complexed with a metal. In this case, westiellamide (1-4) was synthesized17 and screened by 
NMR with a variety of metal salts for binding, including Na(I), Li(I), K(I), Mg(II), Ce(III), Fe(II), 
Fe(III), Ni(II), Cu(I), Cu(II), Ag(I), Au(III), Zn(II), Cd(II) and Hg(II). Most of these metal 
cations showed weak interactions with westiellamide. The sole exception was Ag(I), which was 
found to form a [(1-4)2Ag4]4+ complex with an association constant of >105M-5. The binding of 
four silver ions was a highly cooperative process, and no intermediates could be seen by NMR. 
The structure of the complex was determined by X-ray crystallography (Figure 3). In this 
complex, a trigonal-planar Ag4 cluster was sandwiched between two westiellamide molecules. 
The center Ag ion coordinated to the six backbone carbonyls, while the outside Ag ions bound to 
the nitrogen atoms of the oxazoline rings in a nearly linear arrangement. It is also worthy to 
mention the conformational change of westiellamide upon binding. Figure 4 compares the crystal 
structure of 1-4 with and without18Ag. The unbound 1-4 is rather flat and has its isopropyl 
sidechains adopting pseudoaxial positions while the oxazoline nitrogens point inwards. Upon 
binding, the sidechains adopt pseudoequatorial positions, while the backbone carbonyl oxygens 
point inwards. 
 7 
Figure 3 Crystal structure of [(1-4)2Ag4]4+ complex 
 
 
Figure 4 Comparison of crystal structures of uncomplexed and complexed westiellamide 
 
 
The Hanson group19 investigated the binding of Cu(II) to patellamide D (1-13) (patH4, 
Figure 5) by electron paramagnetic resonance (EPR), circular dichroism (CD) and mass 
spectrometry. Multiple mononuclear copper(II) complexes were identified as well as three 
binuclear complexes ([Cu2(patH2)]2+, [Cu2(patH2)(OH)]+ and [Cu2(patH2)(CO3)]). A plausible 
structure for the latter based on the CD spectra is shown in Figure 6 (1-16). 
Uncomplexed Complexed 
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Figure 5 Patellamide B-E and ascidiacyclamide 
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Figure 6 [Cu2(patH2)(CO3)] complex (1-12) (L=CO32-) and solid state structure of patellamide D (1-13) 
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The square conformation of 1-16 is in sharp contrast20 to the twisted “figure eight” 
conformation of 1-13 in the solid state21-22 (Figure 6). In the solid state, the cyclopeptide 
backbone is held together by two intramolecular hydrogen bonds to form a type-II β-turn 
structure.23 It was found that symmetrically substituted patellamides (e.g. 1-7, 1-13) adopt a 
square conformation both in the solid state and in solution.22,24-26 For the asymmetrically 
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substituted patellamides (e.g. 1-11 to 1-14), the predominant conformation in the solid state is 
the twisted “figure eight”. In solution, the molecule adopts a relaxed “figure eight” conformation. 
This preference over the extended square conformation was attributed to the lack of C2 
symmetry25 in the molecule or the presence of the dipeptidyl oxazoline moiety in the structure.27 
The same preference was also observed for tawicyclamide (8) in the solid state.25 
Later, patellamides A (1-7), B (1-11) and E (1-14) (Figure 5) were found to bind to Cu(II) 
and Zn(II) as well.28 The CD spectra of their metal complex as suggested a square conformation 
as in the case of patellamide D. The association constants for both Cu(II) and Zn(II) were 
determined to be in the range of 2×104 to 2×105 M-1 for the first metal complexation. The binding 
of a second metal to patellamide B has a Ka=230 M-1 (Cu2+) and Ka=16-20 M-1 (Zn2+)28. 
Morris et al.29 further investigated the interaction between patellamides and metal ions and 
found that patellamide C exhibited excellent selectivity towards Cu(II) in the presence of Zn(II), 
while patellamide A was less selective. This finding was attributed to the distortion of the 
planarity of the square conformation of patellamide C and the metal complex by the phenyl side 
chain. A similar selectivity for lissoclinamide 9 (1-6) was found30 with a Ka(Cu2+) value close to 
that of patellamide B. 
A bis(copper(II)) complex (1-17, Figure 7) of ascidiacyclamide (1-15) was characterized31 
and its crystal structure (Figure 8, bottom right) was found to be very similar to the binuclear 
patellamide D-Cu complex. The cyclopeptide backbone in the complex adopts a pseudo-boat 
rectangular conformation, which is very similar to its metal-free form32 (Figure 8, top right).  
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Figure 7 Ascidiacyclamide-Cu complex (L=CO32-) 
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Figure 8 Conformations of 1-15 (top right), 1-17 (bottom right), 1-18 (top left), 1-19 (bottom left) 
 
The Hanson group also conducted an in-depth study on the conformation of 
ascidiacyclamide analogues (Figure 9).33 
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Figure 9 Ascidiacyclamide analogues 
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Compound 1-18 is the synthesis precursor of ascidiacyclamide, lacking the oxazoline 
moiety. It adopted a pseudo-chair conformation in solution as determined by NMR (Figure 8, top 
left). Compound 1-19 is the hydrolysis product of ascidiacyclamide and was found to bind to a 
potassium cation.34 Its crystal structure revealed a pseudo-boat conformation (Figure 8, bottom 
left). 
The Hanson group35-37 also prepared a series of patellamide analogues and studied their 
binding to Zn(II) and Ca(II). These analogues differ from their natural counterparts by either 
shorter side chains (to increase the flexibility of the cyclic peptide) or opened oxazoline rings 
which reduce ring constraints.  Both modifications facilitated the metal binding. Thus, their 
affinity towards metals increased with the increasing flexibility of the cyclopeptide. 
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1.1.3 Synthesis of Lissoclinum Cyclopeptides and Their Analogues 
Organic synthesis plays an important role in the study of marine metabolites due to the limited 
biological availability of these natural products.  
Scheme 1 Total synthesis of patellamide B (1-11) 
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The most widely adopted synthetic method for Lissoclinum peptides is the 
macrocyclization strategy as demonstrated in the synthesis of patellamide B38-39 (Scheme 1). The 
two segments 1-20 and 1-21, prepared by stepwise coupling of amino acid building blocks, were 
coupled to afford 1-22. Deprotection followed by macrocyclization provided 1-23 in excellent 
yield (55%). Treatment of 1-23 with thionyl chloride afforded the natural product 1-11 in 54% 
yield. An alternative approach40 used the precursor 1-26 with a preformed oxazoline moiety for 
macrocyclization (Scheme 2). In this case, the troublesome41 dehydration step to the oxazoline 
was avoided. 
Scheme 2 Synthesis of patellamide B 1-11 with pre-formed oxazoline moiety 
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One interesting feature of the Lissoclinum cyclopeptide synthesis is the ease of 
macrocyclization. Macrocyclization of polypeptides with α-amino acids devoid of Gly or Pro as 
building blocks can be troublesome.42 For Lissoclinum peptides, the oxazole/thiazole moiety 
limits the flexibility of the peptide backbone, while the oxazoline moiety can induce a type II or 
II’ β-turn conformation in the molecule (e.g. patellamide D (1-13)), bringing both N- and C-
termini together. Both factors are able to facilitate ring closure. 
For cyclopeptides with molecular symmetries, a cyclooligomerization approach may be 
viable. Hamada et al.32 reported the total synthesis of the C2 symmetric ascidiacyclamide (1-15) 
(Scheme 3). 
Scheme 3 Total synthesis of ascidiacyclamide 1-15 
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The tetrapeptide fragment 1-27 was treated with thionyl chloride to form the oxazoline ring. 
Epimerization of the oxazoline by NaOMe followed by reesterification with TMSCHN2 afforded 
building block 1-29. Deprotection at both termini was followed by cyclodimerization with DPPA, 
which afforded the natural product in 27% yield.  
Wipf et al.17 adopted a cyclotrimerization strategy in the total synthesis of the C3 
symmetric westiellamide (Scheme 4). 
Scheme 4 Total synthesis of westiellamide 
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The original approach, which included the macrocyclization of the linear hexapeptide 
sequence followed by oxazoline formation, failed. Thus, attention turned to a 
cyclooligomerization strategy. Dipeptide 1-30 was treated with Burgess reagent to form the 
dipeptidyl oxazoline 1-31.43 The oxazoline was opened by acid hydrolysis to provide an O-acyl 
amine, which was then rearranged to give Cbz-Val-allo-Thr-OMe (1-32).44 Reclosing the 
oxazoline with Burgess reagent followed by saponification provided 1-34. Alternatively, 1-34 
could be prepared from Cbz-Val-D-Thr-OMe (1-35) in two steps. Formation of oxazoline 1-36 
was followed by treatment with NaOH to deprotect the methyl ester as well as epimerize the cis-
oxazoline to the trans-configuration. The N-terminus in 1-34 was unmasked and DPPA effected 
the cyclooligomerization to afford the cyclic trimer 1-4 in 20% yield along with 25% of the 
cyclic tetramer. The deprotected 1-34 did not cyclize to diketopiperazine 1-3742 as a consequence 
of the rigid trans-amide linkage fused in the oxazoline ring.  
A double epimer of 1-34 at the C(4) and C(5) position of the oxazoline was prepared45 and 
subjected to the same cyclooligomerization conditions (Scheme 5).  
Scheme 5 Synthesis of westiellamide analogues 
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Interestingly, when compared to the westiellamide synthesis, a significant amount of dimer 
1-39 was obtained along with less tetramer 1-41. The x-ray structure of dimer 1-39 revealed that 
all isopropyl sidechains adopted pseudoequatorial positions, while in case of westiellamide all 
sidechains were in pseudoaxial positions. Thus, the cyclooligomerization process might be 
kinetically controlled. The lower repulsion between equatorial sidechains allowed for the 
formation of smaller ring structures from 1-38.  
The Pattenden group applied the cyclooligomerization strategy to thiazole-containing 
building blocks46 and synthesized a series of analogues of Lissoclinum cyclopeptides (Scheme 6).  
Scheme 6 Cyclooligomerization of dipeptidyl thiazoles 
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Similar to westiellamide, the sidechains in 1-43a were found to adopt pseudoaxial 
orientations. Due to steric reasons, building blocks with larger sidechains favored larger rings 
(cyclotetramer). As expected, the racemic building block rac-1-42a yielded a product that 
contained stereocenters of both configurations to minimize steric repulsion, along with a small 
amount of product in which all sidechains were in the same configuration. 
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The Pattenden group has also pioneered the templating effect of metal ions in the 
cyclooligomerization of 1-42a47 (Table 4). They found that small metal ions favor the formation 
of cyclotrimer while large ions favor cyclotetramer. A silver(I) complex of 1-44a was identified 
and shown to be comprised of five silver ions sandwiched between two macrocycles. 
Table 4 Cyclooligomerization of 1-42a with various metal salts 
Metal 
Salt 
Yield % Ratio 
(trimer:tetramer)
Metal Yield % Ratio 
(trimer:tetramer) 
No metal 95 3:1 NiCl2 78 7:3 
LiBF4 57 4:1 CuCl2 - - 
NaBF4 56 3:1 Cu(BF4)2 - - 
KBF4 91 7:3 CoCl2 - - 
CsBF4 93 3:1 AgBF4 57 2:1 
ZnCl2 81 4:1 NH4PF6 30 11:2 
CdCl2 41 2:1 Zn(BF4)2 42 4:1 
Hg(ClO4)2 35 3:1 Zn(OAc)2 - - 
 
The same group also investigated the templating effect of metal ions in the synthesis of 
nostocyclamide (1-48), which bears no symmetry element (Scheme 7).48  
Cyclization of a 1:1:1 mixture of 1-45, 1-46 and 1-47 yielded 21% of the natural product 1-
48 together with 23% of the positional isomer 1-49 and 21% of by-product 1-50 plus other 
cyclotrimers. When metal salts were added, the overall yield dropped significantly. The ratio of 
the three major isomers 1-48, 1-49 and 1-50 also underwent significant changes (Table 5). It is 
noteworthy that in the presence of AgBF4 the cyclic trimer 1-50 was the only product. However, 
no explanation was provided for this selectivity. 
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Scheme 7 Metal ion templated synthesis of nostocyclamide 
S N N
S
O
N
O
HO NH2
NH2
O
HO O
H2NOH
1. Metal salt, DIPEA
2. FDPP
S N N
S
O
N
O
HNNH
O
O
N
H S N N
S
O
N
O
HNNH
O
O
N
H S N N
S
O
N
O
HNNH
O
O
N
H
1-45 1-46
1-47
1-48 1-49 1-50  
Table 5 Metal effect on the cyclization of 1-48, 1-49 and 1-50 
Composition of Cyclic ProductsMetal Salt Overal Yield % 
 1-48 1-49 1-50 
No Metal 71 21 23 21 
Cu(BF4)2 9 66 34 - 
LiBF4 26 45 13 - 
Ca(BF4)2 28 48 29 - 
Zn(BF4)2 23 25 38 36 
AgBF4 14 - - 100 
NaBF4 34 28 28 44 
KBF4 40 26 26 48 
 
 The Fairlie group demonstrated the feasibility of medium to large scale synthesis of the 
non-Lissoclinum cyclopeptide 3D53 (1-51, Scheme 8).49  
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Scheme 8 Cyclopeptide 3D53 and its synthetic precursors 
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Sequential couplings of commercially available amino acids with mixed anhydride 
provided segments 1-52 and 1-53, which were then coupled and cyclized to 1-51 (31 g) in an 
overall yield of 13%. The key to the success of this synthesis was a minimal use of protection 
groups on the sidechains and no purification of the intermediates throughout the entire synthesis. 
The same group also explored the synthesis of a protein mimetic with a Lissoclinum 
cyclopeptide analogue as a scaffold (Scheme 9).50 The cyclopeptide 1-54 was prepared from 
dipeptidyl oxazoles and thiazoles by sequential couplings and macrocyclization. The sidechains 
in 1-54 were then coupled with two tripeptide segments to provide tricyclic peptide 1-55. The 
rigid polythiazole and -oxazole backbone functioned as a scaffold, supporting two short peptide 
loops projecting orthogonally from the same face of the backbone. This mimicked the two 
interhelical loops of cytochrome b562 illustrated in Figure 10. Thus 1-55 could function as an 
artificial protein. 
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Scheme 9 Synthesis of a protein mimetic with a cyclopeptide scaffold 
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Figure 10 Discontinuous loop surfaces in cytochrome b562.  
Reproduced from Ref. 51. 
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1.1.4 Design of a Tethered Bis-oxazoline Ligand for Ag(I) Binding (Generation I) 
Encouraged by the discovery of a westiellamide-Ag(I) complex, we desired to improve the 
ligand’s  affinity towards silver. For the purpose of extracting silver out of sea water, a 
Ka~1033M-5 is required for a westiellamide ([1-42Ag4]4+) system (assuming 0.24 ug/L silver 
concentration, 10 mM ligand concentration and 90% Ag extraction per cycle). Upon inspection 
of westiellamide’s silver binding pattern, one may recognize the huge entropy loss (ΔS=-191 J 
K-1 mol-1)16 due to the requirement of bringing 6 molecules together for complexing. This can be 
partially compensated by tethering two westiellamides into a cage-like molecule51-54 (Scheme 
10). The linker also allows a potential attachment of the macrocycles to a solid support. 
Scheme 10 Ligand design (generation I) 
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Scheme 11 Synthetic effort towards generation I ligand 
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The aziridines 1-59 and 1-60 were prepared from L-serine and L-threonine,55-56 
respectively (Scheme 11)57. The N-trityl groups were replaced with an Alloc group to activate 
the aziridine ring towards nucleophilic attack. Aziridines 1-61 and 1-62 was successfully opened 
with the assistance of a Lewis acid.58-59 Saponification of 1-63 and 1-64 followed by coupling to 
D-Thr-OMe yielded dipeptides 1-65 and 1-66. DAST effected the formation of oxazoline60 to 
provide 1-67 and 1-68. However, these heterocycles were unstable and unable to tolerate the 
subsequent deprotection steps. After repeated attempts failed, it was concluded that 1-67 and 1-
68 decomposed at their ether moiety by β-elimination of the α-proton on the amino acid 
backbone.  
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1.2 RESULTS AND DISCUSSION 
1.2.1 Generation II Ligand 
Cyclic peptide 1-71 was selected to circumvent the stability problem with the Generation I ligand 
(Scheme 12). We proposed that an additional carbon inserted between the ether linkage and the 
β-position of the amino acid backbone would prevent elimination of the sidechain. 
Scheme 12 Ligand design (generation II) 
 
Retrosynthetically, 1-71 can be prepared from 1-73 by cyclooligomerization. 
Cyclodehydration of dipeptide 1-74 with Burgess reagent or DAST yields 1-73. 1-74 can be 
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prepared from the coupling of 1-75 and D-Thr. The γ-hydroxy valine 1-75 might be derived from 
a Shilov-type oxidation of L-valine61(Scheme 13).   
In the Shilov reaction, the Pt(IV) is oxidized in situ to Pt(VI) by CuCl2. The Pt(VI) species 
complexes with valine and subsequently oxidizes the methyl group to a primary alcohol. The 
resulting γ-hydroxy valine spontaneously closes to lactones 1-77a and 1-77b. The overall yield 
was determined after Boc protection. However, Shilov type reactions often suffer from low 
yields.62 This reaction was no exception (21% overall yield). Another problem was the low 
diastereoselectivity (1.6:1). Repeated attempts (including microwave conditions) to improve the 
yield failed. 
Scheme 13 Oxidation of valine by Pt(VI) 
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1.2.2 Generation III Ligand 
Next we turned our attention to a rather conventional approach (Scheme 14).  The cyclic trimer 
1-79 can be prepared from monomer 1-81, which in turn was made from modified amino acid 1-
83 and D-Thr. 1-83 has been previously prepared from protected L-aspartic acid.63 The benzyl 
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group on its side chain was designed to mimic the methyl group in the natural product, which 
may play an important role in the success of the cyclooligomerization step. 
Scheme 14 Ligand design (generation III) 
 
The synthesis of 1-79 started with the commercially available protected aspartic acid 1-85 
(Scheme 15). Protection of the carboxyl group as a methyl ester followed by β-benzylation with 
LHMDS and benzyl bromide provided 1-86 as the exclusive diastereoisomer.63 The Boc 
protection group was required as its bulky size suppresses enolate formation at the α-carbon. 
The β-carboxyl group was unmasked and reduced to the primary alcohol 1-83. Initially, 
we followed the literature procedure63 using BOP/NaBH4, which resulted in 25-35% yield 
depending on the reaction scale. The major by-product was the lactone resulting from 
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transesterification. After some experimentation, a combination of isobutylchloroformate and 
NaBH4 was found to provide a better yield (65%). 
Scheme 15 Synthetic efforts towards 1-88 
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Etherification of 1-83 by AgOTf/5-iodopentene yielded only 29% of 1-88 along with the 
lactone and N-alkylation product. Other ether formation conditions including NaH/5-
bromopentene, 2,6-di-t-BuPy/pent-4-enyl triflate and reductive etherification64 were tested and 
found to be ineffective. Therefore we decided to protect 1-83 using a silyl group and form the 
ether side chain at a later stage (Scheme 16).  
Protection of 1-83 by the TBDPS group went smoothly to provide 1-89 in 97% yield. The 
Boc group in 1-89 was switched to a Cbz group as mild deprotection conditions are essential for 
oxazoline-containing compounds. Saponification followed by coupling to D-Thr-OMe yielded 
dipeptide 1-93 in quantitative yield. DAST effected the formation of oxazoline 1-94 in 85% 
yield. However, 1-94 was found to be resistant to hydrogenolysis, indicating the contamination 
by sulfur from DAST. Thus, Burgess reagent was used instead to yield 75% of 1-94. 
Deprotection of Cbz by hydrogenolysis was followed by saponification as well as epimerization 
of the cis-oxazoline to the trans-configuration with NaOH. This reaction was quenched with 
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NaHCO3 and the resulting mixture was carried on to the next step without purification. This was 
a critical modification since all acidic workups were found to decompose the intermediate. 
Scheme 16 Revised approach towards 1-95 
CbzHN
O
H
N COOMe
OH
Ph
OTBDPS
CbzHN
O
N COOMe
Ph
OTBDPS
IBCF, NMM
100% (crude)
DAST, 85%
or Burgess
Reagent, 79%
1. Pd(OH)2/C, H2
HN
N
O
O
N
H
N
O
O
NH
N O
O
Ph
Ph
Ph
TBDPSO
OTBDPS
TBDPSO
1-93
1-94
1-95
2. NaOH, MeOH
3. DPPA, NaHCO3,
Na2CO3,
0 oC - rt, 4 d
CbzHN
O
OH
Ph OTBDPS
TFA,PhSMe
LiOH, THF
TBDPSCl,
imidazole, 97%
BocHN
O
OMe
Ph OH
BocHN
O
OMe
Ph OTBDPS
1-83 1-89
1-92
D-Thr-OMe
Cbz-Cl,NaHCO3
CbzHN
O
OMe
Ph OTBDPS
H2N
O
OMe
Ph OTBDPS
1-90 1-91
99% (crude)
91% (crude) 96% (crude)
 
Unfortunately, DPPA was unable to effect a cyclooligomerization. Screening of other 
coupling reagents including FDPP and DEPBT proved to be unsuccessful. In light of these 
results and the difficulty characterizing the epimerized oxazoline, we decided to prepare the 
oxazoline 1-99 with the desired trans-stereochemistry in a way analogous to the westiellamide 
synthesis (Scheme 17). 
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Coupling of 1-92 to L-Thr-OMe followed by treatment with Burgess reagent yielded 
oxazoline 1-97. The oxazoline was opened and re-closed to provide 1-99 with suitable 
stereochemistry for cyclooligomerization. Exposure to the cyclization conditions failed to give 
the cyclic trimer 95. This result suggested that the bulky TBDPS group in 1-99 as well as in 1-94 
was the cause for the failure in the cyclooligomerization step. 
Scheme 17 Cyclooligomerization with confirmed stereochemistry on the oxazoline 
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The next course of action was to remove the TBDPS group prior to cyclooligomerization 
(Scheme 18). The desilylation of 1-94 proved to be surprisingly difficult. TBAF was able to 
remove the TBDPS group, but the product was only obtained crude. Other desilylating reagents, 
including TBAF-AcOH, TAS-F, HF-Pyridine and Et3N-HF, were unable to provide clean 
material either. Crude 1-100 was then subjected to the deprotection and cyclooligomerization 
conditions to yield 8% (0.6 mg) of the cyclic trimer 1-101, which was identified by 1H NMR and 
MS. However, attempts to scale up this process failed, possibly due to the instability of 1-100. 
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Scheme 18 Cyclooligomerization of desilylated oxazoline 
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Presumably, the oxazoline in 1-100 could be destabilized by an intramolecular hydrogen 
bonding interaction (1-102, Scheme 19). Another possibility is that the free hydroxyl group 
might be able to ring-open the oxazoline (1-103, Scheme 19). 
Scheme 19 Possible decomposition pathways of 1-100 
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At this stage, the cyclooligomerization approach did not seem to be viable. Therefore, a 
macrocyclization strategy was investigated (Scheme 20). Dimerization of 1-94 was realized by 
deprotection and subsequent coupling using isobutylchloroformate. The yield, however, was low 
(51%). Unfortunately, all attempts to construct the linear trimer 1-107 failed. A possible cause 
could be the steric hindrance of the substrate. No further studies on this substrate were 
conducted. 
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Scheme 20 Macrocyclization approach towards 1-95 
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1.2.3 Generation IV Ligand 
A decision was made to make a major modification to our target molecule (Scheme 21). The 
hetero-cyclotrimer 1-108 consists of one functionalized oxazoline 1-94 and two unfunctionalized 
oxazolines 110. There are a couple of advantages of this design over the originally proposed 
homo-cyclotrimer 1-95. First, compound 1-108 more closely resembles westiellamide. This 
should increase the chances for success in the macrocyclization step as well as the binding of the 
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macrocycle to silver. Furthermore, compound 1-97 is readily available and decreases the 
required amount of the precious oxazoline 1-94. 
Scheme 21 Ligand design (generation IV) 
 
Commercially available Cbz-L-Val-OH was converted to 1-110 in the same fashion as in 
the westiellamide synthesis (Scheme 22). Dimerization of 1-110 using either IBCF or EDCI was 
unsuccessful due to the decomposition of the oxazoline upon acidic workup of the saponification 
step. This problem was solved by quenching the reaction with NaHCO3 followed by a DPPA-
mediated peptide coupling. To compensate for the decomposition of the oxazoline during the 
coupling reaction, a two fold excess of the free N-terminal compound was used. 
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Scheme 22 Macrocyclization approach towards the heterocyclotrimer 1-115 
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Next, the linear trimer 1-113 was prepared in 80% yield by coupling the dimer 1-112 to the 
functionalized oxazoline 1-94. As expected, the cyclization of 1-113 with DPPA proceeded very 
well to provide the cyclic trimer 1-114 in 60% yield. The use of FDPP as coupling reagent or 
AgBF4 as an additive significantly decreased the yield. Treatment of 1-114 with TBAF afforded 
90% of the desilylated 1-115. Possibly, the rigid structure in 1-115 accounts for its better 
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stability compared to dipeptidyl oxazoline 1-100. 1-115 was converted to its p-bromobenzoyl 
ester 1-116, whose crystal structure was solved (Figure 11). The backbone of 1-116 adopt a 
planar conformation with all the side chains adopt a pseudo-equatorial position. This is 
consistent with the crystal structure of westiellamide (Figure 4). 
Figure 11 Stereoview of the crystal structure of 1-116 
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To determine the ability of 1-115 to bind silver(I), an NMR titration experiment with 
AgClO4 in CD3OD+D2O (9:1, v/v)16 was conducted. Surprisingly, 1-115 showed weak and 
complex association to Ag+. This could possibly be attributed to the absence of C3 symmetry in 
the molecule. Thus, we decided to tether the two hetero-cyclotrimers together, hoping to 
minimize the entropic penalty to improve its affinity towards Ag(I). 
Ether formation with 1-115 was found to be difficult, presumably due to its highly 
functionalized nature. Protocols tested included NaH/5-iodopentene, NaHMDS/5-iodopentene, 
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2,6-di-tBupyridine/pent-4-enyl triflate, AgOAc/5-iodopentene and Mitsunobu conditions, all of 
which proved unsuccessful. In contrast, the esterification of 1-115 was found to be a viable 
alternative (Scheme 23). 
Scheme 23 Tethering the cyclic trimer 
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Alcohol 1-115 was transformed into ester 1-119 with acyl chloride. Dimerization of 1-119 
by metathesis51 catalyzed by Grubb’s 2nd generation catalyst provided 60% of 1-118 as a mixture 
of cis/trans-isomers. Other common metathesis catalysts, including Grubbs’ 1st generation and 
Schrock’s catalyst, were unable to effect the reaction. Pre-assembly of the monomers with 
AgClO4 followed by dimerization with Grubb’s 2nd generation catalyst failed. This could be due 
the decomposition of the catalyst by removal of the chloride ligand by silver(I). Hydrogenation 
of 1-118 with Pd/C yielded the tethered ligand 1-119. A more direct way to prepare 1-119 by 
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using half an equivalent of octanedioyl dichloride failed, presumably due to ketene formation 
and the low concentration of the acyl chloride.  
With 1-119 in hand, an NMR titration with AgClO4 was conducted. To our relief, upon 
treatment with silver, 1-119 showed a similar NMR pattern to the westiellamide-Ag complex, 
forming a [(1-119)Ag4]4+ complex. A series of typical NMR spectra are shown in Figure 12. The 
peak that corresponds to the methyl group in the Val residue (Spectrum A) was split into two sets 
of peaks upon treatment with Ag(I) (Spectrum B). The downfield peak corresponded to 
complexed 1-119, while the upfield peak corresponded to uncomplexed 1-119. After the addition 
of 4 equivalents of Ag(I), nearly all of 1-119 was in complexed form (Spectrum C). The 
spectrum underwent little change when adding more than 4 equivalents of Ag(I) (Spectrum D). 
The small uncomplexed peak in Spectrum D may be attributed to the presence of the epimer of 
1-119. Thus, a stoichiometry of 1:4 (1-119:Ag+) was determined. This result was in sharp 
contrast to most NMR titrations in the literature,65 in which no splitting of peaks were observed 
due to the fast equilibrium between the two species. In those cases, the peak underwent 
concentration-dependent changes in its chemical shift. Thus, the splitting pattern in 1-119 and in 
westiellamide suggested a slow exchange between complexed and uncomplexed forms according 
to the NMR time scale. However, the reaction speed between 1-119 and Ag(I) was fast, as the 
equilibrium was achieved instantaneously upon mixing the reactants. 
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Figure 12 NMR titration of 1-119 with AgClO4.  
A: No Ag(I); B: 2 equivalents Ag(I); C: 4 equivalents Ag(I); D: 20 equivalents Ag(I) 
 
Also worth mentioning is that the binding of 1-119 to four Ag(I) was a highly cooperative 
process, as no intermediate states were observed during the titration. The calculation of Ka was 
based on the integration of the complexed peak (1.18-1.00 ppm) and uncomplexed peak (1.00-
0.74 ppm). A Ka of 1.8±1.4×1011 M-4 in CD3OD and D2O (9:1, v/v) was determined for 1-119. 
The Ka for westiellamide (2.8×1013M-5) was determined in a similar fashion.16 Several factors 
may have attributed to the significant error range observed in the NMR titration. Generally, the 
NMR titration only works well for Ka < 105 M-1 for a 1:1 complex.65 Also, the error may be 
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linked to the partial overlap of peaks in NMR as well as the presence of a trace amount of 
epimers. We attempted the determination of ΔS for Ag binding of 1-119 by using variable 
temperature NMR. Unfortunately, these results were highly variable due to the inconsistencies 
between measurements, which may have resulted from errors in the integration of the NMR 
peaks as well. 
In order to address the issues associated with NMR titration, a competitive binding study of 
1-119 with a fluorophore 1-120 (Figure 13) was conducted. It was demonstrated that Ag(I) binds 
to this fluorophore and causes fluorescence quenching (Figure 14).66 
Figure 13 Fluorophore for competitive binding study. 
N N
N N
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Figure 14 Changes in fluorescence emission spectra of 1-120 upon the addition of AgClO4 in MeOH and H2O (9:1, 
v/v).  
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The addition of 1-119 to the mixture of Ag(I) and 1-120 restored the intensity of 
fluorescence, indicating its competitive binding to Ag(I) cation (Figure 15). In this study, both 
westiellamide and 1-119 exhibited considerably higher Ka’s of 2.8±1.9×1022 M-5 and 
3.5±3.9×1021 M-4, respectively.67-68 The competitive binding experiment with a fluorophore 
represents a more sensitive tool for the determination of high association constants. Most 
importantly, both analytical methods demonstrate that the tether considerably improves potential 
practical applications of the cyclooxazoline scaffold for silver complexation and delivery in the 
low micromolar range. For example, 50% complexation of a 10 µM solution of Ag(I) would 
require 270 µM of westiellamide vs 2 µM of 1-119. 
Figure 15 Competitive binding study of 1-119 with 1-120.  Ligand refers to 1-119. 
 
Next, we examined the effect of the linker’s length on Ag-binding (Scheme 24). Acylation 
of 1-115 with adipoyl chloride provided ligand 1-121, which has two fewer methylene groups in 
the tether chain than 1-119. As expected on the basis of the reduction in entropy loss during 
complexation, the result was a slightly higher Ka of 3.20±2.98×1022 M-4 (determined by 
competitive binding with 1-120) than 1-119. In a similar fashion, 1-115 was cross-linked with 
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pyridine-2,6-dicarboxylate to give ligand 1-122. However, NMR titration of 1-122 showed a 
complex binding pattern to Ag(I), presumably due to the shortness or rigidity of the tether, or 
additional silver-pyridine interactions.  
Scheme 24 Further linker variations 
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1.2.4 Generation V and VI Ligands  
While working on the Generation IV ligand, we also started investigating other modifications on 
westiellamide (Scheme 25). In principle, a C3 symmetric tethered dimer would provide the 
highest affinity towards Ag(I). Thus cyclic trimer 1-124 was chosen instead of an unsymmetrical 
trimer. In 1-124, an additional carbon atom was inserted between the sidechain ether and the 
backbone, in the hope to solve the stability issue with the desilylated oxazoline 1-100. Since the 
decomposition of 1-100 may involve a cyclic transition state (Scheme 19), enlarging the ring 
may disfavor the process. 1-124 may be prepared from monomer 1-126 by cyclooligomerization, 
while 1-126 is derived from amino acid 1-127. This amino acid would arise from the oxidation 
of 128, which can be prepared by hydrogenation of 1-129. Compund 1-129 is readily available 
by homoallylation of imine 1-131.69 
The synthesis started with the hydrozirconation of protected 3-butyne-1-ol (1-130) with 
Schwartz’ reagent (Cp2ZrHCl), transmetallation to zinc, addition to diiodomethane, subsequent 
rearrangement and addition to imine (prepared by the condensation of furaldehyde and 
diphenylphosphinic amide70) to yield 68% of 1-129 (Scheme 26). At this stage, 1-129 seemed to 
be a single diastereomer as demonstrated by LC-MS and NMR data. The relative configration of 
the phosphoramide and olefin groups in 1-129 was unknown. 
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Scheme 25 Ligand design (generation V) 
 
Compound 1-129 was then hydrogenated to give 1-128. The low yield (78%) was 
attributed to the low purity of 1-129 (unknown contaminant). Global deprotection of 1-128 by 
HCl in MeOH and subsequent reprotection with Cbz and TIPS yielded 1-133. The switch of both 
N- and O- protection groups was necessary as the N-diphenylphosphinyl group is critical for the 
homoallylation step, and its selective removal vs the TBDPS group failed. Initially, we used a 
benzyl group for O-protection, allowing a mild deprotection step at a later stage. However, the 
benzyl group was found to be partially oxidized in the next step. Thus, a TIPS group was used 
instead. 
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Scheme 26 Approach utilizing a homoallylation strategy 
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Oxidation of the furan moiety in 1-133 with in situ generated RuO471 provided 43% of 1-
128 while ozonolysis gave a complex mixture. We could have resolved the enantiomers of 1-128 
by means of a chiral base. However, a decision was made to explore the feasibility of this route 
first, postponing further optimizations. Therefore, racemic 1-128 was coupled to D-Thr-OMe to 
 44 
yield a 1:1 mixture of diastereomers 1-134a and 1-134b (inseparable on SiO2). Their relative 
configration was assigned arbitrarily. Formation of the oxazoline by Burgess reagent or DAST 
was rather low yielding (40% and 52% overall yield, respectively). The two diastereomers 1-
135a and 1-135b were successfully separated while their absolute stereochemistry was unknown. 
Therefore, both of them were subjected to the N- and C-termini deprotection and 
cyclooligomerization conditions (Scheme 27). Unfortunately, no cyclic oligomers were observed.  
Scheme 27 Cyclooligomerization of oxazolines 1-135a and 1-135b 
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Deprotection of the TIPS group in 1-135a or 1-135b by TBAF provided the unstable 1-
137a and 1-137b (Scheme 27). Their decomposition pattern was similar to oxazoline 1-100 
(Scheme 19) according to 1H NMR. Therefore, analogous decomposition pathways (1-138, 1-
139) can be proposed. When comparing 1-138 and 1-139, a seven-membered ring is formed for 
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1-138, while 1-139 has a six-membered cycle.  Therefore, 1-139 may resemble the actual 
decomposition pathway.  
We also considered the synthesis of the heterocyclotrimer 1-140 (Generation VI) 
(Scheme 28). This compound can be prepared from oxazolines 1-135 and 1-105 in the same 
fashion as the Generation IV ligand (Scheme 29). 
Scheme 28 Design of ligand (generation VI) 
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Scheme 29 Macrocyclization approach towards the heterocyclotrimer 1-144 
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The coupling of 1-135a to 1-112 yielded 41% of the linear trimer 1-142a. Similarly, the 
coupling with 1-135b afforded 39% of 1-142b (Scheme 29). Both compounds were subjected to 
deprotection and macrocyclization conditions. Interestingly, among the two diastereomers, only 
the trimer 1-142a, which was derived from 1-145a, cyclized to provide 41% of cyclotrimer 1-
143. Hence our initial arbitrary stereochemistry assignment for 1-135a and 1-135b was correct. 
We made the assumption that only the diastereomer with a backbone stereochemistry resembling 
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westiellamide could be cyclized. Desilylation of 1-143 by TBAF provided 70% of 1-144.  An 1H 
NMR of 1-144 in CDCl3 showed 3 signals which corresponded to the three backbone NHs in the 
molecule. However, when 1-144 was dissolved in CD3OD-D2O (9:1, v/v), the peaks were split 
into two sets with a ratio of integration of 1:1. Possibly, 1-144 is a mixture of either 
diastereomers at the β-position of the functionalized residue or epimers at the C-2 positions of 
the backbone oxazolines or rotamers. An LC-MS study on the precursor 1-132 revealed that it 
was a 1:1 mixture of diastereomers (Scheme 30). Due to the difficulty separating the 
diastereomers and the success of the Generation IV ligand, work on this route was suspended.  
Scheme 30 LC-MS study of precursor 1-132 
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1.3 CONCLUSIONS 
 
We have demonstrated the feasibility of improving the unique affinity of the natural product 
westiellamide toward silver ions by structural modifications. The tethered ligands 1-119 and 1-
121 show higher affinities toward Ag(I) than westiellamide and improve the potential for 
practical applications of cyclic oligooxazolines in Ag(I) detection, transport, detoxification, and 
targeted delivery. 
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1.4 EXPERIMENTAL PART 
 
General:  All moisture-sensitive reactions were performed under an atmosphere of N2.  
Glassware was flame dried prior to use. THF and Et2O were dried by distillation over 
Na/benzophenone. DCM was dried by distillation over CaH2. Unless otherwise stated, solvents 
and reagents were used as received. Analytical thin layer chromatography was performed on pre-
coated silica gel 60 F-254 plates (particle size 0.040-0.055 mm, 230-400 mesh) and visualization 
was accomplished with a 254 nm UV light or by staining with an anisaldehyde solution (7.5 mL 
of p-anisaldehyde, 25 mL of concentrated H2SO4 and 7.5 mL of glacial acetic acid in 675 mL of 
95% ethanol) or KMnO4 solution (1.5 g of KMnO4, 10 g of potassium carbonate and 2.5 mL of 
5% aqueous NaOH in 150 mL of H2O). Flash chromatography on SiO2 was used to separate and 
purify the crude reaction mixtures. NMR spectra were recorded at 300 MHz/75 MHz (1H 
NMR/13C NMR) at 21 oC in CDCl3 unless otherwise noted. Chemical shifts () are reported as 
follows: chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, qn=quintet, 
dd=doublet of doublet, ddd= doublet of doublet of doublet, dt=doublet of triplet, dq=doublet of 
quartet, m=multiplet, br=broad, app=apparent). LC/MS analyses were obtained from a Hewlett 
Packard Series 1100 MSD. Infrared spectra were measured on a Nicolet AVATAR 360 FTIR 
E.S.P. spectrometer. Optical rotations were measured on a Perkin-Elmer 241 polarimeter at 25 
oC.  
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For NMR titration and competitive binding study, 1H NMR spectra were recorded at 300 
MHz at 21 oC. Fluorescence spectra were measured on an ISA Instruments Spex Fluorolog 
fluorescence spectrometer at 23 oC. 
 
O O
BocHN BocHN
O O
+
 
tert-Butyl (3S,4S)-4-methyl-2-oxotetrahydrofuran-3-ylcarbamate (1-78a) and tert-
butyl (3S,4R)-4-methyl-2-oxotetrahydrofuran-3-ylcarbamate (1-78b).61 A solution of L-
valine (117 mg, 1.00 mmol), CuCl2•H2O (1.19 g, 7.00 mmol) and K2PtCl4 (20.8 mg, 0.050 
mmol, 5 mol%) in water (3.00 mL) was heated to 160°C (oil bath) for 10 h or 160 oC 
(microwave) for 6 h. The reaction mixture was then cooled to room temperature, treated with 
H2S and filtered through a pad of Celite. The solution was concentrated to dryness under reduced 
pressure. The residue was dissolved in EtOH (2.00 mL) and 1 N NaOH (4.00 mL) and treated 
with a solution of Boc2O (300 mg, 1.40 mmol) in THF (1.00 mL). The mixture was stirred at 
room temperature for 2.5 h. THF was removed under reduced pressure and the resulting solution 
was diluted with water (10.0 mL), cooled to 0 °C and adjusted to pH = 3 (pH paper) with 1 N 
HCl. The aqueous mixture was extracted with EtOAc (3x). The combined organic phases were 
then combined, dried (MgSO4), filtered and concentrated under reduced pressure. The residue 
was redissolved in CHCl3 (0.50 mL) followed by treatment with glacial HOAc (1 drop) and 
Na2SO4 (0.500 g). The reaction mixture was stirred at room temperature for 2 h. Solvent was 
removed under reduced pressure and purification by chromatography on SiO2 
(Hexanes:EtOAc=1:1) yielded 28.0 mg (13%) of 1-78a and 17.0 mg (8%) of 1-78b (oil bath 
heating) or 8.6 mg (4%) of 1-78a (microwave heating) as a clear oil. 1-78a: 1H NMR (CDCl3)  
 50 
5.02 (br s, 1 H), 4.38 (app t, 1 H, J = 8.0 Hz), 4.13–3.92 (m, 1 H), 3.79 (app t, 1 H, J = 10.1 Hz), 
2.58-2.37 (m, 1 H), 1.43 (s, 9 H), 1.19 (d, 3 H, J = 6.5 Hz). 1-78b: 1H NMR (CDCl3)  4.99 (br s, 
1 H), 4.47 (app t, 1 H, J = 6.2 Hz), 4.37 (dd, 1 H, J = 9.3, 5.1 Hz), 4.07 (d, 1 H, J = 9.3 Hz), 
3.02-2.96 (m, 1 H), 1.44 (s, 9 H), 0.97 (d, 3 H, J = 6.5 Hz). 
BocHN
O
COOBn
OMe
 
Boc-L-Asp(OBn)-OMe (1-86).72 A suspension of Boc-Asp(OBzl)-OH (25.0 g, 77.0 
mmol) and K2CO3 (15.5 g, 114 mmol) in anhydrous DMF (178 mL) at 0 oC was treated with 
iodomethane (9.66 mL, 144 mmol) and stirred for 3 h. Water (250 mL) was added and the 
mixture was extracted with EtOAc (3x). The combined organic layers were washed with 
saturated aqueous NaHCO3 (3x) and brine (4x), dried (Na2SO4), filtered through a pad of SiO2 
and concentrated to dryness under reduced pressure to yield 23.0 g (89%) of 1-86 as a clear oil: 
1H NMR (CDCl3),  7.41-7.25 (m, 5 H), 5.49 (br d, 1 H, J = 8.2 Hz), 5.14 (AB, 1 H, J = 12.3 
Hz), 5.12 (AB, 1 H, J = 12.3 Hz), 4.63-4.55 (m, 1 H), 3.70 (s, 3 H), 3.05 (ABX, 1 H, J = 17.0, 
4.5 Hz), 2.87 (ABX, 1 H, J = 17.0, 4.7 Hz), 1.45 (s, 9 H). 
BocHN
O
COOBn
OMe
Ph
 
Methyl 2-tert-butoxycarbonylamino-3-carbobenzyloxy-(2S,3S)-hex-5-enoate (1-87).63 
A solution of 1-86 (20.4 g, 60.5 mmol) in THF (40.0 mL) at -42 oC was treated with a solution of 
LHMDS (prepared by treatment of a solution of HMDS (31.7 mL, 150 mmol) in THF (150 mL) 
at -60 oC with n-BuLi (1.6 M in hexanes, 93.8 mL), warmed to room temperature for 30 min then 
re-cooled to -42 oC, followed by addition of HMPA (6.89 mL, 140 mmol). The reaction mixture 
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was stirred at -42 oC for 30 min before adding benzyl bromide (8.97 mL, 75.0 mmol). The 
mixture was stirred for an additional 4 h at -42 oC,  and saturated aqueous NH4Cl (81 mL) was 
added. The solution was warmed to room temperature and concentrated under reduced pressure. 
The crude product was redissolved in DCM and washed with aqueous NH4Cl (2x) and brine, 
dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc=4:1) yielded 16.3 g (63%) of 1-87 as a clear oil: 1H 
NMR (CDCl3),  7.35-7.18 (m, 10 H), 5.56 (d, 1 H, J = 9.8 Hz), 5.07 (app s, 2 H), 4.47 (dd, 1 H, 
J = 8.3, 2.1 Hz), 3.59 (s, 3 H), 3.41 (app dt, 1 H, J = 7.3, 3.8 Hz), 3.11 (dd, 1 H, J = 13.8, 7.2 
Hz), 2.85 (dd, 1 H, J = 13.8, 8.2 Hz), 1.48 (s, 9 H). 
BocHN
O
OMe
Ph OH
 
Methyl 3-benzyl-2-tert-butoxycarbonylamino-4-hydroxy-(2S,3R)-butanoate (1-83). 63  
A suspension of 1-87 (11.2 g, 26.3 mmol) and 10% Pd/C (0.570 g) in methanol (156 mL) was 
exposed to hydrogen gas (1 atm) for 3 h. The mixture was filtered through celite and the solvent 
was evaporated under reduced pressure. A solution of the crude product (5.53 g, 16.4 mmol) in 
THF (161 mL) at -40 ºC was treated with triethylamine (3.06 mL, 21.3 mmol) followed by 
isobutylchloroformate (2.76 mL, 21.3 mmol) and stirred for 1 h. NaBH4 (1.88 g, 49.2 mmol) was 
added and the reaction mixture was allowed to warm up to 0 ºC over 2 h and stirred for 3.5 h. 
After addition of 5% HCl (125 mL), the organic solvent was removed under reduced pressure. 
The residue was dissolved in EtOAc, washed with water and brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc=2:1) afforded 3.27 g (65%) of 1-83 as a clear oil: 1H NMR (CDCl3)  7.33-
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7.17 (m, 5 H), 5.59 (d, 1 H, J = 8.9 Hz), 4.42 (dd, 1 H, J =7.8, 6.1 Hz), 3.73 (s, 3 H), 3.65-3.49 
(m, 2 H), 2.76-2.71 (m, 2 H), 2.28 (br s, 1 H), 2.04 (br s, 1 H), 1.46 (s, 9 H). 
BocHN
O
OMe
Ph O
 
(2S,3R)-Methyl 3-benzyl-2-(tert-butoxycarbonylamino)-4-(pent-4-enyloxy)- 
butanoate (1-88). A solution of 1-83 (18.9 mg, 0.0585 mmol), 2,6-di-tert-butylpyridine (0.0459 
mL, 0.210 mmol) and AgOTf (45.0 mg, 0.172 mmol) in DCM (0.5 mL) at 0 oC was treated with 
5-iodopent-1-ene (21.0 µL, 0.187 mmol) and stirred at 0 oC for 2 h. The reaction mixture was 
filtered and diluted with DCM, washed with 1 M NaHSO4 and saturated NaHCO3, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:EtOAc=5:1 to 2:1) afforded 6.6 mg (29%) of 1-88 as a clear oil: 1H NMR 
(CDCl3)  7.32-7.18 (m, 5 H), 5.87-5.75 (m, 2 H), 5.06 (d, 1 H, J = 17.1 Hz), 4.99 (d, 1 H, J = 
10.1 Hz), 4.38 (dd, 1 H, J =5.3, 3.4 Hz), 3.70 (s, 3 H), 3.42-3.23 (m, 4 H), 2.78 (app d, 2 H, J = 
7.7 Hz), 2.51-2.39 (m, 1 H), 2.15 (app dd, 2 H, J = 14.3, 7.2 Hz), 1.66 (app qn, 2 H, J = 7.4 Hz), 
1.47 (s, 9 H). HRMS (ESI) m/z calcd for C22H33NO5Na (M+Na) 414.2256, found 414.2277.  
BocHN
O
OMe
Ph OTBDPS
 
(6R,7S)-Methyl 6-benzyl-2,2,11,11-tetramethyl-9-oxo-3,3-diphenyl-4,10-dioxa-8- 
aza-3-siladodecane-7-carboxylate (1-89). A solution of 1-83 (5.42 g, 16.7 mmol) and imidazole 
(1.47 g, 21.8 mmol) in DMF (60.0 mL) was treated with tert-butyldiphenylchlorosilane (5.54 
mL, 21.8 mmol). The resulting mixture was stirred at room temperature for 36 h. After addition 
of a mixture of saturated NH4Cl (25 mL) and water (250 mL), the aqueous layer was extracted 
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with EtOAc (3x). The organic layers were combined, washed with brine, dried (NaSO4), filtered 
and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc=5:1) afforded 9.14 g (97%) of 1-89 as a clear oil: [α]D25 +1.0 (c 5.0, CHCl3); 
IR (neat) 3418, 2931, 1748, 1716, 1495 cm-1; 1H NMR (CDCl3) δ 7.74-7.62 (m, 4 H), 7.48-7.34 
(m, 7 H), 7.26-7.09 (m, 4 H), 6.28 (d, 1 H, J = 8.9 Hz), 4.40 (dd, 1 H, J = 3.7, 8.9 Hz), 3.71-3.61 
(m, 1 H), 3.67 (s, 3 H), 3.51 (dd, 1 H, J = 3.6, 10.8 Hz), 2.88 (ABX, 1 H, J = 14.1, 7.7 Hz), 2.82 
(ABX, 1 H, J = 13.3, 7.4 Hz), 2.42-2.34 (m, 1 H), 1.50 (s, 9 H), 1.14 (s, 9 H); 13C NMR (CDCl3) 
δ 173.1, 156.3, 139.4, 136.0, 132.5, 130.1, 129.3, 128.6, 128.0, 126.5, 79.6, 63.9, 56.6, 52.3, 
43.3, 35.2, 28.6, 27.1, 19.3; HRMS (ESI) m/z calcd for C33H43NO5SiNa (M+Na) 584.2808, 
found 584.2804. 
H2N
O
OMe
Ph OTBDPS
 
(2S,3R)-Methyl 2-amino-3-benzyl-4-(tert-butyldiphenylsilyloxy)butanoate (1-90). A 
solution of 1-89 (9.14 g, 16.3 mmol) in DCM (125 mL) at 0 °C was treated with thioanisole 
(2.00 mL, 19.0 mmol) and trifluoroacetic acid (30.6 mL, 0.456 mol). The mixture was stirred at 
17 °C for 40 min. The reaction mixture was quenched with saturated NaHCO3 (600 mL) at 0 °C 
and extracted with DCM (3x). The organic layers were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc=8:1 to 1:1, all with 1% Et3N) afforded 7.47 g (99%) of crude 1-90 as a clear 
oil: [α]D25 +23.4 (c 0.68, CHCl3); IR (neat) 3391, 2951, 2931, 1737 cm-1; 1H NMR (CDCl3) δ 
7.74-7.62 (m, 4 H), 7.48-7.34 (m, 7 H), 7.28-7.15 (m, 4 H), 3.69-3.59 (m, 2 H), 3.62 (s, 3 H), 
3.48 (app d, 1 H, J = 3.6 Hz), 2.76 (ABX, 1 H, J = 13.7, 7.3 Hz), 2.70 (ABX, 1 H, J = 13.8, 7.9 
Hz), 2.50-2.39 (m, 1 H), 1.67 (s, 2 H), 1.16 (s, 9 H); 13C NMR (CDCl3) δ 176.3, 139.9, 135.6, 
 54 
133.2, 129.7, 129.0, 128.3, 127.7, 126.0, 62.9, 54.6, 51.7, 45.6, 34.6, 26.8, 19.2; HRMS (ESI) 
m/z calcd for C28H36NO3Si (M+H) 462.2482, found 462.2464. 
CbzHN
O
OMe
Ph OTBDPS
 
(5S,6R)-Methyl 6-benzyl-10,10-dimethyl-3-oxo-1,9,9-triphenyl-2,8-dioxa-4-aza-9- 
silaundecane-5-carboxylate (1-91). A solution of 1-90 (7.47 g, 16.2 mmol) and NaHCO3 (6.80 
g, 77.3 mmol) in EtOAc (660 mL) and water (660 mL) at 0 oC was treated with benzyl 
chloroformate (2.57 mL, 18.5 mmol) in EtOAc (260 mL). The reaction mixture was warmed to 
room temperature, stirred for 14 h, and diluted with EtOAc. The aqueous phase was extracted 
with EtOAc (3x). The combined organic phases were washed with brine, dried (Na2SO4), filtered 
and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc=6:1 to 4:1) yielded 8.77 g (91%) of crude 1-91 as a clear oil: [α]D25 -6.7 (c 2.3, 
CHCl3); IR (neat) 3411, 3069, 2952, 1731, 1499 cm-1; 1H NMR (CDCl3) δ 7.75-7.68 (m, 4 H), 
7.49-7.30 (m, 12 H), 7.30-7.13 (m, 4 H), 6.58 (d, 1 H, J = 9.0 Hz), 5.29-5.20 (m, 2 H), 4.59 (dd, 
1 H, J = 8.9, 3.5 Hz), 3.79 (dd, 1 H, J = 10.9, 2.7 Hz), 3.67 (s, 3 H), 3.73-3.58 (m, 1 H), 2.93 
(ABX, 1 H, J = 13.8, 7.8 Hz), 2.86 (ABX, 1 H, J = 13.8, 7.6 Hz), 2.58-2.45 (m, 1 H), 1.19 (s, 9 
H); 13C NMR (CDCl3) δ 172.5, 156.6, 138.9, 136.6, 135.7, 132.2, 130.0, 129.9, 129.0, 128.5, 
128.4, 127.8, 126.3, 66.7, 63.8, 56.3, 52.1, 43.2, 34.9, 26.9, 19.1; HRMS (ESI) m/z calcd for 
C36H41NO5SiNa (M+Na) 618.2621, found 618.2652. 
CbzHN
O
OH
Ph OTBDPS
 
(5S,6R)-6-Benzyl-10,10-dimethyl-3-oxo-1,9,9-triphenyl-2,8-dioxa-4-aza-9- 
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silaundecane-5-carboxylic acid (1-92). A solution of 1-91 (8.77 g, 14.7 mmol) in 
THF:H2O=3:1 (v/v, 119 mL) was treated with LiOH·H2O (0.771 g, 18.4 mmol) and stirred at 
room temperature for 36 h. THF was evaporated and the residue was treated with 1 M aqueous 
KHSO4 (22.3 mL). The resulting solution was extracted with EtOAc (3x), dried (Na2SO4), 
filtered and concentrated under reduced pressure to yield 8.22 g (96%) of crude 1-92 as a clear 
oil: [α]D25 –8.2 (c 2.2, CH2Cl2); IR (neat) 3404, 3069, 3030, 2930, 2858, 1720, 1509, 1471, 1427 
cm-1; 1H NMR (CDCl3) δ 8.25 (br s, 1 H), 7.58-7.54 (m, 4 H), 7.40-6.97 (m, 16 H), 6.45 (d, 1 H, 
J = 8.8 Hz), 5.17 (AB, 1 H, J = 12.6 Hz), 5.14 (AB, 1 H, J = 12.5 Hz), 4.46 (dd, 1 H, J = 8.6, 2.9 
Hz), 3.71 (app d, 1 H, J = 10.8 Hz), 3.48 (dd, 1 H, J = 10.8, 3.9 Hz), 2.81 (ABX, 1 H, J = 13.8, 
7.2 Hz), 2.73 (ABX, 1 H, J = 13.7, 7.6 Hz), 2.49-2.38 (m, 1 H), 1.02 (s, 9 H); 13C NMR (CDCl3) 
δ 177.3, 156.9, 139.0, 136.6, 135.9, 132.2, 130.1, 129.2, 128.7, 128.6, 128.0, 126.6, 67.1, 64.0, 
56.4, 43.1, 35.1, 27.0, 19.2; HRMS (ESI) m/z calcd for C35H39NO5SiNa (M+Na) 604.2495, 
found 604.2517. 
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(2R,3S)-Methyl 2-((2S,3R)-3-benzyl-2-(benzyloxycarbonylamino)-4-(tert-butyl 
diphenylsilyloxy)butanamido)-3-hydroxybutanoate (1-93). A solution of 1-92 (3.20 g, 5.50 
mmol) and N-methylmorpholine (0.664 mL, 6.10 mmol) in DCM (21.0 mL) at -20 oC was 
treated with isobutylchloroformate (0.787 mL, 6.10 mmol). After 5 min, a suspension of D-
threonine methyl ester hydrochloride73 (1.12 g, 6.60 mmol) and Et3N (0.934 mL, 6.60 mmol) in 
DMF (10.0 mL) was added dropwise. The reaction mixture was warmed to room temperature, 
stirred for 1 h and quenched with saturated NaHCO3 solution. The mixture was diluted with 
EtOAc and the organic layer was washed with 0.1 M HCl, saturated aqueous NaHCO3 and brine, 
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dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc=1:1) yielded 3.83 g (100%) of crude 1-93 as a clear 
oil: [α]D25 -12.6 (c 2.0, CHCl3); IR (neat) 3369, 3069, 3029, 2953, 2931, 1731, 1669, 1514, 1428 
cm-1; 1H NMR (CDCl3) δ 7.68-7.57 (m, 4 H), 7.46-6.92 (m, 17 H), 5.48-5.08 (m, 2 H), 4.56 (app 
d, 1 H, J = 8.5 Hz), 4.41-4.26 (m, 2 H), 3.98 (app d, 1 H, J = 9.6 Hz), 3.67 (s, 3 H), 3.76-3.56 (m, 
1 H), 2.88 (dd, 1 H, J = 13.5, 7.9 Hz), 2.73 (dd, 1 H, J = 13.7, 7.3 Hz), 2.62-2.49 (m, 1 H), 2.26 
(d, 1 H, J = 4.6 Hz), 1.20-1.05 (m, 3 H), 1.12 (s, 9 H), 0.94 (d, 1 H, J = 6.7 Hz); 13C NMR 
(CDCl3) δ 171.9, 171.0, 156.8, 139.0, 136.6, 136.0, 135.9, 132.4, 130.2, 130.1, 129.1, 128.7, 
128.3, 128.0, 126.5, 68.3, 67.3, 64.5, 58.2, 57.5, 52.7, 42.3, 35.1, 27.1, 19.3, 19.2; HRMS (ESI) 
m/z calcd for C40H48N2O7SiNa (M+Na) 719.3124, found 719.3129. 
CbzHN
O
N COOMe
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(4R,5R)-Methyl 2-((5S,6R)-6-benzyl-10,10-dimethyl-3-oxo-1,9,9-triphenyl-2,8- dioxa-
4-aza-9-silaundecan-5-yl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-94). A solution of 
1-93 (0.908 g, 1.30 mmol) and Burgess reagent (0.336 g, 1.43 mmol) in THF (7.65 mL) was 
heated to 75 oC for 2.5 h in a sealed tube. The resulting mixture was evaporated onto SiO2 and 
purified by chromatography on SiO2 (Hexanes:EtOAc=2:1 to 1:1) to yield 0.701 g (79%) of 1-94 
as a clear oil: [α]D25 –35.0 (c 2.0, CHCl3); IR (neat) 3408, 3069, 3029, 2953, 2931, 2857, 1731, 
1662, 1506, 1454 cm-1; 1H NMR (CDCl3) δ 7.67-7.59 (m, 4 H), 7.46-7.29 (m, 12 H), 7.24-7.15 
(m, 2 H), 7.10-7.05 (m, 2 H), 6.51 (d, 1 H, J = 8.7 Hz), 5.23 (AB, 1 H, J = 12.5 Hz), 5.15 (AB, 1 
H, J = 12.5 Hz), 4.88-4.75 (m, 1 H), 4.75-4.60 (m, 2 H), 3.94 (dd, 1 H, J = 10.8, 2.6 Hz), 3.67 (s, 
3 H), 3.72-3.58 (m, 1 H), 2.95 (ABX, 1 H, J = 13.8, 7.0 Hz), 2.84 (ABX, 1 H, J = 13.9, 7.9 Hz), 
2.44-2.26 (m, 1 H), 1.28 (d, 3 H, J =6.3 Hz), 1.10 (s, 9 H); 13C NMR (CDCl3) δ 170.0, 169.9, 
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156.3, 139.2, 136.8, 135.80, 135.75, 132.7, 132.5, 129.9, 129.8, 129.1, 128.5, 128.4, 127.9, 
127.7, 126.3, 78.5, 71.3, 66.8, 63.6, 52.4, 52.0, 44.4, 34.7, 27.1, 19.3, 16.0; HRMS (ESI) m/z 
calcd for C40H47N2O6Si (M+H) 679.3203, found 679.3181. 
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(2S,3R)-Methyl 2-((2S,3R)-3-benzyl-2-(benzyloxycarbonylamino)-4-(tert-butyl 
diphenylsilyloxy)butanamido)-3-hydroxybutanoate (1-96). A solution of 1-92 (1.12 g, 1.93 
mmol) and N-methylmorpholine (0.232 mL, 2.12 mmol) in DCM (7.60 mL) at -20 oC was 
treated with isobutylchloroformate (0.275 mL, 2.12 mmol). After 5 min, a suspension of D-
threonine methyl ester hydrochloride (0.396 g, 2.12 mmol) and Et3N (0.327 mL, 2.12 mmol) in 
DMF (3.54 mL) was added dropwise. The reaction mixture was warmed to room temperature, 
stirred for 1 h and quenched with saturated aqueous NaHCO3 solution. The mixture was diluted 
with EtOAc and the organic layer was washed with 0.1 M HCl, saturated aqueous NaHCO3 and 
brine, dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc=1:1) yielded 1.24 g (93%) of 1-96 as a clear oil: 
[α]D25 -8.48 (c 2.0, DCM); IR (neat) 3368, 3066, 2953, 2930, 2891, 2857, 1728, 1689, 1666, 
1514, 1471, 1454 cm-1; 1H NMR (CDCl3) δ 1H NMR (CDCl3) δ 7.70-7.54 (m, 4 H), 7.45-7.28 
(m, 12 H), 7.20-7.13 (m, 2 H), 7.08-6.95 (m, 2 H), 6.64 (d, 1 H, J = 7.3 Hz) 5.20 (AB, 1 H, J = 
12.3 Hz), 5.16 (AB, 1 H, J = 12.1 Hz), 4.54 (dd, 1 H, J = 8.6, 2.4 Hz), 4.44 (dd, 1 H, J = 7.1, 4.6 
Hz), 4.35-4.25 (m, 1 H), 3.89 (dd, 1 H, J = 10.9, 2.7 Hz), 3.73 (s, 3 H), 3.81-3.60 (m, 1 H), 2.86 
(dd, 1 H, J = 14.0, 7.0 Hz), 2.63 (dd, 1 H, J = 13.7, 8.2 Hz), 2.57-2.45 (m, 1 H), 2.03 (d, 1 H, J = 
5.4 Hz), 1.14 (dd, 3 H, J = 6.4 Hz), 1.10 (s, 9 H), 0.94 (d, 1 H, J = 6.8 Hz); 13C NMR (CDCl3) 
δ172.0, 171.2, 156.7, 139.2, 136.7, 135.9, 132.8, 132.7, 130.1, 129.1, 128.7, 128.3, 128.2, 
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128.01, 127.98, 126.5, 76.5, 68.3, 67.3, 64.3, 57.5, 52.7, 42.9, 34.7, 27.2, 20.3, 19.4; HRMS 
(ESI) m/z calcd for C40H48N2O7SiNa (M+Na) 719.3129, found 719.3107.  
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(4S,5S)-Methyl 2-((5S,6R)-6-benzyl-10,10-dimethyl-3-oxo-1,9,9-triphenyl-2,8-dioxa-
4-aza-9-silaundecan-5-yl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-97). A solution of 
1-96 (56.8 mg, 0.0815 mmol) and Burgess reagent (21.0 mg, 0.0900 mmol) in THF (0.480 mL) 
was heated to 75 oC for 2.5 h in a sealed tube. The resulting mixture was evaporated onto SiO2 
and purified by chromatography on SiO2 (Hexanes:EtOAc=2:1 to 1:1) to yield 32.4 mg (59%) of 
1-97 as a clear thick oil: [α]D25 +0.22 (c 0.89, DCM); IR (neat) 3407, 3230, 3030, 2952, 2931, 
2857, 1727, 1663, 1603, 1588, 1454 cm-1; 1H NMR (CDCl3) δ 7.76-7.61 (m, 4 H), 7.50-7.28 (m, 
12 H), 7.23-7.13 (m, 2 H), 7.10-7.05 (m, 2 H), 6.62 (d, 1 H, J = 8.6 Hz), 5.22 (AB, 1 H, J = 12.5 
Hz), 5.11 (AB, 1 H, J = 12.5 Hz), 4.90-4.75 (m, 1 H), 4.77 (d, 1 H, J = 8.4, 3.5 Hz), 4.61 (dd, 1 
H, J = 7.1, 2.8 Hz), 3.61 (s, 3 H), 3.66-3.57 (m, 1 H), 2.92 (ABX, 1 H, J = 13.8, 7.5 Hz), 2.85 
(ABX, 1 H, J = 13.8, 7.5 Hz), 2.35-2.25 (m, 1 H), 1.21 (d, 3 H, J =6.2 Hz), 1.10 (s, 9 H); 13C 
NMR (CDCl3) δ170.1, 156.4, 139.5, 136.9, 136.0, 132.7, 130.1, 129.9, 129.3, 128.7, 128.5, 
128.00, 127.95, 127.88, 126.4, 78.6, 71.5, 66.9, 64.5, 53.6, 52.2, 52.1, 43.9, 34.8, 27.1, 19.4, 
16.1; HRMS (ESI) m/z calcd for C40H47N2O6Si (M+H) 679.3203, found 679.3201. 
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(2S,3S)-Methyl 2-((2S,3R)-3-benzyl-2-(benzyloxycarbonylamino)-4-(tert-butyl 
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diphenylsilyloxy)butanamido)-3-hydroxybutanoate (1-98). A solution of 1-97 (32.4 mg, 
0.0477 mmol) THF (1.82 mL) was treated with 0.5 M HCl (1.82 mL, 0.910 mmol). After 15 
min, the pH was adjusted to 9.5 by 1 M K2CO3. The reaction mixture was stirred for 16 h and 
neutralized by 1 M HCl. THF was evaporated and the residue was extracted with EtOAc (2x). 
The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc=2:1 to 1:2) 
yielded 31.0 mg (93%) of crude 1-98 as a clear oil: [α]D25 -1.68  (c 1.1, DCM); IR (neat) 3390, 
3068, 2952, 2930, 2359, 2341, 1739, 1711, 1683, 1514, 1454 cm-1; 1H NMR (CDCl3) δ 7.75-7.53 
(m, 4 H), 7.49-7.27 (m, 12 H), 7.23-7.15 (m, 2 H), 7.02-6.95 (m, 2 H), 6.82 (d, 1 H, J = 7.1 Hz), 
5.22 (AB, 1 H, J = 12.3 Hz), 5.17 (AB, 1 H, J = 12.4 Hz), 4.58 (dd, 1 H, J = 6.7, 3.5 Hz), 4.34 
(dd, 1 H, J = 6.9, 4.7 Hz), 4.18-4.07 (m, 1 H), 3.91 (dd, 1 H, J = 10.9, 2.1 Hz), 3.76 (s, 3 H,), 
3.80-3.60 (m, 1 H), 2.85 (dd, 1 H, J = 13.4, 7.1 Hz), 2.68 (dd, 1 H, J = 13.7, 7.9 Hz), 2.56-2.44 
(m, 1 H), 1.76-1.62 (m, 1 H), 1.10 (s, 9 H), 1.20-1.10 (m, 3 H); 13C NMR (CDCl3) δ172.0, 171.2, 
156.7, 139.1, 136.6, 135.9, 132.7, 132.6, 130.1, 129.1, 128.7, 128.3, 128.2, 128.00, 127.97, 
126.5, 77.4, 68.2, 67.3, 64.2, 57.8, 57.4, 52.7, 42.8, 34.7, 27.2, 20.3, 19.3; HRMS (ESI) m/z 
calcd for C40H48N2O7SiNa (M+Na) 719.3129, found 719.3146. 
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(4S,5R)-Methyl 2-((5S,6R)-6-benzyl-10,10-dimethyl-3-oxo-1,9,9-triphenyl-2,8-dioxa-
4-aza-9-silaundecan-5-yl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-99). A solution of 
1-98 (31.0 mg, 0.0440 mmol) and Burgess reagent (11.5 mg, 0.0484 mmol) in THF (0.260 mL) 
was heated to 75 oC for 2.5 h in a sealed tube. The resulting mixture was evaporated onto SiO2 
and purified by chromatography on SiO2 (Hexanes:EtOAc=2:1 to 1:1) to yield 22.0 mg (74%) of 
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crude 1-99 as a clear oil: [α]D25 +19.1 (c 1.0, DCM); IR (neat) 3406, 3231, 3068, 3030, 2998, 
2952, 2930, 2857, 1727, 1659, 1497, 1471 cm-1; 1H NMR (CDCl3) δ 7.68-7.60 (m, 4 H), 7.45-
7.27 (m, 12 H), 7.23-7.13 (m, 2 H), 7.08-7.02 (m, 2 H), 6.56 (d, 1 H, J = 8.7 Hz), 5.23 (AB, 1 H, 
J = 12.5 Hz), 5.12 (AB, 1 H, J = 12.5 Hz), 4.82-4.71 (m, 1 H), 4.63 (dd, 1 H, J = 8.4, 3.5 Hz), 
4.29 (d, 1 H, J = 7.1 Hz), 3.97 (dd, 1 H, J = 10.6, 2.6 Hz), 3.65 (s, 3 H), 3.59 (dd, 1 H, J =10.6, 
3.2), 2.94-2.78 (m, 1 H), 2.35-2.28 (m, 1 H), 1.39 (d, 3 H, J =6.3 Hz), 1.10 (s, 9 H); 13C NMR 
(CDCl3) δ 171.5, 168.3, 156.4, 139.4, 136.9, 136.0, 132.7, 130.1, 130.0, 129.3, 128.7, 128.6, 
128.0, 137.9, 126.4, 79.9, 74.8, 66.9, 63.7, 52.6, 52.2, 44.1, 34.8, 27.1, 21.1, 19.4; HRMS (ESI) 
m/z calcd for C40H47N2O6Si (M+H) 679.3203, found 679.3193. 
CbzHN
O
N COOMe
Ph OH
 
(4R,5R)-Methyl 2-((1S,2R)-2-benzyl-1-(benzyloxycarbonylamino)-3- 
hydroxypropyl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-100). A solution of 1-94 (16.0 
mg, 0.0236 mmol) in THF (0.250 mL) was treated with TBAF (1.0 M in THF, 47.1 µL, 0.0471 
mmol) and stirred at room temperature for 4 h. Water (1 mL) was added and the mixture was 
extracted with EtOAc (3x). The combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:EtOAc=1:1 to 100% EtOAc) yielded 7.4 mg (70%) of 1-100 (impure) as a clear 
oil: 1H NMR (CDCl3) δ 7.45-7.11 (m, 10 H), 6.08 (d, 1 H, J = 8.7 Hz), 5.18 (AB, 1 H, J = 12.1 
Hz), 5.10 (AB, 1 H, J = 12.4 Hz), 4.87-4.76 (m, 1 H), 4.68-4.58 (m, 1 H), 4.30 (d, 1 H, J = 6.6 
Hz), 3.90-3.60 (m, 1 H), 3.77 (s, 3 H), 3.55 (dd, 1 H, J =11.5, 3.2), 2.93-2.67 (m, 4 H), 2.36-2.18 
(m, 2 H), 1.51-1.20 (m, 7 H); 13C NMR (CDCl3) δ 171.6, 171.3, 170.0, 156.6, 139.6, 136.5, 
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129.3, 129.0, 128.5, 128.1, 126.3, 80.2, 73.9, 67.1, 60.8, 60.5, 52.7, 51.7, 44.4, 34.5, 21.0, 14.3; 
HRMS (ESI) m/z calcd for C24H28N2O6Na (M+Na)  463.1845, found 463.1852. 
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Homocyclic trimer (1-101). A solution of 1-100 (11.7 mg, 0.0266 mmol) and 10% 
Pd(OH)2/C (2.4 mg) in MeOH (0.23 mL) was exposed to H2 (1 atm) for 90 min. The mixture 
was filtered through celite and the filtrate was treated with aqueous NaOH (1 M, 33.0 µL, 0.0330 
mmol) and stirred at room temperature for 2.5 h. After addition of NaHCO3 (11.9 mg, 0.135 
mmol), the solvent was evaporated under reduced pressure. The residual water was removed by 
azeotropic distillation with benzene (2x). The residue was dissolved in DMF (2.00 mL), treated 
with DPPA (8.8 µL, 0.0410 mmol) at 0 oC and stirred for 24 h at 0 oC, 24 h at 4 oC and 24 h at 
room temperature. The reaction mixture was quenched with saturated aqueous NaHCO3 (0.250 
mL) and stirring was continued for 1 h. The solvent was evaporated under reduced pressure and 
the residue was partitioned between water and EtOAc. The aqueous layer was extracted with 
EtOAc (2x) and the combined organic layers were washed with brine, dried (Na2SO4), filtered 
and concentrated under reduced pressure. Purification by chromatography on SiO2 
(DCM:MeOH=18:1) yielded 0.6 mg (8%) of 1-101 as a clear solid: 1H NMR (CDCl3) δ 7.86 (d, 
1 H, J = 8.4 Hz), 7.32-6.92 (m, 5 H), 5.00-4.87 (m, 1 H), 4.87-4.73 (m, 1 H), 4.30 (dd, 1 H, J = 
8.5, 1.9 Hz), 3.67-3.39 (m, 3 H), 2.93 (dd, 1 H, J =13.6, 4.9), 2.70-2.55 (m, 1 H), 2.39 (dd, 1 H, J 
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= 13.8, 9.6 Hz), 1.61 (d, 3 H, J = 6.1 Hz); HRMS (ESI) m/z calcd for C45H55N6O9 (M+H)  
823.4031, found 823.4009. 
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(4S,5R)-Methyl 2-((1S,2R)-2-benzyl-1-((4S,5R)-2-((5S,6R)-6-benzyl-10,10-dimethyl- 
3-oxo-1,9,9-triphenyl-2,8-dioxa-4-aza-9-silaundecan-5-yl)-5-methyl-4,5-dihydrooxa-zole-4-
carboxamido)-3-(tert-butyldiphenylsilyloxy)propyl)-5-methyl-4,5-dihydro-oxazole-4-
carboxylate (1-106). A solution of 1-94 (0.331 g, 0.490 mmol) in 4.30 mL MeOH was treated 
with 1 M aqueous NaOH (0.586 mL, 0.586 mmol). The reaction mixture was stirred at room 
temperature for 90 min. 5% citric acid was added and the resulting solution was extracted with 
EtOAc (3x), dried (Na2SO4), filtered and concentrated under reduced pressure. A solution of the 
crude product and N-methylmorpholine (0.0432 mL, 0.541 mmol) in DCM (1.40 mL) at -20 oC 
was treated with isobutylchloroformate (0.0512 mL, 0.541 mmol). After 5 min, a solution of the 
oxazoline with free N-terminal (0.490 mmol, prepared by the hydrogenolysis of 1-94 (0.243 g, 
0.490 mmol) with 10% Pd(OH)2/C (24.3 mg) in MeOH (4.50 mL)) in DCM (0.660 mL) was 
added dropwise. The reaction mixture was warmed to room temperature, stirred for 1 h and 
quenched with saturated aqueous NaHCO3 solution. The mixture was diluted with EtOAc and 
the organic layer was washed with saturated aqueous NaHCO3 and brine, dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc=3:1 to 1:1) yielded 0.213 g (50%) of 1-106 as a clear oil: [α]D25 +3.0 (c 0.1, 
DCM); IR (neat) 3399, 3068, 3028, 2930, 2891, 1728, 1685, 1660, 1509 cm-1; 1H NMR (CDCl3) 
δ 7.62-7.49 (m, 8 H), 7.44-6.90 (m, 32 H), 6.50 (d, 1 H, J = 7.6 Hz), 5.10-5.00 (m, 2 H), 4.90-
4.61 (m, 6 H), 4.15 (d, 1 H, J = 7.5 Hz), 3.87 (app d, 1 H, J = 10.3 Hz), 3.66 (s, 3 H), 3.76-3.61 
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(m, 1 H), 3.59-3.47 (m, 2 H), 2.90-2.64 (m, 4 H), 2.39-2.17 (m, 2 H), 1.39 (d, 1 H, J = 6.2 Hz), 
1.28 (d, 3 H, J =6.2 Hz), 1.07 (s, 9 H), 1.06 (s, 9 H); 13C NMR (CDCl3) δ 170.9, 170.2, 168.9, 
168.7, 156.1, 139.2, 136.7, 136.00, 135.9, 135.8, 133.5, 133.3, 132.5, 130.0, 129.8, 129.3, 129.2, 
128.7, 128.5, 127.9, 127.8, 127.7, 126.5, 78.4, 77.4, 75.3, 71.4, 67.0, 63.5, 1.9, 52.2, 48.9, 44.6, 
34.6, 34.8, 27.2, 27.1, 22.0, 19.4, 16.3, 14.4; HRMS (ESI) m/z calcd for C71H83N4O9Si2 (M+H) 
1191.5699, found 1191.5710. 
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(4R,5R)-Methyl 2-((S)-1-(benzyloxycarbonylamino)-2-methylpropyl)-5-methyl-4,5- 
dihydrooxazole-4-carboxylate (1-110). Compound 1-110 was prepared from Cbz-Val-OH in 
59% overall yield according to the literature45: [α]D25 -38 (c 0.35, DCM); IR (neat) 3324, 3033, 
2962, 2359, 1727, 1662, 1586, 1526, 1455 cm-1; 1H NMR (CDCl3) δ 7.37-7.25 (m, 5 H), 5.43 (d, 
1 H, J = 9.0 Hz), 5.12 (AB, 1 H, J = 12.1 Hz), 5.08 (AB, 1 H, J = 12.3 Hz), 4.94-4.83 (m, 1 H), 
4.76 (d, 1 H, J = 10.1 Hz), 4.42 (dd, 1 H, J = 9.0, 5.6 Hz), 3.72 (s, 3 H), 2.18-2.03 (m, 1 H), 1.28 
(d, 1 H, J = 6.3 Hz), 0.98 (d, 3 H, J = 6.8 Hz), 0.94 (d, 3 H, J = 6.8 Hz); 13C NMR (CDCl3) δ 
169.6, 168.6, 155.8, 136.2, 128.2, 128.1, 128.0, 127.7, 77.9, 70.5, 66.4, 54.5, 51.6, 31.3, 18.4, 
17.5, 15.7; MS (EI) m/z (rel intensity) 348 (20%), 198 (50%),91 (100%),; HRMS (EI) m/z calcd 
for C18H24N2O5 348.1685, found 348.1696. 
CbzHN
O
N C N
H
O
N COOMe
O
 
(4R,5R)-Methyl 2-((S)-1-((4S,5R)-2-((S)-1-(benzyloxycarbonylamino)-2-methyl- 
 64 
propyl)-5-methyl-4,5-dihydrooxazole-4-carboxamido)-2-methylpropyl)-5-methyl-4,5-
dihydrooxazole-4-carboxylate (1-112). A solution of 1-110 (2.69 g, 7.70 mmol) in MeOH (67.2 
mL) was treated with 1 M aqueous NaOH (18.5 mL, 18.5 mmol) at room temperature and the 
mixture was stirred for 90 min. NaHCO3 (3.40 g, 38.5 mmol) was added and the solvent was 
evaporated under reduced pressure. The water was removed by azeotropic distillation with 
benzene (2x). The residue was dissolved in DMF (78.0 mL) together with the oxazoline with free 
N-terminal (15.4 mmol, prepared by the hydrogenolysis of 1-110 (5.37 g, 15.4 mmol) with 10% 
Pd/C (0.537 g) in MeOH (134 mL)). The resulting solution was cooled to 0 oC and treated with 
DIPEA (3.09 mL, 18.5 mmol) followed by DPPA (2.51 mL, 11.6 mmol). The reaction mixture 
was allowed to warm to room temperature and stirred for 48 h. The reaction mixture was 
quenched with saturated aqueous NaHCO3 (25 mL) and stirring was continued for 1 h. The 
solvent was evaporated under reduced pressure and the residue was partitioned between water 
and EtOAc. The aqueous layer was extracted with EtOAc (2x) and the combined organic layers 
were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc=1:1 to 100% EtOAc, all with 1% 
Et3N) yielded 1.94 g (47%) of 1-112 as a yellow oil: [α]D25 -10.4 (c 1.1, DCM); IR (neat) 3324, 
3034, 2964, 2934, 2875, 2359, 2341, 1724, 1658, 1521, 1455 cm-1; 1H NMR (CDCl3) δ 7.42-
7.28 (m, 5 H), 6.90 (d, 1 H, J = 9.2 Hz), 5.40 (d, 1 H, J = 8.8 Hz), 5.15 (AB, 1 H, J = 11.9 Hz), 
5.10 (AB, 1 H, J = 12.1 Hz), 4.89-4.82 (m, 1 H), 4.81-4.73 (m, 2 H), 4.68 (dd, 1 H, J = 9.4, 6.2 
Hz), 4.41 (dd, 1 H, J = 8.4, 4.9 Hz), 4.18 (app d, 1 H, J = 7.7 Hz), 3.74 (s, 3 H), 2.20-2.03 (m, 2 
H), 1.50 (d, 3 H, J = 6.2 Hz), 1.32 (d, 3 H, J = 6.4 Hz), 1.03-0.76 (m, 12 H); 13C NMR (CDCl3) δ 
171.0, 170.1, 168.8, 168.6, 156.2, 136.5, 128.8, 128.4, 81.0, 78.5, 74.8, 71.2, 67.3, 54.9, 52.6, 
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52.2, 32.8, 18.9, 18.1, 17.8, 16.2; HRMS (ESI) m/z calcd for C27H38N4O7 (M+H) 531.2819, 
found 531.2819. 
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(4R,5R)-Methyl 2-((S)-1-((4S,5R)-2-((S)-1-((4S,5R)-2-((5S,6R)-6-benzyl-10,10- 
dimethyl-3-oxo-1,9,9-triphenyl-2,8-dioxa-4-aza-9-silaundecan-5-yl)-5-methyl-4,5- 
dihydrooxazole-4-carboxamido)-2-methylpropyl)-5-methyl-4,5-dihydrooxazole-4- 
carboxamido)-2-methylpropyl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-113). A 
solution of 1-94 (1.24 g, 1.83 mmol) in MeOH (16.0 mL) was treated with 1 M aqueous NaOH 
(2.16 mL, 2.16 mmol) at room temperature and the mixture was stirred for 2 h. After addition of 
NaHCO3 (0.791 g, 9.15 mmol), the solvent was evaporated under reduced pressure. The water 
was removed by azeotropic distillation with benzene (2x). The residue was dissolved in DMF 
(36.6 mL) together with the oxazoline dimer with free N-terminal (3.66 mmol, prepared by the 
hydrogenolysis of 1-112 (1.94 g, 3.66 mmol) with 10% Pd(OH)2/C (0.194 g) in MeOH (44 mL)). 
The resulting solution was cooled to 0 oC and treated with DIPEA (1.45 mL, 9.32 mmol) 
followed by DPPA (1.19 mL, 5.52 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 48 h. The reaction mixture was quenched with saturated aqueous 
NaHCO3 (15 mL) and stirring was continued for 1 h. The solvent was evaporated under reduced 
pressure and the residue was partitioned between water and EtOAc. The aqueous layer was 
extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:EtOAc=1:2 to 100% EtOAc, all with 1% Et3N) yielded 1.54 g (80%) of 1-113 as 
a yellow oil: [α]D25 +6.5 (c 0.40, DCM); IR (neat) 3390, 3305, 3030, 2962, 2931, 2857, 1727, 
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1680, 1659, 1518, 1454, 1428 cm-1; 1H NMR (CDCl3) δ 7.62-7.54 (m, 4 H), 7.46-7.26 (m, 12 H), 
7.24-7.14 (m, 2 H), 7.06-6.90 (m, 4 H), 6.53 (d, 1 H, J = 7.8 Hz), 5.16 (AB, 1 H, J = 12.2 Hz), 
5.12 (AB, 1 H, J = 12.5 Hz), 4.95-4.83 (m, 1 H), 4.82-4.58 (m, 5 H), 4.57-4.47 (m, 1 H), 4.18 
(app d, 1 H, J = 7.5 Hz), 4.15-4.06 (m, 1 H), 3.93-3.82 (m, 1 H), 3.76-3.65 (m, 1 H), 3.72 (s, 3 
H), 3.59 (dd, 1 H, J = 10.7, 4.6 Hz), 2.97-2.69 (m, 2 H), 2.37-2.25 (m, 1 H), 2.18-1.97 (m, 2 H), 
1.47 (d, 3 H, J = 5.7 Hz), 1.41 (d, 3 H, J = 6.2 Hz), 1.30 (d, 3 H, J = 6.4 Hz), 1.07 (s, 9 H), 0.96 
(d, 3 H, J = 6.8 Hz), 0.94 (d, 3 H, J = 5.2 Hz), 0.90 (d, 3 H, J = 7.2 Hz), 0.87 (d, 3 H, J = 7.2 
Hz); 13C NMR (CDCl3) δ 171.1, 171.0, 170.1, 169.1, 168.4, 168.0, 156.1, 39.0, 136.6, 135.7, 
135.6, 132.5, 132.4, 130.0, 129.9, 129.0, 128.6, 128.5, 128.1, 127.8, 126.4, 80.8, 80.5, 78.2, 75.0, 
74.7, 71.0, 66.8, 63.4, 60.4, 52.74, 52.65, 52.57, 52.1, 44.2, 34.6, 31.4, 31.2, 27.0, 21.9, 21.8, 
21.1, 19.2, 18.9, 18.3, 18.1, 16.1, 14.3; HRMS (ESI) m/z calcd for C58H75N6O10Si (M+H) 
1043.5314, found 1043.5310. 
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Cyclo[γ-phenyl-allo-homoThr(TBDPS)-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-
Thr(oxaz)] (1-114). A solution of 1-113 (1.16 g, 1.12 mmol) and 10% Pd(OH)2/C (117 mg) was 
exposed to H2 (1 atm) for 90 min. The mixture was filtered through celite and the filtrate was 
treated with 1 M aqueous NaOH (1.34 mL, 1.34 mmol) and stirred at room temperature for 2 h. 
After addition of NaHCO3 (0.468 g, 5.60 mmol), the solvent was evaporated under reduced 
pressure. The residual water was removed by azeotropic distillation with benzene (2x). The 
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residue was dissolved in DMF (84.0 mL), treated with DPPA (0.362 mL, 1.60 mmol) at 0 oC and 
stirred for 24 h at 0 oC, 24 h at 4 oC and 24 h at room temperature. The reaction mixture was 
quenched with saturated aqueous NaHCO3 (15.0 mL) and stirring was continued for 1 h. The 
solvent was evaporated under reduced pressure and the residue was partitioned between water 
and EtOAc. The aqueous layer was extracted with EtOAc (2x) and the combined organic layers 
were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc=1:1 with 1% Et3N) yielded 0.589 g 
(60%) of 1-114 as a white solid: mp 116.0-119.0 oC (DCM); [α]D25 +105 (c 0.10, DCM); IR 
(KBr) 3376, 3070, 3027, 2962, 2931, 2858, 1738, 1690, 1651, 1589, 1525 cm-1; 1H NMR 
(CDCl3) δ 7.94 (d, 1 H, J = 6.9 Hz), 7.72 (d, 1 H, J = 6.7 Hz), 7.68-7.63 (m, 1 H), 7.60-7.55 (m, 
1 H), 7.47-7.27 (m, 9 H), 7.22-7.10 (m, 3 H), 7.05-7.00 (m, 2 H), 5.24-5.16 (m, 1 H), 5.05-4.90 
(m, 1 H), 4.85-4.72 (m, 1 H), 4.72-4.52 (m, 3 H), 4.28 (dd, 1 H, J = 8.4, 2.0 Hz), 4.20 (dd, 2 H, J 
= 8.6, 1.8 Hz), 3.78-3.69 (m, 1 H), 3.48 (dd, 1 H, J = 10.0, 6.4 Hz), 2.77-2.59 (m, 2 H), 2.38-2.06 
(m, 3 H), 1.66-1.46 (m, 9 H), 1.02 (s, 9 H), 0.79 (d, 3 H, J = 6.9 Hz), 0.71 (d, 3 H, J = 6.9 Hz) , 
0.67 (d, 3 H, J = 6.9 Hz) , 0.61 (d, 3 H, J = 6.9 Hz); 13C NMR (CDCl3) δ 170.7, 170.4, 170.3, 
168.7, 168.5, 168.4, 139.1, 135.7, 133.3, 129.9, 129.8, 128.8, 128.5, 127.9, 127.8, 126.4, 82.9, 
82.3, 77.4, 74.2, 73.9, 73.7, 62.7, 52.5, 48.1, 46.4, 32.8, 31.7, 31.5, 26.9, 22.2, 22.1, 21.9, 21.3, 
19.4, 18.7, 18.6, 17.03, 16.95, 14.4; HRMS (ESI) m/z calcd for C49H65N6O7Si (M+H) 877.4684, 
found 877.4692. 
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Cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] (1-
115). A solution of 1-114 (0.372 g, 0.424 mmol) in THF (4.43 mL) was treated with TBAF (1.0 
M in THF, 0.848 mL, 0.848 mmol). The mixture was stirred at room temperature for 4 h. Water 
(4.00 mL) was added and the mixture was extracted with EtOAc (3x). The combined organic 
layers were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (100% EtOAc with 1% Et3N) yielded 0.236 g (87%) of 
crude 1-115 as a white solid: mp 117.0-122.0 oC (DCM); [α]D25 +148 (c 0.12, DCM); IR (KBr) 
3370, 2963, 2930, 2873, 1686, 1652, 1528, 1454 cm-1; 1H NMR (CDCl3) δ 8.02 (d, 1 H, J = 7.6 
Hz), 7.80 (d, 1 H, J = 7.8 Hz), 7.73 (d, 1 H, J = 7.9 Hz), 7.34-7.07 (m, 5 H), 4.96-4.74 (m, 1 H), 
4.68 (app t, 1 H, J = 2.9 Hz), 4.65 (app t, 1 H, J = 2.6 Hz), 4.34-4.18 (m, 3 H), 3.58-3.40 (m, 2 
H), 2.88 (dd, 1 H, J = 11.2, 2.0 Hz), 2.51-2.18 (m, 3 H), 1.66-1.52 (m, 11 H), 0.89 (d, 3 H, J = 
6.9 Hz), 0.88 (d, 3 H, J = 6.9 Hz), 0.82 (d, 3 H, J = 6.8 Hz), 0.81 (d, 3 H, J = 6.8 Hz); 13C NMR 
(CDCl3) δ 170.9, 170.7, 170.5, 168.75, 168.71, 168.65, 139.2, 129.0, 128.6, 126.5, 82.9, 82.7, 
82.6, 73.94, 73.89, 61.5, 52.43, 52.36, 49.1, 46.4, 34.4, 31.6, 31.5, 22.0, 21.9, 18.7, 16.91, 16.87; 
m/z calcd for C33H46N6O7Na (M+Na) 661.3326, found 661.3306. 
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Cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] p-
bromo-benzoate (1-116). A solution of 1-115 (6.8 mg, 0.011 mmol), triethylamine (15 µL, 0.11 
mmol) and catalytic DMAP (0.5 mg, 0.004 mmol) in DCM (0.50 mL) at 0 oC was treated with p-
bromobenzoyl chloride (6.9 mg, 0.033 mmol). The mixture was stirred at room temperature for 1 
h. The mixture was concentrated under reduced pressure. Purification by preparative TLC 
(Hexanes:EtOAc=2:1) yielded 6.8 mg (78%) of 1-116 as a clear solid. A crystal was obtained 
from DCM-Hexanes: mp 119.0-123.0 oC (DCM); 1H NMR (CDCl3) δ 8.19 (d, 1 H, J = 6.4 Hz), 
7.84 (d, 1 H, J = 7.7 Hz), 7.79-7.69 (m, 3 H), 7.57-7.47 (m, 2 H), 7.27-7.14 (m, 3 H), 7.09-7.02 
(m, 2 H), 5.04-4.90 (m, 3 H), 4.85-4.76 (m, 1 H), 4.71-4.60 (m, 2 H), 4.45 (dd, 1 H, J = 11.3, 7.9 
Hz), 4.32-4.20 (m, 3 H), 4.18-4.09 (m, 1 H), 2.90-2.78 (m, 2 H), 2.35-2.17 (m, 3 H), 1.68-1.56 
(m, 9 H), 0.85 (d, 3 H, J = 6.9 Hz), 0.83 (d, 3 H, J = 6.9 Hz), 0.75 (app d, 6 H, J = 6.8 Hz).  
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Cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] 
pent-4-enoate (1-117). A solution of 1-115 (0.121 g, 0.190 mmol), triethylamine (77.0 µL, 
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0.570 mmol) and catalytic DMAP (2.0 mg, 0.016 mmol) in DCM (7.06 mL) at 0 oC was treated 
with pent-4-enoyl chloride (29.2 µL, 0.285 mmol). The mixture was stirred at room temperature 
for 2 h. Brine (4.00 mL) was added and the mixture was extracted with EtOAc (3x). The 
combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc=1:2) yielded 
0.123 g (90%) of 1-117 as a sticky clear solid: [α]D25 +401 (c 0.45, DCM); IR (neat) 3376, 2963, 
2930, 1738, 1689, 1652, 1523, 1454 cm-1; 1H NMR (CDCl3) δ 8.09 (d, 1 H, J = 6.6 Hz), 7.83 (d, 
1 H, J = 7.7 Hz), 7.73 (d, 1 H, J = 8.0 Hz), 7.29-7.16 (m, 3 H), 7.10-7.05 (m, 2 H), 5.85-5.66 (m, 
1 H), 5.10-4.82 (m, 5 H), 4.82-4.74 (m, 1 H), 4.74-4.60 (m, 2 H), 4.30-4.14 (m, 3 H), 4.10 (dd, 1 
H, J = 7.0, 3.5 Hz), 3.98 (dd, 1 H, J = 11.3, 5.9 Hz), 2.84-2.61 (m, 2 H), 2.34-2.14 (m, 7 H), 
1.65-1.52 (m, 9 H), 0.87 (d, 3 H, J = 6.9 Hz), 0.83 (d, 3 H, J = 6.9 Hz), 0.77 (d, 3 H, J = 7.1 Hz), 
0.74 (d, 3 H, J = 8.0 Hz); 13C NMR (CDCl3) δ 172.7, 170.7, 170.2, 168.7, 168.6, 167.6, 138.2, 
136.8, 128.9, 128.7, 126.8, 115.7, 83.2, 82.9, 82.2, 74.1, 73.9, 63.7, 53.6, 52.7, 52.5, 48.8, 43.2, 
34.0, 33.5, 31.7, 31.6, 28.9, 22.1, 22.0, 18.7, 17.2, 17.1; HRMS (ESI) m/z calcd for 
C38H52N6O8Na (M+Na) 743.3744, found 743.3727. 
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Di-cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] 
oct-4-enedioate (1-118). A solution of 1-117 (0.123 g, 0.171 mmol) in DCM (1.00 mL) at room 
temperature was treated with Grubb’s 2nd generation catalyst (14.5 mg, 0.0171 mmol). The 
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mixture was stirred at room temperature for 14 h. water (2.00 mL) was added and the mixture 
was extracted with EtOAc (3x). The combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:EtOAc=1:1 to 1:3, all with 1% Et3N) yielded 47.5 mg (39%) of 1-118 and 50.7 
mg (41%) of starting material 1-117. The recovered 1-117 was re-subjected to the above 
condition to provide 1-118 (72.5 mg) in a combined yield of 60%. 1-118 is a sticky brown solid: 
[α]D25 +127 (c 2.21, DCM); IR (neat) 3376, 2963, 2928, 2872, 1739, 1689, 1652, 1524, 1454 cm-
1; 1H NMR (CDCl3) δ 8.08 (d, 1 H, J = 6.5 Hz), 7.81 (d, 1 H, J = 7.7 Hz), 7.71 (d, 1 H, J = 8.0 
Hz), 7.28-7.11 (m, 3 H), 7.07-7.02 (m, 2 H), 5.48-5.27 (m, 1 H), 4.99-4.84 (m, 3 H), 4.84-4.74 
(m, 1 H), 4.68-4.59 (m, 2 H), 4.29-4.18 (m, 3 H), 4.14-4.04 (m, 1 H), 4.01-3.92 (m, 1 H), 2.80-
2.62 (m, 2 H), 2.30-2.11 (m, 7 H), 1.65-1.55 (m, 9 H), 0.85 (d, 3 H, J = 6.9 Hz), 0.82 (d, 3 H, J = 
6.9 Hz), 0.75 (d, 3 H, J = 8.1 Hz), 0.72 (d, 3 H, J = 7.3 Hz); 13C NMR (CDCl3) δ 172.8, 170.7, 
170.6, 168.7, 168.6, 167.6, 138.1, 129.5, 128.8, 128.7, 126.8, 83.2, 83.0, 82.2, 74.0, 73.9, 73.8, 
63.7, 52.7, 52.4, 48.7, 43.2, 34.0, 33.8, 31.7, 31.6, 27.8, 22.2, 22.1, 22.0, 18.7, 17.1, 17.0; HRMS 
(ESI) m/z calcd for C74H100N12O16Na (M+Na) 1435.7278, found 1435.7157. 
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Di-cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] 
suberate (1-119). A solution of 1-118 (47.5 mg, 0.0336 mmol) and 10% Pd/C (24.0 mg) in 
MeOH (0.750 mL) at room temperature was exposed to H2 (1 atm) for 4 h. The mixture was 
 72 
filtered and concentrated under reduced pressure to provide 48.0 mg (100%) of 1-119 as a sticky 
tan solid: [α]D25 +132 (c 3.6, DCM); IR (neat) 3376, 2963, 2928, 2872, 1737, 1689, 1652, 1524, 
1454 cm-1; 1H NMR (CDCl3) δ 8.08 (d, 1 H, J = 6.5 Hz), 7.82 (d, 1 H, J = 7.7 Hz), 7.73 (d, 1 H, 
J = 8.0 Hz), 7.30-7.11 (m, 3 H), 7.08-7.04 (m, 2 H), 4.99-4.84 (m, 3 H), 4.84-4.75 (m, 1 H), 
4.70-4.59 (m, 2 H), 4.30-4.16 (m, 3 H), 4.09 (dd, 1 H, J = 11.3, 8.5 Hz), 3.97 (dd, 1 H, J = 11.2, 
5.8 Hz), 2.82-2.58 (m, 2 H), 2.32-2.03 (m, 5 H), 1.67-1.48 (m, 11 H), 1.27-1.22 (m, 2 H), 0.86 
(d, 3 H, J = 7.0 Hz), 0.83 (d, 3 H, J = 6.9 Hz), 0.76 (d, 3 H, J = 7.6 Hz), 0.74 (d, 3 H, J = 7.3 
Hz); 13C NMR (CDCl3) δ 173.4, 170.6, 170.2, 168.7, 168.5, 167.6, 138.1, 128.8, 128.7, 126.7, 
83.2, 82.9, 82.2, 74.0, 73.8, 73.7, 63.5, 52.6, 52.4, 48.6, 43.1, 34.1, 33.9, 31.7, 31.6, 28.9, 24.7, 
22.10, 22.06, 21.99, 18.7, 18.6, 17.1, 17.0; HRMS (ESI) m/z calcd for C74H103N12O16 (M+H) 
1415.7615, found 1415.7627. 
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Di-cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] 
adipate (1-121). A solution of 1-119 (59.9 mg, 0.0938 mmol) and pyridine (45.5 µL, 0.563 
mmol) in DCM (1.00 mL) at 0 oC was treated with adipoyl chloride (6.82 µL, 0.0469 mmol). 
The mixture was stirred at room temperature for 18 h. Purification by chromatography on SiO2 
((Hexanes:EtOAc=1:2 with 1% Et3N) followed by preparative HPLC on a Rainin® Dynamax™ 
60 normal phase column (Hexanes:EtOAc=3:7 to 100% EtOAc) yielded 29.4 mg (45%) of 1-121 
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as a clear sticky solid: [α]D25 +120 (c 0.38, DCM); IR (neat) 3376, 2963, 2929, 2872, 1737, 1689, 
1653, 1525, 1454 cm-1; 1H NMR (CDCl3) δ 8.09 (d, 1 H, J = 6.6 Hz), 7.82 (d, 1 H, J = 7.7 Hz), 
7.72 (d, 1 H, J = 7.7 Hz), 7.28-7.14 (m, 3 H), 7.07-7.03 (m, 2 H), 5.00-4.84 (m, 3 H), 4.84-4.75 
(m, 1 H), 4.69-4.60 (m, 2 H), 4.30-4.18 (m, 3 H), 4.09 (dd, 1 H, J = 11.3, 8.5 Hz), 3.97 (dd, 1 H, 
J = 11.3, 5.9 Hz), 2.81-2.63 (m, 2 H), 2.35-2.09 (m, 5 H), 1.79-1.47 (m, 11 H), 0.86 (d, 3 H, J = 
7.0 Hz), 0.82 (d, 3 H, J = 6.9 Hz), 0.75 (d, 3 H, J = 7.4 Hz), 0.73 (d, 3 H, J = 7.4 Hz); 13C NMR 
(125MHz) (CDCl3) δ 173.0, 170.7, 170.2, 168.8, 168.6, 167.6, 138.2, 128.9, 128.8, 126.8, 83.3, 
83.0, 82.2, 74.0, 73.9, 73.8, 63.7, 52.7, 52.5, 48.7, 43.2, 33.9, 33.8, 31.6, 24.3, 22.1, 22.0, 18.7, 
17.1; HRMS (ESI) m/z calcd for C72H99N12O16 (M+H) 1387.7302, found 1387.7324. 
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Di-cyclo[γ-phenyl-allo-homoThr-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] 
pyridine-2,6-dicarboxylate (1-122). A solution of 1-115 (10.0 mg, 0.0157 mmol), triethylamine 
(11.0 µL, 0.0783 mmol) and catalytic DMAP (0.5 mg, 0.006 mmol) in DCM (0.20 mL) at 0 oC 
was treated with 2,6-dicarbonylpyridine dichloride (1.6 mg, 0.0075 mmol). The mixture was 
stirred at room temperature for 2 h. Purification by preparative TLC (100% EtOAc with 1% 
Et3N) yielded 8.5 mg (81%) of 1-123 as a sticky clear solid: [α]D25 +12.2 (c 0.85, DCM); IR 
(neat) 3376, 2964, 2930, 2873, 1751, 1724, 1689, 1652, 1524, 1454 cm-1; 1H NMR (CDCl3) δ 
8.14 (d, 2 H, J = 6.5 Hz), 8.06 (d, 2 H, J = 7.7 Hz), 7.89 (app t, 1 H, J = 7.2 Hz), 7.85 (d, 2 H, J = 
7.8 Hz), 7.73 (d, 2 H, J = 8.0 Hz),  7.27-7.08 (m, 10 H), 5.02-4.90 (m, 6 H), 4.87-4.76 (m, 2 H), 
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4.74-4.57 (m, 4 H), 4.50 (dd, 2 H, J = 11.5, 8.1 Hz), 4.31-4.17 (m, 8 H), 2.96-2.79 (m, 4 H), 
2.44-2.17 (m, 6 H), 1.64-1.56 (m, 18 H), 0.94-0.73 (m, 24 H); 13C NMR (CDCl3) δ 170.8, 170.7, 
170.2, 168.8, 168.7, 167.6, 163.9, 148.4, 138.3, 129.0, 128.8, 128.1, 126.8, 83.4, 83.0, 82.2, 74.1, 
73.9, 65.3, 52.7, 52.5, 48.9, 43.4, 34.0, 31.8, 31.6, 22.1, 22.0, 18.7, 17.2, 17.1; HRMS (ESI) m/z 
calcd for C73H93N13O16Na (M+Na) 1430.6761, found 1430.6757. 
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N-(Furan-2-ylmethylene)-P,P-diphenylphosphinic amide (1-131).70,74 A solution of 
diphenylphosphinic amide (2 g, 9.21 mmol), furaldehyde (0.76 mL, 9.2 mmol) and triethylamine 
(3.8 mL, 28 mmol) in DCM (40 mL) at 0 oC was treated with a solution of TiCl4 (0.56 mL, 5.1 
mmol) in DCM (8 mL). The reaction mixture was stirred at room temperature for 16 h and 
subsequently poured into anhydrous ether (80 mL). The resulting suspension was filtered 
through a mixture of SiO2 and celite (1:1 v/v) and concentrated under reduced pressure. The 
residue was dissolved in minimal DCM. Hexanes were added to precipitate the product (1.3 g, 
48%) as a yellow solid: 1H NMR (CDCl3) δ 9.06 (d, 1 H, J = 32.8 Hz), 8.00-7.88 (m, 2 H), 7.72 
(app s, 1 H), 7.54-7.41 (m, 8 H), 7.21 (d, 1 H, J = 3.4 Hz), 6.62 (dd, 1 H, J = 3.5, 1.7 Hz). 
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N-(2-(2-(tert-Butyldiphenylsilyloxy)ethyl)-1-(furan-2-yl)but-3-enyl)-P,P-
diphenylphosphinic amide (1-129). A suspension of Cp2ZrHCl (10.3 g, 11.0 mmol) in DCM 
(87.0 mL) at 0 oC was treated with (but-3-ynyloxy)(tert-butyl)diphenylsilane(11.1 g, 35.9 mmol) 
and stirred at room temperature for 30 min. The yellow solution was cooled to -78 oC, treated 
with Me2Zn (2.0 M solution in toluene, 16.3 mL, 33.0 mmol), warmed to room temperature over 
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a period of 5 min, treated with CH2I2 (4.34 mL, 54.0 mmol), stirred for 2 min, and treated with a 
solution of imine 1-131 (3.19 g, 10.8 mmol) in 20.0 mL of DCM. The reaction mixture was 
stirred at room temperature for 3 h, quenched with saturated NH4Cl, diluted with EtOAc and 
saturated NaHCO3, filtered through Celite, washed with water and brine, dried (MgSO4), filtered 
through a pad of Florisil and concentrated in vacuo. Purification by chromatography on SiO2 
(Hexanes:EtOAc=1:1) yielded 4.52 g (68%) of crude 1-129 (yellow oil) as a 1:1 (inseparable) 
mixture of diastereomers: IR (neat) 3367, 3182, 3071, 2997, 2930, 2856, 1590, 1483 cm-1; 1H 
NMR (CDCl3) δ 7.90-7.73 (m, 4 H), 7.73-7.59 (m, 4 H), 7.47-7.27 (m, 12 H), 6.23 (dd, 1 H, J = 
3.2, 1.3 Hz), 5.98 (d, 1 H, J = 3.2 Hz), 5.60 (app t, 0.45 H, J = 9.9 Hz), 5.54 (app t, 0.53 H, J = 
9.9 Hz), 5.22-5.11 (m, 2 H), 4.31 (app t, 0.43 H, J = 5.1 Hz), 4.25 (app t, 0.54 H, J = 5.0 Hz), 
3.67-3.50 (m, 4 H), 2.87-2.75 (m, 1 H), 1.43-1.23 (m, 2 H), 1.03 (s, 9 H); 13C NMR (CDCl3) δ 
154.0, 153.9, 144.8, 141.3, 137.4, 135.3, 133.71, 133.66, 133.59, 132.9, 132.2, 132.1, 132.0, 
131.6, 131.4, 131.2, 129.4, 128.3, 128.2, 128.0, 127.4, 118.7, 109.8, 107.2, 61.5, 51.8, 47.22, 
47.16, 34.1, 26.7, 19.0; HRMS (ESI) m/z calcd for C38H42NO3SiPNa (M+Na) 642.2569 
(product), found 642.2598, also calcd for C39H45NO3SiPNa 634.2906 (contaminant), found 
634.2939. 
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N-(4-(tert-Butyldiphenylsilyloxy)-2-ethyl-1-(furan-2-yl)butyl)-P,P- 
diphenylphosphinic amide (1-128). A solution of 1-129 (7.73 g, 12.5 mmol) and 10% Pd/C 
(0.773 g) in MeOH (160 mL) at room temperature was exposed to H2 (1 atm) for 5 h. The 
mixture was filtered through celite and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc=1:1) to provide 6.09 g (78%) of crdue 1-119 as a 
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yellow oil: IR (neat) 3193, 3070, 3053, 2958, 2930, 2857, 1590, 1504, 1471, 1461 cm-1; 1H 
NMR (CDCl3) δ 7.88-7.73 (m, 4 H), 7.64-7.57 (m, 4 H), 7.48-7.27 (m, 13 H), 6.24 (dd, 1 H, J = 
3.4, 1.9 Hz), 6.05 (d, 1 H, J = 3.2 Hz), 4.26 (app t, 0.49 H, J = 5.4 Hz), 4.21 (app t, 0.48 H, J = 
5.5 Hz), 3.71-3.53 (m, 2 H), 3.34 (app dd, 1 H, J = 10.6, 8.2 Hz), 1.99-1.89 (m, 1 H), 1.88-1.75 
(m, 1 H), 1.56-1.41 (m, 2 H), 1.26-1.12 (m, 2 H), 0.99 (s, 9 H), 0.73 (t, 3 H, J = 7.4); 13C NMR 
(CDCl3) δ 155.75, 155.69, 141.4, 135.8, 134.1, 134.0, 132.7, 132.6, 132.2, 132.1, 132.02, 
131.98, 131.9, 131.8, 129.8, 128.7, 128.6, 128.4, 127.8, 110.3, 107.1, 62.5, 1.9, 42.0, 41.9, 32.7, 
27.1, 23.4, 19.3, 11.6; HRMS (ESI) m/z calcd for C38H44NO3SiPNa (M+Na) 644.2726, found 
644.2756. 
O OH
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Benzyl 2-ethyl-1-(furan-2-yl)-4-hydroxybutylcarbamate (1-132). A solution of 1-128 
(6.09 g, 9.79 mmol) in MeOH (52.4 mL) was treated with HCl (1 M solution in MeOH, 50.0 mL, 
50.0 mmol). The reaction mixture was stirred at room temperature for 14 h and concentrated 
under reduced pressure. The residue was redissolved in EtOAc (70.0 mL) and water (70.0 mL), 
cooled to 0 oC and treated with NaHCO3 (4.21 g, 47.8 mmol) and benzyl chloroformate (1.68 
mL, 11.8 mmol). The reaction mixture was warmed to room temperature, stirred for 14 h and 
diluted with EtOAc. The aqueous phase was extracted with EtOAc (3x). The combined organic 
phases were washed with brine, dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc=3:1 to 1:1) yielded 2.41 g 
(77%) of 1-132 as a yellow oil: IR (neat) 3411, 3322, 3065, 3033, 2960, 2936, 2877, 1701, 1587, 
1535, 1504, 1455 cm-1; 1H NMR (CDCl3) δ 7.38-7.32 (m, 6 H), 6.31 (dd, 1 H, J = 3.2, 1.9 Hz), 
6.18 (d, 1 H, J = 3.0 Hz), 5.55 (d, 1 H, J = 9.2 Hz), 5.12 (s, 2 H), 4.94 (dd, 1 H, J = 9.1, 6.2 Hz), 
 77 
3.82-3.54 (m, 2 H), 2.05-1.94 (m, 1 H), 1.45-1.34 (m, 2 H), 1.33-1.20 (m, 2 H), 0.92 (t, 3 H, J = 
7.4); 13C NMR (CDCl3) δ 156.4, 154.2, 141.5, 136.4, 128.4, 128.01, 127.97, 127.7, 110.1, 106.5, 
66.8, 30.1, 51.7, 40.1, 31.9, 23.0, 11.1; HRMS (ESI) m/z calcd for C18H23NO4Na  (M+Na) 
340.1525, found 340.1518. 
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Benzyl 2-ethyl-1-(furan-2-yl)-4-(triisopropylsilyloxy)butylcarbamate (1-133). A 
Solution of 1-132 (0.914 g, 2.88 mmol) and 2,6-lutidine (1.00 mL, 8.70 mmol) in DCM (7.00 
mL) at 0 oC was treated with triisopropylsilyl triflate (0.869 mL, 3.20 mmol). The reaction 
mixture was stirred at room temperature for 2 h, quenched with 2 M HCl, extracted with EtOAc 
(3x). The combined organic layers were washed with 2 M HCl and brine, dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by chromatography on SiO2 
(Hexanes:EtOAc=14:1) yielded 1.19 g (87%) of 1-133 as a yellow oil: IR (neat) 3324, 2958, 
2942, 2891, 2865, 1725, 1712, 1530, 1503, 1463 cm-1; 1H NMR (CDCl3) δ 7.38-7.27 (m, 6 H), 
6.31 (dd, 1 H, J = 3.1, 1.8 Hz), 6.19 (d, 1 H, J = 3.0 Hz), 5.81 (d, 1 H, J = 9.0 Hz), 5.11 (s, 2 H), 
4.88 (dd, 1 H, J = 8.8, 6.2 Hz), 3.80-3.61 (m, 2 H), 2.10-1.95 (m, 1 H), 1.72-1.61 (m, 2 H), 1.57-
1.25 (m, 5 H), 1.06 (s, 18 H), 0.95 (t, 3 H, J = 7.3); 13C NMR (CDCl3) δ 156.4, 155.0, 141.6, 
136.7, 128.6, 128.2, 110.3, 106.5, 67.0, 61.5, 51.9, 40.3, 32.6, 23.8, 18.2, 12.1, 11.6; MS (EI) m/z 
(rel intensity) 473 (15), 430 (25), 338 (20), 264 (55), 221 (40), 149 (30), 91 (100); HRMS (EI) 
m/z calcd for C27H43NO4Si 473.2961, found 473.2959. 
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CbzHN
O
OH
OTIPS
 
6-Ethyl-10,10-diisopropyl-11-methyl-3-oxo-1-phenyl-2,9-dioxa-4-aza-10-siladodeca-
ne-5-carboxylic acid (1-128). A mixture of NaIO4 (6.64 g, 31.4 mmol), water (13.8 mL), MeCN 
(19.8 mL) and CCl4 (13.8 mL) was treated with RuCl3·H2O (3.9 mg, 0.019 mmol) and 
ultrasonicated for 30 min at room temperature. Compound 1-133 (0.897 g, 1.89 mmol) was 
added and the reaction mixture was ultrasonicated for 43 min. After the addition of 2 M HCl, the 
aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with 
20% NaHSO3 (2x) and brine, dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
chromatography on SiO2 (Hexanes:EtOAc=2:1 with 0.5% AcOH) yielded 0.37 g (43%) of 1-128 
as a yellow oil: IR (neat) 3304, 3091, 3066, 3034, 2942, 2866, 2755, 2624, 1720, 1687, 1517, 
1462 cm-1; 1H NMR (CDCl3) δ 7.57-7.26 (m, 5 H), 5.97 (d, 1 H, J = 7.9 Hz), 5.12 (s, 2 H), 4.61 
(dd, 1 H, J = 8.1, 4.2 Hz), 3.95-3.60 (m, 2 H), 2.17-1.98 (m, 2 H), 1.77-1.55 (m, 2 H), 1.55-1.40 
(m, 2 H), 1.20-0.71 (s, 24 H); 13C NMR (CDCl3) δ 176.9, 176.2, 156.6, 136.5, 128.7, 128.5, 
128.3, 67.3, 61.6, 56.0, 40.2, 32.8, 23.5, 18.1, 12.1, 11.9; HRMS (ESI) m/z calcd for 
C24H41NO5SiNa (M+Na) 474.2652, found 474.2642. 
CbzHN
O
H
N
OTIPS
COOMe
OH
+
CbzHN
O
H
N
OTIPS
COOMe
OH  
(2R,3S)-Methyl 2-((2S)-2-(benzyloxycarbonylamino)-3-ethyl-5-(triisopropylsilyloxy)-
pentanamido)-3-hydroxybutanoate (1-134a) and (2R,3S)-methyl 2-((2R)-2-(benzyloxy-
carbonylamino)-3-ethyl-5-(triisopropylsilyloxy)pentanamido)-3-hydroxybutanoate (1-134b) 
A solution of 1-133 (0.454 g, 1.01 mmol) and N-methylmorpholine (0.121 mL, 1.10 mmol) in 
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DCM (3.87 mL) at -20 oC was treated with isobutylchloroformate (0.143 mL, 1.10 mmol). After 
5 min, a suspension of D-threonine methyl ester hydrochloride (0.343 g, 2.02 mmol) and Et3N 
(0.283 mL, 2.02 mmol) in DMF (1.83 mL) was added dropwise. The reaction mixture was 
warmed to room temperature, stirred for 1 h and quenched with saturated aqueous NaHCO3 
solution. The mixture was diluted with EtOAc and the organic layer was washed with 0.1 M 
HCl, saturated aqueous NaHCO3 and brine, dried (Na2SO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc=2:1) yielded 0.605 
g (100%) of 1-134a and 1-134b (yellow oil) as an 1:1 (inseparable) mixture of diastereomers: IR 
(neat) 3305, 3033, 2942, 2868, 1728, 1662, 1510, 1461 cm-1; 1H NMR (CDCl3) δ 7.47-7.20 (m, 5 
H), 7.04 (app t, 1 H, J = 9.6 Hz), 6.40 (d, 0.5 H, J = 7.5 Hz), 6.33 (d, 0.5 H, J = 7.7 Hz), 5.14 
(AB, 1 H, J = 12.0 Hz), 5.06 (AB, 1 H, J = 11.9 Hz), 4.57 (dq, 1 H, J = 8.9, 2.7 Hz), 4.32-4.24 
(m, 2 H), 3.87 (d, 1 H, J = 6.7 Hz), 3.85-3.66 (m, 5 H), 2.33-2.10 (m, 1 H), 1.75-1.63 (m, 1 H), 
1.63-1.50 (m, 1 H), 1.50-1.30 (m, 3 H), 1.25 (app d, 2 H, J = 6.2 Hz), 1.17 (d, 3 H, J = 6.3 Hz), 
1.03 (s, 9 H), 1.02 (s, 9 H), 0.94 (t, 3 H, J = 6.7 Hz); 13C NMR (CDCl3) δ 172.54, 172.47, 171.9, 
171.2, 171.1, 157.3, 156.8, 136.3, 128.4, 128.2, 128.1, 71.4, 68.0, 67.8, 67.6, 67.1, 61.8, 61.3, 
59.4, 57.9, 57.6, 57.6, 52.39, 52.35, 59.3, 39.2, 32.3, 32.0, 28.0, 23.6, 23.3, 19.9, 19.0, 18.0, 11.8, 
11.5, 11.2; MS (EI) m/z (rel intensity) 566 (10), 548 (20), 523 (35), 505 (15), 406 (15), 318 (20), 
91 (100); HRMS (ESI) m/z calcd for C29H50N2O7Si 566.3387 (M+H), found 566.3336. 
CbzHN
O
N COOMe
OTIPS
+ CbzHN
O
N COOMe
OTIPS
 
(4R,5R)-Methyl 2-((5S)-6-ethyl-10,10-diisopropyl-11-methyl-3-oxo-1-phenyl-2,9- 
dioxa-4-aza-10-siladodecan-5-yl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (135a) and 
(4R,5R)-methyl 2-((5R)-6-ethyl-10,10-diisopropyl-11-methyl-3-oxo-1-phenyl-2,9-dioxa-4-aza 
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-10-siladodecan-5-yl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-135b). A solution of 1-
134a and 1-134b (0.103 g, 0.181 mmol) and Burgess reagent (46.6 mg, 0.198 mmol) in THF 
(1.06 mL) was heated to 75 oC for 2.5 h in a sealed tube. The resulting mixture was evaporated 
onto SiO2 and purified by chromatography on SiO2 (DCM:EtOAc=12:1 to 7:1, all with 1% Et3N) 
to yield 18.1 mg (18%) of 1-134a and 22.2 mg (22%) of 1-134b as a clear oil. 1-134a: IR (neat) 
3305, 2943, 2866, 1728, 1662, 1510, 1463 cm-1; 1H NMR (CDCl3) δ 7.38-7.30 (m, 5 H), 5.69 (d, 
1 H, J = 9.2 Hz), 5.13 (AB, 1 H, J = 5.1 Hz), 5.09 (AB, 1 H, J = 5.1 Hz), 5.00-4.88 (m, 1 H), 
4.79 (dd, 1 H, J = 10.1, 1.3 Hz), 4.70-4.59 (m, 1 H), 3.79-3.73 (m, 2 H), 3.74 (s, 3 H), 2.06-1.95 
(m, 1 H), 1.85-1.72 (m, 2 H), 1.51-1.35 (m, 3 H), 1.31-1.24 (m, 5 H), 1.04 (s, 18 H), 0.96 (t, 3 H, 
J = 6.7 Hz); 13C NMR (CDCl3) δ 170.3, 170.2, 156.6, 136.6, 128.6, 128.3, 128.2, 78.7, 71.2, 
67.1, 61.3, 52.2, 51.3, 39.7, 32.3, 23.1, 18.2, 16.3, 12.1, 12.0; MS (ESI) m/z (rel intensity) 549.3 
(90), 571.3 (100). 1-134b: IR (neat) 3305, 3033, 2943, 2866, 1728, 1662, 1510, 1463 cm-1; 1H 
NMR (CDCl3) δ 7.38-7.28 (m, 5 H), 5.80 (d, 1 H, J = 8.9 Hz), 5.12 (app s, 2 H), 4.95-4.84 (m, 1 
H), 4.78 (dd, 1 H, J = 10.1, 1.3 Hz), 4.64 (app dd, 1 H, J = 9.0, 4.9 Hz), 3.81-3.68 (m, 2 H), 3.74 
(s, 3 H), 2.10-1.91 (m, 1 H), 1.81-1.58 (m, 2 H), 1.57-1.39 (m, 3 H), 1.32-1.25 (m, 5 H), 1.04 (s, 
18 H), 1.00-0.93 (m, 3 H); 13C NMR (CDCl3) δ 170.2, 169.9, 156.5, 136.7, 128.6, 128.3, 128.2, 
78.5, 71.3, 67.1, 61.3, 52.2, 51.8, 40.0, 32.7, 23.5, 18.2, 16.3, 12.1, 11.8; MS (ESI) m/z (rel 
intensity) 549.3 (100) (M+H), 571.3 (80) (M+Na). 
N
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(4R,5R)-Methyl 2-((S)-1-((4S,5R)-2-((S)-1-((4S,5R)-2-((5S)-6-ethyl-10,10-diisopropyl-
11-methyl-3-oxo-1-phenyl-2,9-dioxa-4-aza-10-siladodecan-5-yl)-5-methyl-4,5-dihydro-
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oxazole-4-carboxamido)-2-methylpropyl)-5-methyl-4,5-dihydrooxazole-4-carboxamido)-2-
methylpropyl)-5-methyl-4,5-dihydrooxazole-4-carboxylate (1-142a) and (4R,5R)-Methyl 2-
((S)-1-((4S,5R)-2-((S)-1-((4S,5R)-2-((5R)-6-ethyl-10,10-diisopropyl-11-methyl-3-oxo-1-
phenyl-2,9-dioxa-4-aza-10-siladodecan-5-yl)-5-methyl-4,5-dihydro-oxazole-4-carboxamido) 
-2-methylpropyl)-5-methyl-4,5-dihydrooxazole-4-carboxamido)-2-methylpropyl)-5-methyl-
4,5-dihydrooxazole-4-carboxylate (1-142b). A solution of 1-135a (35.9 mg, 0.0654 mmol) in 
MeOH (0.560 mL) was treated with 1 M aqueous NaOH (0.158 mL, 0.158 mmol) at room 
temperature and the mixture was stirred for 3 h. After addition of NaHCO3 (28.8 mg, 0.327 
mmol), the solvent was evaporated under reduced pressure. The water was removed by 
azeotropic distillation with benzene (2x). The residue was dissolved in DMF (1.31 mL) together 
with the oxazoline dimer with free N-terminal (0.138 mmol, prepared by the hydrogenolysis of 
1-112 (70.9 mg, 0.138 mmol) with 10% Pd(OH)2/C (7.1 mg) in MeOH (1.59 mL)). The resulting 
solution was cooled to 0 oC and treated with DIPEA (0.0532 mL, 0.327 mmol) followed by 
DPPA (0.0430 mL, 0.196 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 48 h. The reaction mixture was quenched with saturated aqueous 
NaHCO3 (1 mL) and stirring was continued for 1 h. The solvent was evaporated under reduced 
pressure and the residue was partitioned between water and EtOAc. The aqueous layer was 
extracted with EtOAc (2x) and the combined organic layers were  washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (100% EtOAc with 1% Et3N) yielded 24.7 mg (42%) of 1-142a as a clear oil: IR (neat) 
3389, 3308, 3033, 2962, 2941, 2893, 2867, 1724, 1659, 1521, 1463 cm-1; 1H NMR (CDCl3) δ 
7.38-7.29 (m, 5 H), 7.08-7.00 (m, 2 H), 5.93 (d, 1 H, J = 8.7 Hz), 5.13 (AB, 1 H, J = 11.9 Hz), 
5.10 (AB, 1 H, J = 12.3 Hz), 4.93-4.72 (m, 4 H), 4.64 (app dd, 1 H, J = 9.7, 6.6 Hz); 4.56 (app 
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dd, 1 H, J = 8.7, 6.6 Hz); 4.48 (app dd, 1 H, J = 8.4, 5.6 Hz); 4.21-4.10 (m, 2 H), 3.79-3.65 (m, 2 
H), 3.74 (s, 3 H), 2.19-2.07 (m, 2 H), 2.07-1.95 (m, 1 H), 1.80-1.62 (m, 2 H), 1.55-1.36 (m, 3 H), 
1.44 (d, 3 H, J = 5.3 Hz), 1.30 (d, 6 H, J = 6.4 Hz), 1.34-1.22 (m, 2 H), 1.04 (s, 18 H), 1.10-1.00 
(m, 3 H), 1.00-0.85 (m, 12 H); 13C NMR (CDCl3) δ 171.4, 171.2, 170.2, 169.3, 138.5, 138.0, 
156.7, 136.5, 128.7, 128.34, 128.27, 80.9, 80.6, 78.4, 74.9, 74.8, 71.2, 67.2, 61.2, 52.9, 52.7, 
52.2, 52.1, 37.1, 32.4, 32.4, 32.2, 23.5, 22.0, 21.9, 19.1, 19.0, 18.3, 18.2, 16.2, 12.1, 11.6; MS 
(ESI) m/z (rel intensity) 457.4 (100), 914.4 (90) (M+H), 935.4 (100) (M+Na). 
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Cyclo[3-ethyl-5-hydroxy-Nva(TIPS)-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-
Thr(oxaz)] 1-143. A solution of 1-142a (24.7 mg, 0.0270 mmol) and 10% Pd(OH)2/C (2.5 mg) 
was exposed to H2 (1 atm) for 90 min. The reaction mixture was filtered through celite and the 
filtrate was treated with 1 M aqueous NaOH (0.0325 mL, 0.0325 mmol) and stirred at room 
temperature for 2 h. After addition of NaHCO3 (11.4 mg, 0.135 mmol), the solvent was 
evaporated under reduced pressure. The residual water was removed by azeotropic distillation 
with benzene (2x). The residue was dissolved in DMF (2.10 mL), treated with DPPA (8.73 µL, 
0.0405 mmol) at 0 oC and stirred for 24 h at 0 oC, 24 h at 4 oC and 24 h at room temperature. The 
reaction mixture was quenched with saturated aqueous NaHCO3 (0.500 mL) and stirring was 
continued for 1 h. The solvent was evaporated under reduced pressure and the residue was 
partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (2x) and the 
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combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc=2:1 with 1% 
Et3N) yielded 8.2 mg (41%) of 1-114 as a sticky clear solid: IR (neat) 3379, 2962, 2866, 1688, 
1651, 1524, 1463 cm-1; 1H NMR (CDCl3) δ 7.65 (d, 1 H, J = 7.6 Hz), 7.54 (d, 1 H, J = 7.7 Hz), 
7.42 (d, 1 H, J = 6.6 Hz), 5.16-5.07 (m, 1 H), 4.87-4.75 (m, 2 H), 4.72-4.63 (m, 2 H), 4.59 (app 
dt, 1 H, J = 7.7, 2.8 Hz); 4.23 (app dd, 1 H, J = 7.5, 2.0 Hz); 4.17 (d, 1 H, J = 9.4 Hz), 4.15 (app 
dd, 1 H, J = 9.1, 2.2 Hz); 2.31-2.20 (m, 2 H), 2.13-2.04 (m, 1 H), 1.81-1.68 (m, 2 H), 1.60 (d, 3 
H, J = 6.1 Hz), 1.55 (d, 3 H, J = 6.2 Hz), 1.50 (d, 3 H, J = 6.2 Hz), 1.46-1.36 (m, 2 H), 1.33-1.18 
(m, 3 H), 1.07 (s, 18 H), 1.01 (t, 3 H, J = 7.2 Hz), 0.88 (d, 6 H, J = 6.9 Hz), 0.85 (d, 3 H, J = 6.9 
Hz), 0.75 (d, 3 H, J = 6.9 Hz); 13C NMR (CDCl3) δ 171.0, 170.5, 169.0, 168.9, 167.6, 82.8, 82.3, 
79.9, 74.7, 74.5, 74.0, 62.0, 52.5, 50.7, 40.7, 33.7, 32.0, 31.7, 23.3, 22.3, 22.1, 20.9, 18.7, 18.3, 
17.9, 17.1, 12.5, 12.2; HRMS (ESI) m/z calcd for C38H67N6O7Si (M+H) 747.4841, found 
747.4816. 
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Cyclo[3-ethyl-5-hydroxy-Nva-D-Thr(oxaz)-Val-D-Thr(oxaz)-Val-D-Thr(oxaz)] 144. 
A solution of 1-143 (3.8 mg, 0.0051 mmol) in THF (0.15 mL) was treated with TBAF (1.0 M in 
THF, 0.012 mL, 0.012 mmol). The reaction mixture was stirred at room temperature for 4 h. 
Water (1.0 mL) was added and the mixture was extracted with EtOAc (3x). The combined 
organic layers were washed with brine, dried (Na2SO4), filtered and concentrated under reduced 
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pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc=1:1 to 100% EtOAc, all 
with 1% Et3N) yielded 2.1 mg (70%) of 1-144 as a sticky clear solid: IR (neat) 3378, 2965, 2932, 
2875, 1685, 1650, 1525, 1455 cm-1; 1H NMR (CDCl3) δ 7.85 (d, 1 H, J = 5.0 Hz), 7.72 (d, 1 H, J 
= 7.3 Hz), 7.51 (d, 1 H, J = 7.9 Hz), (in CD3OD+D2O 9:1 these three peaks splits to 8.25 (d, 0.5 
H, J = 8.1 Hz), 8.18 (d, 0.5 H, J = 9.9 Hz), 7.81 (d, 0.5 H, J = 10.6 Hz), 7.74 (d, 0.5 H, J = 7.6 
Hz), 7.66 (d, 0.5 H, J = 8.2 Hz), 7.47 (d, 0.5 H, J = 7.5 Hz)), 5.08-4.98 (m, 1 H), 4.88-4.81 (m, 1 
H), 4.76-4.69 (m, 2 H), 4.67-4.59 (m, 2 H), 4.23 (app dd, 1 H, J = 7.7, 2.0 Hz), 4.21-4.15 (m, 2 
H), 4.03-3.88 (m, 1 H), 3.88-3.76 (m, 1 H), 3.39-3.26 (m, 1 H), 2.36-2.18 (m, 2 H), 2.18-2.07 (m, 
1 H), 1.81-1.65 (m, 4 H) 1.62 (d, 3 H, J = 6.2 Hz), 1.56 (d, 3 H, J = 6.3 Hz), 1.53 (d, 3 H, J = 6.3 
Hz), 0.96 (t, 3 H, J = 7.2 Hz), 0.90 (d, 3 H, J = 7.0 Hz), 0.88 (d, 3 H, J = 6.8 Hz), 0.85 (d, 3 H, J 
= 6.9 Hz), 0.76 (d, 3 H, J = 6.9 Hz); 13C NMR (CDCl3) δ 170.9, 170.3, 170.0, 168.8, 167.9, 
167.8, 82.9, 82.5, 80.1, 74.3, 74.2, 73.9, 60.8, 52.8, 52.4, 50.2, 40.2, 32.8, 31.9, 31.7, 23.1, 22.3, 
21.1, 18.75, 18.67, 17.9, 17.0, 12.6. 
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NMR Titration of 1-119:  Compound 1-119 (2.8 mg, 2.0 µmol) in 0.5 mL CD3OD and 
D2O (9:1, v/v) was titrated with a solution of AgClO4 (0.158 M, in CD3OD and D2O (9:1, v/v)). 
The process was monitored by 1H NMR (see figures below). The data is summarized in Table 6. 
 
Table 6 NMR titration data of 1-119 
Amount of 
AgClO4 
added 
(equivalents) 
Initial 
conc. of 
AgClO4 
(mM) 
Initial conc. 
of ligand 1-
119 
(mM) 
Integration* 
of 
uncomplexed 
1-119 
Integration** 
of 
complexed 
1-119 
[1-
119Ag4]*** 
(mM) 
[D]*** 
(mM) 
[Ag]*** 
(mM) 
Ka  
calculated 
(M-4) 
0.8 3.11 3.88 5.75 1.00 0.575223 3.30713 0.80499 4.14×1011 
1.2 4.61 3.84 3.72 1.00 0.814029 3.030631 1.357475 7.91×1010 
1.6 6.09 3.81 2.30 1.00 1.153741 2.653951 1.477343 9.13×1010 
2.0 7.54 3.77 1.57 1.00 1.467596 2.303832 1.672473 8.14×1010 
2.4 8.97 3.74 1.11 1.00 1.768114 1.967735 1.89358 6.99×1010 
3.2 11.7 3.67 0.448 1.00 2.532928 1.133739 1.601621 3.40×1011 
*: Integration number of 1H NMR peak at 1.0-0.7 ppm (sidechain methyl groups on the uncomplexed cyclic peptide) 
**: Integration number of 1H NMR peak at 1.2-1.0 ppm (sidechain methyl groups on the complexed cyclic peptide) 
***: The concentrations at equilibrium were calculated by the integration number of uncomplexed and complexed 1-119 
Ka = 1.8±1.4×1011 M-4 
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Figure 16 1H NMR spectrum of 1-119 in CD3OD and D2O (9:1, v/v) and an expansion of 1.8-0 ppm region 
 
 
 
Sidechain methyl groups of 
the cyclic peptide 
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Figure 17 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 0.8 equivalent of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
 
Figure 18 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 1.2 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
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Figure 19 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 1.6 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
 
Figure 20 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 2.0 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
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Figure 21 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 2.4 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
 
Figure 22 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 3.2 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
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Figure 23 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 4 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v) 
 
Figure 24 1H NMR spectrum (1.8-0 ppm region) of 1-119 and 8 equivalents of AgClO4 in CD3OD and D2O (9:1, 
v/v). 
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Competitive binding study of 1-119:  Stock solution of 1-120 (0.520 mM),  AgClO4 
(1.10 mM) and 1-119 (2.72 mM) were prepared using MeOH and H2O (9:1, v/v). Test solutions 
were prepared by placing 47.1 µL of the 1-120 stock solution into a volumetric flask, adding an 
appropriate aliquot of AgClO4 stock, and diluting the solution to 5 mL with MeOH and H2O 
(9:1, v/v). For all measurements, excitation was at 367 nm; emission was measured at 420 nm. 
The fluorescence spectra are shown in Figure 25 and the data is summarized in Table 7. 
Figure 25 Changes in fluorescence emission spectra of 1-120 upon the addition of AgClO4 in MeOH and H2O (9:1, 
v/v).  
The spectrum with 100 and 200 equivalents of AgClO4 overlaps with each other, indicating the saturation of 1-120 
at these AgClO4 concentrations. 
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Table 7 Titration of 1-120 with AgClO4 in MeOH and H2O (9:1, v/v) 
Entry Initial Conc. 
of 1-120 
(M) 
Amount of 
AgClO4 added 
(equivalents 
relative to 1-
120) 
Observed 
fluorescence 
intensity (cps) 
at 420 nm 
Ka calculated 
(M-1) 
1 4.89×10-6 0 6.91×105  
2 4.89×10-6 1.0 6.06×105 8.09×104 
3 4.89×10-6 2.0 5.26×105 1.09×105 
4 4.89×10-6 4.0 4.53×105 1.15×105 
5 4.89×10-6 6.0 4.04×105 1.44×105 
6 4.89×10-6 100 3.26×105  
7 4.89×10-6 200 3.25×105  
 
The association constant was calculated according to Equation 1:75  
0
0 )(1
II
CC
CCII
K
FCFAg
AgF
FCa 

       Eq. 1 
where Ka is the association constant, I is the observed fluorescence intensity, I0 is the 
fluorescence of initial concentration of the fluorophore (without silver(I)), εC is the fluorescence 
constant of the complex (calculation based on Entry 7 in Table 7, where 1-120 was saturated 
with silver(I)), εF is the fluorescence constant of 1-120 (calculation based on Entry 1 in Table 7), 
CF is the initial concentration of 1-120, while CAg is the initial concentration of AgClO4. Thus, 
the Ka was determined as 9.2±5.5×104 M-1 (Lit.66 1.25×105M-1 in CHCl3 and Ethanol (7:3, v/v)). 
Next, the competitive binding study was conducted with 1-119 (2.72 mM stock solution in 
MeOH and H2O (9:1, v/v). Test solutions were prepared by mixing 47.1 µL of the 1-120 stock 
solution (0.520 mM), 44.6 µL (2 equivalents) of the AgClO4 stock solution (1.10 mM) and an 
appropriate aliquot of 1-119 stock. The resulting solution was diluted to 5 mL with MeOH and 
H2O (9:1, v/v). Three control experiments were conducted: a. 1-119 has no observable 
fluorescence emission; b. 1-119 with 8 equivalents of AgClO4 showed no observable 
fluorescence emission; c. adding 16 equivalents of 1-119 to a solution of 1-120 had no impact on 
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its fluorescence intensity. The competitive binding fluorescence spectra are shown in Figure 26 
and the data is summarized in Table 8. 
Figure 26 Ligand 1-119 restores the fluorescence emission of Ag(I)-complexed 1-120. 
 
 
Table 8 Data for Competitive binding study of 1-119 with fluorophore 1-120 
Entry Initial 
Conc. of 
1-120 (M) 
Initial conc. 
of AgClO4 
(M) 
Amount of 1-119 
added (equivalents 
relative to 1-120) 
Observed 
fluorescence 
intensity (cps) 
at 420 nm 
Ka 
calculated 
(M-4) 
1 4.89×10-6 0 0 6.91×105  
2 4.89×10-6 9.78×10-6 0 5.26×105  
3 4.89×10-6 9.78×10-6 16 5.89×105 3.90×1019 
4 4.89×10-6 9.78×10-6 32 6.57×105 9.03×1021 
5 4.89×10-6 9.78×10-6 64 6.47×105 1.50×1021 
 
 
The association constants were calculated according to Equation 2, 3 and 4:68  
PC
QPKK
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I
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     Eq. 2 
 94 




IAg
IQ     Eq. 3 
1
1
 Q
C
QK
CP I
I
Ag    Eq. 4 
where Ka is the association constant of 1-119, KI is the association constant of 1-120, CS is the 
initial concentration of 1-119, ε is the apparent fluorescence constant of the system, εI is the 
fluorescence constant of 1-120, εIAg is the fluorescence constant of 1-120 and silver(I) complex, 
CI is the initial concentration of 1-120, while CAg is the initial concentration of AgClO4. Thus, 
the Ka of 1-119 was determined as 3.5±3.9×104 M-4. 
Competitive binding study of 1-121 and westiellamide:  The Ka of 1-121 was 
determined in a way analogous to 1-119. For westiellamide, the following equations68 were used 
for the calculation of Ka:  
2
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
IAg
IQ     Eq. 3 
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QK
CP I
I
Ag    Eq. 4 
where CS is the initial concentration of westiellamide. 
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2.0  SYNTHESIS OF BOTULINUM A METALLOPROTEASE INHIBITORS 
2.1 INTRODUCTION  
 
Botulinum neurotoxins (BoNTs) are well-known for being classified as “the most toxic poisons 
known to humans”.76 They are produced by Clostridium botulinum and cause botulism, a severe 
neurological disease with a life-threatening flaccid paralysis affecting both humans and animals. 
Their potency is best recognized by the fact that they are listed as category A biowarfare 
agents.77 On the other hand, BoNTs also gained popularity in the therapeutic field. Their utility 
includes the treatment of muscle hyperactivity and spasticity disorders, as well as cosmetic 
applications.78-79  
BoNTs comprise of seven serotypes (A-G), with BoNT A being the most potent one.80 All 
BoNTs are proteins consisting of a 100 kDa heavy-chain (HC) and a 50 kDa light-chain Zinc-
dependent protease (LC) linked by a disulfide bridge.81 Their mode of action is demonstrated in 
Figure 27.82  
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Figure 27 Mechanism of action of BoNTs.  
Reproduced from Ref. 82. 
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. BoNTs first bind to cholinergic nerve terminals with their HC domain and are 
subsequently endocytosed into an intracellular vesicle.  The LC domain is then translocated into 
the cytosol with the cleavage of the disulfide linkage between the LC and the HC. In the cytosol, 
the LC performs proteolytic cleavage of SNARE proteins (SNARE: soluble N-ethylmaleimide-
sensitive factor-attachment protein receptors). Each BoNT serotype cleaves one of the three 
SNARE proteins (BoNT /A, /E: SNAP25 (synaptosomal associated protein of 25 kD); BoNT /B, 
/D, /F, /G: VAMP (vesicle-associated membrane protein, VAMP); BoNT C: SNAP25 and 
syntaxin). SNARE are critical for the release of neurotransmitters at nerve terminals as they form 
a complex to mediate vesicle fusion. The cleavage of SNARE proteins by BoNT LC prevents the 
formation of functional SNARE complex, thus blocking the release of neurotransmitter. The 
result is a paralysis of muscle fibers, causing either respiratory or cardiac failure. 
Due to their potency and wide therapeutic application, there is an urgent need for 
therapeutic strategies to counter BoNTs’ toxicity. Of particular interest are small molecule 
inhibitors targeted at either BoNT HC or LC activity. A few HC inhibitors have been 
identified,83-88 but most of the work so far has focused on LC inhibition. Early work in this field 
has primarily relied on peptide and peptidomimetics.89-99 For example, Schmidt et al. developed 
a series of peptide mimics for the inhibition of BoNT /A LC.97 Their design was based on 
cysteine’s ability to complex with zinc. A 17-residue substrate containing the SNAP-25 194-200 
region (the active site domain100 with the cleavage occuring between Gln197 and Arg198) was 
chosen to be mutated in a Cys scan. A number of LC/A inhibitors were identified and subsequent 
truncation of their sequence provided several octapeptides with Ki values in the low micromolar 
range. Further optimization by using cysteine mimics effectively pushed the Ki value to the 
nanomolar range.96 Analogous to the cysteine approach, a few zinc-complexing hydroxamic 
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acids were also identified as LC/A inhibitors (Figure 28).101 A crystal structure of 2-3 complexed 
with LC/A confirmed the interaction between the hydroxamate and the zinc cation.102 
Figure 28 Hydroxamic acids as LC/A inhibitors 
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As an alternative approach to the identification of LC/A inhibitors, Gussio and coworkers 
conducted a high-throughput screening of the National Cancer Institute (NCI) Diversity set.103 
Several non-peptidic small molecule inhibitors were identified (Figure 29, 2-4, 2-5, 2-6). 
Conformational analyses of these compounds, in conjunction with molecular docking studies, 
were used to model a common pharmacophore for LC/A inhibitors.103-104 A similar approach 
involving in silico screening of 2.5 million compounds and molecular dynamic simulations 
identified hydroxamic acid 2-7 (Figure 29).105 
Figure 29 LC/A inhibitors identified by high-throughput screening 
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The pharmacophore proposed by Gussio et al. was further refined by the docking study of 
the aforementioned peptide mimic inhibitors developed by Schmidt et al. with a crystal structure 
of LC/A.106 As shown in Figure 30, the newly proposed pharmacophore B contains two new 
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search query components (F and G) when compared to the previous pharmacophore A. Based on 
this hypothesis, a search in NCI’s Open Repository identified several hits, which were assayed 
against LC/A. The four most potent inhibitors were found to occupy pharmacophore components 
A-C and F (Figure 31). Among the four pharmacophore components, component C was 
proposed to wedge between the side chain phenyls of Phe-162 and Phe-193. The heteroatom 
associated with pharmacophore plane A was thought to interfere with the catalytic site residues 
of the enzyme. Component F was believed to engage in hydrogen bonds with Glu-54 and Glu-63 
of LC/A. Of the four hits, NSC 240898 (Figure 32) showed dose-dependent protection of SNAP-
25 cleavage and displayed no cellular toxicity in up to 40 µM concentration. Thus, it was chosen 
as a lead for a structure-activity relationship (SAR) study and with the goal to find a more potent 
inhibitor. 
Figure 30 Proposed pharmacophore for LC/A.  
A: Components A and B represent two planar moieties, one of which contains a heteroatom. Components C and D 
are two hydrophobic substituents, while E is a positive ionizable substituent. B: The peptide mimic inhibitor (2-
mercapto-3-phenylpropionyl-RATKML) was mapped to the common pharmacophore A. Components F (Lys side 
chain) and G (Met side chain) represent potential new binding sites (distance unit: Å). Reproduced from Ref. 106. 
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Peptide mimic inhibitor: 
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Figure 31 LC/A Inhibitors and search query mappings.  
Reproduced from Ref. 106. 
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Figure 32 Structures of LC/A inhibitors 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Inhibitor Library Design 
The synthetic modifications to NSC 240898 are summarized in Figure 33. Specifically, the two 
polar terminal amidines were replaced with more hydrophobic imidazolines, -CF3 and an 
amidine-quinoline moiety to study the nature of their interaction with LC/A (A and B  in Figure 
33). In order to gather the information about the geometry of the binding pocket, the amidine at 
the indole C-6 position was shifted to the C-5 position (C). Similarly, the ether linkage was 
replaced with a thio ether (G). The incorporation of heteroarenes (D and F) was meant to 
improve solubility, decrease metabolism and/or induce additional interactions with LC/A. Finally, 
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substitution on the central phenyl ring (E) allowed us to explore further electronic and steric 
effects on binding. 
Figure 33 Summary of modifications made to NSC 240898 
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H
F replaced with nitrogen
B replaced with imidazoline or
amidine-quinoline moiety
A replaced with -CF3, imidazoline or
amidine-quinoline moiety
C amidine/imidazoline group
at indole C-5 position
D replaced with nitrogen
G replaced with sulfur
 
2.2.2 1st Generation Inhibitors 
We first synthesized benzimidazoles 2-10 and 2-11 (Scheme 31). Aldehyde 2-8107 and 
diaminobenzonitrile were condensed to provide 2-9,108 which was further elaborated to amidine 
2-11 (formic acid salt) via an imidate intermediate. The bis-nitrile functionality in 2-9 can also 
undergo aminolysis with neat ethylene diamine in the presence of sulfur to provide imidazoline 
2-11 in good yield.109 This microwave assisted nitrile aminolysis reaction was found to have a 
good substrate scope in regard to the nitrile. However, C-substitution on ethylene diamine was 
found to inhibit the reaction.110 
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Scheme 31 Synthesis of benzimidazole analogues 
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Another series of analogs possessing a CF3 group at the C-6 position on the indole was 
generated as shown in Scheme 32. We expected a strong dipole induced by the CF3 group at this 
position would be well tolerated in the binding pocket of the cationic substituent, without 
suffering the desolvation penalty. The aldehyde group in 2-8 was converted into an ethynyl 
group, which underwent a Sonogashira coupling to provide 2-13 in excellent yield. After 
extensive screening of catalysts, we found that the indole formation was best effected by 5 mol% 
Au(I) to provide 2-14,111 which was further derivatized to amidine 2-15 and imidazoline 2-16, 
analogous to the preparations of 2-10 and 2-11.  
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Scheme 32 Synthesis of CF3 analogues 
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Utilizing an iterative coupling sequence, we synthesized two other groups of analogs 
(Scheme 33) with an amidine group at the indole C-5 position (2-19, 2-20), or a pyridine group 
replacing the central phenyl ring (2-24, 2-25). Most reactions proceeded with good to excellent 
yields, with the exception of the nitrile aminolysis of the indole C-5 analogue (2-18 to 2-20). 
This low yield was attributed to an incomplete reaction (mono-imidazoline was observed) and 
sample loss during HPLC purification. The cycloisomerization reaction of the pyridine analogue 
(2-22 to 2-23) was also found to be low yielding, presumably due to the product’s low solubility 
in most organic solvents.  
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Scheme 33 Synthesis of indole C-5 and pyridine analogues 
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Another set of analogues bearing substituents on the central phenyl ring was prepared by 
Julia Widom using the same synthetic sequence (Scheme 34).112 
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Scheme 34 Analogues bearing substitution group on the central phenyl ring 
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A summary of the effects of structural modifications on BoNT/A LC inhibitory potency is 
provided in Table 9.112 While none of the new analogues were as potent as NSC 240898, relative 
degrees of inhibition ranging from one third (i.e., of NSC 240898 activity) to nearly equal 
potency were observed. Correlation of the biological data in Table 9 to the corresponding 
structures allows a better understanding of the electrostatic and steric requirements for this 
scaffold in its BoNT/A LC binding site and forms the foundations for future inhibitor 
refinements.  
Table 9 List of synthetic analogues and activity against BoNT A LC 
Compound Structure    % BoNT/A LC Inhibition 
         (20 μM)* 
2-10 
N
H
N
O
HOOCH.H2N
NH
NH
HOOCH.H2N
 
24.7 (± 1.5) 
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2-11 
N
H
N
OH
N
N
N
HN
 
34.8 (± 1.4) 
2-19 
N
H
O
NH2.HCl
HN
NH
ClH.H2N
 
58.8 (± 3.3) 
2-20 
N
H
O
NH.AcOH
N
NH.AcOH
N
 
51.4 (± 4.6) 
2-15 
N
H
O
NH2.HCl
HN
F3C  
25.2 (± 3.4) 
2-16 
N
H
O
NH.AcOH
N
F3C  
43.3 (± 7.2) 
2-26 
N
H
O
NH2
.HCl
HN
NH2.HCl
HN
Cl  
64.4 (± 2.1) 
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2-27 
N
H
O
N
HN
N
NH Cl  
64.8 (± 4.4) 
2-28 
N
H
O
NH2
.HCl
HN
NH2.HCl
HN
OMe  
58.0 (± 6.7) 
2-29 
N
H
O
N
HN
N
NH OMe  
69.8 (± 1.8) 
2-24 
N
H
N
O
NH2.HCOOH
HN
NH2
.HCOOH
HN
 
52.7 (± 5.5) 
2-25 
N
H
N
O
NH
N
N
NH  
46.1 (± 1.2) 
NSC 
240898 
N
H
O
HN
NH2HCl
NH2HCl
HN
 
73.5 (± 7.5) 
* Values are the averages of two independent experiments. All bis-nitrile compounds were 
inactive. 
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Changing the substituents at sites A, B and C from bis-amidines to bis-imidazolines had 
no significant impact on activity (for example, 2-10 vs. 2-11 and 2-19 vs. 2-20). However, not 
unexpectedly, replacing the basic amidines with neutral nitrile functions was not tolerated; in 
contrast, replacing the amidine group on the indole ring with trifluoromethyl (2-15 and 2-16) 
resulted in moderately active inhibitors. While our data suggests that a strongly basic amidine or 
imidazoline substituent is preferred at the A position (Figure 33), for hydrogen-bonding or ionic 
interactions with the binding site,113-114 it also suggests that there is a degree of binding site 
plasticity.  These results are consistent with recent X-ray co-crystal structures,115 demonstrating 
that the BoNT/A LC 370 loop, which is adjacent to the amidine at site A (Figure 33) in the 
predicted binding mode for NSC 240898,106 can undergo a conformational flip to present either 
the polar side chain of Asp370 or the hydrophobic side chain of Phe369 (Figure 34112). This 
reorientation accommodates either basic or hydrophobic inhibitor substituents at the same 
binding site location, but not an acidic residue as demonstrated by the inactivity of a bis-tetrazole 
analogue of NSC 240898 (vide infra). A binding site plasticity hypothesis is further supported by 
the fact that switching the amidine from the C-6 position of the indole to the C-5 position (2-19 
and 2-20) results in only a moderate decrease in inhibitory potency. 
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Figure 34 Proposed binding mode for NSC 240898 (shown with cyan carbons).  
Oxygen atoms are red and nitrogen atoms are blue. The BoNT/A LC backbone is displayed in green ribbons, and the 
catalytic zinc is gray (space filled). Side chain residues are rendered in stick with green carbons. Hydrogen bonds 
between NSC 240898 and residues Glu 56 and Asp 370 are displayed as dashed yellow lines. Reproduced from Ref. 
112. 
 
 For analogues 2-10 and 2-11, replacing the C-3 carbon of the indole ring with a nitrogen 
(site D in Figure 33), to give the benzimidazole derivative, results in a marked reduction in 
potency. This is indicative of the presence of a complementary hydrophobic BoNT/A LC contact 
for the C-3 atom. Similarly, but to a lesser degree, 2-24 and 2-25 reveal that incorporating a 
nitrogen in the C-3 position of the central phenyl ring is not optimal for binding. Again, this is 
most likely due to unfavorable contacts with a corresponding hydrophobic binding surface. In 
contrast, substitution on the same position in the central phenyl ring (site F in Figure 33) with a 
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chloro (2-26 and 2-27) or a methoxy (2-28 and 2-29) group results in a level of BoNT/A LC 
inhibition that is nearly equipotent to that of NSC 240898. This is an important finding, since it 
demonstrates that there is available steric volume surrounding this hydrophobic inhibitor binding 
site, and that this space may be accessed without incurring a dramatic loss in potency. 
 Finally, a 2D (molecular topology) search of the NCI Open Repository identified an 
analogue possessing an amine (versus an oxygen) at the biaryl hinge (marked G in Figure 33) of 
the scaffold.112 Subsequent biological testing of this derivative, designated NSC 377363, 
revealed that it was equipotent to the parent (70% inhibition at 20 μM concentration, Figure 35), 
and thus demonstrated that either a H-bond donor or H-bond acceptor is feasible at this position.  
Figure 35 Structure of NSC 377363 
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In order to shed further light on the biological significance of the diarylether linkage, two 
thioether analogues, 2-33 and 2-34 (Scheme 35), were prepared. Biological evaluation of 2-33 
and 2-34 at 20 mM concentrations revealed 67.3 (± 3.6)% and 80.3 (± 6.7)% inhibition of the 
BoNT/A LC, respectively. While the bis-amidine 2-33 is equipotent to the parent, i.e., NSC 
240898, the bis-imidazoline 2-34 is more active. This surprising finding may indicate that the 
derivative with the imidazoline substituents is binding in a subtly different manner that favors 
desolvation. Since, for the oxygen analogue of 2-34, the activity is always slightly less 
(compared to NSC 240898) for the derivative possessing imidazolines, it is hypothesized that the 
sharper bond angle provided by the sulfur atom of 2-34 (versus the oxygen atom at that position) 
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allows for better placement of the larger imidazoline head pieces in the enzyme binding site, 
such that hydrophobic contacts are improved.   
Scheme 35 Synthesis of thioether analogues 
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2.2.3 2nd Generation Inhibitors 
At this stage, our collaborator at the National Cancer Institute conducted a search in the NCI 
Open Repository based on the structure elements of NSC 240898.116 Ten small molecule hits 
were identified, and upon testing, three demonstrated inhibitory activity. Of these, one possessed 
a rigid diazachrysene scaffold (NSC 328398, Figure 36), whose structure resembles a previously 
identified LC/A inhibitor103,117 (Q2-15, Figure 36).  
Figure 36 Structures of Q2-15 and NSC 328398, with structural similarities colored red. 
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Superimposing the 3D alignments of NSC 240898 and NSC 328398 demonstrated 
comparable steric and functional group occupancy in 3D space (Figure 37a116). Meanwhile, the 
diazachrysene moiety in NSC 328398 is comparable to the 4-aminoquinoline substructure in Q2-
15 (Figure 37b116) and they both share the same aminoalkyl linker. This led to the 
superimposition of Q2-15 and NSC 328398 (Figure 37c116). Based on the alignment, a refined 
pharmacophore possessing three zones was proposed (Figure 37c116).  
Figure 37 3D alignments of NSC 240898, Q2-15 and NSC 328398.  
Reproduced from Ref. 116. Chlorines are light green, nitrogen atoms are blue, and oxygen is red: a) NSC 240898 and 
NSC 328398 superimposed. NSC 240898 carbon atoms are green and NSC 328398 carbon atoms are cyan; b) NSC 
328398 and Q2-15 superimposed. NSC 328398 carbons are cyan and Q2-15 carbons are magenta; c) NSC 240898, 
NSC 328398, and Q2-15 superimposed.  
 
Based on this result, we proposed a new inhibitor design occupying all three zones by 
tethering the quinoline moiety to one of the amidine groups of NSC 240898 via a propyl linker 
(2-35 and 2-36, Figure 38).118 At this stage, the orientation of NSC 240898 in the binding site 
was not clear. Therefore, a decision was made to synthesize both regioisomers (2-35 and 2-36). 
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Figure 38 Proposed three-zone inhibitors 
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A straightforward method to simultaneously prepare both regioisomers was the exchange 
reaction of NSC 240898 with one equivalent of quinoline 2-38 (Scheme 36). The reaction was 
carried out with thiophenol for 30 min in a microwave reactor at 150 °C, and RP-HPLC 
purification afforded a 4:1 mixture of TFA salts (inseparable).  
Scheme 36 Synthesis of the three-zone inhibitors 2-35 and 2-36 
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In vitro testing of this mixture of 2-35 and 2-36 resulted in 95% BoNT/A LC inhibition (at 
20 µM inhibitor conc.). A more detailed analysis of the inhibition kinetics revealed that the 
regioisomers possess a Ki = 600 nM (±100 nM) (NSC 240898: Ki = 10 µM106), a 15.7-fold 
increase in potency. 
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Next, we decided to investigate the relationship between activity and position of the 
quinoline side chain. A new series of inhibitors was prepared (2-41 and 2-44, Scheme 37, 
Scheme 38). Reduction of biaryl ether 2-12 to the benzyl alcohol followed by TBS protection 
provided intermediate 2-39. A subsequent four-step sequence, including Sonogashira coupling, 
Au(I) catalyzed indole formation, desilylation and Dess-Martin oxidation, proceeded smoothly to 
provide indole 2-40. Intermediate 2-40 underwent reductive amination with the quinoline amine 
2-38 and subsequent imidazoline formation under microwave heating to provide 2-42. 
Unfortunately, formation of the amidine analogue failed, presumably due to the harsh reaction 
conditions.  
Scheme 37 Synthesis of 2-42 
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Initially, we attempted to prepare the other regioisomer via a similar route (Scheme 38). 
Alkyne 2-12 underwent Sonogashira coupling followed by a palladium-catalyzed 
cycloisomerization to provide indole 2-43. Upon deprotection at 2-43’s benzylic position, both 
the benzyl alcohol and its oxidation product 2-44 were found to be unstable (2-44 decomposes in 
minutes at room temperature). Hence, an alternative route was developed (Scheme 39). 
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Scheme 38 Attempted synthesis of 2-45 
1. PdCl2(PPh3)2, CuI, Et3N; 86%
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Intermediate 2-46 was prepared from biaryl ether 2-12 via a sequence including 
Sonogashira coupling, Boc protection of the aniline group, desilylation and oxidation. Reductive 
amination with the quinoline amine 2-38 was followed by transposition of the Boc group from 
the aniline position to the benzyl position. Indole formation required excess catalyst due to the 
strong chelation of substrate 2-47 to palladium. The Boc group was subsequently cleaved by 
TFA and the product was further elaborated to imidazoline 2-45.  
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Scheme 39 Synthesis of 2-45 
1. PdCl2(PPh3)2, CuI, Et3N; 85%
ITBSOH2C
NH2
2. Boc2O; 71%
3. TBAF
4. Dess-Martin; 97%
O
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1. HC(OEt)3, 80 oC, 2 h,
then NaBH3CN; 77%
2. TFA (neat)
3. Boc2O, Et3N; 46%
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1. PdCl2(PhCN)2 (150 mol%), 80 oC 30min
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30 min;
23% after RP-HPLC
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Upon testing with BoNT/A LC, compounds 2-42 and 2-45 exhibited similar activities 
(65±2.2% and 69±2.2% inhibition at 10 µM), which suggests that the binding pocket in BoNT A 
LC may not be highly directional. 
2.3 CONCLUSIONS 
 
Based on the NSC 240898 scaffold, we have successfully prepared a variety of analogues by the 
concise use of transition metal catalyzed cross-couplings and heterocycle annulations. 
Examination of these derivatives for BoNT/A LC inhibition provides a rich SAR. In addition, 
two sets of analogues (2-34, 2-35 and 2-36) displayed significantly increased potency against 
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BoNT LC/A when compared to NSC 240898. These findings are significant for the further 
optimization of the NSC 240898 lead structure during all phases of development. 
 
2.4 EXPERIMENTAL PART 
 
General:  All moisture-sensitive reactions were performed under an atmosphere of N2.  
Glassware was flame dried prior to use. THF and Et2O were dried by distillation over 
Na/benzophenone. DCM was dried by distillation over CaH2.  The solution of lithium 
diisopropylamide (2.0 M in a mixture of heptane, diethylbenzene and THF) was purchased from 
Aldrich. Unless otherwise stated, solvents and reagents were used as received. Analytical thin 
layer chromatography was performed on pre-coated silica gel 60 F-254 plates (particle size 
0.040-0.055 mm, 230-400 mesh) and visualization was accomplished with a 254 nm UV light or 
by staining with an anisaldehyde solution (7.5 mL of p-anisaldehyde, 25 mL of concentrated 
H2SO4 and 7.5 mL of glacial acetic acid in 675 mL of 95% ethanol) or KMnO4 solution (1.5 g of 
KMnO4, 10 g of potassium carbonate and 2.5 mL of 5% aqueous NaOH in 150 mL of H2O). 
Flash chromatography on SiO2 was used to separate and purify the crude reaction mixtures. 
NMR spectra were recorded at 300 MHz/75 MHz (1H NMR/13C NMR) at 21 oC in CDCl3 unless 
otherwise noted. Chemical shifts () are reported as follows: chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, qn=quintet, dd=doublet of doublet, ddd= doublet of 
doublet of doublet, dt=doublet of triplet, dq=doublet of quartet, m=multiplet, br=broad, 
app=apparent). LC/MS analyses were obtained from either a Hewlett Packard Series 1100 MSD 
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or Applied Biosystem 2100 MSD. Infrared spectra were measured on either a Nicolet AVATAR 
360 FTIR E.S.P. spectrometer or Smith IdentifyIR.  
N
H
N
O
NC
CN
 
2-(4-(4-Cyanophenoxy)phenyl)-3H-benzo[d]imidazole-5-carbonitrile (2-9). A sus-
pension of 2-8107 (0.224 g, 1.00 mmol) in 40% NaHSO3 (2.0 mL) was stirred at room 
temperature for 2 h followed by the treatment with a suspension of 3,4-diaminobenzonitrile 
(0.173 g, 1.30 mmol) in EtOH (5.0 mL). The reaction mixture was heated at reflux for 14 h, 
poured into water and filtered. The precipitate was redissolved in EtOAc, dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by chromatography on SiO2 
(hexanes:THF = 3:1) afforded 0.305 g (91%) of 2-9 as a yellow solid: mp 226.0 C (decomp.) 
(THF); IR (KBr) 3426, 3269, 3068, 2230, 1623, 1596, 1500, 1483 cm-1; 1H NMR (DMSO-d6)  
13.45 (s, 1 H), 8.30-8.23 (m, 2 H), 8.12 (app br s, 1 H), 7.88 (d, 2 H, J = 8.7 Hz), 7.73 (app d, 1 
H, J = 8.1 Hz), 7.58 (dd, 1 H, J = 8.3, 1.2 Hz), 7.35-7.29 (m, 2 H), 7.22 (d, 2 H, J = 8.7 Hz); 13C 
NMR (DMSO-d6)  160.1, 156.8, 153.7, 134.8, 129.1, 125.7, 120.2, 120.0, 119.0, 118.6, 106.0, 
104.0, 159.2, 155.5, 134.4, 133.8, 132.0, 129.9, 127.1, 121.2, 118.6, 118.2, 107.5; MS (EI) m/z 
(rel intensity) 336 (100), 206 (12), HRMS (EI) m/z calcd for C21H12N4O 336.1011, found 
336.1001. 
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2-(4-(4-Carbamimidoylphenoxy)phenyl)-3H-benzo[d]imidazole-5-carboximidamide 
diformate (2-10). A solution of 2-9 (30.4 mg, 0.0903 mmol) in EtOH:CHCl3 = 1:1 (v/v, 10 mL) 
at 0 C was bubbled with HCl gas for 30 min and then stirred at room temperature for 24 h. The 
solvent was evaporated and EtOH (6.0 mL) was added. The solution was bubbled with NH3 gas 
at room temperature for 10 min. After 24 h stirring at room temperature, the reaction mixture 
was bubbled with NH3 gas again and stirred for another 24 h. The solvent was evaporated and 
the residue was co-evaporated with EtOH (x2). The residue was redissolved in EtOH (2 mL) and 
filtered. The filtrate was poured into Et2O (10 mL) and treated with formic acid (final 
concentration of HCOOH ~ 50% v/v) and stirred for 30 min at room temperature. The precipitate 
was collected by filtration to yield 11.0 mg (28%) of 2-10 as a yellow solid: mp 232.6 C 
(decomp.) (DMSO); IR (KBr) 3368, 3136, 1674, 1627, 1599, 1481, 1451, 1401 cm-1; 1H NMR 
(DMSO-d6)  9.47 (s, 2 H), 9.30 (s, 1 H), 9.26 (s, 1 H), 8.45 (d, 2 H, J = 8.3 Hz), 7.97 (d, 1 H, J 
= 8.4 Hz), 7.83-7.70 (m, 1 H), 7.57 (app s, 2 H), 7.40 (app s, 2 H); 7.34-7.24 (m, 2 H), 7.23 (app 
s, 2 H); 13C NMR (DMSO-d6)  166.1, 164.8, 163.0, 160.7, 167.5, 164.4, 143.2, 130.8, 129.9, 
129.6, 122.9, 122.4, 121.6, 119.9, 119.2, 118.6, 118.4; HRMS (ESI) m/z calcd for C21H19N6O  
(M+H) 371.1620, found 371.1594. 
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6-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy)-
phenyl)-1H-benzo[d]imidazole (2-11). A mixture of sulfur (1.42 mg, 0.0433 mmol) and 2-9 
(30.0 mg, 0.0892 mmol) was treated with ethylene diamine (0.5 mL), then heated in the 
microwave at 110 C for 30 min. The reaction mixture was suspended in water and filtered, and 
the solid was rinsed with water (3x). The residue was then dried under vacuum, affording 2-11 
(30.7 mg, 81%) as a yellow solid: mp 252.9 C (decomp.) (DMSO); IR (KBr) 3340, 1603, 1507, 
1486, 1451 cm-1; 1H NMR (DMSO-d6)  8.26-8.07 (m, 2 H), 8.06-7.98 (m, 1 H), 7.91-7.81 (m, 2 
H), 7.79-7.65 (m, 1 H), 7.64-7.49 (m, 1 H), 7.22-7.00 (m, 4 H), 3.64 (s, 4 H), 3.60 (s, 4 H); 13C 
NMR (DMSO-d6)  164.4, 163.0, 157.8, 157.6, 152.5, 142.9, 139.2, 129.2, 129.0, 128.6, 126.3, 
125.6, 124.0, 121.6, 120.3, 119.0, 118.5, 49.6, 49.3; HRMS (ESI) m/z calcd for C25H23N6O 
(M+H) 423.1933, found 423.1928. 
O
CN
 
4-(4-Ethynylphenoxy)benzonitrile (2-12). A solution of lithium diisopropylamide (2.0 
M in a mixture of heptane, diethylbenzene and THF, 1.40 mL, 2.80 mmol) in THF (18.6 mL) at -
78 °C was treated with TMSCHN2 (2.0 M in ether, 1.40 mL, 2.80 mmol). The reaction mixture 
was stirred at -78 °C for 30 min and a solution of 2-8107 (0.519 g, 2.32 mmol) in THF (4.7 mL) 
was added. The reaction mixture was stirred at -78 ºC for 1 h and heated at reflux for 3 h. The 
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reaction mixture was quenched with cold water and extracted with Et2O (3x). The organic layers 
were combined, dried (Na2SO4), filtered and concentrated under reduced pressure. Purification 
by chromatography on SiO2 (Hexanes:Et2O = 10:1) afforded 0.279 g (55%) of 2-12 as a white 
solid: mp 87.2-87.9 ºC (acetone); IR (KBr) 3097, 3063, 2224, 1608, 1592, 1492 cm-1; 1H NMR 
(CDCl3) δ 7.64 (d, 2 H, J = 9.0 Hz), 7.54 (d, 2 H, J = 8.8 Hz), 7.07-6.99 (m, 4 H), 3.10 (s, 1 H); 
13C NMR (CDCl3) δ 160.8, 155.4, 134.3, 134.2, 120.0, 118.8, 118.7, 118.5, 106.6, 82.7; MS (EI) 
m/z (rel intensity) 219 (100), 190 (25); HRMS (EI) m/z calcd for C15H9NO 219.0684, found 
219.0678. 
NH2
O
CN
F3C
 
4-(4-((2-Amino-4-(trifluoromethyl)phenyl)ethynyl)-2-chlorophenoxy)benzonitrile (2-
13). A solution of 2-12 (0.570 g, 2.60 mmol) and 2-iodo-5-trifluoromethylphenylamine119 (0.672 
g, 2.34 mmol) in MeCN (18 mL) was degassed and treated with PdCl2(PPh3)2 (91.2 mg, 0.130 
mmol) and CuI (54.5 mg, 0.286 mmol). The reaction mixture was degassed again and treated 
with Et3N (1.81 mL, 13.0 mmol). The reaction mixture was heated at reflux for 1.5 h, diluted 
with Et2O and filtered through a pad of Celite and Florisil (1:1, v/v). The pad was washed with 
Et2O (3x) and the filtrate was concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:THF = 6:1 to 4:1) yielded 0.993 g (100%) of 2-13 as a yellow 
solid: mp 121.9-123.8 ºC (THF); IR (KBr) 3482, 3379, 2232, 1621, 1513 cm-1; 1H NMR 
(CDCl3) δ 7.65 (d, 2 H, J = 8.9 Hz), 7.58 (d, 2 H, J = 8.8 Hz), 7.45 (d, 1 H, J = 8.1 Hz), 7.10-
7.04 (m, 4 H), 7.00-6.93 (m, 2 H), 4.46 (s, 2 H); 13C NMR (CDCl3) δ 160.8, 155.4, 148.1, 134.3, 
133.6, 132.5, 131.3 (q, J = 31.5 Hz), 120.1, 119.3, 118.8, 118.5, 114.0 (q, J = 3.7 Hz), 110.8, 
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110.7 (q, J = 3.8 Hz), 106.5, 95.6, 85.0; MS (EI) m/z (rel intensity) 378 (100), 276 (15), 248 (10), 
84 (45); HRMS (EI) m/z calcd for C22H13N2OF3 378.0980, found 378.0993. 
N
H
O
CN
F3C  
4-(4-(6-(Trifluoromethyl)-1H-indol-2-yl)phenoxy)benzonitrile (2-14). A solution of 2-
13 (0.103 g, 0.271 mmol) in DCM (6.0 mL) was treated with AuClPPh3 (6.08 mg, 0.0134 mmol) 
followed by AgClO4 (6.080 mg, 0.0298 mmol) at room temperature. The reaction mixture was 
stirred in the dark at room temperature for 14 h and filtered through a pad of Celite and Florisil 
(1:1, v/v). The pad was washed with Et2O (3x). The organic phases were combined and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes:THF = 
4:1) yielded 90.2 mg (87%) of 2-14 as a yellow solid: mp 198.5-201.6 ºC (THF); IR (KBr) 3357, 
2228, 1598, 1491, 1460 cm-1; 1H NMR (DMSO-d6) δ 12.05 (s, 1 H), 7.98 (d, 2 H, J = 9.0 Hz), 
7.84 (d, 2 H, J = 9.0 Hz), 7.73-7.67 (m, 2 H), 7.31-7.20 (m, 2 H), 7.15 (d, 2 H, J = 9.0 Hz), 7.00 
(s, 1 H); 13C NMR (DMSO-d6) δ 160.8, 154.5, 140.2, 135.9, 134.6, 131.3, 128.4, 127.5, 121.8 (q, 
J = 30.8 Hz), 120.73, 120.66, 118.7, 118.3, 115.8-115.6 (m), 108.4 (q, J = 4.5 Hz), 105.4, 99.0; 
MS (EI) m/z (rel intensity) 378 (16), 276 (20), 248 (20), 102 (100), 75 (32); HRMS (EI) m/z 
calcd for C22H13F3N2O 378.0980, found 378.0973. 
N
H
O
NH2.HCl
HN
F3C  
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4-(4-(6-(Trifluoromethyl)-1H-indol-2-yl)phenoxy)benzimidamide hydrochloride (2-
15). A solution of 2-14 (30.0 mg, 0.0793 mmol) in EtOH:CHCl3 = 1:1 (v/v, 10 mL) at 0 oC was 
bubbled with HCl gas for 30 min. The reaction mixture was stirred at room temperature for 24 h 
and the solvent was removed. The residue was redissolved in EtOH (6.0 mL) and bubbled with 
NH3 gas for 20 min at room temperature. The reaction mixture was stirred for 24 h, re-bubbled 
with NH3 gas and stirred for another 24 h. The solvent was evaporated and the residue was co-
evaporated with EtOH (x2). The residue was redissolved in EtOH (2.0 mL) and filtered through 
a pad of SiO2. The filtrate was poured into Et2O (10 mL) and bubbled with HCl for 1 min. After 
30 min stirring, the precipitate was decanted, washed with Et2O (2x) and dried under vacuum to 
afford 23.8 mg (70%) of 2-15 as a white solid: mp 206.8 ºC (decomp.; EtOH-Et2O); IR (KBr) 
3126, 1673, 1600, 1513, 1478, 1401 cm-1; 1H NMR (DMSO-d6) δ 12.38 (s, 1 H), 9.39 (s, 1 H), 
9.21 (s, 1 H), 8.18 (d, 1 H, J = 8.8 Hz), 8.05 (app dd, 2 H, J = 8.7, 2.3 Hz), 7.92 (d, 2 H, J = 8.7 
Hz), 7.75-7.68 (m, 2 H), 7.51 (app s, 1 H), 7.35-7.15 (m, 4 H), 7.05-7.01 (m, 1 H); 13C NMR 
(DMSO-d6) δ 164.8, 161.4, 154.8, 140.2, 135.9, 131.2, 130.7, 128.2, 127.6, 122.3, 121.6 (q, J = 
30.7 Hz), 120.7, 120.5, 117.8, 117.7, 115.8-115.5 (m), 108.5 (q, J = 3.7 Hz), 98.8, MS (EI) m/z 
(rel intensity) 396 (55), 285 (60), 273 (75), 199 (90), 125 (100); HRMS (EI) m/z calcd for 
C22H16F3N3O 395.1245, found 395.1239. 
N
H
O
NH.AcOH
N
F3C  
2-(4-(4-(4,5-Dihydro-1H-imidazol-2-yl)phenoxy)phenyl)-6-(trifluoromethyl)-1H-
indole (2-16). A mixture of sulfur (0.846 mg, 0.0215 mmol) and 2-14 (20.0 mg, 0.0529 mmol) 
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was treated with ethylene diamine (0.5 mL), then heated in the microwave at 130 C for 30 min. 
The reaction mixture was suspended in water and filtered, and the solid was rinsed with water 
(3x) and dried under vacuum, affording 2-16 (14.2 mg, 42%) as a sticky yellow solid: IR (Neat) 
3222, 1603, 1563, 1506, 1492, 1461 cm-1; 1H NMR (DMSO-d6)  12.03 (s, 1 H), 7.94 (d, 2 H, J 
= 9.0 Hz), 7.86 (d, 2 H, J = 9.0 Hz), 7.72, 7.67 (s, 1 H), 7.28 (d, 1 H, J = 9.0 Hz), 7.19(d, 2 H, J 
= 9.0 Hz), 7.10 (d, 2 H, J = 9.0 Hz), 7.00 (s, 1 H), 3.66 (s, 4 H); 13C NMR (DMSO-d6)  163.0, 
158.1, 156.1, 140.4, 135.8, 131.3, 129.1, 127.3, 127.2, 126.0, 123.6, 121.6 (q, J = 30.7 Hz), 
120.6, 119.6, 118.0, 115.8-115.5 (m), 108.3 (q, J = 4.5 Hz); MS (EI) m/z (rel intensity) 421 
(100), 392 (45), 378 (15), 196 (22), 177 (20); HRMS (EI) m/z calcd for C24H18N3OF3 421.1402, 
found 421.1391. 
NH2
O
CN
NC
 
4-Amino-3-((4-(4-cyanophenoxy)phenyl)ethynyl)benzonitrile (2-17). A solution of 2-
12 (16.1 mg, 0.0734 mmol) and 4-amino-3-iodobenzonitrile (28.7 mg, 0.117 mmol) in MeCN 
(0.5 mL) was degassed and treated with PdCl2(PPh3)2 (2.58 mg, 0.00367 mmol)  and CuI (1.54 
mg, 0.00807 mmol). The reaction mixture was degassed again and treated with Et3N (51.1 μL, 
0.367 mmol). The reaction mixture was heated at reflux for 4 h, diluted with Et2O and filtered 
through a pad of Celite and Florisil (1:1, v/v). The pad was washed with Et2O (3x) and the 
filtrate was concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc = 3:1 to 2:1 to 1:1) yielded 21.7 mg (89%) of 2-17 as a white solid: mp 168.5-
171.2 ºC (acetone); IR (KBr) 3457, 3360, 3216, 2224, 2211, 1628, 1594, 1554, 1495 cm-1; 1H 
NMR (acetone-d6) δ 7.79 (d, 2 H, J = 9.0 Hz), 7.69 (d, 2 H, J = 8.9 Hz), 7.63 (d, 1 H, J = 2.0 
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Hz), 7.41 (dd, 1 H, J = 8.6, 2.0 Hz), 7.19-7.13 (m, 4 H), 6.90 (d, 1 H, J = 8.6 Hz), 6.07 (br s, 2 
H); 13C NMR (acetone-d6) δ 161.6, 156.3, 153.5, 136.9, 135.2, 134.4, 133.9, 120.9, 120.1, 119.9, 
119.5, 119.0, 114.9, 107.7, 107.4, 99.2, 95.3; MS (EI) m/z (rel intensity) 335 (95), 239 (35), 322 
(25), 278 (30), 216 (100), 199 (75); HRMS (EI) m/z calcd for C22H13N3O 335.1059, found 
335.1043. 
N
H
O
CN
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2-(4-(4-Cyanophenoxy)phenyl)-1H-indole-5-carbonitrile (2-18). A solution of 2-17 
(15.0 mg, 0.0446 mmol) in DCM (1.0 mL) was treated with AuClPPh3 (1.0 mg, 0.00223 mmol) 
followed by AgClO4 (1.0 mg, 0.00491 mmol) at room temperature. The reaction mixture was 
stirred in the dark at room temperature for 4 h and filtered through a pad of Celite and Florisil 
(1:1, v/v). The pad was washed with Et2O (3x). The organic phases were combined and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Toluene:Et2O = 
4:1) yielded 13.2 mg (88%) of 2-18 as a yellow solid: mp 260 ºC (decomp.) (acetone); IR (KBr) 
3385, 3123, 2961, 2924, 2220, 1597, 1493 cm-1; 1H NMR (acetone-d6) δ 11.28 (br s, 1 H), 8.04-
7.96 (m, 2 H), 7.80 (d, 2 H, J = 8.9 Hz), 7.63-7.55 (m, 2 H), 7.42 (dd, 1 H, J = 8.2, 1.6 Hz), 7.26 
(d, 2 H, J = 8.8 Hz), 7.20 (d, 2 H, J = 8.9 Hz), 7.06 (dd, 1 H, J = 2.2, 0.7 Hz); 13C NMR 
(acetone-d6) δ 161.9, 156.0, 140.6, 139.9, 135.2, 129.8, 126.2, 125.2, 121.5, 120.9, 119.2, 119.0, 
113.1, 107.1, 103.6, 100.4; MS (EI) m/z (rel intensity) 335 (100), 222 (20); HRMS (EI) m/z calcd 
for C22H13N3O 335.1059, found 335.1062. 
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2-(4-(4-Carbamimidoylphenoxy)phenyl)-1H-indole-5-carboximidamide 
dihydrochloride (2-19). A solution of 2-18 (13.2 mg, 0.0394 mmol) in EtOH:CHCl3 = 1:1 (v/v, 
4.4 mL) at 0 oC was bubbled with HCl gas for 30 min. The reaction mixture was stirred at room 
temperature for 20 h and the solvent was removed. The residue was redissolved in EtOH (2.7 
mL) and bubbled with NH3 gas for 20 min at room temperature. The reaction mixture was stirred 
for 24 h, re-bubbled with NH3 gas and stirred for another 24 h. The solvent was evaporated and 
the residue was co-evaporated with EtOH (x2), dissolved in EtOH (1.0 mL) and filtered. The 
filtrate was poured into Et2O (5.0 mL) and bubbled with HCl for 1 min. After 30 min stirring, the 
precipitate was decanted, washed with Et2O (2x) and dried under vacuum to afford 13.3 mg 
(76%) of 2-19 as a yellow solid: mp 254 ºC (decomp.) (EtOH-Et2O); IR (KBr) 3144, 1669, 1600, 
1517, 1479 cm-1; 1H NMR (CD3OD) δ 9.21 (br s, 1 H), 9.06 (br s, 2 H), 8.74 (br s, 1 H), 8.53 (br 
s, 2 H), 8.12 (d, 1 H, J = 1.2 Hz), 7.94 (d, 2 H, J = 8.8 Hz), 7.85 (d, 2 H, J = 8.9 Hz), 7.61 (d, 1 H, 
J = 8.6 Hz), 7.56 (dd, 1 H, J = 8.6, 1.8 Hz), 7.24-7.15 (m, 4 H), 7.01 (s, 1 H); 13C NMR 
(CD3OD) δ 169.2, 167.5, 164.0, 156.5, 142.0, 141.4, 131.4, 130.4, 130.1, 128.6, 123.5, 122.3, 
121.9, 121.8, 120.0, 119.2, 113.0, HRMS (ESI) m/z calcd for C22H20N5O (M+H) 370.1668, 
found 370.1642. 
N
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5-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy)-
phenyl)-1H-indole diacetate (2-20). A solution of 2-18 (17.2 mg, 0.0513 mmol) and sulfur 
(0.81 mg, 0.0253 mmol) in ethylenediamine 0.5 mL was heated in the microwave at 110 °C for 
30 min. The product was precipitated out with water (5.0 mL). The precipitate was collected by 
filtration, washed with water (x3) and dried under vacuum to afford 16.2 mg of crude product. A 
sample of this crude product was purified by reverse-phase HPLC (MeOH-1% aq. AcOH) to 
yield 2-20 as a sticky yellow solid: 1H NMR (DMSO-d6) δ 11.74 (s, 1 H), 8.01-7.95 (m, 1 H), 
7.94-7.88 (m, 2 H), 7.64 (dd, 2 H, J = 8.6, 1.4 Hz), 7.38 (d, 1 H, J = 8.8 Hz), 7.18-7.11 (m, 2 H), 
7.10-7.05 (m. 2 H), 6.94-6.90 (m, 1 H), 3.61 (s, 4 H), 3.58 (s, 4 H), 1.81 (s, 6 H); LC-MS (ESI) 
(M+H) m/z 422.2; MS (EI) m/z (rel intensity) 421 (40), 392 (20), 207 (40); HRMS (EI) m/z calcd 
for C26H23N5O 421.1903, found 421.1922. 
N
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4-(5-Formylpyridin-2-yloxy)benzonitrile (2-21). A solution of 6-bromo-3-
pyridinecarboxaldehyde (1.07 g, 5.75 mmol) and 4-cyanophenol (0.690 g, 5.75 mmol) in DMF 
(34.5 mL) was treated with potassium carbonate (3.16 g, 22.9 mmol) and heated to 150 C for 3 
h. The reaction mixture was poured into water and extracted with EtOAc (3x). The combined 
organic layers were washed with water (3x) and brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (hexanes: EtOAc = 4:1 to 2:1) 
afforded 0.990 g (77%) of 2-21 as a yellow solid: mp 132.0-134.1 C (DCM); IR (KBr) 3424, 
3099, 2925, 2867, 2230, 1697, 1609, 1593, 1571, 1505 cm-1; 1H NMR (CDCl3)  9.99 (s, 1 H), 
8.60 (d, 1 H, J = 2.0 Hz), 8.24 (dd, 1 H, J = 8.5, 2.3 Hz), 7.72 (d, 2 H, J = 8.8 Hz), 7.29 (d, 2 H, J 
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= 8.8 Hz), 7.13 (d, 1 H, J = 8.5 Hz); 13C NMR (CDCl3)  189.2, 165.9, 156.5, 152.2, 139.4, 
134.0, 128.5, 122.6, 118.5, 112.9, 109.2; MS (EI) m/z (rel intensity) 224 (100), 195 (45), 168 
(50), 142 (35); HRMS m/z calcd for C13H8N2O2 224.0586, found 224.0579. 
N
O
CN
 
4-(5-Ethynylpyridin-2-yloxy)benzonitrile. A solution of lithium diisopropylamide (2.0 
M in heptane, diethylbenzene and THF, 2.65 mL, 5.30 mmol) in THF (35.3 mL) at -78 °C was 
treated with TMSCHN2 (2.0 M in ether, 2.65 mL, 5.30 mmol). The reaction mixture was stirred 
at -78 °C for 30 min and a solution of 2-21 (0.990 g, 4.41 mmol) in THF (9.00 mL) was added. 
The reaction mixture was stirred at -78 ºC for 1 h and heated at reflux for 3 h. The reaction 
mixture was quenched with cold water and extracted with Et2O (3x). The organic layers were 
combined, dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:Et2O = 7:1) afforded 0.475 g (49%) of the title compound as 
a white solid: mp 121.9-123.9 ºC (THF); IR (KBr) 3426, 3250, 3098, 3061, 2231, 2224, 1606, 
1589, 1562, 1503, 1476 cm-1; 1H NMR (CDCl3) δ 8.30 (d, 1 H, J = 1.9 Hz), 7.84 (dd, 1 H, J = 
8.3, 2.3 Hz), 7.71 (d, 2 H, J = 8.8 Hz), 7.25 (d, 2 H, J = 8.9 Hz), 6.98 (dd, 1 H, J = 8.5, 0.5 Hz), 
3.20 (s, 1 H); 13C NMR (CDCl3) δ 161.6, 157.2, 150.9, 143.0, 13.8, 121.8, 118.5, 115.1, 111.9, 
108.2, 80.4, 79.7; MS (EI) m/z (rel intensity) 220 (100), 192 (50), 102 (40); HRMS (EI) m/z 
calcd for C14H8N2O 220.0637, found 220.0630. 
NH2
N
O
CN
NC
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3-Amino-4-((6-(4-cyanophenoxy)pyridin-3-yl)ethynyl)benzonitrile (2-22). A solution 
of 4-(5-ethynylpyridin-2-yloxy)benzonitrile (0.332 g, 1.51 mmol) and 4-amino-3-
iodobenzonitrile (0.334 g, 1.372 mmol) in MeCN (10 mL) was degassed and treated with 
PdCl2(PPh3)2 (48.2 mg, 0.0686 mmol) and CuI (28.8 mg, 0.151 mmol). The reaction mixture was 
degassed again and treated with Et3N (0.954 mL, 6.86 mmol). The reaction mixture was heated 
at reflux for 2 h, diluted with THF and filtered through a pad of Celite and Florisil (1:1, v/v). The 
pad was washed with THF (3x) and the filtrate was concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Tolene:THF = 3:1, then repeated with DCM:THF = 
10:1) yielded 0.453 g (98%) of 2-22 as a yellow solid: mp 209.2-212.8 ºC (THF); IR (KBr) 3474, 
3372, 3061, 2224, 1623, 1604, 1583, 1550, 1500, 1467 cm-1; 1H NMR (acetone-d6) δ 8.42 (dd, 1 
H, J = 2.4, 0.6 Hz), 8.11 (dd, 1 H, J = 8.7, 2.4 Hz), 7.86 (d, 2 H, J = 9.0 Hz), 7.46 (d, 1 H, J = 7.8 
Hz), 7.40 (d, 2 H, J = 9.0 Hz), 7.19 (dd, 1 H, J = 8.4 , 0.6 Hz), 7.12 (d, 1 H, J = 1.2 Hz), 6.94 (dd, 
1 H, J = 8.1, 1.5 Hz); 13C NMR (DMSO-d6) δ 161.3, 157.2, 150.2, 150.0, 143.1, 134.3, 132.8, 
122.0, 118.9, 118.5, 116.4, 115.4, 112.2, 111.8, 109.5, 107.3, 93.2, 87.8; MS (EI) m/z (rel 
intensity) 336 (80), 262 (100), 234 (30), 219 (90), 205 (40); HRMS (EI) m/z calcd for C21H12N4O 
336.1011, found 336.1008. 
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2-(6-(4-Cyanophenoxy)pyridin-3-yl)-1H-indole-6-carbonitrile (2-23). A solution of 2-
22 (185 mg, 0.550 mmol) in MeCN (21.5 mL) and DMF (0.715 mL) was treated with PdCl2 (103 
mg, 0.578 mmol). The reaction mixture was stirred at room temperature for 24 h and filtered 
through a pad of Celite and Florisil (1:1, v/v). The pad was washed with THF (3x). The organic 
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phases were combined and concentrated under reduced pressure. Purification by chromatography 
on SiO2 (toluene:THF = 10:1) yielded 58.3 mg (32%) of 2-23 as a yellow solid: mp 256.0 ºC 
(decomp., THF); IR (KBr) 3140, 3051, 1671, 1599, 1539, 1454, 1406 cm-1; 1H NMR (DMSO-d6) 
δ 12.80 (s, 1 H), 9.51 (s, 2 H), 9.37 (s, 2 H), 9.32 (s, 2 H), 9.14 (s, 2 H), 8.88 (d, 1 H, J = 1.8 Hz), 
7.98 (s, 1 H), 7.95 (d, 2 H, J = 8.7 Hz), 7.71 (d, 1 H, J = 8.4 Hz), 7.58 (s, 1 H), 7.45 (d, 1 H, J = 
9.9 Hz), 7.41 (d, 2 H, J = 8.4 Hz), 7.30 (d, 1 H, J = 8.7 Hz), 7.24 (s, 2 H), 7.11 (s, 1 H); 13C 
NMR (DMSO-d6) δ 167.0, 165.5, 163.4, 162.2, 158.6, 145.3, 139.0, 138.1, 136.6, 132.9, 130.6, 
124.3, 121.7, 120.7, 120.6, 119.3, 112.8, 112.6, 100.0; HRMS (ESI) m/z calcd for C21H13N4O 
(M+H) 337.1089, found 337.1058. 
N
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2-(6-(4-Carbamimidoylphenoxy)pyridin-3-yl)-1H-indole-6-carboximidamide 
diformate (2-24). A solution of 2-23 (30.0 mg, 0.0892 mmol) in EtOH:CHCl3 = 1:1 (v/v, 10 
mL) at 0 C was bubbled with HCl gas for 30 min and then stirred at room temperature for 24 h. 
The reaction mixture was bubbled with HCl gas again and stirred for another 24 h at room 
temperature. The solvent was evaporated and EtOH (6.0 mL) was added. The solution was 
bubbled with NH3 gas at room temperature for 10 min. After 24 h stirring at room temperature, 
the reaction mixture was bubbled with NH3 gas again and stirred for another 24 h. The solvent 
was evaporated and the residue was co-evaporated with EtOH (x2). The residue was redissolved 
in EtOH (1 mL) and filtered. The filtrate was treated with formic acid (final concentration of 
HCOOH ~ 50% v/v) and stirred for 30 min at room temperature. Ether (10 mL) was added and 
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the precipitate was collected by filtration to yield 30.5 mg (74%) of 2-24 as a yellow solid: mp 
232.6 C (DMSO, dec.); IR (KBr) 3368, 3136, 1674, 1627, 1599, 1481, 1451, 1401 cm-1; 1H 
NMR (DMSO-d6)  9.47 (s, 2 H), 9.30 (s, 1 H), 9.26 (s, 1 H), 8.45 (d, 2 H, J = 8.3 Hz), 7.97 (d, 1 
H, J = 8.4 Hz), 7.83-7.70 (m, 1 H), 7.57 (app s, 2 H), 7.40 (app s, 2 H); 7.34-7.24 (m, 2 H), 7.23 
(app s, 2 H); 13C NMR (DMSO-d6)  166.1, 164.8, 163.0, 160.7, 167.5, 164.4, 143.2, 130.8, 
129.9, 129.6, 122.9, 122.4, 121.6, 119.9, 119.2, 118.6, 118.4; HRMS (ESI) m/z calcd for 
C21H19N6O (M+H) 371.1621, found 371.1614. 
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6-(4,5-Dihydro-1H-imidazol-2-yl)-2-(6-(4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy)-
pyridin-3-yl)-1H-indole (2-25). A mixture of sulfur (0.723 mg, 0.0226 mmol) and 2-23 (15.2 
mg, 0.0452 mmol) was treated with ethylene diamine (0.5 mL), then heated in the microwave at 
110 C for 30 min. The reaction mixture was suspended in water and filtered, and the solid was 
rinsed with water (3x), and dried under vacuum, affording 2-25 (12.4 mg, 65%) as a yellow 
solid: mp 188.2 C (ethylene diamine/H2O, dec.); IR (KBr) 3420, 2928, 2868, 1603, 1570, 1513, 
1457 cm-1; 1H NMR (DMSO-d6)  11.86 (s, 1 H), 8.71 (d, 1 H, J = 2.0 Hz), 8.35 (dd, 1 H, J = 
8.5, 2.2 Hz), 7.90-7.83 (m, 3 H), 7.54 (app s, 2 H), 7.24-7.17 (m, 3 H), 3.64 (s, 4 H), 3.61 (s, 4 
H); 13C NMR (DMSO-d6)  164.7, 163.0, 162.0, 155.5, 144.3, 137.0, 136.6, 136.5, 130.2, 128.6, 
126.9, 123.9, 123.4, 120.5, 119.5, 119.1, 112.0, 110.5, 99.3; MS (EI) m/z (rel intensity) 422 
(100), 393 (30), 182 (30); HRMS (EI) m/z calcd for C25H22N6O 422.1855, found 422.1842. 
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4-(4-Formylphenylthio)benzonitrile (2-30). A solution of 4-fluorobezaldehyde (1.61 
mL, 15.0 mmol) and 4-mercaptobenzonitrile120 (2.03 g, 15.0 mmol) in DMF (90 mL) was treated 
with potassium carbonate (2.28 g, 16.5 mmol) and heated to 120 C for 14 h. The reaction 
mixture was poured into water and extracted with EtOAc (3x). The combined organic layers 
were washed with 5% aqueous K2CO3 (2x), water (3x) and brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (hexanes: EtOAc 
= 8:1) afforded 2.93 g (77%) of 2-30 as a white solid: mp 111.7-112.5 C (Hexanes-EtOAc); IR 
(neat) 3427, 3078, 2835, 2744, 2231, 2225, 1701, 1690, 1671, 1586, 1561, 1483 cm-1; 1H NMR 
(CDCl3)  10.0 (s, 1 H), 7.86 (d, 2 H, J = 8.4 Hz), 7.61 (d, 2 H, J = 8.4 Hz), 7.50 (d, 2 H, J = 8.1 
Hz), 7.42 (d, 2 H, J = 8.7 Hz); 13C NMR (CDCl3)  191.1, 141.7, 141.5, 135.6, 133.0, 131.4, 
130.9, 130.7, 118.4, 111.1; MS (EI) m/z (rel intensity) 239 (50), 209 (15), 127 (10), 84 (100); 
HRMS m/z calcd for C14H9NOS 239.0405, found 239.0393. 
S
CN
 
4-(4-Ethynylphenylthio)benzonitrile. A solution of lithium diisopropylamide (2.0 M in 
heptane, diethylbenzene and THF, 0.187 mL, 0.374 mmol) in THF (2.50 mL) at -78 °C was 
treated with TMSCHN2 (2.0 M in ether, 0.187 mL, 0.374 mmol). The reaction mixture was 
stirred at -78 °C for 30 min and a solution of 2-30 (0.0747 g, 0.312 mmol) in THF 0.63 mL was 
added. The reaction mixture was stirred at -78 ºC for 1 h and heated at reflux for 2 h, quenched 
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with cold water and extracted with Et2O (3x). The organic layers were combined, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:Et2O = 10:1) afforded 0.0397 g (54%) of the title compound as a white solid: mp 
76.4-78.2 ºC (DCM); IR (neat) 3286, 2226, 1590, 1482 cm-1; 1H NMR (CDCl3) δ 7.52 (d, 4 H, J 
= 8.4 Hz), 7.42 (d, 2 H, J = 8.4 Hz), 7.23 (d, 2 H, J = 8.7 Hz), 3.19 (s, 1 H); 13C NMR (CDCl3) δ 
144.4, 133.6, 133.5, 132.8, 132.7, 128.5, 123.1, 118.7, 109.7, 82.8, 79.4; MS (EI) m/z (rel 
intensity) 235 (100), 190 (10); HRMS (EI) m/z calcd for C15H9NS 235.0456, found 235.0455. 
NH2
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3-Amino-4-((4-(4-cyanophenylthio)phenyl)ethynyl)benzonitrile (2-31). A solution of 
4-(4-ethynylphenylthio)benzonitrile (39.7 mg, 0.169 mmol) and 3-amino-4-iodobenzonitrile 
(41.1 mg, 0.169 mmol) in MeCN (1.23 mL) was degassed and treated with PdCl2(PPh3)2 (5.94 
mg, 0.00845 mmol) and CuI (3.55 mg, 0.0186 mmol). The reaction mixture was degassed again 
and treated with Et3N (118 μL, 0.845 mmol). The reaction mixture was stirred at room 
temperature for 48 h, diluted with THF and filtered through a pad of Celite and Florisil (1:1, v/v). 
The pad was washed with THF (3x) and the filtrate was concentrated under reduced pressure. 
Purification by chromatography on SiO2 (first with Hexanes:THF = 4:1 to 1:1, then repurified 
with tolene:Et2O = 20:1) yielded 65.5 mg (73%) of 2-31 as a yellow solid: mp 198.0-200.2 ºC 
(THF); IR (neat) 3468, 3369, 2221, 1621, 1586, 1506, 1481 cm-1; 1H NMR (DMSO-d6) δ 7.76 
(d, 2 H, J = 8.1 Hz), 7.74 (d, 2 H, J = 6.9 Hz), 7.53 (d, 2 H, J = 8.4 Hz), 7.39 (d, 1 H, J = 7.8 Hz), 
7.32 (d, 2 H, J = 8.4 Hz), 7.06 (s, 1 H), 6.89 (d, 1 H, J = 7.8 Hz), 6.09 (br s, 2 H); 13C NMR 
(DMSO-d6) δ 150.0, 143.4, 133.2, 133.0, 132.9, 131.8, 128.3, 122.9, 118.9, 118.5, 118.3, 116.4, 
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111.8, 109.6, 108.7, 96.1, 87.1; MS (EI) m/z (rel intensity) 351 (100), 235 (35), 117 (70); HRMS 
(EI) m/z calcd for C22H13N3S 351.0830, found 351.0840. 
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2-(4-(4-Cyanophenylthio)phenyl)-1H-indole-6-carbonitrile (2-32). A solution of 2-31 
(43.3 mg, 0.123 mmol) in DCM (2.75 mL) was treated with AuClPPh3 (3.04 mg, 0.00670 mmol) 
followed by AgClO4 (3.04 mg, 0.0149 mmol) at room temperature. The reaction mixture was 
stirred in the dark at room temperature for 14 h and filtered through a pad of Celite and Florisil 
(1:1, v/v). The pad was washed with THF (3x). The organic phases were combined and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (toluene:Et2O = 
10:1) yielded 32.0 mg (74%) of 2-32 as a yellow solid: mp 270 ºC (decomp.) (DMSO); IR (neat) 
3315, 3052, 2238, 1619, 1598, 1589, 1498, 1482 cm-1; 1H NMR (acetone-d6) δ 12.25 (s, 1 H), 
7.85 (s, 1 H), 7.75 (d, 2 H, J = 8.4 Hz), 7.71 (d, 1 H, J = 8.4 Hz), 7.64 (d, 2 H, J = 8.4 Hz), 7.40-
7.28 (m, 3 H), 7.15 (d, 1 H, J = 0.9 Hz); 13C NMR (acetone-d6) δ 144.6, 141.0, 136.5, 134.8, 
133.4, 132.4, 130.9, 128.2, 127.4, 122.7, 121.7, 120.9, 119.0, 116.5, 108.7, 103.5, 101.0; MS 
(EI) m/z (rel intensity) 91 (100), 172 (40), 351 (30); HRMS (EI) m/z calcd for C22H13N3S 
351.0830, found 351.0839. 
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2-(4-(4-Carbamimidoylphenylthio)phenyl)-1H-indole-6-carboximidamide 
dihydrochloride (2-33). A solution of 2-32 (45.0 mg, 0.128 mmol) in EtOH:CHCl3 = 1:1 (v/v, 
10 mL) at 0 oC was bubbled with HCl gas for 30 min. The reaction mixture was stirred at room 
temperature for 24 h and the solvent was removed. The residue was redissolved in EtOH (6.0 
mL) and bubbled with NH3 gas for 20 min at room temperature. The reaction mixture was stirred 
for 24 h, re-bubbled with NH3 gas and stirred for another 24 h. The solvent was evaporated and 
the residue was co-evaporated with EtOH (x2). The residue was redissolved in EtOH (2.0 mL) 
and filtered through a pad of SiO2. The filtrate was poured into Et2O (10 mL) and bubbled with 
HCl for 1 min. After 30 min stirring, the precipitate was decanted, washed with Et2O (2x) and 
dried under vacuum to afford 42.0 mg (72%) of 2-33 as a brown solid: mp 246 ºC (decomp.) 
(EtOH-Et2O); IR (neat) 3367, 3150, 1669, 1622, 1595, 1539, 1473, 1457 cm-1; 1H NMR 
(DMSO-d6) δ 12.69 (s, 1 H), 9.49 (s, 2 H), 9.37 (s, 2 H), 9.30 (s, 2 H), 9.15 (s, 2 H), 8.12 (d, 1 H, 
J = 8.4 Hz), 7.99 (s, 1 H), 7.83 (d, 2 H, J = 8.4 Hz), 7.73 (d, 1 H, J = 8.1 Hz), 7.60 (d, 2 H, J = 
8.4 Hz), 7.46 (d, 1 H, J = 8.4), 7.39 (d, 2 H, J = 8.7 Hz), 7.15 (s, 1 H); 13C NMR (DMSO-d6) δ 
167.1, 165.4, 144.6, 141.3, 136.8, 134.3, 133.0, 132.4, 131.6, 129.6, 128.3, 127.6, 125.9, 121.0, 
120.0, 120.9, 112.7, 100.6, HRMS (ESI) m/z calcd for C22H20N5S (M+H) 386.1439, found 
386.1432. 
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6-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)phenylthio) 
phenyl)-1H-indole (2-34). A mixture of sulfur (1.46 mg, 0.0456 mmol) and 2-32 (32.0 mg, 
 137 
0.0911 mmol) was treated with ethylene diamine (1.0 mL), then heated in the microwave at 110 
C twice for 30 min. The reaction mixture was suspended in water and filtered, and the solid was 
rinsed with water (3x), and dried under vacuum, affording (22.3 mg, 56%) of 2-34 as a yellow 
solid: mp 154 ºC (decomp.) (Etylene diamine-H2O); IR (neat) 3407, 2934, 2866, 1606, 1502, 
1480 cm-1; 1H NMR (DMSO-d6)  11.86 (s, 1 H), 7.92 (d, 2 H, J = 8.4 Hz), 7.88 (s, 1 H), 7.79 
(d, 2 H, J = 8.4 Hz), 7.53 (s, 2 H), 7.48 (d, 2 H, J = 8.4 Hz), 7.33 (d, 2 H, J = 8.4 Hz), 6.98 (s, 1 
H), 3.62 (s, 4 H), 3.58 (s, 4 H); 13C NMR (DMSO-d6)  164.7, 163.0, 138.7, 137.9, 136.7, 132.7, 
132.2, 131.5, 130.1, 129.24, 129.15, 128.1, 126.3, 123.9, 119.6, 119.0, 110.5, 99.6, 49.4; HRMS 
(ESI) m/z calcd for C26H24N5S (M+H) 438.1752, found 438.1737. 
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Quinoline indoles 2-35 and 2-36 (inseparable mixture, trifluoroacetate salts). A 
suspension of 2-(4-(4-cyanophenoxy)phenyl)-1H-indole-6-carbonitrile121 (100 mg, 0.298 mmol) 
in EtOH/CHCl3 (1:1, 20 mL) at 0 °C was bubbled with HCl gas for 30 min. The reaction mixture 
was stirred at room temperature for 12 h and the solvent was evaporated. The residue was co-
evaporated with EtOH twice to remove the remaining HCl and provide the crude iminoester 
intermediate.  
A solution of the crude residue (0.0298 mmol) and N1-(7-chloroquinolin-4-yl)propane-1,3-
diamine122 (7.04 mg, 0.0298 mmol) in EtOH (1.0 mL) was treated with PhSH (0.306 µL, 
0.00298 mmol) and heated in the microwave at 150 °C for 30 min. The solvent was evaporated 
under reduced pressure and the residue was purified by reverse-phase HPLC (MeOH-0.1% aq. 
TFA) to yield 5.8 mg (33%) of 2-35 and 2-36 as an inseparable, sticky yellow solid (ca. 4:1 
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mixture of regioisomers): IR (neat) 3392, 1662, 1596, 1445, 1241, 1195, 1129 cm-1; 1H NMR of 
both isomers (CD3OD) δ 8.43 (d, 1 H, J = 7.2 Hz), 8.41 (d, 1 H, J = 9.0 Hz), 7.95 (d, 2 H, J = 
8.7 Hz), 7.93 (s, 1 H), 7.90-7.81 (m, 2 H), 7.79-7.72 (m, 2.3 H), 7.72-7.62 (m, 1 H), 7.45 (dd, 
0.91 H, J = 8.4, 1.8 Hz), 7.36 (dd, 0.24 H, J = 8.4, 1.8 Hz), 7.25-7.16 (m, 4 H), 6.98-6.92 (m, 2 
H), 3.82-3.73 (m, 2 H), 3.70-3.57 (m, 2 H), 2.32-2.21 (m, 2 H); 13C NMR of major isomer (125 
MHz, DMSO-d6) δ 169.4, 165.6, 163.6, 163.2, 163.0, 157.9, 157.1, 144.2, 143.5, 141.3, 140.2, 
138.2, 135.4, 131.6, 131.5, 130.1, 129.0, 126.2, 124.8, 122.1, 121.9, 121.7, 120.5, 119.8, 119.4, 
117.2, 112.9, 100.7, 100.0, 42.5, 42.0, 27.3; HRMS (ESI) m/z calcd for C34H31N7OCl (M+H) 
588.2279, found 588.2299; the content of TFA in the product was determined by adding a known 
amount of trifluoroethanol as an internal standard and comparing the integration of the 
trifluoroacetate and trifluoroethanol in the 19F NMR. 
O
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(4-(4-Ethynylphenoxy)phenyl)methanol.* A solution of 2-39 (0.219 g, 1.00 mmol) in 
DCM (2.3 mL) and toluene (1.6 mL) at -78 °C was treated with DIBAL (1.0 M in hexanes, 1.00 
mL, 1.00 mmol). The reaction mixture was stirred at -78 °C for 3 h, quenched with a saturated 
aqueous solution of NH4Cl, warmed to room temperature and extracted with EtOAc (1x). The 
organic layer was washed with 0.3 M HCl (1x), water (2x) and brine (1x), dried (Na2SO4), 
filtered and concentrated under reduced pressure to afford the crude aldehyde. A solution this 
crude aldehyde in MeOH (9.6 mL) was treated with NaBH4 (23.6 mg, 0.62 mmol) at room 
temperature. The reaction mixture was stirred at room temperature for 30 min and quenched with 
                                                 
* (CWD095: procedure, melting point, IR, HRMS and carbon NMR; CWD079: proton NMR) 
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0.3 M HCl. The mixture was extracted with EtOAc (3x), washed with water (1x) and brine (1x), 
dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 3:1) afforded 0.111 g (50%) of the title compound 
as a white solid: mp 93.0-94.3 ºC (DCM); IR (neat) 3395, 3304, 3284, 2949, 2886, 1904, 1609, 
1599, 1502, 1420, 1412 cm-1; 1H NMR (CDCl3) δ 7.46 (d, 2 H, J = 8.4 Hz), 7.37 (d, 2 H, J = 8.4 
Hz), 7.03 (d, 2 H, J = 8.4 Hz), 6.93 (d, 2 H, J = 8.7 Hz), 4.68 (s, 2 H), 2.98 (s, 1 H); 13C NMR 
(CDCl3) δ 158.1, 155.8, 136.6, 133.9, 128.9, 119.7, 118.3, 116.7, 83.4, 76.8, 64.7; MS (EI) m/z 
(rel intensity) 224 (100), 207 (10), 165 (10), 118 (20), 89 (20); HRMS (EI) m/z calcd for 
C15H12O2 224.0837, found 224.0838. 
O
CH2OTBS
 
tert-Butyl(4-(4-ethynylphenoxy)benzyloxy)dimethylsilane (2-40).* A solution of (4-(4-
ethynylphenoxy)phenyl)methanol (0.111 g, 0.496 mmol), imidazole (0.169 g, 2.48 mmol) and 
TBSCl (0.180 g, 1.19 mmol) in DMF (0.67 mL) at room temperature was stirred for 16 h and 
quenched with water. The mixture was extracted with EtOAc (3x). The combined organic layers 
were washed with water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes:Et2O = 20:1) afforded 0.165 
g (98%) of 2-40 as a clear oil: IR (neat) 3292, 3039, 2929, 2953, 2885, 2856, 2108, 1598, 1497, 
1468, 1412 cm-1; 1H NMR (CDCl3) δ 7.48 (d, 2 H, J = 9.0 Hz), 7.36 (d, 2 H, J = 8.1 Hz), 7.04 (d, 
2 H, J = 8.4 Hz), 6.95 (d, 2 H, J = 8.7 Hz), 4.77 (s, 2 H), 3.06 (s, 1 H), 1.00 (s, 9 H), 0.16 (s, 6 
H); 13C NMR (CDCl3) δ 158.5, 155.2, 137.4, 133.9, 127.9, 119.7, 118.2, 116.6, 83.5, 76.7, 64.7, 
                                                 
* (CWD096:  procedure, IR, HRMS, proton and carbon NMR) 
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26.2, 19.0, -5.0; MS (EI) m/z (rel intensity) 338 (80), 221 (10), 323 (20), 295 (20), 281 (90), 207 
(100); HRMS (EI) m/z calcd for C21H26O2Si 338.1702, found 338.1703. 
NH2
O
CH2OTBS
NC
 
3-Amino-4-((4-(4-((tert-butyldimethylsilyloxy)methyl)phenoxy)phenyl)ethynyl)-
benzonitrile.* A solution of 2-40 (0.165 g, 0.487 mmol) and 3-amino-4-iodobenzonitrile (0.119 
g, 0.487 mmol) in MeCN (3.5 mL) was degassed and treated with PdCl2(PPh3)2 (17.1 mg, 0.0244 
mmol) and CuI (10.2 mg, 0.0536 mmol). The reaction mixture was degassed again and treated 
with Et3N (0.339 mL, 2.44 mmol). The reaction mixture was stirred at room temperature for 14 h 
and at 80 °C for 3 h, diluted with THF and filtered through a pad of Celite and Florisil (1:1, v/v). 
The pad was washed with THF (3x) and the filtrate was concentrated under reduced pressure. 
Purification by chromatography on SiO2 (first with Hexanes:THF = 8:1 to 4:1, then re-
chromatographed with Hexanes:THF = 4:1) yielded 0.218 g (99%) of the title compound 
(contaminated with BHT from THF) as a yellow solid: mp 162.1-166.7 ºC (THF); IR (neat) 
3383, 2952, 2928, 2885, 2855, 2230, 1596, 1557, 1497 cm-1; 1H NMR (CDCl3) δ 7.50 (d, 2 H, J 
= 8.4 Hz), 7.44-7.33 (m, 3 H), 7.07-6.96 (m, 6 H), 4.76 (s, 2 H), 4.50 (s, 2 H), 0.98 (s, 9 H), 0.14 
(s, 6 H); 13C NMR (CDCl3) δ 158.8, 155.0, 147.9, 137.6, 133.4, 132.7, 127.9, 121.2, 119.8, 
119.1, 118.3, 117.0, 116.6, 112.8, 112.4, 98.1, 83.8, 64.7, 30.5, 26.1, 18.2, -5.0; MS (EI) m/z (rel 
intensity) 454 (80), 411 (30), 337 (20), 323 (100), 117 (55); HRMS (EI) m/z calcd for 
C28H30N2O2Si 454.2077, found 454.2074. 
                                                 
* (CWD098: procedure, melting point, HRMS, IR; CWD084: proton and carbon NMR) 
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O
N
HNC
CH2OTBS
 
2-(4-(4-((tert-Butyldimethylsilyloxy)methyl)phenoxy)phenyl)-1H-indole-6-
carbonitrile. *  A solution of 3-amino-4-((4-(4-((tert-butyldimethylsilyloxy)methyl)-phenoxy)-
phenyl)-ethynyl)-benzonitrile (0.218 g, 0.480 mmol) in DCM (11 mL) was treated with 
AuClPPh3 (11.8 mg, 0.0240 mmol) followed by AgClO4 (11.0 mg, 0.0528 mmol) at room 
temperature. The reaction mixture was stirred in the dark at room temperature for 16 h and 
filtered through a pad of Celite and Florisil (1:1, v/v). The pad was washed with THF (3x). The 
organic phases were combined and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:THF = 8:1) yielded 0.137 g (63%) of the title compound 
(contaminated with BHT from THF) as a yellow solid: mp 153.4-155.8 ºC (THF); IR (neat) 3366, 
2951, 2926, 2881, 2853, 2212, 1604, 1492 cm-1; 1H NMR (CDCl3) δ 8.94 (s, 1 H), 7.74 (s, 1 H), 
7.70-7.62 (m, 3 H), 7.36 (app d, 3 H, J = 8.7 Hz), 7.13-7.04 (m, 4 H), 6.82 (d, 1 H, J = 1.2 Hz), 
4.77 (s, 2 H), 0.98 (s, 9 H), 0.15 (s, 6 H); 13C NMR (CDCl3) δ 158.6, 155.4, 141.8, 137.4, 135.7, 
132.9, 128.0, 127.3, 126.1, 123.5, 121.2, 121.1, 119.6, 119.0, 115.7, 104.0, 100.0, 64.8, 30.5, 
26.2, -5.0; MS (EI) m/z (rel intensity) 454 (20), 323 (100), 75 (80); HRMS (EI) m/z calcd for 
C28H30N2O2Si 454.2077, found 404.2065. 
 
 
                                                 
* (CWD099: procedure, melting point, HRMS and IR; CWD086: proton and carbon NMR) 
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O
N
HNC
CHO
 
2-(4-(4-Formylphenoxy)phenyl)-1H-indole-6-carbonitrile (2-41).* A solution of 2-(4-
(4-((tert-butyldimethylsilyloxy)methyl)phenoxy)phenyl)-1H-indole-6-carbonitrile (0.137 g, 
0.301 mmol) in THF (3.2 mL) was treated with TBAF (1 M in THF, 0.602 mL, 0.602 mmol) at 
room temperature. The reaction mixture was stirred for 2 h and filtered through a pad of SiO2. 
The pad was washed with THF (3x). The organic phases were combined and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (toluene:THF = 3:1) yielded 0.119 g 
of the alcohol. A solution of this alcohol in DCM (7.3 mL) and DMSO (2.5 mL) was treated with 
Dess-Martin periodinane (0.148 g, 0.350 mmol) at room temperature. The reaction mixture was 
stirred for 1 h and quenched with a mixture of 5% aqueous Na2S2O3 and saturated NaHCO3. The 
mixture was extracted with DCM (1x). The organic layer was dried (MgSO4) and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (toluene:Et2O = 4:1) afforded 
60.9 mg (37% over four steps) of 2-41 as a yellow solid: mp 202.6-203.6 ºC (THF); IR (neat) 
3324, 2218, 1688, 1592, 1579, 1540, 1490 cm-1; 1H NMR (DMSO-d6) δ 12.17 (s, 1 H), 9.93 (s, 1 
H), 8.00 (d, 2 H, J = 8.7 Hz), 7.94 (d, 2 H, J = 8.7 Hz), 7.83 (s, 1 H), 7.69 (d, 1 H, J = 8.4 Hz), 
7.33 (d, 1 H, J = 8.1, 1.2 Hz), 7.28 (d, 2 H, J = 8.7 Hz), 7.20 (d, 2 H, J = 8.4 Hz), 7.05 (d, 2 H, J 
= 0.9 Hz), 4.77 (s, 2 H), 0.98 (s, 9 H), 0.15 (s, 6 H); 13C NMR (DMSO-d6) δ 191.6, 162.0, 155.0, 
141.2, 135.9, 132.1, 131.9, 131.6, 127.8, 127.7, 122.3, 121.0, 120.68, 120.66, 118.0, 115.9, 102.6, 
99.5; MS (EI) m/z (rel intensity) 338 (10), 257 (20), 236 (20), 165 (20), 111 (40), 97 (75), 83 
(100); HRMS (EI) m/z calcd for C22H14N2O2 338.1055, found 338.1065. 
                                                 
* (CWD101: procedure, melting point, HRMS, IR, proton and carbon NMR) 
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O
N
H
H
N
N •4TFA
N
H
NH
NCl
 
N1-(7-chloroquinolin-4-yl)-N3-(4-(4-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-
yl)phenoxy)benzyl)propane-1,3-diamine (2-42, trifluoroacetate salt). *  A solution of 2-41 
(19.0 mg, 0.0562 mmol) and N1-(7-chloroquinolin-4-yl)propane-1,3-diamine122 (26.5 mg, 0.112 
mmol) in MeOH (2.0 mL) was treated with NaBH3CN (7.1 mg, 0.112 mmol) at room 
temperature. The reaction mixture was stirred for 14 h and quenched with saturated aqueous 
NaHCO3. The mixture was extracted with DCM (3x). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure. Purification by chromatography on SiO2 
(toluene:Et2O = 1:1 with 0.2% Et3N) afforded the crude amine (43.3 mg). A mixture of sulfur 
(0.9 mg, 0.028 mmol) and the crude amine (21.6 mg) was treated with ethylene diamine (0.5 
mL), then heated in the microwave at 130 C for 30 min. Additional sulfur (0.9 mg, 0.028 mmol) 
was added. The reaction mixture was heated in the microwave at 130 C for 30 min, suspended 
in water and filtered, and the solid was rinsed with water (3x), and purified by reverse-phase 
HPLC (MeOH-0.1% aq. TFA) to yield 5.4 mg (32%) of 2-42 as a sticky yellow solid: IR (neat) 
3416, 1668, 1485, 1456 cm-1; 1H NMR (CD3OD) δ 8.47-8.35 (m, 2 H), 7.99-7.84 (m, 4 H), 7.76-
7.67 (m, 2 H), 7.54-7.45 (m, 3 H), 7.16-7.06 (m, 4 H), 6.95 (s, 1 H), 6.92 (d, 1 H, J = 7.2 Hz), 
4.23 (s, 2 H), 4.09 (s, 4 H), 3.72 (t, 2 H, J = 6.9 Hz), 3.34-3.19 (m, 2 H), 2.99 (s, 1 H), 2.85 (s, 1 
H), 2.29-2.12 (m, 3 H); 13C NMR (150 MHz, CD3OD) δ 168.9, 164.9, 163.1, 162.9, 162.7, 162.4, 
159.5, 158.5, 157.8, 144.3, 144.1, 141.2, 140.1, 138.0, 135.7, 135.6, 133.0, 128.9, 128.7, 127.5, 
126.0, 122.0, 121.9, 120.6, 120.41, 120.37, 119.9, 117.1, 115.3, 113.1, 100.5, 99.8, 51.9, 45.9, 
                                                 
* (CWF070 and CWF065: procedure, proton and carbon NMR, HRMS, IR) 
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45.7, 41.8, 36.9, 31.6, 25.9; HRMS (ESI) m/z calcd for C36H34N6OCl (M+H) 601.2483, found 
601.2457; the content of TFA in the product was determined by adding a known amount of 
trifluoroethanol as an internal standard and comparing the integration of the trifluoroacetate and 
trifluoroethanol in the 19F NMR. 
I
NH2
AcOH2C
 
3-Amino-4-iodobenzyl acetate.* A solution of (4-iodo-3-nitrophenyl)methanol123 (0.623 
g, 2.50 mmol) in pyridine (20 mL) was treated with Ac2O (1.18 mL, 12.5 mmol) at room 
temperature. The reaction mixture was stirred for 12 h and concentrated under reduced pressure. 
The residue was partitioned between EtOAc and saturated aqueous CuSO4. The organic layer 
was washed with saturated aqueous CuSO4 (2x), water (2x), brine (1x), dried (Na2SO4) and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc 
= 6:1) yielded 0.730 g of the acetate as a yellow solid. A solution of this acetate (0.555 g, 1.73 
mmol) in AcOH (3.5 mL), EtOH (3.5 mL) and conc. aqueous HCl (0.052 mL) was treated with 
iron powder (0.380 g, 6.79 mmol) at room temperature. The reaction mixture was heated at 
reflux for 4 h, quenched with a mixture of water and Na2CO3 and extracted with EtOAc (4x). 
The combined organic layers were washed with saturated aqueous NaHCO3, dried (Na2SO4) and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc 
= 6:1) afforded 0.382 g (69% over two steps) of the title compound as a white solid: mp 526.-
54.4 ºC (DCM); IR (neat) 3455, 3363, 1731, 1613, 1481, 1425 cm-1; 1H NMR (CDCl3) δ 7.59 (d, 
1 H, J = 8.1 Hz), 6.72 (app s, 1 H), 6.46 (dd, 1 H, J = 8.1, 1.5 Hz), 4.97 (s, 2 H), 4.17 (br s, 2 H), 
                                                 
* . (CWD171: procedure, melting point, HRMS, IR, proton NMR, CWD162: carbon NMR) 
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2.10 (s, 3 H); 13C NMR (CDCl3) δ 171.0, 147.1, 139.3, 137.6, 119.7, 114.3, 83.7, 65.8, 21.2; MS 
(EI) m/z (rel intensity) 291 (80), 249 (100), 232 (30), 104 (50); HRMS (EI) m/z calcd for 
C9H10NO2I 290.9756, found 290.9767. 
O
CN
AcOH2C
NH2  
3-Amino-4-((4-(4-cyanophenoxy)phenyl)ethynyl)benzyl acetate. *  A solution of 3-
amino-4-iodobenzyl acetate (0.382 g, 1.31 mmol) and 2-12 (0.288 g, 1.31 mmol) in MeCN (9.5 
mL) was degassed and treated with PdCl2(PPh3)2 (46.0 mg, 0.0655 mmol) and CuI (27.5 mg, 
0.144 mmol). The reaction mixture was degassed again, treated with Et3N (0.911 mL, 6.55 
mmol), heated at reflux for 1.5 h, diluted with THF and filtered through a pad of Celite and 
Florisil (1:1, v/v). The pad was washed with THF (3x) and the filtrate was concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 4:1 to 2:1) yielded 
0.429 g (86%) of the title compound as a sticky yellow solid: IR (neat) 3460, 3363, 2225, 1731, 
1619, 1606 cm-1; 1H NMR (CDCl3) δ 7.64 (d, 2 H, J = 9.0 Hz), 7.57 (d, 2 H, J = 8.7 Hz), 7.36 (d, 
1 H, J = 7.8 Hz), 7.05 (app d, 4 H, J = 8.1 Hz), 6.76-6.68 (m, 2 H), 5.04 (s, 2 H), 4.32 (s, 2 H), 
2.13 (s, 3 H); 13C NMR (CDCl3) δ 170.9, 161.1, 155.1, 148.1, 138.0, 134.4, 133.6, 132.5, 120.3, 
120.1, 118.8, 118.6, 117.7, 113.9, 107.6, 106.6, 94.1, 86.1, 66.1, 21.1; MS (EI) m/z (rel intensity) 
382 (100), 323 (90), 193 (25). 
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AcOH2C NH
O
CN
 
(2-(4-(4-cyanophenoxy)phenyl)-1H-indol-6-yl)methyl acetate (2-43). *A solution of 3-
amino-4-((4-(4-cyanophenoxy)phenyl)ethynyl)benzyl acetate (0.429 g, 1.12 mmol) in DMF (13 
mL) was treated with PdCl2(PhCN)2 (87.6 mg, 0.224 mmol) at room temperature. The reaction 
mixture was stirred at 80 °C for 0.5 h, quenched with water, extracted with EtOAc (3x). The 
organic layers were combined, dried (Na2SO4) and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 3:1 to 2:1) yielded 0.235 g (55%) of 
2-43 as a yellow solid: mp 153.9-159.0 ºC (DCM); IR (neat) 3384, 2970, 2223, 1720, 1690, 1587, 
1567, 1496, 1449 cm-1; 1H NMR (CDCl3) δ 9.14 (s, 1 H), 7.72 (d, 2 H, J = 8.4 Hz), 7.67-7.57 (m, 
3 H), 7.43 (app s, 1 H), 7.20-7.00 (m, 1 H), 7.12 (d, 2 H, J = 9.0 Hz), 7.05 (d, 2 H, J = 8.7 Hz), 
6.81 (d, 1 H, J =  0.9 Hz), 5.25 (s, 2 H), 2.11 (s, 3 H); 13C NMR (CDCl3) δ 171.5, 161.4, 154.4, 
137.9, 137.0, 134.3, 129.8, 129.4, 129.3, 127.0, 121.1, 120.8, 120.7, 118.9, 118.1, 111.7, 106.0, 
99.7, 67.4, 21.2; MS (EI) m/z (rel intensity) 382 (50%), 323 (100), 193 (25), 102 (20); HRMS 
(EI) m/z calcd for C24H18N2O3 382.1317, found 382.1329. 
O
CN
TBSOH2C
NH2  
4-(4-((2-Amino-4-((tert-butyldimethylsilyloxy)methyl)phenyl)ethynyl)phenoxy)-
benzonitrile. †  A solution of 2-12 (3.38 g, 15.4 mmol) and 5-((tert-butyldimethylsilyloxy)-
                                                 
* (CWD172 and CWD174: procedure, melting point, HRMS, proton and carbon NMR) 
† (CWD263: procedure, proton NMR; CWD209: melting point, HRMS, IR; CWD124 carbon NMR) 
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methyl)-2-iodoaniline123 (5.60 g, 16.5 mmol) in MeCN (112 mL) was degassed and treated with 
PdCl2(PPh3)2 (0.541 g, 0.770 mmol) and CuI (0.323 g, 1.69 mmol). The reaction mixture was 
degassed again, treated with Et3N (10.7 mL, 77.0 mmol), heated at reflux for 3 h, diluted with 
THF and filtered through a pad of Celite and Florisil (1:1, v/v). The pad was washed with THF 
(3x) and the filtrate was concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:THF = 10:1 to 8:1) yielded 5.96 g (85%) of the title compound as a yellow solid: 
mp 86.3-89.3 ºC (DCM); IR (neat) 3376, 2952, 2925, 2881, 2225, 1606, 1591 cm-1; 1H NMR 
(CDCl3) δ 7.64 (d, 2 H, J = 8.7 Hz), 7.56 (d, 2 H, J = 8.7 Hz), 7.32 (d, 2 H, J = 7.8 Hz), 7.09-
7.00 (m, 4 H), 6.75 (s, 1 H), 6.67 (d, 1 H, J = 7.8 Hz), 4.68 (s, 2 H), 4.29 (s, 2 H), 0.96 (s, 9 H), 
0.12 (s, 6 H); 13C NMR (CDCl3) δ 161.2, 154.9, 148.0, 143.9, 134.4, 133.5, 132.2, 125.7, 120.4, 
120.3, 118.5, 115.9, 112.0, 106.6, 106.3, 93.4, 86.6, 64.9, 30.5, 26.2, 18.6, -5.1; HRMS (ESI) 
m/z calcd for C28H31N2O2Si (M+H) 455.2155, found 455.2146. 
O
CN
TBSOH2C
NHBoc  
tert-Butyl 5-((tert-butyldimethylsilyloxy)methyl)-2-((4-(4-cyanophenoxy)phenyl) ethy 
nyl)-phenylcarbamate. *  A solution of 4-(4-((2-amino-4-((tert-butyldimethylsilyloxy)-
methyl)phenyl)-ethynyl)phenoxy)benzonitrile (5.96 g, 13.1 mmol) and Boc2O (4.62 g, 21.0 
mmol) in THF (81 mL) was heated at reflux for 24 h. The reaction mixture was treated with 
additional Boc2O (4.62 g, 21.0 mmol) and heated at reflux for another 24 h. The reaction mixture 
was partitioned between EtOAc and water. The aqueous phase was washed with EtOAc (2x). 
                                                 
* (CWD264: procedure, proton NMR; CWD210: HRMS; CWD202: IR, carbon NMR) 
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The combined organic layers were washed with brine (1x), dried (Na2SO4) and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (first with Hexanes:THF = 10:1, 
then re-chromatographed with Hexanes:Et2O = 20:1 to 10:1) yielded 6.34 g (71%) of the title 
compound as a clear oil (contaminated with BHT from ether): IR (neat) 3407, 2954, 2930, 2885, 
2856, 2227, 1809, 1733, 1593, 1572, 1525, 1496 cm-1; 1H NMR (CDCl3) δ 8.08 (s, 1 H), 7.65 (d, 
2 H, J = 8.7 Hz), 7.59 (d, 2 H, J = 8.7 Hz), 7.45 (d, 1 H, J = 8.1 Hz), 7.29 (s, 1 H), 7.11-7.05 (m, 
5 H), 1.55 (s, 12 H), 0.96 (s, 9 H), 0.12 (s, 6 H); 13C NMR (CDCl3) δ 161.0, 155.5, 152.5, 144.0, 
139.5, 134.5, 133.7, 132.0, 125.7, 120.4, 120.0, 119.7, 118.8, 118.7, 115.2, 109.6, 106.8, 94.8, 
85.2, 81.1, 65.1, 27.6, 26.2, 18.6, -5.1; HRMS (ESI) m/z calcd for C33H38N2O4NaSi (M+Na) 
577.2499, found 577.2520.  
O
CN
OHC
NHBoc  
tert-Butyl 2-((4-(4-cyanophenoxy)phenyl)ethynyl)-5-formylphenylcarbamate (2-46).* 
A solution of tert-butyl 5-((tert-butyldimethylsilyloxy)methyl)-2-((4-(4-cyanophenoxy)phenyl)-
ethynyl)phenylcarbamate (6.34 g, 9.34 mmol) in THF (76 mL) was treated with a solution of 
TBAF (1 M in THF, 18.7 mL, 18.7 mmol) at room temperature. The reaction mixture was stirred 
for 2 h, quenched with water and extracted with EtOAc (3x). The combined organic layers were 
washed with water (2x), brine (1x), dried (Na2SO4) and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 3:1 to 2:1) yielded 4.89 g (71%) of 
the alcohol. A solution of this alcohol and NaHCO3 (2.96 g, 33.6 mmol) in DCM (100 mL) was 
                                                 
* (CWD267 and CWD268: procedure, melting point, proton NMR; CWD206: IR; CWD216: HRMS and 
carbon NMR) 
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treated with Dess-Martin periodinane (6.70 g, 15.8 mmol) at room temperature. The reaction 
mixture was stirred for 4 h and partitioned between saturated aqueous Na2S2O3 and EtOAc. The 
organic layer was washed with brine (1x), dried (Na2SO4) and concentrated under reduced 
pressure. Purification by chromatography on SiO2 (first with Hexanes:Et2O = 5:1 to 2:1 to 
Hexanes:THF = 1:1, then re-chromatographed with Hexanes:Et2O = 15:1 to 3:1 to 2:1 to 
Hexanes:THF = 5:1) yielded 4.72 g (97%) of 2-46 as a white solid: mp 163.2-164.8 (DCM); IR 
(neat) 3405, 2978, 2226, 1731, 1696, 1592, 1570, 1523, 1496 cm-1; 1H NMR (CDCl3) δ 10.02 (s, 
1 H), 8.72 (s, 1 H), 7.70-7.54 (m, 6 H), 7.38 (s, 1 H), 7.13-7.07 (m, 4 H), 1.58 (s, 12 H); 13C 
NMR (CDCl3) δ 191.6, 160.5, 156.1, 152.2, 140.2, 136.8, 134.4, 133.8, 132.3, 121.9, 120.2, 
119.8, 118.9, 118.6, 118.4, 116.6, 107.0, 98.6, 84.2, 81.6, 28.3; MS (EI) m/z (rel intensity) 438 
(5), 382 (80), 364 (90), 338 (100), 191 (30); HRMS (EI) m/z calcd for C27H22N2O4 438.1580, 
found 438.1598. 
NHBoc
O
CN
NH
NHN
Cl
 
tert-Butyl 5-((3-(7-chloroquinolin-4-ylamino)propylamino)methyl)-2-((4-(4-cyano-
phenoxy)-phenyl)ethynyl)phenylcarbamate.* A solution of 2-46 (2.69 g, 6.13 mmol) and N1-
(7-chloroquinolin-4-yl)propane-1,3-diamine122 (2.89 g, 12.3 mmol) in HC(OEt)3 (135 mL) was 
heated to 80 °C for 1.5 h. The reaction mixture was cooled to room temperature, diluted with 
MeOH (135 mL) and treated with NaBH3CN (3.86 g, 61.3 mmol). The reaction mixture was 
stirred for 14 h at room temperature. Most of the solvent was evaporated under reduced pressure. 
                                                 
* (CWD270: procedure; CWD208: proton NMR and HRMS; CWD228: carbon NMR and IR) 
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Purification of the residue by chromatography on SiO2 (toluene:THF = 4:1 to 2:1 to 1:1 with 1% 
Et3N) afforded 3.12 g (77%) of the title compound as a clear oil (contaminated with BHT from 
THF): IR (neat) 3636, 3404, 3247, 2956, 2227, 1730, 1609, 1581, 1495 cm-1; 1H NMR (CDCl3) 
δ 8.48 (d, 1 H, J = 5.4 Hz), 8.25 (s, 1 H), 7.91 (s, 1 H), 7.70-7.60 (m, 4 H), 7.59-7.43 (m, 3 H), 
7.42-7.33 (m, 3 H), 7.20-6.95 (m, 6 H), 6.32 (d, 1 H, J = 5.4 Hz), 3.86 (s, 2 H), 3.49-3.39 (m, 2 
H), 3.02-2.95 (m, 2 H), 2.00-1.92 (m, 2 H), 1.53 (s, 9 H); 13C NMR (CDCl3) δ 160.8, 155.6, 
152.0, 150.6, 149.1, 142.0, 139.9, 137.9, 134.4, 133.7, 132.1, 129.1, 128.3, 125.4, 124.9, 122.4, 
122.3, 120.3, 119.3, 118.7, 117.6, 117.4, 110.1, 106.8, 98.4, 95.5, 84.7, 81.2, 54.4, 49.2, 43.8, 
28.4; HRMS (ESI) m/z calcd for C39H37N5O3Cl (M+H) 658.2585, found 658.2548. 
NH2
O
CN
NBoc
NHN
Cl
 
tert-Butyl 3-amino-4-((4-(4-cyanophenoxy)phenyl)ethynyl)benzyl(3-(7-chloro-quino-
lin-4-ylamino)propyl)carbamate (2-47). *  A solution of tert-butyl 5-((3-(7-chloroquinolin-4-
ylamino)propylamino)methyl)-2-((4-(4-cyanophenoxy)-phenyl)ethynyl)-phenylcarbamate (3.12 
g, 4.74 mmol) in TFA (5.0 mL) was stirred at room temperature for 5 min. The reaction mixture 
was basified with 5% aqueous K2CO3 and extracted with EtOAc (3x). The combined organic 
layers were washed with water (2x), brine (1x), dried (Na2SO4) and concentrated under reduced 
pressure. A solution of this crude product in DCM (58 mL) was treated with Et3N (1.06 mL, 7.62 
mmol) and Boc2O 1.68 g, 7.62 mmol) at room temperature. The reaction mixture was stirred at 
room temperature for 3 h and partitioned between EtOAc and water. The organic layer was 
                                                 
* (CWD275 and CWD276: procedure and proton NMR; CWD238: IR; CWD250: carbon NMR) 
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washed with water (1x), brine (1x), dried (Na2SO4) and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (toluene:THF = 15:1 to 4:1 to 1:1) afforded 1.44 g (46%) 
of 2-47 as a clear oil (contaminated with BHT from THF): IR (neat) 3367, 2965, 2225, 1669, 
1606, 1578, 1490 cm-1; 1H NMR (CDCl3) δ 8.48 (d, 1 H, J = 4.5 Hz), 7.94 (s, 1 H), 7.61-7.51 
(m, 4 H), 7.37-7.13 (m, 4 H), 7.03-6.97 (m, 4 H), 6.62-6.57 (m, 2 H), 6.31 (d, 1 H, J = 5.1 Hz), 
4.52 (s, 2 H), 4.36 (s, 2 H), 3.40-3.23 (m, 4 H)1.87-1.76 (m, 2 H), 1.52 (s, 9 H); 13C NMR 
(CDCl3) δ 161.1, 155.2, 151.9, 149.1, 148.2, 140.4, 135.2, 134.5, 133.6, 132.7, 129.24, 129.20, 
128.7, 128.6, 128.5, 125.7, 120.4, 120.2, 118.8, 118.6, 107.1, 106.7, 94.1, 86.0, 80.9, 79.3, 51.0, 
30.5, 28.7, 21.4; HRMS (ESI) m/z calcd for C39H37N5O3Cl (M+H) 658.2585, found 658.2552. 
•4TFA
H
NHN
N
N
H
O
NH
N
Cl
 
N1-(7-Chloroquinolin-4-yl)-N3-((2-(4-(4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy)-
phenyl)-1H-indol-6-yl)methyl)propane-1,3-diamine (TFA salt, 2-45). *  A solution of 2-47 
(0.713 g, 1.08 mmol) in DMF (9.6 mL) was degassed and treated with PdCl2(PhCN)2 (0.622 g, 
1.62 mmol) at room temperature. The reaction mixture was degassed again and stirred at 80 °C 
for 0.5 h. The solvent was evaporated under reduced pressure. The crude mixture was 
redissolved in TFA (20 mL) and stirred at room temperature for 30 min. The solvent was 
evaporated under reduced pressure. One third of the crude mixture and sulfur (57.6 mg, 1.8 
mmol) was treated with ethylene diamine (1.0 mL), then heated in the microwave at 130 C for 
                                                 
* (CWD279 and CWD282: procedure, proton NMR, IR, HRMS and carbon NMR) 
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30 min. The reaction mixture was suspended in water and filtered, and the solid was rinsed with 
water (3x), and purified by reverse-phase HPLC (MeOH-0.1% aq. TFA) to yield 77.2 mg (23%) 
of 2-45 as a sticky brown solid: IR (neat) 3216, 3098, 2957, 1672, 1611, 1503, 1485 cm-1; 1H 
NMR (CD3OD) δ 8.35 (d, 1 H, J = 7.2 Hz), 8.29 (d, 1 H, J = 9.0 Hz), 7.91-7.83 (m, 4 H), 7.80 (d, 
1 H, J = 1.8 Hz), 7.61 (dd, 1 H, J = 9.0, 2.1 Hz), 7.56-7.48 (m, 2 H), 7.19 (app d, 4 H, J = 8.7 
Hz), 7.09 (dd, 1 H, J = 8.1, 1.2 Hz), 6.81 (d, 1 H, J = 7.2 Hz), 6.77 (s, 1 H), 4.31 (s, 2 H), 4.07 (s, 
4 H), 3.65 (t, 2 H, J = 6.9 Hz), 3.21 (t, 2 H, J = 7.5 Hz), 2.23-2.12 (m, 2 H); 13C NMR (CD3OD) 
δ 167.1, 164.6, 157.6, 155.8, 143.9, 141.0, 140.1, 139.9, 138.7, 131.8, 131.4, 131.3, 130.9, 128.3, 
125.9, 125.1, 122.1, 122.0, 120.3, 119.1, 117.6, 116.9, 114.1, 100.0, 99.7, 53.1, 45.9, 45.2, 41.7, 
25.8; HRMS (ESI) m/z calcd for C36H34N6OCl (M+H) 601.2483, found 601.2489; the content of 
TFA in the product was determined by adding a known amount of trifluoroethanol as an internal 
standard and comparing the integration of the trifluoroacetate and trifluoroethanol in the 19F 
NMR. 
Assay of BoNT/A light chain proteolytic activity in the presence of different small molecule 
Inhibitors (performed by our collaborators at NCI). The HPLC based assay for BoNT/A SNAP-
25 cleavage was conducted as described previously without modification.124-125 The BoNT/A 
inhibition activities of different compounds were compared by measuring reaction velocities in 
the presence of 20 μM inhibitor and then calculating percent inhibition values using uninhibited 
control reactions. Assays were conducted at 100 μM substrate concentration and reported percent 
inhibition values are the averages of two independent experiments. 
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3.0  TOTAL SYNTHESIS OF HAOUAMINE A 
3.1 INTRODUCTION 
 
3.1.1 Haouamines: Structure and Biological Activity 
Haouamines A and B (Figure 39) were isolated in 2003 from the tunicate Aplidium haouarianum 
collected off Tarifa Island in Spain.126 The more stable haouamine A was obtained in significant 
quantity (150 mg), whereas the less stable haouamine B was isolated in minor quantity (5.8 mg). 
The structure of haouamine A was established by interpretation of its spectroscopic data and 
those of the N-methyl derivative, and confirmed by X-ray crystallographic analysis. The 
structure of haouamine B was deduced via spectroscopic studies of its peracetyl derivative. 
Figure 39 Structures of haouamine A and B 
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The most striking structure feature of the haouamines is their bent biphenol residing in the 
strained aza-paracyclophane system (Figure 40). Despite its boat-like conformation, the B-ring 
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exhibits standard aromatic chemical shifts in the 1H and 13C NMR spectra (Figure 41), which 
indicate the presence of ring current. In addition, all six carbon-carbon bonds in the ring have 
similar bond lengths (1.40 Å), resembling the behavior of planar aromatic systems. The presence 
of aromaticity in haouamines proved to be critical for their synthesis, for it served as a driving 
force for the formation of the strained paracyclophane.127-129 
Figure 40 X-ray structure of haouamine A and its boat-like phenyl ring. 
 
Figure 41 Chemical shift values (ppm) and C-C bond lengths (Å) of the central phenyl ring in haouamine A 
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At ambient temperature both haouamine A and B exist as two NMR-detectable 
interconverting forms in solution.126,130 All attempts to separate the isomers by means of 
chromatography failed; high temperature NMR experiments also did not simplify the spectra.126 
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Additionally, the ratio of isomers was found to be dependent upon the NMR solvent used (e.g. 
2:1 in acetone-d6, 1:3 in DMSO-d6). In contrast to the NMR study, a crystal structure of 
haouamine A demonstrated a pattern with a single molecular geometry (Figure 40). Redissolving 
the crystal resulted in the same mixture of the two equilibrating isomers as detected by NMR. 
Zubia and co-workers proposed that the origin of the two interconverting isomers was from 
either atropisomerism of the central phenyl ring or from inversion at the nitrogen center (Figure 
42). Synthetic studies by Baran et al.128 provided a pair of stable and separable haouamine A 
atropisomers, which indicated that the N-inversion may account for the interconverting isomers. 
This was further supported by a computational study.130  
Figure 42 Proposed atropisomerism and N-inversion in haouamines 
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Zubia et al. tested haouamine A and B against human lung carcinoma A-549, human colon 
carcinoma HT-29 and HCT-116, mice endothelial cells MS-1, and human prostate carcinoma 
PC-3. Haouamine A showed high and selective activity against the HT-29 cell line with an IC50 
of 0.1 µg/mL, while haouamine B (2) was only slightly cytotoxic against the MS-1 cell line with 
an IC50 of 5 µg/mL.126 A subsequent study by Baran et al. using synthetic material (single 
enantiomer) revealed that haouamine A exhibits moderate activity against PC3 human prostate 
cancer cells with IC50 = 29±2 μM. The atropisomer of haouamine A also shows comparable 
activity (IC50 = 32±3 μM).128 
 156 
The biosynthetic origins of the haouamines remain ambiguous. Baran et al. proposed the 
condensation of four meta-hydroxylated phenylacetaldehydes with ammonia followed by two 
oxidative couplings (Scheme 40). However, they were unable to demonstrate this process in 
vitro.127,131 
Scheme 40 Biosynthesis of haouamine A proposed by Baran et al. 
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3.1.2 Cyclophanes in Natural Product Synthesis 
The construction of the aza-paracyclophane moiety in haouamines is arguably the most 
challenging part of their total synthesis. A variety of cyclophane-containing natural products are 
known, among which many have been synthesized. For example, Smith et al. reported the total 
synthesis of (-)-cylindrocyclophanes A and F with a cross-metathesis reaction as the key 
cyclophane formation step (Scheme 41).132 
Scheme 41 Cross-metathesis in the total synthesis of (-)-cylindrocyclophanes F 
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The total synthesis of biphenomycin B has been accomplished featuring a microwave-
assisted intramolecular Suzuki-Miyaura reaction for the formation of a biaryl cyclophane system 
(Scheme 42). 133 
Scheme 42 Suzuki cross-coupling in the total synthesis of biphenomycin B 
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In a synthesis of alnusone dimethyl ether, Semmelhack et al. successfully constructed a 
meta,meta-biaryl cyclophane utilizing a Ni-promoted aryl iodide homocoupling procedure 
(Scheme 43).134 
Scheme 43 Ni-promoted aryl iodide homocoupling in the total synthesis of alnusone dimethyl ether 
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A common feature of the previous work on the synthesis of naturally-occurring 
cyclophanes is the lack of significant strain energy in the macrocycle. The strained aza-
cyclophane in haouamine poses a major challenge to synthetic chemists. Model cyclophanes 
with bent phenyl rings have been prepared for theoretical studies.135 For example, Tobe et al. 
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prepared a [6]paracyclophane (paracyclophane with a six-carbon linker) utilizing a [2+2] 
cycloaddition, ring-contraction (Wolff rearrangement) and Dewar benzene isomerization 
sequence (Scheme 44).136 The x-ray analysis of 3-11 revealed the distortion of the benzene ring 
from planarity (Figure 43).  
Scheme 44 Synthesis of 8-carboxy[6]paracyclophane  
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Figure 43 X-ray structure of 3-11 
 
Besides the haouamines, only one synthesis of a strained aza-paracyclophane system has 
been reported. Hasiak et al. described the preparation of 2-aza-(7)-paracyclophane 3-13 
(haouamines have 3-aza-[7]-paracyclophane systems) from the methiodide of 2-aza-(7)-
metacyclophane 3-12.137 The key step was a Sommelet-Hauser rearrangement to provide 3-13 
along with a Stevens 1,2 shift to afford 3-14. 
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Scheme 45 Synthesis of 2-aza-(7)-paracyclophane 
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3.1.3 Previous Work on the Total Synthesis of Haouamines 
The synthetic community was intrigued by haouamines’ unprecedented structure features. In 
2005, Rawal and co-workers reported a Friedel-Crafts approach towards a model system 
representing the tetrahydropyridine core of haouamine A.138 This result coincided with Trauner 
and co-workers’ preparation of a model system towards at haouamine B.139  
In 2006, Baran and co-workers reported the first racemic total synthesis of haouamine A 
(Scheme 46).127  
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Scheme 46 Baran’s 1st generation total synthesis of haouamine A: preparation of substrate for the Diels-Alder 
reaction 
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Indanone 3-15 was prepared from 7-methoxyindanone in 4 steps. Subsequent allylation 
with 3-16 followed by condensation with hydroxylamine provided oxime 3-17. Bromination of 
3-17 yielded the transient bromonium ion, which was trapped intramolecularly with the oxime 
moiety to form nitrone 3-18. In situ reduction of 3-18 with NaBH4 provided the ring-expansion 
product 3-21 via the intermediate hydroxylamine 3-19 and aziridinium ion 3-20. N-O bond 
cleavage in 3-21 was affected with elemental indium to provide tetrahydropyridine 3-22. The 
proposed mechanism of this sequence was supported by the X-ray analysis of two related 
intermediates (Figure 44). At this stage, the authors stated that attempted construction of the 
paracyclophane with several standard approaches such as transition metal based biaryl synthesis, 
Witkop photocyclization, and intramolecular alkylation all failed. Thus, they decided to utilize a 
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pyrone-alkyne Diels-Alder reaction to overcome the strain energy in the aza-paracyclophane 
system. Consequently, intermediate 3-22 was elaborated into 3-23 for the key intramolecular 
Diels-Alder reaction. 
Figure 44 Related intermediate structures confirmed by X-ray analysis 
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Before the key cycloaddition reaction, the phenol protecting groups in 3-23 were switched 
from methyls to acetates to suppress decomposition. After being heated in the microwave at 250 
°C, acetate 3-26 underwent the pyrone Diels-Alder reaction followed by decarboxylation and 
acetate removal to provide a mixture of haouamine A and the atropisomer of haouamine A (10:1) 
in 21% overall yield. 
The same group later prepared intermediate 3-17 in an enantioselective fashion (the 
absolute stereochemistry was established by X-ray analysis) and carried it through the synthesis. 
Through a comparison of the CD spectra of their synthetic material and the natural product, they 
established the absolute stereochemistry of haouamine A (Figure 39). 
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Scheme 47 Completion of the synthesis: pyrone Diels-Alder reaction 
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After the completion of the first total synthesis of haouamine A, it was noted that the 
Diels-Alder step was difficult to reproduce.128,140 In 2009, the Baran group published their 
second generation total synthesis (Scheme 48).128 Starting from 3-28 (an intermediate in their 
first generation total synthesis), they converted the aryl bromide to a boronic ester and coupled it 
to vinyl iodide 3-29. The vinyl iodide 3-29 was a racemic mixture; thus the coupling product 3-
30 was a mixture of 1:1 diastereomers. In principle, this mixture would lead to a 1:1 mixture of 
haouamine A and its atropisomer. Subsequent macrocyclization of 3-30 produced a 1.45:1 
mixture of 3-31 and 3-32 (structures confirmed by X-ray) in 79% overall yield, indicating one 
diastereomer reacted with higher efficiency than the other. The two diastereomers were separated 
and carried on individually. Treatment of 3-31 and 3-32 with LHMDS and Mukaiyama’s reagent 
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yielded double-enones, which tautomerized to phenol 3-33 and 3-34. Global deprotection with 
BBr3 produced haouamine A and its atropisomer in > 100 mg quantities. 
Scheme 48 Baran’s 2nd generation synthesis of haouamine A and its atropisomer 
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Soon after the publication of Baran’s first generation total synthesis, several formal 
syntheses were reported in the literature. Coincidentally, all of them relied on Baran’s pyrone 
Diels-Alder strategy for access to the paracyclophane system, and the differences lie in the 
construction the tetrahydropyridine core.  
In 2006, Weinreb et al. reported the preparation of intermediate 3-22 (racemic) in Baran’s 
synthesis (Scheme 49).141 Starting from isochromanone 3-35, aldehyde 3-36 was constructed and 
subsequently condensed with benzyl hydroxylamine to afford nitrone 3-37. Intramolecular 
dipolar cycloaddition provided isoxazolidine 3-38, which was further elaborated into aldehyde 3-
39. A one-pot intramolecular aldol-elimination reaction furnished dihydropyridone 3-40. The 
lactam moiety in 3-40 was reduced to a secondary amine to give the Baran pentacycle 3-22. 
Scheme 49 Weinreb’s formal synthesis of haouamine A 
O
OMe O OMe
O
OMe
PhCH2NHOH
Tol, Et3N, rt, 30 min
OMe
N
OMe
O
Ph
Tol, 130 oC
45 h;
N
O
Ph
H
OMe
OMe
73%
overall NH
O
H
OMe
OMe
O
OMe
K2CO3, MeOH,
60 oC overnight;
98%
H
OMe
OMe
N
H
O
OMe
LAH, ZnCl2, THF,
-10 oC to rt, 1 h;
75%Br
Br
H
OMe
OMe
N
H
OMe
Br
intermediate
in Baran's total synthesis
3-35 3-36
3-37
3-38 3-39
3-40 3-22
 
Two years later, Fürstner et al. reported an asymmetric formal synthesis of haouamine A 
(Scheme 50).140 Starting from enone 3-42, Heck cyclization followed by conjugate addition 
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provided tetracycle 3-44. The nitrogen in 3-44 was unmasked and alkylated with a 
homopropagyl iodide to give 3-45. Regioselective enolization of the ketone moiety in 3-45, 
subsequent trapping as the triflate, and Stille cross-coupling afforded 3-47. Removal of the 
alkynyl silyl group yielded Baran’s substrate for the Diels-Alder reaction. Compound 3-23 was 
carried through Baran’s end-game procedures to provide haouamine A.  
Scheme 50 Fürstner’s formal synthesis of haouamine A 
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In 2009, Ishibashi et al. reported their contribution to haouamine A by synthesizing 
Baran’s intermediate 3-22 (racemic) (Scheme 51).142 Highlights of their synthesis include a 
cascade Heck reaction to access the tetracycle 3-50 in high efficiency and a Suzuki cross-
coupling to install the aryl bromide moiety in 3-52. 
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Scheme 51 Ishibashi’s formal synthesis of haouamine A 
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Our group joined this arena soon after the isolation of the haouamines. Dr. Furegati, a 
former Wipf group member, evaluated strategies for the formation of the aza-paracyclophane 
moiety. Most of the conventional cyclization methods failed, including epoxide opening with an 
amine, macrolactamization, Staudinger ligation for ring-contraction and Ireland-Claisen 
rearrangement.143 Therefore, attention was turned to an aromatization approach (Scheme 52).129 
Suzuki cross-coupling of boronic ester 3-55 and vinyl triflate 3-56 followed by desilylation gave 
bicycle 3-57. The amine and alcohol functionalities in 3-58 were unmasked and cyclized under 
Mitsunobu conditions to provide macrocycle 3-58. A formal allylic oxidation of 3-58 was 
performed with a three-step protocol (epoxidation of the olefin, acid-catalyzed rearrangement to 
an allylic alcohol and oxidation to an enone) to afford enone 3-60. Upon heating with a weak 
base, enone 3-59 first lost one molecule of MeOH and tautomerized to a phenol. Protection of 
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the phenol yielded biaryl system 3-60 in good yield. Deprotection of the nosyl group followed by 
formation of the HCl salt provided crystals suitable for x-ray analysis. 
Scheme 52 Wipf’s aza-paracyclophane model system synthesis 
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X-ray analysis of 3-61·HCl provided convincing evidence that ring distortion and folding 
of this subunit are a close match of the natural product (Figure 45). This work serves as proof-of-
concept for our total synthesis of haouamine A. 
Figure 45 X-ray structure of 3-61·HCl 
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3.2 SYNTHESIS OF HAOUAMINE A 
3.2.1 1st Generation Approach: Ring-Closing Metathesis 
Initially, we envisioned that the olefinic subunit in the tetrahydropyridine core of haouamine A 
could be formed via a ring-closing metathesis reaction (3-62 to 3-63, Scheme 53). Subsequent N-
alkylation would simplify 3-63 to alcohol 3-64143 and aza-paracyclophane 3-65. 
Scheme 53 1st Generation retrosynthetic analysis 
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Ring-closing metathesis on a neopentyl olefin is a challenging task due to steric 
congestion.144 Consequently, we prepared a model system to validate our synthetic strategy (3-
66,Scheme 54). It was envisioned that 3-66 would undergo a ring-closing metathesis reaction to 
give cyclic system 3-67. The carbonate tether in 3-67 would then be removed to expose the 
amino alcohol functionality. Activation of the alcohol moiety and subsequent intramolecular 
displacement by nitrogen (or an elimination/hydroamination sequence) would provide 
tetrahydropyridine 3-68. 
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Scheme 54 Model system for the RCM reaction 
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The substrate 3-66 was prepared in five steps from commercial materials (Scheme 55). 
The key step, segment coupling between amine 3-73 and chloroformate 3-74, proceeded 
smoothly to give carbonate 3-66 in excellent yield. 
Scheme 55 Preparation of model system 3-72 for the RCM reaction 
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The RCM reaction of 3-66 to give 3-67, however, proved to be challenging. All attempts 
resulted in nearly quantitative recovery of the starting material 3-66. The catalysts screened 
include Grubbs’ first and second generation catalysts, Hoveyda-Grubbs’ catalyst and Schrock’s 
catalyst. This result was not unexpected due to the considerable steric hindrance around the 
olefin. We quickly turned to a revised strategy, namely a relay ring-closing metathesis approach 
(Scheme 56).145 
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Scheme 56 Model system for the relay RCM reaction 
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We planned to subject triene 3-75 to metathesis conditions. Compound 3-75 was expected 
to react with the catalyst to give a metal-carbene complex at the terminus of the heptadiene 
moiety. An RCM reaction would produce a cyclopentene and leave the metal-carbene complex at 
the benzylic position, which was expected to undergo another RCM to afford 3-67. This strategy 
would generate the benzylic metal-carbene complex in an intramolecular fashion as opposed to 
the intermolecular case outlined in Scheme 54. To examine this approach, 3-75 was easily 
prepared from intermediate 3-71 (Scheme 57). The cis/trans isomers 3-76a and 3-76b were 
isolated and carried on separately.  
 171 
Scheme 57 Preparation of model system 3-75 for the relay RCM reaction 
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Both 3-75a and 3-75b were subjected to a variety of relay RCM conditions (Scheme 58), 
including those using Ti(iPrO)4 as an additive to disrupt the chelation between the metal and the 
carbonate moiety. As expected, they exhibited a similar reactivity pattern. However, instead of 
the desired product 3-67, we obtained a mixture of dimer 3-78 (even at a substrate concentration 
as low as 0.2 mM) and truncated product 3-68. Based on this finding, we believe that the 
transient benzylic metal-carbene complex was formed in the reaction. However, it did not react 
with the neopentyl olefin. Instead, it abstracted a methylene group from another substrate to 
afford 3-66. 
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Scheme 58 Byproducts observed in the relay RCM reaction 
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Next, we briefly explored variations in tether length (Scheme 59). A substrate with longer 
tether (3-80) afforded no observable desired products. 
Scheme 59 Variations in tether length in the RCM reaction 
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3.2.2 2nd Generation Approach: Intramolecular Aldol and Reductive Amination 
At this stage, it was clear that a more steric-tolerant strategy was needed to construct the 
congested tetrahydropyridine core. Inspired by Weinreb and co-worker’s formal synthesis of 
haouamine A,141 we decided to utilize an intramolecular aldol reaction for the central ring 
formation (3-83 to 3-82, Scheme 60). The keto-aldehyde 3-83 could be prepared from a 
reductive amination reaction between amine 3-84 and ketone 3-85. 
Scheme 60 2nd Generation retrosynthetic analysis 
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The feasibility of the key reductive amination step was tested on a model system (3-85143 
and 3-86, Scheme 61). However, no desired product was observed even under forcing conditions 
(e.g., heating with Ti(iPrO)4). In most cases, starting material 3-85 was recovered, presumably 
due to the steric hindrance around the ketone moiety.  
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Scheme 61 Reductive amination on model ketone 3-85 
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An alternative method for reductive amination is transition metal catalyzed C-N cross-
coupling.146 Towards this end, we prepared the enol triflate of 3-85 but found that the allyl group 
had a detrimental effect on the palladium-catalyzed C-N cross coupling reaction, possibly due to 
an intramolecular Heck reaction. Therefore, the allyl group was replaced with a protected alcohol 
(Scheme 62), and secondary amine 3-91 was chosen as the coupling partner. Unfortunately, no 
desired product 3-92 was observed. In fact, reduction product 3-93 was isolated, suggesting the 
system was too congested to accept the nitrogen nucleophile.  
Scheme 62 Palladium-catalyzed C-N cross-coupling on model system 3-90 
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3.2.3 3rd Generation Approach: Intramolecular Aldol and  Suzuki Cyclization  
In order to address the problem associated with the reductive amination strategy, we decided to 
reduce the size of the nitrogen nucleophile by using a primary amine. As shown in Scheme 63, 
haouamine A could be simplified via our aromatization strategy to give 3-94, which in turn could 
be made by means of an intramolecular aldol reaction and a Suzuki cyclization from 3-95. 
Amide 3-95 would be prepared from ketone 3-96. 
Scheme 63 3rd Generation retrosynthetic analysis 
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Ketone 3-96 was prepared by a Mukaiyama aldol reaction between 3-97143 and 2-
methyoxy-1,3-dioxolane (Scheme 64). Subsequent reductive amination or C-N cross-coupling 
with phenethylamine proved to be difficult. In the case of C-N cross-coupling, the reduced 
product 3-100 was isolated. 
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Scheme 64 Attempted functionalization of 3-96 with phenethylamine 
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Logically, one could address the steric hindrance issue with a smaller nitrogen source, i.e. 
an ammonia equivalent. We chose to use an oxime intermediate (Scheme 65). Condensation of 
ketone 3-96 with hydroxylamine was followed by dissolving metal-reduction and Cbz protection 
to provide 3-101 and 3-102 in a diastereomeric ratio of 1:2.3). An X-ray analysis of major 
diastereomer 3-102 demonstrated the undesired trans-relationship between the acetal and the 
nitrogen moieties.  
Scheme 65 Functionalization of ketone 3-96 with oxime formation/reduction 
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Next we needed to address the diastereoselectivity issue. The Greenè group developed a 
novel methodology to prepare five-membered lactam rings.147-149 For example, in a total 
synthesis of (-)-anisomycin, Greenè et al. performed a [2+2] cycloaddition between the in situ 
generated dichloroketene and enol ether 3-103 to generate cyclobutanone 3-104 (Scheme 66).147 
Treatment of 3-104 with MSH effected a smooth Beckmann rearrangement to insert a nitrogen 
atom into the α-position of the ketone moiety with exclusive regioselectivity and retention of 
configuration at the adjacent stereocenter. The geminal dichloro moiety was reduced with zinc-
copper couple to provide lactam 3-105, which was further transformed into (-)-anisomycin. 
Scheme 66 Greenè’s synthesis of (-)-anisomicin 
R*O OMe
Cl3CCOCl,
Zn-Cu;
R*O OMe
O
H H
Cl
Cl
R*O OMe
H H
68% over three steps
NH
O
S
O
O
O NH2MSH =
1. MSH
2. Zn-Cu, NH4Cl
HO OMe
H H
NH
OCOCH3H
(-)-anisomycin
R* = chiral auxiliary
3-103 3-104
3-105  
We envisioned that the [2+2] cycloaddition and Beckmann rearrangement sequence was a 
perfect method to double-functionalize an olefin to provide β-amino aldehyde 3-95 in Scheme 63. 
The dichloroketene is both compact and highly energized to react with sterically congested 
systems. The subsequent Beckmann rearrangement has sufficient driving force through strain 
relieved from the cyclobutanone. In addition, it operates on the carbonyl group that is distant to 
the quaternary center, minimizing the steric interactions. Thus, we constructed olefin 3-106143,150 
and subjected it to the cycloaddition reaction conditions. Gratifyingly, cyclobutanone 3-107 was 
obtained in good to moderate yield.151 The Beckmann rearrangement proceeded in excellent 
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yield, providing 3-108 as a single regioisomer. The hydrolysis of the geminal dichloro moiety 
proved to be difficult due to the adjacent congested quaternary carbon. Eventually, it was found 
that an indirect hydrolysis via a dimethyl acetal intermediate followed by heating with perchloric 
acid was feasible. Despite the harsh conditions, product 3-109 was sufficiently clean without 
purification. In fact, 3-109 crystallized spontaneously from the crude product mixture to provide 
an X-ray quality crystal. Subsequent X-ray analysis confirmed the desired relative 
stereochemistry. Protection of the nitrogen in 3-109 with a Boc group provided α-keto lactam 3-
110 in excellent overall yield. 
Scheme 67 Dichloroketene cycloaddition, Beckmann rearrangement and hydrolysis to intermediate 3-110 
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Compared to β-amino aldehyde 3-95, lactam 3-110 has one additional carbon. Thus, the 
next step was a hydrolytic decarboxylation reaction,152-156 yielding a Boc-protected β-amino acid, 
which was masked as a methyl ester (3-111, Scheme 68). β-Amino acid 3-111 was then 
transformed into primary amine 3-112 via N-deprotection with HCl and debromination under 
hydrogenation conditions. Reductive amination of 3-112 with racemic aldehyde 3-115 (prepared 
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in two steps from 3-113129) provided 3-116 as a 1:1 mixture of diastereomers. The two 
diastereomers were not separable by chromatography on SiO2, and consequently we carried the 
mixture through the synthesis. Ultimately, one of them would lead to haouamine A whereas the 
other one would lead to atrop-haouamine A.  
Scheme 68 Synthesis of substrate 3-120 for the Suzuki cyclization 
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The next step was the acylation on the secondary amine. The acyl coupling partner 3-119 
was prepared from iodo-3-methoxylphenylacetic acid 3-117129 in three steps. It is of particular 
interest that the pinacolboronic ester survived the saponification reaction to give crude 3-119 in 
high yield and purity. Despite the hindered nature of the secondary amine in 3-116, its acylation 
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with 3-119 under peptide coupling conditions proceeded smoothly to provide 3-120 in excellent 
yield. 
We were now at the stage of our first key cyclization (Scheme 69). The intramolecular 
Suzuki cyclization was found to work with remarkable efficiency (82% yield) as well as 
excellent scalability and reproducibility.157 The key to the success of this reaction lies in the 
addition of water.158-159 The initial experiment was performed without water. The reaction took 8 
h and the yield was ~40%. We then experimented with adding 1, 2, 3 and 4 equivalents of water 
and saw a steady increase in reaction rate and yield until we added 4 equivalents of water, where 
the yield dropped to ~60%. Possible explanations for the water acceleration effect include 
acceleration of the transmetallation step with hydroxyl anions produced by water reacting with 
the base, or hydrolysis of the boronic ester to the acid before the transmetallation occurs. In the 
case of excess water, protodeboronation might become prevalent. This would be detrimental to 
the yield, since in our system the ratio of the two coupling components was kept strictly at 1:1, 
whereas most intermolecular Suzuki reactions are performed with an excess of the boronic acid.  
Scheme 69 Suzuki cyclization 
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With the desired macrocycle in hand, we set out to perform our next key cyclization 
reaction: the intramolecular aldol condensation (Scheme 70). Our initial attempt to directly 
reduce the ester functionality in 3-121 to aldehyde 3-122 was met with failure (starting material 
was recovered). We reasoned that steric hindrance at the neopentyl position was the cause. 
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Similarly, attempts to saponify the ester failed even at high temperatures (LiOH, 100 °C in 
sealed tube).  
Alternatively, the intramolecular reaction (Dieckmann condensation) of 3-121 proceeded 
smoothly to provide ketoamide 3-124. Reduction of the keto moiety with lithium borohydride 
was sluggish but provided alcohol 3-125 in good overall yield. 
Scheme 70 Intramolecular aldol and Dieckmann condensation approaches to the tetrahydropyridine core 
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The elimination of the secondary hydroxyl group to generate dihydropyridone 3-123 
proved to be challenging. Conditions screened include heating with an acid or weak base, 
SOCl2/POCl3, Martin Sulfurane and Burgess Reagent. We also attempted to activate the 
hydroxyl group with a mesylate, brosylate, acetate, triflate, phosphoramide and methyl group. 
All hydroxy functionalization met with failure. When heated with magic methyl or methyl 
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triflate, elimination of the methoxyl group on the cyclohexene ring was observed. Once again, 
the steric congestion might have played a role here. Finally, we found the reaction could be 
effected with KH, albeit with diminished yield (23%). Moreover, among all intermediates shown 
in Scheme 70, none of the diastereomers could be isolated by chromatography on SiO2 without 
significant loss of material. 
Consequently, we decided to make a major modification to our synthetic strategy. Because 
operations on the dihydropyridone core were difficult when the macrocyclic system was present, 
we decided to install the core ring prior to the Suzuki cyclization reaction (Scheme 71).  
Scheme 71 Preparation of the substrate for Suzuki cyclization with preinstalled tetrahydropyridine core 
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Common intermediate 3-111 was reduced to a primary alcohol. Subsequent acylation on 
the nitrogen provided amide 3-126. Transformation of 3-126 to tetrahydropyridine 3-128 is 
known,141 although we replaced the Dess-Martin oxidation with a Swern reaction due to better 
reproducibility. The spectroscopic data of 3-127 matches that in the literature.141 Acylation of 3-
128 with acid 3-131 provided the substrate for the Suzuki cyclization. 
When 3-132 was subjected to Suzuki cross-coupling conditions, the desired product was 
not obtained (Scheme 72). Instead, ketone 3-134 was isolated in low yield. When oxygen was 
vigorously excluded and the temperature was increased to 160 °C in order to make the amide 
bond freely-rotating, trace amounts of debromination product 3-135 were observed. This 
indicates that the oxidative addition of the aryl bromide to palladium was successful, but 
subsequent transmetallation did not occur. 
Scheme 72 Attempted Suzuki cyclization of 3-132 
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Similarly, a system (3-138, Scheme 73) which more closely resembled our successful 
Suzuki cyclization system 3-120 did not yield any desired product. Protodeboronation product 3-
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139 was isolated in good yield. One possible explanation is that the steric interaction between the 
pinacolboronic ester and the tetrahydropyridine core forces the boron out of conjugation with the 
aromatic ring, weakening the B-C bond. 
Scheme 73 Attempted Suzuki cyclization of 3-138 
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We also explored a macrolactamization approach (Scheme 74). Suzuki cross-coupling 
between 3-136 and 3-130 afforded protected amino acid 3-140. Subsequent deprotection and 
macrolactamization failed to provide any desired macrocycle. In all cases decomposition was 
observed. 
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Scheme 74 Preparation of 3-133 via a macrolactamization approach 
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We decided to explore the macrolactamization approach more exhaustively by using a 
pentafluorophenyl ester 3-141. Boc removal of 3-141 was followed by heating with 4-
pyrrolidinopyridine at up to 150 °C under microwave irradiation. We observed no desired 
product. Instead, dimerization occurred. 
Scheme 75 Macrolactamization with pentafluorophenyl ester 3-141 
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At this stage, another major overhaul of our synthetic strategy was clearly needed. We 
believed the failure of our previous approaches could be partly attributed to the rigid nature of 
our intermediates (e.g., fused rings with conjugated sp2 centers), which might prevent the 
molecule from accommodating incoming reagents. In addition, the products are potentially 
strained, disfavoring the process. In order to “relax” the molecule, we decided to convert some of 
the sp2-hydridized centers in our intermediates to sp3-hydridized centers (Scheme 76). In this 
design, the cyclohexene moiety would be epoxidized prior to the formation of the core ring, 
eliminating two sp2-hybridized centers. 
Scheme 76 Intramolecular cyclization with an epoxide substrate 
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Accordingly, we synthesized substrate 3-142 and 3-143 using our established Suzuki 
cyclization process (Scheme 77). After the epoxidation of the macrocycle 3-148, the two 
diastereomers 3-149 and 3-150 were separated by chromatography on SiO2. They were carried 
through the synthesis individually as denoted by the two yields for each subsequent step. 
Desilylation of 3-149 and 3-150 was followed by a Swern oxidation to provide aldehydes 3-142 
and 3-143. Interestingly, in the Swern oxidation, one diastereomer reacted cleanly, while the 
other afforded a minor chlorination byproduct, resulting in a lower yield. 
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Scheme 77 Preparation of epoxide substrates for intramolecular aldol condensation 
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With the two aldehydes in hand, we set out to cyclize them under the aldol conditions 
(Scheme 78). One diastereomer was heated to 65 °C for two months to afford the desired product 
in 68% yield. The other diastereomer was then heated to 100 °C for 11 d to give the desired 
product in 46% yield. As a comparison, under the same conditions, the more rigid cyclohexene 
analogue 3-125 yielded only trace amounts of product 3-123. 
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Scheme 78 Intramolecular aldol reaction on epoxidized substrates 
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We were pleased by the success of our alternative strategy, but there was a need for 
further improvement as the key intranolecular aldol step was sluggish. This led to the 4th 
generation approach. 
 
3.2.4 4th Generation Approach: Intramolecular Aldol/Dieckmann Condensation on a 
Less Strained System 
In order to have a more pronounced strain-release effect, we considered reducing the amide 
moiety in 3-125 to an amine (3-155) prior to the elimination step (Scheme 79). By removing the 
amide sp2-hydridized center and its conjugation to the nitrogen, we expected to see a more 
flexible core ring; thus easing the elimination step to form two new sp2-hybridized centers. 
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Scheme 79 Releasing strain in the molecule by reducing the amide moiety to an amine 
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However, there was a technical challenge associated with this route. The subsequent 
aromatization step would require two oxidation steps that are incompatible with the tertiary 
amine moiety. Consequently, we decided to postpone the reduction of the amide moiety until 
after the aromatization step (Scheme 80). Cyclohexene 3-124 would be epoxidized and 
aromatized to the aza-paracyclophane 3-158. Reduction of the amide moiety would afford the 
hydroxylpiperidine 3-159. Elimination and deprotection would provide haouamine A. 
Scheme 80 4th Generation synthetic plan 
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We started with the epoxidation of our previously synthesized ketoamide 3-124 (Scheme 
81). Surprisingly, only one diastereomer exhibited normal reactivity (i.e., 100% conversion after 
~ 5 h at room temperature). The other diastereomer reacted at a much slower rate (~ 48 h). This 
led to the decomposition of the products during the reaction, diminishing the yield. In addition, 
we could not separate the product from the starting material by chromatography on SiO2, nor 
could we separate the diastereomers of 3-124 without significant loss of material. 
Scheme 81 Epoxidation of 3-124 
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The observed differential reactivity of the two diastereomers was intriguing and coincided 
with the results shown in Scheme 77. We decided to investigate this problem further. After 
repeated chromatography, the diastereomers of 3-124 were resolved. An X-ray analysis of the 
diastereomer that reacted rapidly in the epoxidation reaction demonstrated a dihedral angle of 
53° at the aryl-cyclohexene junction. This observation indicates that the aryl system is not 
perpendicular to the cyclohexene. Assuming the other diastereomer adopts a similar 
conformation, the aryl group will selectively block one of the two groups on the cyclohexene 
unit, either the methylene or the vinyl group (Scheme 82). This results in the discrimination 
between the two diastereomers. In addition, the fast-reacting diastereomer 3-124a will lead to the 
atropisomer of haouamine A, while the slow-reacting diastereomer 3-124b will produce 
haouamine A. 
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Scheme 82 Comparison of reactivities of diastereomers 3-124a and 3-124b 
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A simple solution to this reactivity issue was to move back one step and use a less rigid 
precursor (Scheme 83). Indeed, the epoxidation of 3-121 proceeded smoothly to provide the two 
diastereomers in excellent yield. In addition, separation of the diastereomers was easily achieved 
by chromatography on SiO2.160 
Scheme 83 Epoxidation of 3-121 
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At this stage, we were uncertain about the configuration of the diastereomers. 
Consequently, we subjected both of them to the next set of conditions. The initial plan was to 
conduct a cascade Dieckmann condensation and base-promoted epoxide rearrangement to an 
allylic alcohol (3-159 to 3-160, Scheme 84). To our surprise, we obtained a mixture of products, 
the major one being 3-161. The structure was elucidated with X-ray analysis and 2D NMR. We 
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proposed a mechanism of initial Dieckmann condensation followed by an intramolecular epoxide 
opening with the enolate. The other diastereomer 3-158 gave a similar result. 
Scheme 84 Attempted cascade of Dieckmann condensation-epoxide rearrangement 
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We then decided to convert the highly reactive epoxide functionality in 3-158 and 3-159 
to a more inert moiety before the Dieckmann condensation, namely a methylated phenol 
(Scheme 85).  
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Scheme 85 Preparation of aza-paracyclophane 3-165 by aromatization reaction 
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Epoxide 3-158 was subjected to acidic hydrolysis conditions to provide allylic alcohol 3-
163. Oxidation of 3-163 to an enone was followed by our established aromatization process to 
give aza-paracyclophane 3-165 in excellent yield. Remarkably, the aromatization step required 
much milder conditions than in our previous model system (78 °C vs. 150 °C). 
As expected, the Dieckmann condensation of aza-paracyclophane 3-165 was more 
difficult than the less strained 3-121. Treatment of 3-165 with LDA at room temperature or in 
refluxing THF resulted in no reaction. However, when heated with KH in refluxing toluene, 3-
165 was smoothly converted to the ketoamide 3-166 in good yield (Scheme 86). 
Scheme 86 Dieckmann condensation of 3-165 
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The structure of 3-166 was elucidated by X-ray analysis. It clearly demonstrated a bent 
phenyl ring along with the correct atropisomerism. In addition, both the keto and the amide 
moiety sit in a deep cavity where the carbonyl carbons are completely shielded from nucleophilic 
attack. This prediction is in line with the experimental observations, as all attempts to reduce 3-
166 failed. Conditions screened include common metal hydrides, borane/alane, thioamide 
formation, single electron transfer processes (e.g., dissolving metal reductions, SmI2 etc.) and 
enolate trapping (vinyl triflate). In all cases the starting material was either recovered or 
decomposed.  
As an interesting side reaction, when treated with LiH for an extended period of time, 3-
166 was converted into 3-167 (Scheme 87). The structure of 3-167 was confirmed by X-ray 
analysis, which showed the central phenyl ring with a virtually flat conformation. Therefore, 
relief of the ring strain may be a driving force for this reaction. The mechanism of this 
transformation may resemble that of a very similar reaction found in literature,161 with molecular 
oxygen being the oxidant (see appendix). 
Scheme 87 “LiH oxidation” of 3-166 
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While working on haouamine A, we also briefly explored the synthetic route towards the 
atropisomer of haouamine A (Scheme 88). Most of the steps proceeded with comparable yields 
to those of haouamine A, with the exception of the Dieckmann condensation step (3-170 to 3-
171), which was found to be low-yielding and difficult to scale-up. 
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Scheme 88 Aromatization and Dieckmann condensation towards atrop-haouamine A 
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As we encountered difficulties in the reduction of 3-166, we considered changing the 
oxidation state of the neopentyl position before the cyclization step. This would allow us to 
bypass the reduction of a sterically encumbered center. Gratifyingly, this route turned out to be 
productive (Scheme 89). A two-step reduction-oxidation sequence converted ester 3-165 to 
aldehyde 3-173. The key intramolecular aldol reaction provided 3-174 in 57% yield.  
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Scheme 89 Intramolecular aldol reaction to 3-174  
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The structure of 3-174 was confirmed by X-ray analysis. Both the hydroxyl and amide 
groups are exposed in a more open cavity than in 3-166, which might make subsequent 
transformations more feasible. 
Despite the promising conformation observed in the X-ray analysis, the reduction of 3-174 
proved to be challenging (Scheme 90). Surprisingly, reduction with LAH afforded ring-opened 
product 3-175, presumably due to the strain in the azaparacyclophane moiety. The structure of 3-
175 was confirmed by an X-ray analysis of its HCl salt, in which the central phenyl ring adopts a 
virtually flat conformation. 
Treatment of 3-174 with common amide reduction conditions, including borane, DIBAL, 
hydrosilylation162 and thioamide formations, resulted in no reaction,. Moving to the more 
reactive alanes, we started observing more favorable reactions. For example, treatment of 3-174 
with alane afforded ring-opening product 3-176 exclusively, most likely due to the ring stain. 
Ojima and co-workers reported a similar problem for the reduction of β-lactams, and the authors 
used monochloroalane and dichloroalane to surpress the undesired ring-opening process.163 In 
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our case, with monochloroalane, we observed a small amount of desired product 3-177 along 
with amino alcohol 3-176 as the major product. The reduction with dichloroalane was extremely 
sluggish and less successful. We propose that the alanes formed an ate complex with the 
hydroxyl group in 3-174 first, followed by an intramolecular hydride delivery to the amide bond. 
This helps to explain the low reactivity exhibited by dichloroalane.164 Fortunately, we found 
amino alcohol 3-176 can be converted to 3-177 via a sequence of selective mesylation at the 
primary hydroxyl group followed by an intramolecular displacement with the secondary amine 
moiety. The structure of 3-177 was confirmed by X-ray analysis. 
Scheme 90 Reduction of 3-174 
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3.3 CONCLUSIONS 
We have evaluated four generations of approaches towards the total synthesis of haouamine A. A 
promising route featuring a Suzuki cyclization, aromatization and intramolecular aldol reaction 
as the key transformations (Scheme 91) was established. A late-stage intermediate 3-177 was 
prepared, and its structure was secured by X-ray analysis. Currently, only two steps (elimination 
and global deprotection128) remain to finish haouamine A. 
Scheme 91 Summary of the remaining synthetic transformations towards haouamine A 
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3.4 EXPERIMENTAL PART 
 
General: All reactions were performed under an N2 atmosphere and all glassware was dried in 
an oven at 140 °C for 2 h prior to use. Reactions carried out at -78 °C employed a CO2/acetone 
bath. THF and Et2O were distilled over sodium/benzophenone ketyl, Et3N was distilled from 
CaH2, and CH2Cl2 and toluene were purified using an alumina column filtration system. 
Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 μm 
layer thickness) and visualization was accomplished with a 254 nm UV light and by staining 
with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 95% EtOH), p-anisaldehyde 
solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 100 mL of 
95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 in 100 mL 
of a 3.5 N H2SO4 solution) or a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL 
of a 0.1% NaOH solution). Flash chromatography on SiO2 was used to purify the crude reaction 
mixtures. 1H spectra were obtained at 300 MHz in CDCl3 unless otherwise noted. Chemical 
shifts were reported in parts per million with the residual solvent peak used as an internal 
standard. 1H NMR spectra were obtained and are tabulated as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), number of protons, 
and coupling constant(s). 13C NMR spectra were run at 75 MHz using a proton-decoupled pulse 
sequence with a d1 of 5 sec, and are tabulated by observed peak. 
 200 
OMe
MeO
O
NBoc  
tert-Butyl 2-(3,4-dimethoxyphenyl)-2-oxoethyl(methyl)carbamate (3-71).* A solution 
of 3-69 (2.18 g, 10 mmol) in DMF (53 mL) and Et3N (1.40 mL, 10 mmol) was treated with 
Boc2O (2.62 g, 12 mmol) in DMF (20 mL) at room temperature. The reaction mixture was 
stirred overnight, diluted with DCM and treated with aqueous NaHSO4 (1 M). The aqueous layer 
was extracted with DCM (2x). The combined organic layers were washed with water (2x), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:EtOAc = 3:2 to 1:1) afforded 2.45 g (87%) of the phenol as a clear oil. This 
phenol was dissolved in DMF (33 mL) and treated with K2CO3 (2.93 g, 21.4 mmol) followed by 
MeI (1.32 mL, 21.4 mmol) at room temperature. The reaction mixture was stirred for 16 h and 
diluted with Et2O and water. The aqueous layer was extracted with Et2O (2x). The combined 
organic layers were dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 2:1 to 1:1) afforded 2.47 g (91%) of 
3-71 as a clear sticky foam: IR (neat) 2970, 2931, 1679, 1593, 1585, 1513, 1449 cm-1; 1H NMR 
(mixture of rotamers) (CDCl3)  7.36-7.30 (m, 1 H), 7.29-7.25 (m, 1 H), 6.72-6.64 (m, 1 H), 4.41 
(s, 1 H), 4.36 (s, 1 H), 3.70 (s, 1 H), 3.69 (s, 3 H), 3.66 (s, 2 H), 2.73 (s, 1.5 H), 2.71 (s, 1.5 H), 
1.26 (s, 5 H), 1.15 (s, 4 H); 13C NMR (mixture of rotamers) (CDCl3)  193.2, 192.9, 155.8, 
155.5, 153.2, 153.1, 148.8, 148.6, 128.0, 122.0, 121.9, 109.8, 109.7, 109.5, 79.4, 79.3, 55.6, 55.5, 
                                                 
* (CWC225B, CWC226: procedure, IR, proton, carbon NMR and HRMS) 
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55.4, 54.8, 54.3, 35.3, 35.2, 28.0, 27.8; MS (EI) m/z (rel intensity) 309 (40%), 253 (20%), 236 
(30%), 180 (50%), 165 (100%); HRMS (EI) m/z calcd for C16H23NO5 309.1576, found 309.1582. 
OMe
MeO
NBoc  
tert-Butyl 2-(3,4-dimethoxyphenyl)allyl(methyl)carbamate (3-72). *  A suspension of 
Ph3PCH3Br (11.1 g, 31.9 mmol) in toluene (64 mL) was treated with KOtBu (3.49 g, 31.9 mmol) 
at room temperature. The reaction mixture was stirred for 2 h at 50 °C, re-cooled to room 
temperature and treated with a solution of 3-71 (2.47 g, 7.97 mmol) in toluene (6.5 mL). The 
reaction mixture was stirred for 18 h, diluted with water and Et2O. The aqueous layer was 
extracted with Et2O (1x). The combined organic layers were dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc 
= 6:1) afforded 2.35 g (96%) of 3-72 as a white solid: mp 51.4-53.0 C (DCM); IR (neat) 2970, 
2931, 2834, 1684, 1600, 1578, 1515, 1449 cm-1; 1H NMR (mixture of rotamers) (CDCl3)  7.00-
6.82 (m, 2 H), 6.74 (s, 1 H), 6.71 (s, 1 H), 5.35-5.20 (m, 1 H), 5.00-4.92 (m, 1 H), 4.27-4.10 (m, 
2 H), 3.81 (s, 3 H), 3.77 (s, 3 H), 2.76-2.59 (m, 3 H), 1.35 (s, 9 H); 13C NMR (mixture of 
rotamers) (CDCl3)  155.6, 148.6, 143.7, 132.0, 131.1, 118.5, 112.7, 111.8, 110.7, 109.5, 79.2, 
55.7, 53.3, 52.6, 51.5, 33.4, 32.7, 28.2; HRMS (ESI) m/z calcd for C17H25NO4K (M+K) 
346.1421, found 346.1436. 
                                                 
* (CWC228: procedure, melting point, IR, proton, carbon NMR and HRMS) 
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(1S*,2R*)-7-Methoxy-1-(3-methoxyphenyl)-1-vinyl-2,3-dihydro-1H-inden-2-yl 2-
(3,4-dimethoxyphenyl)allyl(methyl)carbamate (3-66).* A solution of triphosgene (16.7 mg, 
0.169 mmol) in DCM (0.5 mL) at 0 °C was treated with 3-64143 (25.0 mg, 0.0845 mmol) in 
DCM (0.5+0.5 mL) followed by the treatment with pyridine (13.7 µL, 0.169 mmol) (dropwise). 
The reaction mixture was stirred for 2 h at room temperature and diluted with cold water and 
DCM. The organic layer was washed with cold water (1x), dried (MgSO4), filtered and 
concentrated under reduced pressure to afford 30.1 mg (99%) of crude chloroformate 3-74 (used 
without purification). 
A solution of 3-72 (0.113 g, 0.367 mmol) in TFA (neat, 2.8 mL) was stirred for 5 min at 
room temperature. The reaction mixture was cooled to 0 °C, quenched with 5% aqueous K2CO3 
and diluted with DCM. The organic layer was washed with 5% aqueous K2CO3 (3x), dried 
(MgSO4), filtered and concentrated under reduced pressure to afford 70.5 mg (93%) of crude 
amine 3-73 (used without purification). 
A solution of 3-73 (20.9 mg, 0.101 mmol) and DIPEA (73.4 µL, 0.420 mmol) in DCM 
(1.5 mL) was treated with 3-74 (30.1 mg, 0.0839 mmol) in DCM (0.5+0.5 mL) at room 
temperature. The reaction mixture was stirred for 14 h and diluted with DCM and water. The 
aqueous layer was extracted with DCM (1x). The combine organic layer was dried (MgSO4), 
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filtered and concentrated under reduced pressure. Purification by PTLC (Hexanes:EtOAc = 2:1) 
afforded 43.8 mg (99%) of 3-66 as a clear oil: IR (neat) 3458, 2998, 2935, 1694, 1599, 1589, 
1515, 1479 cm-1; 1H NMR 348K (DMSO-d6)  7.29 (t, 1 H, J = 7.8 Hz), 7.06 (t, 1 H, J = 8.1 
Hz), 6.94-6.81 (m, 4 H), 6.71 (dd, 1 H, J = 8.1, 2.4 Hz), 6.67-6.50 (m, 3 H), 5.60 (t, 1 H, J = 6.6 
Hz), 5.29 (app s, 1 H), 5.22-5.09 (m, 2 H), 4.82 (app s, 1 H), 4.08-3.97 (m, 1 H), 3.83-3.72 (m, 1 
H), 3.77 (s, 3 H), 3.76 (s, 3 H), 3.60 (s, 6 H), 3.29 (dd, 1 H, J = 16.2, 6.9 Hz), 2.75 (dd, 1 H, J = 
16.2, 5.7 Hz), 2.41 (br s, 3 H); 13C NMR 348K (DMSO-d6)  158.4, 155.8, 154.4, 148.8, 148.5, 
142.4, 141.1, 140.9, 140.2, 131.1, 131.0, 129.0, 127.6, 120.3, 118.2, 116.9, 114.3, 112.6, 111.9, 
111.5, 110.9, 110.4, 110.2, 78.4, 61.3, 55.51, 55.48, 54.7, 54.5, 51.0, 40.4, 37.0; MS (EI) m/z (rel 
intensity) 529 (20%), 278 (35%), 251 (15%), 234 (100%); HRMS (EI) m/z calcd for C32H35NO6 
529.2464, found 529.2483. 
OMe
MeO
NBoc
OMe
MeO
NBoc
+
 
(Z)-tert-Butyl 2-(3,4-dimethoxyphenyl)octa-2,7-dienyl(methyl)carbamate and (E)-
tert-butyl 2-(3,4-dimethoxyphenyl)octa-2,7-dienyl(methyl)carbamate (3-76a and 3-76b).* A 
suspension of hex-5-enyltriphenylphosphonium iodide (3.78 g, 8.00 mmol) in toluene (16 mL) 
was treated with KOtBu (0.896 g, 8.00 mmol) at room temperature. The reaction mixture was 
stirred for 2 h at 50 °C, re-cooled to room temperature and treated with a solution of 3-71 (0.618 
                                                 
* (CWD013: procedure, IR, carbon NMR and HRMS, CWC265: proton NMR and IR) 
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g, 2.00 mmol) in toluene (8.0+8.0 mL). The reaction mixture was stirred 50 °C for 2 h, diluted 
with water and Et2O. The aqueous layer was extracted with Et2O (1x). The combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 6:1) afforded 0.130 g (17%) of 3-76a as a clear oil, 
0.305 g (41%) of 3-76b as a clear oil and 0.268 g (36%) of 3-76a + 3-76b. 3-76a: IR (neat) 
3075, 2927, 2835, 1694, 1640, 1602, 1582, 1515 cm-1; 1H NMR (mixture of rotamers) (CDCl3)  
7.02-6.75 (m, 3 H), 5.88-5.67 (m, 2 H), 5.04-4.87 (m, 2 H), 4.43-4.26 (m, 2 H), 3.90 (s, 3 H), 
3.87 (s, 3 H), 2.63-2.46 (m, 3 H), 2.27 (app dd, 2 H, J = 15.0, 7.5 Hz), 2.13 (app dd, 2 H, J = 1.7, 
7.2 Hz), 1.61-1.47 (m, 2 H), 1.40 (s, 9 H); 13C NMR (mixture of rotamers) (CDCl3)  156.0, 
148.5, 148.2, 138.4, 136.3, 134.4, 133.5, 131.9, 131.3, 119.3, 118.6, 114.9, 111.0, 110.6, 109.9, 
79.3, 79.1, 55.9, 46.3, 44.6, 36.7, 33.4, 32.1, 29.1, 28.4, 27.7; HRMS (ESI) m/z calcd for 
C22H33NO4Na (M+Na) 398.2307, found 398.2324. 3-76b: IR (neat) 2972, 2927, 2853, 1692, 
1513, 1453 cm-1; 1H NMR (mixture of rotamers) (CDCl3)  6.85-6.57 (m, 3 H), 5.81-5.62 (m, 1 
H), 5.46 (t, 1 H, J = 7.2 Hz), 5.03-4.82 (m, 2 H), 4.17-3.95 (m, 2 H), 3.87 (s, 3 H), 3.86 (s, 3 H), 
2.83-2.62 (m, 3 H), 2.20-1.95 (m, 4 H), 1.51-1.24 (m, 11 H); 13C NMR (mixture of rotamers) 
(CDCl3)  155.4, 148.5, 147.9, 138.3, 136.6, 131.5, 130.9, 128.7, 128.4, 120.8, 114.4, 111.8, 
110.8, 110.7, 78.9, 55.9, 55.7, 54.4, 33.4, 33.2, 33.1, 29.1, 28.2, 28.1; HRMS (ESI) m/z calcd for 
C22H33NO4Na (M+Na) 398.2307, found 398.2271. 
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(1S*,2R*)-7-Methoxy-1-(3-methoxyphenyl)-1-vinyl-2,3-dihydro-1H-inden-2-yl (E)-2-
(3,4-dimethoxyphenyl)octa-2,7-dienyl(methyl)carbamate (3-75b).* A solution of triphosgene 
(7.7 mg, 0.0260 mmol) in DCM (0.22 mL) at 0 °C was treated with 3-64143 (11.6 mg, 0.0391 
mmol) in DCM (0.5+0.5 mL) followed by the treatment with pyridine (6.33 µL, 0.0779 mmol) 
(dropwise). The reaction mixture was stirred for 2 h at room temperature and diluted with cold 
water and DCM. The organic layer was washed with cold water (1x), dried (MgSO4), filtered and 
concentrated under reduced pressure to afford 13.3 mg (95%) of crude chloroformate 3-74 (used 
without purification). 
A solution of 3-76b (21.3 mg, 0.0567 mmol) in TFA (neat, 0.5 mL) was stirred for 5 min 
at room temperature. The reaction mixture was cooled to 0 °C, quenched with 5% aqueous 
K2CO3 and diluted with DCM. The organic layer was washed with 5% aqueous K2CO3 (3x), 
dried (MgSO4), filtered and concentrated under reduced pressure to afford 12.8 mg (82%) of 
crude amine 3-77b (used without purification). 
A solution of 3-77b (12.8 mg, 0.0465 mmol) and DIPEA (32.4 µL, 0.185 mmol) in DCM 
(0.67 mL) was treated with 3-74 (13.3 mg, 0.0371 mmol) in DCM (0.2+0.2 mL) at room 
temperature. The reaction mixture was stirred for 16 h and diluted with DCM and water. The 
aqueous layer was extracted with DCM (1x). The combine organic layer was dried (MgSO4), 
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filtered and concentrated under reduced pressure. Purification by PTLC (Hexanes:EtOAc = 2:1) 
afforded 18.6 mg (84%) of 3-75b as a clear oil: 1H NMR 348K (DMSO-d6)  7.28 (dd, 1 H, J = 
8.2, 7.5 Hz), 7.11 (t, 1 H, J = 8.0 Hz), 6.92-6.82 (m, 3 H), 6.74 (ddd, 1 H, J = 8.1, 2.6, 0.7 Hz), 
6.64-6.50 (m, 5 H), 5.79-5.66 (m, 1 H), 5.51 (t, 1 H, J = 6.2 Hz), 5.29-5.20 (m, 1 H), 5.15 (dd, 1 
H, J = 10.9, 0.7 Hz), 5.09 (d, 1 H, J = 17.8 Hz), 4.96-4.86 (m, 2 H), 3.89-3.80 (m, 1 H), 3.76 (s, 
3 H), 3.70 (s, 3 H), 3.63 (s, 3 H), 3.60 (s, 3 H), 3.17 (dd, 1 H, J = 16.0, 6.8 Hz), 3.06 (s, 2 H), 
2.63-2.54 (m, 1 H), 2.42 (br s, 3 H), 1.99-1.87 (m, 2 H), 1.42-1.31 (m, 2 H); 13C NMR 348K 
(DMSO-d6)  158.4, 155.8, 154.3, 148.3, 147.8, 141.1, 140.9, 140.2, 138.0, 135.6, 131.1, 130.6, 
129.0, 127.7, 127.6, 120.4, 120.3, 116.8, 114.4, 114.2, 112.64, 112.55, 112.0, 110.9, 110.2, 78.0, 
61.1, 55.5, 54.8, 54.3, 36.7, 32.2, 28.1, 27.2; MS (EI) m/z (rel intensity) 597 (45%), 366 (15%), 
302 (100%), 279 (70%), 244 (55%); HRMS (EI) m/z calcd for C37H43NO6 597.3090, found 
597.3119. 
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(1S*,2R*)-7-Methoxy-1-(3-methoxyphenyl)-1-vinyl-2,3-dihydro-1H-inden-2-yl (Z)-2-
(3,4-dimethoxyphenyl)octa-2,7-dienyl(methyl)carbamate (3-75a).* in DCM (0.1 mL) at 0 °C 
was treated with 3-64143 (5.2 mg, 0.0177 mmol) in DCM (0.1+0.1 mL) followed by the treatment 
with pyridine (2.9 µL, 0.0354 mmol) (dropwise). The reaction mixture was stirred for 2 h at 
room temperature and diluted with cold water and DCM. The organic layer was washed with 
                                                 
* (CWC256B: procedure, proton, HRMS). A solution of triphosgene (3.51 mg, 0.0118 mmol) 
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cold water (1x), dried (MgSO4), filtered and concentrated under reduced pressure to afford 5.9 
mg (92%) of 3-74 (used without purification). 
A solution of 3-76a (8.0 mg, 0.0213 mmol) in TFA (neat, 0.25 mL) was stirred for 5 min 
at room temperature. The reaction mixture was cooled to 0 °C, quenched with 5% aqueous 
K2CO3 and diluted with DCM. The organic layer was washed with 5% aqueous K2CO3 (3x), 
dried (MgSO4), filtered and concentrated under reduced pressure to afford 5.0 mg (85%) of 3-
77a (used without purification). 
A solution of 3-77a (5.0 mg, 0.0182 mmol) and DIPEA (15.9 µL, 0.0912 mmol) in DCM 
(0.33 mL) was treated with 3-74 (5.9 mg, 0.0164 mmol) in DCM (0.1+0.1 mL) at room 
temperature. The reaction mixture was stirred for 16 h and diluted with DCM and water. The 
aqueous layer was extracted with DCM (1x). The combine organic layer was dried (MgSO4), 
filtered and concentrated under reduced pressure. Purification by PTLC (Hexanes:EtOAc = 2:1) 
afforded 7.8 mg (80%) of 3-75a as a clear oil: 1H NMR representative signals of one rotamer 
(CDCl3)  6.31 (d, 1 H, J = 7.7 Hz), 3.90 (s, 3 H), 3.85 (s, 3 H), 3.66 (s, 3 H), 2.52 (s, 3 H), 2.26-
2.18 (m, 2 H), 1.60-1.45 (m, 2 H); MS (EI) m/z (rel intensity) 597 (45%), 366 (15%), 279 (90%), 
244 (80%), 163 (35%), 121 (100%); HRMS (EI) m/z calcd for C37H43NO6 597.3090, found 
597.3105. 
 
 
 
 208 
OMe
MeO
O
N
H
O
MeO OMe
 
Attempted Preparation of 3-67.* A solution of 3-75a (5.0 mg, 8.35 µmol) in degassed 
DCM (1.0 mL) was added to a solution of Hoveyda-Grubbs’ catalyst (0.523 mg, 0.835 µmol) in 
degassed DCM (0.5 mL) over 30 min (syringe pump) at 50 °C. The reaction mixture was stirred 
for 5 min and purified directly by PTLC (Hexanes:EtOAc = 3:2) to afford 1.8 mg (36%) of 
starting material and 2.5 mg (51%) of 3-78 as a sticky clear solid: (note the NMR data are not 
provided here due to the inherent low quality of spectra); HRMS (ESI) m/z calcd for 
C72H82N2O12Na (M+Na) 1189.5765, found 1189.6106. 
Alternatively, a solution of 3-75b (3.9 mg, 6.50 µmol) in degassed toluene (32.5 mL) was 
treated with Grubb’s 2nd generation catalyst (0.55 mg, 0.650 µmol) at 110 °C with argon 
sparging. The reaction mixture was stirred for 5 min and purified directly by chromatography on 
SiO2 (Hexanes:EtOAc = 4:1 to 1:1) to afford 0.1 mg (3%) of starting material, 1.2 mg (35%) of 
3-66 and 0.8 mg (21%) of 3-78. 
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(1S*,2R*)-7-Methoxy-1-(3-methoxyphenyl)-1-vinyl-2,3-dihydro-1H-inden-2-yl 4-
(((E)-2-(3,4-dimethoxyphenyl)octa-2,7-dienyl)(methyl)amino)-4-oxobutanoate (3-80). *  A 
solution of 3-77b (36.7 mg, 0.133 mmol) in DCM (0.50 mL) was treated with succinic anhydride 
(16.0 mg, 0.160 mmol) at room temperature. The reaction mixture was heated at reflux for 20 h, 
cooled to room temperature and diluted with water and DCM. The aqueous layer was extracted 
with DCM (1x). The combine organic layers were dried (MgSO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (CHCl3:EtOH = 95:5 to 10:1) 
afforded 23.1 mg (50%) of the acid. A solution of the acid and MF2060F1 (11.1 mg, 0.0375 
mmol) in DCM (0.50 mL) was treated with DCC (8.5 mg, 0.0413 mmol) at 0 °C. The reaction 
mixture was stirred at room temperature for 20 h. The reaction mixture was filtered through a 
plug of cotton and concentrated under reduced pressure. Purification by PTLC (Hexanes:EtOAc 
= 1:1) afforded 18.9 mg (70%) of 3-80 as a clear oil: IR (neat) 3076, 2955, 2927, 2855, 1729, 
1647, 1599, 1479 cm-1; 1H NMR 348K (DMSO-d6)  7.29 (t, 1 H, J = 8.1 Hz), 7.10 (t, 1 H, J = 
8.1 Hz), 6.94-6.87 (m, 2 H), 6.74 (ddd, 1 H, J = 8.1, 2.4, 0.9 Hz), 6.70-6.48 (m, 4 H), 5.80-5.64 
(m, 2 H), 5.41 (t, 1 H, J = 7.2 Hz), 5.16 (dd, 1 H, J = 11.1, 0.9 Hz), 5.11 (dd, 1 H, J = 17.7, 0.6 
Hz), 4.97-4.85 (m, 2 H), 4.04 (br s, 2 H), 3.76 (s, 3 H), 3.73 (s, 3 H), 3.65 (s, 3 H), 3.58 (s, 3 H), 
3.29 (dd, 1 H, J = 16.2, 6.6 Hz), 3.01 (s, 2 H), 2.79 (dd, 1 H, J = 16.5, 4.5 Hz), 2.72 (s, 2 H), 
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2.20-1.89 (m, 5 H), 1.47-1.35 (m, 1 H); 13C NMR 348K (DMSO-d6)  170.6, 158.2, 155.8, 
141.2, 140.9, 139.8, 137.9, 135.5, 131.1, 130.8, 129.0, 127.6, 127.3, 120.44, 120.41, 116.8, 
114.5, 114.1, 112.8, 112.6, 112.2, 111.0, 110.2, 77.3, 61.7, 55.53, 55.46, 54.7, 54.5, 36.6, 32.8, 
32.1, 28.8, 28.1, 27.1; MS (EI) m/z (rel intensity) 653 (20%), 279 (30%), 244 (100%); HRMS 
(EI) m/z calcd for C40H47NO7 653.3353, found 653.3325. 
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1-(2-Hydroxyethyl)-7-methoxy-1-(3-methoxyphenyl)-1H-inden-2(3H)-one (3-88). *  A 
solution of 3-85143 (50.0 mg, 0.162 mmol) in DCM (2.6 mL) and MeOH (0.65 mL) at -78 °C was 
bubbled with ozone until the color changed to blue. The solution was then bubbled with Ar for 
20 min at -78 °C followed by the treatment with Me2S (0.0910 mL, 1.24 mmol). The reaction 
mixture was stirred for 14 h at room temperature and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 4:1) afforded 40.7 mg (81%) of the 
aldehyde. A solution of the aldehyde in THF (1.7 mL) was treated with LiAlH(OCHEt2)3 (0.41 
M in THF, 0.347 mL, 0.142 mmol, prepared by the addition of 3-ethyl-3-pentanol (1.22 mL, 
8.61 mmol) to a solution of LAH (105 mg, 2.76 mmol) in THF (5.5 mL) at room temperature, 
then refluxing for 2 h) at -78 °C. The reaction mixture was stirred for 7 h and treated with 
additional LiAlH(OCHEt2)3 (0.10 mL), stirred for another 2 h and treated with additional 
LiAlH(OCHEt2)3 (0.10 mL). The reaction mixture was stirred for 1 h and quenched with HCl (2 
M). The mixture was extracted with EtOAc (3x). The combined organic layers were washed with 
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NaHCO3 (2x), brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 2:1) afforded 36.8 mg (90%) of 3-88 
as a clear oil (product existed as a mixture of keto alcohol and hemiacetal): IR (neat) 3400, 2953, 
2933, 2883, 1748, 1602, 1584, 1481 cm-1; 1H NMR (CD3OD)  7.37 (t, 0.5 H, J = 8.1 Hz), 7.24 
(t, 0.5 H, J = 8.1 Hz), 7.11 (t, 1 H, J = 8.1 Hz), 7.03 (d, 0.5 H, J = 7.5 Hz), 6.94 (d, 0.5 H, J = 8.4 
Hz), 6.85 (d, 0.5 H, J = 7.5 Hz), 6.79 (d, 0.5 H, J = 8.1 Hz), 6.75-6.64 (m, 3 H), 4.13 (dt, 0.5 H, J 
= 7.8, 2.7 Hz), 3.71-3.67 (m, 4.5 H), 3.64 (s, 1.5 H), 3.54 (s, 1 H), 3.49-3.39 (m, 1 H), 3.19-3.16 
(m, 1 H), 3.14-3.06 (m, 0.5 H), 2.91-2.76 (m, 1.5 H), 2.63 (s, 0.5 H), 2.59-2.51 (m, 0.5 H); 13C 
NMR (CD3OD)  217.8, 161.1, 160.7, 158.4, 157.9, 144.4, 143.8, 143.0, 140.2, 130.6, 130.3, 
130.1, 129.5, 121.3, 119.9, 118.4, 118.2, 115.3, 115.2, 113.8, 112.7, 112.2, 110.6, 110.5, 68.3, 
65.3, 62.3, 60.4, 55.6, 55.53, 55.48, 44.8, 43.1, 39.3, 34.4; MS (EI) m/z (rel intensity) 312 (95%), 
268 (100%), 239 (100%); HRMS (EI) m/z calcd for C19H20O4 312.1362, found 312.1355. 
OMe
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1-(2-(tert-Butyldimethylsilyloxy)ethyl)-7-methoxy-1-(3-methoxyphenyl)-1H-inden-
2(3H)-one (3-89).* A solution of 3-88 (36.8 mg, 0.118 mmol), imidazole (40.2 mg, 0.591 mmol) 
and TBSCl (42.8 mg, 0.283 mmol) in DMF (2.5 mL) at room temperature was stirred for 14 h, 
quenched with water and extracted with EtOAc (3x). The combined organic layers were washed 
with water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 10:1) afforded 22.8 mg (45%) of 3-
                                                 
* (CWD113: procedure, IR, HRMS, proton and carbon NMR) 
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89 as a clear oil: IR (neat) 2953, 2927, 2854, 1753, 1598, 1585, 1482, 1470, 1433 cm-1; 1H NMR 
(CDCl3) δ 7.35 (t, 1 H, J = 7.8 Hz), 7.19-7.12 (m, 1 H), 6.99 (dd, 1 H, J = 5.7, 0.6 Hz), 6.86 (d, 2 
H, J = 8.1 Hz), 6.77-6.71 (m, 3 H), 3.75 (s, 3 H), 3.72 (s, 3 H), 3.59-3.50 (m, 1 H), 3.53 (s, 2 H), 
3.21 (dt, 1 H, J = 10.5, 4.8 Hz), 3.01-2.90 (m, 1 H), 0.77 (s, 9 H), -0.12 (s, 3 H), -0.16 (s, 3 H); 
13C NMR (CDCl3) δ 214.7, 159.7, 157.2, 143.3, 139.3, 130.1, 129.4, 129.3, 119.1, 117.5, 113.0, 
111.9, 109.5, 61.3, 60.9, 55.4, 55.3, 42.5, 38.8, 26.1, 18.6, -5.59, -5.62; MS (EI) m/z (rel 
intensity) 369 (100), 353 (90); HRMS (EI) m/z calcd for C21H25O4Si 369.1522, found 369.1525. 
OMe
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1-(2-(tert-Butyldimethylsilyloxy)ethyl)-7-methoxy-1-(3-methoxyphenyl)-1H-inden-2-
yl trifluoromethanesulfonate (3-90). *  A solution of 3-89 (22.8 mg, 0.0534 mmol) and N-
phenylbis(trifluoromethane)sulfonimide (22.9 mg, 0.0641 mmol) in THF (0.35 mL) at -78 °C 
was slowly treated with a solution of KHMDS (0.302 M in THF, 0.194 mL, 0.0641 mmol). The 
reaction mixture was then stirred for 2 h at room temperature, quenched with saturated aqueous 
NH4Cl and extracted with EtOAc (1x). The organic layer was washed with brine (1x), dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:Et2O = 15:1) afforded 27.2 mg (91%) of 3-90 as a clear sticky solid: IR (neat) 
2953, 2926, 2855, 1600, 1582, 1425 cm-1; 1H NMR (CDCl3) δ 7.30 (dd, 1 H, J = 8.1, 7.8 Hz), 
7.17 (t, 1 H, J = 8.1 Hz), 6.99 (d, 1 H, J = 7.5 Hz), 6.82-6.72 (m, 4 H), 6.51 (s, 1 H), 3.74 (s, 3 
H), 3.67 (s, 3 H), 3.39-3.28 (m, 1 H), 3.28-3.18 (m, 1 H), 3.00-2.89 (m, 1 H), 2.67-2.56 (m, 1 H), 
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0.83 (s, 9 H), -0.07 (s, 6 H); 13C NMR (CDCl3) δ 159.8, 158.9, 155.0, 141.0, 139.5, 130.8, 129.7, 
129.4, 120.6, 118.9, 116.4, 115.5, 113.9, 112.8, 112.6, 109.9, 59.6, 57.9, 55.5, 55.4, 33.4, 26.1, 
18.5, -5.3; MS (EI) m/z (rel intensity) 501 (35), 368 (70), 293 (30), 265 (100); HRMS (EI) m/z 
calcd for C22H24O6F3SiS (M-tBu) 501.1015, found 501.1006. 
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tert-Butyl(2-(7-methoxy-1-(3-methoxyphenyl)-1H-inden-1-yl)ethoxy)dimethylsilane 
(3-93).* A solution of Pd(OAc)2 (0.109 mg, 0.487 µmol) and rac-BINAP (0.449 mg, 0.721 µmol) 
in 0.10 mL PhMe was treated with 3-90 (5.44 mg, 9.74 µmol) in PhMe (0.10 mL), 
PhCH2CH2NHCH3 (2.83 µL, 19.5 µmol) and KOtBu (1.53 mg, 13.6 µmol, freshly sublimed) 
sequentially at room temperature. The reaction mixture was stirred for 3 h at 80 °C, cooled to 
room temperature, treated with NaBH(OAc)3 (3.1 mg, 14.6 µmol) and stirred for 48 h. The 
reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc (3x). 
The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by PTLC (Hexanes:Et2O = 4:1) afforded 1.6 mg (39%) of 3-
93 as a clear sticky solid along with 1.0 mg (18%) of 3-89: 1H NMR (CDCl3) δ 7.29-7.21 (m, 1 
H), 7.14 (t, 1 H, J = 8.1 Hz), 6.95 (d, 1 H, J = 7.2 Hz), 6.87-6.82 (m, 2 H), 6.74-6.66 (m, 2 H), 
6.63 (d, 1 H, J = 5.7 Hz), 6.41 (d, 1 H, J = 5.4 Hz), 3.74 (s, 3 H), 3.72 (s, 3 H), 3.35 (dt, 1 H, J = 
9.9, 5.1 Hz), 3.20 (dt, 1 H, J = 9.9, 5.7 Hz), 2.87-2.76 (m, 1 H), 2.67-2.56 (m, 1 H), 0.83 (s, 9 H), 
-0.06 (s, 6 H). 
                                                 
* (CWD117: procedure, proton and COSY) 
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1-(1,3-Dioxolan-2-yl)-7-methoxy-1-(3-methoxyphenyl)-1H-inden-2(3H)-one (3-96). * 
A solution of 3-97143 (2.47 g, 9.22 mmol) in DCM (50 mL) was treated with Et3N (3.89 mL, 27.6 
mmol) followed by TMSCl (3.53 mL, 27.6 mmol) at room temperature. The reaction mixture 
was stirred for 2 h, diluted with DCM, washed with cold water (1x), cold CuSO4 (saturated) (2x), 
cold water (2x), dried (MgSO4), filtered and concentrated under reduced pressure to afford 9.19 
g (100%) of the crude enol ether (mixture of 2.3:1 regioisomers favoring the desired one). A 
solution of the enol ether (0.825 g, 2.42 mmol) and 2-Methoxy-1,3-dioxolane (0.693 mL, 7.27 
mmol) in DCM (75 mL) at -20 °C was treated with a solution of TMSOTf (1.0 M in DCM, 0.242 
mL, 0.242 mmol). The reaction mixture was stirred for 2.5 h, quenched with saturated aqueous 
NaHCO3 and extracted with DCM (3x). The combined organic layers were dried (MgSO4), 
filtered and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc = 10:1 to 3:1 to 2:1) afforded 0.383 g (46%, 58% BORSM) of 3-96 as a clear 
oil along with 0.131 g (20%) of 3-97: IR (neat) 3069, 2939, 2895, 2836, 1754, 1586, 1484 cm-1; 
1H NMR (CDCl3) δ 7.35 (t, 1 H, J = 7.8 Hz), 7.19 (t, 1 H, J = 8.1 Hz), 7.04-6.94 (m, 3 H), 6.85 
(d, 1 H, J = 8.4 Hz), 6.78 (dd, 1 H, J = 8.1, 2.4 Hz), 5.97 (s, 1 H), 4.05-3.92 (m, 2 H), 3.87-3.75 
(m, 2 H), 3.76 (s, 3 H), 3.67 (s, 3 H), 3.70-3.50 (m, 2 H); 13C NMR (CDCl3) δ 213.2, 159.4, 
156.8, 139.3, 139.1, 130.3, 130.0, 129.0, 120.9, 117.4, 115.0, 112.2, 110.4, 105.6, 66.3, 66.1, 
                                                 
* (CWF055: procedure and proton NMR; CWD203: HRMS; CWD146: carbon NMR; CWD156: IR) 
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65.4, 55.6, 55.4, 44.4; HRMS (ESI) m/z calcd for C20H20O5Na (M+Na) 363.1208, found 
363.1180. 
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1-(1,3-Dioxolan-2-yl)-7-methoxy-1-(3-methoxyphenyl)-1H-inden-2-yl 
trifluoromethanesulfonate (3-99). *  A solution of 3-96 (0.1279 g, 0.376 mmol) and N-
phenylbis(trifluoromethane)sulfonimide (0.161 g, 0.451 mmol) in THF (2.4 mL) at -78 °C was 
slowly treated with a solution of KHMDS (0.302 M in THF, 1.50 mL, 0.451 mmol). The reaction 
mixture was then stirred for 1 h at room temperature, quenched with saturated aqueous NH4Cl 
and extracted with EtOAc (1x). The organic layer was washed with brine (1x), dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc = 6:1) afforded 0.139 g (78%) of 3-99 as a white solid: mp 94.0-95.4  °C 
(DCM); IR (neat) 3583, 2895, 1605, 1583, 1480 cm-1; 1H NMR (CDCl3) δ 7.33 (t, 1 H, J = 8.1 
Hz), 7.22 (t, 1 H, J = 8.1 Hz), 7.11-7.07 (m, 1 H), 7.05-6.99 (m, 2 H), 6.87-6.78 (m, 2 H), 6.68 
(s, 1 H), 6.12 (s, 1 H), 4.14 (dd, 1 H, J = 13.5, 6.9 Hz), 4.01 (dd, 1 H, J = 13.8, 7.2 Hz), 3.95-
3.81 (m, 2 H), 3.78 (s, 3 H), 3.69 (s, 3 H); 13C NMR (CDCl3) δ 159.6 156.1, 154.5, 140.7, 136.0, 
134.2, 130.0, 129.7, 129.3, 127.4, 124.8, 123.5, 120.6, 120.2, 119.3, 116.3, 115.7, 114.3, 112.9, 
112.1, 110.6, 103.9, 65.8, 65.2, 63.7, 55.6, 55.3; MS (EI) m/z (rel intensity) 472 (8), 340 (20), 
266 (50), 238 (60), 293 (30), 165 (100); HRMS (EI) m/z calcd for C21H19O7F3S 472.0804, found 
472.0804. 
                                                 
* (CWD218: procedure, mp, proton and carbon NMR, IR and HRMS) 
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2-(7-Methoxy-1-(3-methoxyphenyl)-1H-inden-1-yl)-1,3-dioxolane (3-100).* A solution 
of Pd(OAc)2 (0.476 mg, 2.12 µmol) in DMF (0.20 mL) was degassed and treated with P(OMe)3 
(0.68 µL, 5.77 µmol) 3-99 (10.0 mg, 21.2 µmol) in PhMe (0.10+0.10 mL), Et3N (5.82 µL, 41.9 
µmol), PhCH2CH2NH2 (5.3 µL, 42.4 µmol) and KOtBu (4.8 mg, 42.4 µmol) sequentially at 
room temperature. The reaction mixture was stirred for 1.5 h at 110 °C, diluted with Et2O, 
filtered through a pad of Celite and concentrated to dryness. The residue was dissolved in DCE 
(0.50 mL) and treated with NaBH(OAc)3 (22.5 mg, 0.106 mmol) at troom temperature. The 
reaction mixture was stirred for 24 h, quenched with saturated aqueous NaHCO3 and extracted 
with EtOAc (3x). The combined organic layers were washed with brine, dried (Na2SO4), filtered 
and concentrated under reduced pressure. Purification by PTLC (Hexanes:Et2O = 1:1) afforded 
0.7 mg (7%) of 3-100 as a clear oil along with 2.3 mg (32%) of 3-96: IR (neat) 3064, 2952, 
2887, 2835, 1600, 1562, 1473 cm-1; 1H NMR (CDCl3) δ 7.33 (t, 1 H, J = 8.1 Hz), 7.23 (t, 1 H, J 
= 8.1 Hz), 7.18-7.15 (m, 1 H), 7.13-7.08 (m, 1 H), 7.05 (d, 1 H, J = 7.2 Hz), 6.87 (d, 1 H, J = 5.7 
Hz), 6.84-6.78 (m, 2 H), 6.67 (d, 1 H, J = 5.7 Hz), 6.29 (s, 1 H), 4.12-3.98 (m, 2 H), 3.85 (app t, 
2 H, J = 6.3 Hz), 3.80 (s, 3 H), 3.78 (s, 3 H); 13C NMR (CDCl3) δ 159.3, 155.1, 145.9, 140.7, 
139.7, 134.6, 132.0, 129.5, 128.9, 120.2, 114.8, 114.3, 111.6, 109.4, 104.9, 66.5, 65.73, 65.71, 
55.4, 55.1; MS (EI) m/z (rel intensity) 324 (0.5), 251 (2.5), 205 (4), 165 (4); HRMS (EI) m/z 
calcd for C20H20O4 324.1366, found 324.1347. 
                                                 
* (CWD219: procedure; CWD221 and CWD177: proton and carbon NMR, HRMS, IR) 
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2(E)-1-(1,3-Dioxolan-2-yl)-7-methoxy-1-(3-methoxyphenyl)-1H-inden-2(3H)-one 
oxime. *  A solution of 3-96 (1.22 g, 3.58 mmol), pyridine (0.870 mL, 16.7 mmol) and 
hydroxylamine hydrochloride salt (1.25 g, 17.9 mmol) in EtOH (61 mL) was heated at reflux for 
6 h, quenched with saturated aqueous NaHCO3 and filtered. The filtrate was extracted with 
EtOAc (1x) and the organic layer was washed with water (1x) and brine (1x), dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc = 2:1 to 1:1, all with 1% Et3N) afforded 1.04 g (81%) of the title compound as 
a yellow solid: mp 201.3 °C (decomp.) (DCM); IR (neat) 3267, 2943, 2893, 2837, 1607, 1587, 
1482 cm-1; 1H NMR (CD2Cl2) δ 8.00 (s, 1 H), 7.25 (t, 1 H, J = 7.8 Hz), 7.09 (t, 1 H, J = 7.8 Hz), 
6.96-6.88 (m, 2 H), 6.81 (d, 1 H, J = 7.8 Hz), 6.73-6.65 (m, 2 H), 5.99 (s, 1 H), 6.29 (s, 1 H), 
3.96-3.70 (m, 4 H), 3.67 (s, 3 H), 3.54 (s, 3 H); 13C NMR (CD2Cl2) δ 264.6, 159.8, 156.6, 144.1, 
141.5, 132.6, 130.2, 129.1, 120.8, 117.9, 114.9, 111.7, 110.4, 105.4, 66.6, 65.6, 63.8, 55.8, 55.6, 
35.1; HRMS (ESI) m/z calcd for C20H21NO5Na (M+Na) 378.1317, found 378.1293. 
 
 
                                                 
* (CWF058: procedure, mp, IR and proton NMR; CWD249: carbon NMR; CWE009: HRMS) 
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Benzyl (1R,2R)-1-(1,3-dioxolan-2-yl)-7-methoxy-1-(3-methoxyphenyl)-2,3-dihydro-
1H-inden-2-ylcarbamate (3-102) and benzyl (1R,2S)-1-(1,3-dioxolan-2-yl)-7-methoxy-1-(3-
methoxyphenyl)-2,3-dihydro-1H-inden-2-ylcarbamate (3-101). * . A solution of the oxime 
(0.292 g, 0.822 mmol) in boiling nPrOH (59 mL) was treated with Na (3.82 g, 166 mmol) in 
small protions over 7 h. The reaction mixture was cooled to room temperature, poured into brine 
and extracted with EtOAc (2x). The combined organic layers were dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford crude amine 3-101 and 3-102. A solution of 90% 
of the crude mixture and NaHCO3 (0.297 g, 3.53 mmol) was treated with benzyl chloroformate 
(0.120 mL, 0.842 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h, 
diluted with EtOAc and washed with brine (1x). The organic layer was dried (Na2SO4), filtered 
and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:EtOAc = 3:1) three times afforded 0.214 g (59%) of 3-102 as a clear oil and 0.0828 g 
(24%) of 3-101 as a clear oil. 3-102: IR (neat) 3332, 2958, 2879, 1692, 1587, 1476 cm-1; 1H 
NMR (CDCl3) δ 7.39-7.23 (m, 6 H), 7.19 (t, 1 H, J = 8.1 Hz), 6.92-6.85 (m, 2 H), 6.81-6.70 (m, 
3 H), 5.94 (s, 1 H), 5.10 (AB, 1 H, J = 12.3 Hz), 5.05 (AB, 1 H, J = 12.3 Hz), 5.01-4.92 (m, 1 H), 
4.41 (d, 1 H, J = 9.6 Hz), 4.19-4.03 (m, 2 H), 4.00-3.80 (m, 2 H), 3.70 (s, 3 H), 3.64 (s, 3 H), 
3.33 (dd, 1 H, J = 15.6, 8.1 Hz), 2.61 (dd, 1 H, J = 15.6, 10.2 Hz); 13C NMR (CDCl3) δ 159.9, 
156.0, 155.8, 142.4, 139.9, 137.2, 132.4, 129.6, 129.5, 128.5, 128.0, 127.9, 121.0, 117.2, 115.1, 
                                                 
* (CWF063, CWF069: procedure, proton and carbon NMR, HRMS, IR, mp) 
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112.4, 110.0, 105.9, 66.4, 66.1, 65.1, 62.1, 55.6, 55.2, 53.4, 38.4; HRMS (ESI) m/z calcd for 
C28H29NO6 (M+H) 498.1893, found 498.1863. Approx. 10 mg of 3-102 was dissolved in EtOAc 
(0.50 mL) and placed in a freezer at -20 °C for 3 days to provide X-ray quality white crystal: mp 
147.9-150.0 °C (EtOAc). 3-101: IR (neat) 3412, 2957, 2892, 1716, 1589, 1507, 1496 cm-1; 1H 
NMR 600 MHz (CDCl3) δ 7.30-7.18 (m, 6 H), 7.10 (t, 1 H, J = 8.1 Hz), 6.87-6.80 (m, 3 H), 6.76 
(d, 1 H, J = 7.8 Hz), 6.71-6.67 (m, 1 H), 6.24 (d, 1 H, J = 7.8 Hz), 5.61 (s, 1 H), 5.05 (AB, 1 H, J 
= 12.0 Hz), 4.99 (AB, 1 H, J = 12.6 Hz), 4.80-4.76 (m, 1 H), 3.83-3.77 (m, 4 H), 3.67 (s, 3 H), 
3.65 (s, 3 H), 2.97 (dd, 1 H, J = 15.6, 6.0 Hz), 2.80 (dd, 1 H, J = 15.6, 3.6 Hz); 13C NMR 150 
MHz (CDCl3) δ 159.5, 157.4, 156.0, 144.4, 143.1, 137.1, 130.5, 129.8, 129.0, 128.6, 128.14, 
128.09, 120.5, 118.1, 114.6, 112.0, 110.2, 107.0, 66.5, 65.3, 64.4, 63.1, 61.6, 55.7, 55.3, 39.6; 
HRMS (ESI) m/z calcd for C28H29NO6 (M+H) 498.1893, found 498.1881. 
OMe
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(2aR*,7aS*)-6-Bromo-2,2-dichloro-3-methoxy-2a-(3-methoxyphenyl)-2,2a,7,7a-
tetrahydro-1H-cyclobuta[a]inden-1-one (3-107).* A solution of 3-106165 (2.52 g, 7.61 mmol) 
and zinc-copper couple166 (5.47 g, 83.7 mmol) in Et2O (25 mL) at room temperature was treated 
with a solution of POCl3 (7.24 mL, 79.1 mmol, distilled from K2CO3) and Cl3CCOCl (8.83 g, 
79.1 mmol) over 5 h (syringe pump). The reaction mixture was stirred for 14 h at room 
temperature and filtered through a pad of Celite. The filtrate was washed with ice-water (2x), 
cold aqueous NaHCO3 (2x) and brine (1x), dried (MgSO4), filtered and concentrated under 
                                                 
* (CWG029: procedure, proton NMR; CWG023: carbon NMR, IR, MS) 
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reduced pressure. Purification by recrystallization from DCM afforded 2.37 g (71%) of 3-107 as 
a yellow solid: mp 167.4-169.3 C (DCM); IR (neat) 3582, 3000, 2936, 2836, 1808, 1762, 1603, 
1580, 1473, 1436 cm-1; 1H NMR (CDCl3)  7.28 (d, 1 H, J = 4.5 Hz), 7.28 (t, 1 H, J = 7.8 Hz), 
7.07 (t, 1 H, J = 2.1 Hz), 7.02 (d, 1 H, J = 7.8 Hz), 6.85 (dd, 1 H, J = 8.1, 2.1 Hz), 6.60 (d, 1 H, J 
= 8.7 Hz), 4.52 (d, 1 H, J = 2.7 Hz), 3.85 (s, 3 H), 3.74 (s, 3 H), 3.57 (d, 1 H, J = 17.4 Hz) , 3.35 
(dd, 1 H, J = 17.1, 8.4 Hz); 13C NMR (CDCl3)  195.9, 158.8, 157.2, 144.0, 139.3, 134.0, 130.9, 
128.6, 120.6, 115.2, 112.6, 112.4, 110.6, 71.0, 64.1, 55.33, 55.28, 36.0; MS (EI) m/z (rel 
intensity) 442 (65%), 408 (45%), 298 (30%), 264 (65%), 251 (100%); HRMS (EI) m/z calcd for 
C19H15O3Cl2Br 439.9582, found 439.9601. 
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(3aR*,8aS*)-7-Bromo-3,3-dichloro-4-methoxy-3a-(3-methoxyphenyl)-3,3a,8,8a-
tetrahydroindeno[2,1-b]pyrrol-2(1H)-one (3-108).* A solution of 3-107 (2.25 g, 5.11 mmol) 
and anhydrous Na2SO4 (2.61 g, 18.4 mmol) in DCM (20 mL) at room temperature was treated 
with Tamura’s reagent167 (3.96 g, 18.4 mmol). The reaction mixture was stirred for 72 h, treated 
with additional Tamura’s reagent (4.00 g, 18.6 mmol, stirred for 48 h, diluted with toluene and 
filtered through a column of basic alumina, eluting with MeOH. The solvents were evaporated 
under reduced pressure. The residue was dissolved in DCM, filtered and concentrated under 
reduced pressure to afford 2.06 g (88%) of crude 3-108 as a white powder: mp 238.0-240.0 C 
(DCM); IR (neat) 3315, 2937, 2834, 1694, 1599, 1587, 1470, 1438 cm-1; 1H NMR (CDCl3)  
                                                 
* (CWG033: procedure, proton NMR; CWG031: carbon NMR; CW090-043: IR and mp; CWG027: MS) 
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7.52 (d, 1 H, J = 8.7 Hz), 7.23 (t, 1 H, J = 8.1 Hz), 6.86-6.78 (m, 4 H), 6.57 (s, 1 H), 4.31 (ddd, 1 
H, J = 8.4, 6.0, 2.1 Hz), 3.82 (s, 3 H), 3.76 (s, 3 H), 3.45 (dd, 1 H, J = 16.8, 8.4 Hz), 3.00 (dd, 1 
H, J = 17.1, 6.0 Hz); 13C NMR (CDCl3)  170.8, 159.3, 157.3, 145.0, 143.0, 133.9, 129.5, 129.3, 
119.1, 113.9, 112.3, 110.8, 73.0, 64.6, 55.9, 55.4, 40.8; HRMS (ESI) m/z calcd for 
C19H16NO3NaCl2Br (M+Na) 477.9588, found 477.9553. 
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(3aR*,8aS*)-7-Bromo-4-methoxy-3a-(3-methoxyphenyl)-8,8a-dihydroindeno[2,1-
b]pyrrole-2,3(1H,3aH)-dione (3-109).* A suspension of 3-108 (1.01 g, 2.20 mmol) in NaOMe 
(0.6 M in MeOH 66.1 mL) was heated at reflux for 48 h. The reaction mixture was acidified with 
10% aqueous NaHSO4 and extracted with EtOAc (3x). The combined organic layers were 
washed with water (1x), saturated NaHCO3 (1x) and brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford the crude product. Half of the crude product was 
dissolved in THF (13 mL) and treated with 70% aqueous HClO4 (3.29 mL, 38.5 mmol). The 
reaction mixture was heated at reflux for 16 h, diluted with water and extracted with EtOAc (3x). 
The combined organic layers were washed with water (1x), saturated NaHCO3 (1x) and brine 
(1x), dried (Na2SO4), filtered and concentrated under reduced pressure to afford 0.437 g (99%) 
of crude 3-109 as a white powder: IR (neat) 3639, 2952, 2909, 2868, 1766, 1725, 1599, 1580, 
1472 cm-1; 1H NMR (CDCl3)  7.84 (s, 1 H), 7.51 (d, 1 H, J = 8.7 Hz), 6.84 (dd, 1 H, J = 8.4, 2.7 
                                                 
* (CWG078, CW090-008: procedure; CWG076: proton NMR; CWG076: X-ray and mp; CWG053: HRMS, 
carbon NMR; CWG082 : IR) 
 222 
Hz), 6.73 (d, 1 H, J = 8.7 Hz), 6.58-6.49 (m, 2 H), 4.47 (d, 1 H, J = 6.0 Hz), 3.75 (s, 3 H), 3.71 
(s, 3 H), 3.37 (dd, 1 H, J = 17.7, 5.7 Hz), 3.10 (d, 1 H, J = 17.7 Hz); 13C NMR (CDCl3)  194.8, 
160.8, 160.1, 158.0, 144.1, 137.8, 134.8, 130.2, 126.1, 119.8, 114.1, 113.1, 112.7, 111.2, 68.4, 
62.6, 56.0, 55.5, 40.2; HRMS (ESI) m/z calcd for C19H16NO4NaBr (M+Na) 424.0160, found 
424.0160. X-ray quality crystal was obtained by dissolving the crude product in EtOAc and 
slowly evaporating the solvent in air at room temperature: colorless needle, mp 264.0-266.7 C 
(EtOAc). 
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(3aR*,8aS*)-tert-Butyl 7-bromo-4-methoxy-3a-(3-methoxyphenyl)-2,3-dioxo- 
3,3a,8,8a-tetrahydroindeno[2,1-b]pyrrole-1(2H)-carboxylate (3-110). *  A solution of 3-109 
(0.443 g, 1.10 mmol) and DMAP (6.72 mg, 5.50 mmol) in THF (9.0 mL) at room temperature 
was treated with Et3N (0.309 mL, 2.20 mmol) and Boc2O (0.481 g, 2.20 mmol). The reaction 
mixture was stirred for 18 h, diluted with water and extracted with EtOAc (3x). The combined 
organic layers were washed with brine, dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 6:1 to 4:1) afforded 0.469 
g (85%) of 3-110 as a yellow solid: mp 86.7 C (decomp.) (DCM); IR (neat) 2974, 2933, 2834, 
1787, 1770, 1755, 1725, 1599, 1582, 1474 cm-1; 1H NMR (CDCl3)  7.24 (d, 1 H, J = 8.1 Hz), 
7.26 (t, 1 H, J = 8.1 Hz), 6.85 (dd, 1 H, J = 8.1, 2.4 Hz), 6.71 (d, 1 H, J = 8.7 Hz), 6.58-6.54 (m, 
1 H), 6.51 (t, 1 H, J = 2.1 Hz), 4.76 (dd, 1 H, J = 6.3, 0.9 Hz), 3.76 (s, 3 H), 3.68 (s, 3 H), 3.51 
                                                 
* (CW090-011: procedure, MS, mp; CWG081: IR, proton and carbon NMR) 
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(dd, 1 H, J = 18.6, 6.6 Hz), 3.28 (d, 1 H, J = 18.3 Hz), 1.61 (s, 9 H); 13C NMR (CDCl3)  192.5, 
160.1, 157.6, 157.0, 149.7, 144.3, 138.4, 135.0, 130.3, 125.2, 119.6, 113.9, 113.1, 112.7, 110.9, 
85.7, 66.1, 65.6, 56.1, 55.5, 40.4, 28.1; HRMS (ESI) m/z calcd for C24H24NO6NaBr (M+Na) 
524.0685, found 524.0697. 
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(1R*,2R*)-Methyl 4-bromo-2-(tert-butoxycarbonylamino)-7-methoxy-1-(3- 
methoxyphenyl)-2,3-dihydro-1H-indene-1-carboxylate (3-111).* A solution of 3-110 (4.83 g, 
9.61 mmol) in MeOH (136 mL) and aqueous NaOH (3 M, 71 mL) at room temperature was 
treated with aqueous H2O2 (30%, 47.0 mL, 423 mmol). The reaction mixture was stirred for 20 h 
and treated with additional aqueous H2O2 (30%, 47.0 mL, 423 mmol), stirred at room 
temperature for another 20 h, acidified with 10% aqueous NaHSO4 and extracted with EtOAc 
(3x). The combined organic layers were washed with brine (2x), dried (Na2SO4), filtered and 
concentrated under reduced pressure. The crude product was dissolved in DMF (60 mL) and 
treated with K2CO3 (1.97 g, 14.2 mmol) followed by MeI (1.13 mL, 18.1 mmol) at 0 °C. The 
reaction mixture was stirred for 3 h at the same temperature, quenched with water and extracted 
with EtOAc (3x). The combined organic layers were washed with saturated NaHCO3 (1x), water 
(2x) and brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 6:1) afforded 3.58 g (74%) of 3-111 
as a white foam: mp 68.4-72.7 C (DCM); IR (neat) 3440, 2968, 1703, 1599, 1580, 1489, 1472, 
                                                 
* (CW090-059 and CW090-061: procedure, IR, MS, mp, proton NMR; CW090-004: carbon NMR) 
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1429 cm-1; 1H NMR (CDCl3)  7.45 (d, 1 H, J = 8.7 Hz), 7.22 (t, 1 H, J = 8.1 Hz), 6.88-6.67 (m, 
4 H), 6.59 (d, 1 H, J = 10.2 Hz), 4.77-4.67 (m, 1 H), 3.75 (s, 3 H), 3.72 (s, 3 H), 3.69 (s, 3 H), 
3.20 (dd, 1 H, J = 16.5, 7.2 Hz), 2.90 (dd, 1 H, J = 16.5, 5.4 Hz), 1.41 (s, 9 H); 13C NMR 
(CDCl3)  172.4, 159.3, 156.6, 155.5, 144.0, 140.4, 133.0, 131.0, 128.9, 120.8, 114.5, 112.3, 
112.1, 111.0, 79.6, 67.9, 63.1, 56.0, 55.3, 52.7, 40.0, 28.5; HRMS (ESI) m/z calcd for 
C24H28NO6NaBr (M+Na) 528.0998, found 528.1045. 
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4-Allyl-4-methoxycyclohex-1-enyl trifluoromethanesulfonate (3-114).* A solution of 
3-113168 (13.0 g, 77.3 mmol, dried by co-evaporating with benzene (2x) and THF (1x)) and N-
phenylbis(trifluoromethane)sulfonimide (29.3 g, 81.1 mmol) in THF (564 mL) at -78 °C was 
slowly treated with a solution of KHMDS (0.302 M in THF, 243 mL, 73.4 mmol). The reaction 
mixture was then stirred for 2 h at room temperature, quenched with saturated aqueous NH4Cl 
and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:Et2O = 40:1) afforded 18.66 g (80%) of 3-114 as a clear oil: IR (neat) 2933, 1410, 
1244, 1200 cm-1; 1H NMR (CDCl3)  5.89-5.70 (m, 1 H), 5.68-5.60 (m, 1 H), 5.19-5.07 (m, 2 H), 
3.23 (s, 3 H), 2.56-2.42 (m, 1 H), 2.41-2.14 (m, 5 H), 2.03-1.93 (m, 1 H), 1.77-1.66 (m, 1 H); 13C 
NMR (CDCl3)  148.9, 133.0, 125.1, 120.9, 118.5, 116.6, 115.3, 112.4, 73.1, 49.1, 39.9, 39.6, 
36.0, 33.0, 32.7, 32.5, 30.4, 30.2, 25.0; MS (EI) m/z (rel intensity) 259 (75%), 227 (10%), 167 
                                                 
* (CW135-070: procedure, proton NMR, IR, HRMS; CWF064: carbon NMR) 
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(90%), 163 (40%), 109 (50%), 97 (100%), 77 (100%); HRMS (EI) (-C3H5, de-allylation) m/z 
calcd for C8H10O4F3S 259.0252, found 259.0251. 
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(1R*,2S*)-Methyl 7-methoxy-2-(2-(1-methoxy-4-(trifluoromethylsulfonyloxy) 
cyclohex-3-enyl)ethylamino)-1-(3-methoxyphenyl)-2,3-dihydro-1H-indene-1-carboxylate (3-
116).* A solution of 3-111 (3.57 g, 7.05 mmol) and NaOAc·3H2O (1.06 g, 7.76 mmol) in EtOH 
(91 mL) was subjected to H-Cube (20 bar, room temperature, 1 ml/min, Pd/C cartridge). The 
reaction mixture was concentrated under reduced pressure, treated with 5% aqueous K2CO3 and 
extracted with EtOAc (3x). The combined organic layers were washed with brine (1x), dried 
(Na2SO4), filtered and concentrated under reduced pressure. The crude product was dissolved in 
HCl/MeOH (1 M, 141 mL, 1.90 mol) and stirred at room temperature for 3 h. The reaction 
mixture was cooled to 0 °C, quenched with 5% aqueous K2CO3 and extracted with EtOAc (3x). 
The combined organic layers were washed with brine (1x), dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford 1.97 g (85%) of crude product. A fraction of the 
crude product (1.48 g, 4.53 mmol) and aldehyde 3-115 (1.64 g, 5.44 mmol) (for preparation see 
3-130, 3-115 must be used immediately to avoid decomposition) was dissolved in MeOH (55 
mL) and treated with NaBH(OAc)3 (2.02 g, 9.07 mmol) at room temperature. The reaction 
mixture was stirred for 16 h, quenched with 5% aqueous K2CO3 and extracted with EtOAc (3x). 
                                                 
* (CW090-064, CW090-065 and CW106-068: procedure; CW090-032: proton NMR and carbon NMR; 
CW090-029: IR and MS) 
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The combined organic layers were washed with brine (1x), dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc 
= 3:1 to 1:1, with 1% Et3N) afforded 1.88 g (58% over three steps) of 3-116 (mixture of 
diastereomers, ratio = 1:1) as a yellow oil: IR (neat) 2953, 2830, 1733, 1599, 1585, 1477, 1412 
cm-1; 1H NMR 600 MHz (CD2Cl2)  7.30 (t, 1 H, J = 7.8 Hz), 7.16 (t, 1 H, J = 8.4 Hz), 6.90 (d, 1 
H, J = 7.2 Hz), 6.85-6.82 (m, 2 H), 6.81 (d, 1 H, J = 8.4 Hz), 6.76 (dd, 1 H, J = 7.8, 1.8 Hz), 
5.62-5.59 (m, 1 H), 3.73 (s, 3 H), 3.69 (s, 3 H), 3.65 (s, 3 H), 3.65-3.60 (m, 1 H), 3.19 (dd, 1 H, J 
= 15.6, 7.2 Hz), 3.132 (s, 1.5 H), 3.127 (s, 1.5 H), 2.90 (dd, 1 H, J = 15.6, 5.4 Hz), 2.80-2.74 (m, 
1 H), 2.56-2.51 (m, 1 H), 2.48-2.39 (m, 1 H), 2.33-2.26 (m, 1 H), 2.26-2.11 (m, 2 H), 2.01-1.94 
(m, 1 H), 1.73-1.54 (m, 4 H); 13C NMR 150 MHz (CD2Cl2)  172.9, 159.3, 157.3, 149.2, 149.1, 
144.9, 143.8, 130.6, 130.1, 128.5, 120.8, 120.0, 117.9, 117.8, 115.64, 115.59, 114.93, 114.90, 
111.6, 109.8, 73.6, 72.9, 72.8, 67.3, 55.7, 55.4, 52.2, 49.1, 43.27, 43.25, 39.2, 35.8, 35.7, 33.7, 
33.6, 30.6, 25.1, 25.0; MS (EI) m/z (rel intensity) 613 (50%), 582 (30%), 480 (40%), 381 (25%), 
325 (100%), 280 (60%), 252 (50%), 191 (40%), 167 (30%); HRMS (EI) m/z calcd for 
C29H34NO8F3S 613.1953, found 613.1957. 
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(1R*,2S*)-1-((tert-Butyldimethylsilyloxy)methyl)-7-methoxy-1-(3-methoxyphenyl)-
2,3-dihydro-1H-inden-2-amine (3-118). *  A solution of 3-117129 (12.9 g, 44.2 mmol) and 
                                                 
* (CW135-064, CW182-061: procedures; CWF076: proton and carbon NMR, HRMS; CW090-028: IR) 
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K2CO3 (9.05 g, 65.5 mmol) in DMF (103 mL) was treated with MeI (5.18 mL, 83.2 mmol) at 0 
°C. The reaction mixture was stirred at the same temperature for 2 h, quenched with water and 
extracted with EtOAc (3x). The combined organic layers were washed with saturated NaHCO3 
(3x), water (3x), brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:Et2O = 8:1) afforded 12.7 g (94%) of the ester 
as a white solid. A solution of the ester (2.14 g, 6.99 mmol), Pd(OAc)2 (31.4 mg, 0.140 mmol) 
and DPEPhos (0.113 g, 0.210 mmol) in dioxane (28 mL) was degassed by two freeze-pump-
thaw cycles and treated with Et3N (3.44 mL, 24.5 mmol) and pinacolborane (1.52 mL, 10.5 
mmol) at room temperature. The reaction mixture was stirred at 85 °C for 4 h, cooled to room 
temperature, quenched with saturated NH4Cl and extracted with EtOAc (3x). The combined 
organic layers were washed with brine (1x), dried (Na2SO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes:Et2O = 10:1) afforded 1.79 
g (84%) of 3-118 as a yellow oil: IR (neat) 2976, 2948, 1736, 1600, 1565, 1379 cm-1; 1H NMR 
(CDCl3)  7.79 (d, 1 H, J = 8.4 Hz), 6.81 (d, 1 H, J = 8.4, 2.7 Hz), 6.75 (d, 1 H, J = 2.4 Hz), 3.97 
(s, 2 H), 3.82 (s , 3 H), 3.67 (s, 3 H), 1.31 (s, 12 H); 13C NMR (CDCl3)  172.9, 162.0, 142.7, 
138.2, 116.4, 111.8, 83.6, 55.3, 51.9, 41.3, 25.0; HRMS (ESI) m/z calcd for C16H23BO5Na 
(M+Na) 329.1536, found 329.1542. 
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2-(5-Methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid (3-
119).* A solution of 3-118 (1.77 g, 5.77 mmol) in THF (95 mL) was treated with LiOH (1 M 
aqueous solution, 17.3 mL, 17.3 mmol) at room temperature. The reaction mixture was stirred 
for 2 h, quenched with 10% NaHSO4 and extracted with EtOAc (3x). The combined organic 
layers were washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced 
pressure to afford 1.40 g (83%) of 3-119 as a white solid: mp 115.7-117.7 °C (DCM); IR (neat) 
2970, 2931, 1705, 1600, 1420, 1345 cm-1; 1H NMR (CDCl3)  7.79 (d, 1 H, J = 8.4 Hz), 6.90-
6.80 (m, 2 H), 3.91 (s, 2 H), 3.83 (s , 3 H), 3.67 (s, 3 H), 1.37 (s, 12 H); 13C NMR (CDCl3)  
162.2, 142.0, 138.3, 116.5, 112.2, 84.0, 55.3, 41.7, 24.9; HRMS (ESI) m/z calcd for 
C17H20BO5Na (M+Na) 315.1404, found 315.1398. 
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(1R*,2S*)-Methyl 7-methoxy-2-(2-(5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2- 
                                                 
* (CW210-012: procedure, proton NMR, melting point; CW135-084: carbon NMR; CW182-070: HRMS; 
CW090-032: IR) 
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dioxaborolan-2-yl)phenyl)-N-(2-(1-methoxy-4-(trifluoromethylsulfonyloxy)cyclohex-3-
enyl)ethyl)acetamido)-1-(3-methoxyphenyl)-2,3-dihydro-1H-indene-1-carboxylate (3-120). * 
A solution of 3-116 (1.88 g, 3.06 mmol) and 3-119 (1.07 g, 3.07 mmol) in DMF (36 mL) was 
treated with DIPEA (1.07 mL, 6.13 mmol) followed by HATU (1.63 g, 4.29 mmol) at room 
temperature. The reaction mixture was stirred for 14 h, quenched with water and extracted with 
EtOAc (3x). The combined organic layers were washed with water (3x) and brine (1x), dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification on SiO2 
(Hexanes:EtOAc = 3:1 to 2:1) afforded 2.11 g (78%) of 3-120 (mixture of diastereomers, ratio = 
1:1) as a yellow foam: IR (neat) 2972, 2940, 2832, 1723, 1645, 1600, 1479, 1412 cm-1; 
Representative 1H NMR of one diastereomer 600 MHz (CDCl3)  5.64-5.58 (m, 1 H), 3.77 (s, 3 
H), 3.71 (s, 3 H), 3.14 (s, 3 H); 13C NMR of a mixture of both diastereomers and rotamers 150 
MHz (CDCl3)  173.73, 173.68, 172.5, 171.8, 162.04, 161.97, 159.4, 158.9, 157.04, 156.96, 
148.8, 148.70, 148.65, 148.6, 145.0, 144.9, 144.3, 144.23, 144.16, 144.1, 143.7, 143.5, 141.7, 
141.6, 138.4, 138.2, 132.4, 131.3, 130.5, 130.34, 130.30, 129.2, 128.6, 123.1, 120.9, 120.8, 
117.0, 116.6, 116.53, 116.49, 116.46, 116.3, 115.5, 115.4, 115.3, 115.1, 114.99, 114.96, 114.9, 
112.3, 111.7, 111.62, 111.59, 111.20, 111.16, 110.3, 109.9, 83.41, 83.35, 72.7, 72.6, 70.6, 70.4, 
68.0, 67.9, 67.6, 55.8, 55.7, 55.29, 55.28, 52.72, 52.66, 49.63, 49.58, 49.55, 41.5, 41.04, 41.00, 
39.9, 39.8, 37.0, 36.9, 36.4, 36.2, 34.11, 34.08, 34.0, 33.9, 33.42, 33.35, 32.9, 32.5, 30.37, 30.36, 
30.3, 30.0, 25.3, 25.23, 25.20, 25.1, 25.01, 25.00, 24.94, 24.92; HRMS (ESI) m/z calcd for 
C44H53B1N1O12F3NaS (M+Na) 910.3231, found 910.3190. 
                                                 
* (CW106-072: procedure; CW090-033: IR and NMRs; CW090-004: MS) 
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Preparation of 3-121.* A mixture of 3-120 (1.42 g, 1.60 mmol) and K2CO3 (0.442 g, 3.22 
mmol) in DMSO (318 mL) and water (0.0864 mL, 4.80 mmol) was degassed by two freeze and 
thaw cycles and treated with a solution of Pd(PPh3)4 (92.4 mg, 0.0800 mmol) in degassed DMSO 
(17 mL). The reaction mixture was heated to 85 °C for 1.5 h, cooled to room temperature, 
quenched with water and extracted with EtOAc (3x). The combined organic layers were washed 
with water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:THF = 3:1) afforded 0.798 g (82%) of 3-121 
(mixture of diastereomers, ratio = 1:1) as a white foam: IR (neat) 2931, 2832, 1716, 1636, 1602, 
1591, 1477 cm-1; 1H NMR not provided due to the complex chemical shift pattern; 13C NMR of a 
mixture of both diastereomers 150 MHz (CDCl3) 174.8, 174.5, 174.2, 173.1, 172.3, 172.1, 172.0, 
171.8, 159.5, 159.3, 159.1, 158.8, 158.7, 158.3, 156.8, 156.7, 156.6, 147.1, 146.3, 144.6, 144.4, 
143.7, 143.6, 141.3, 141.1, 139.4, 138.6, 137.6, 136.2, 135.9, 135.6, 135.5, 135.4, 134.8, 133.5, 
132.3, 132.0, 131.8, 130.6, 130.5, 130.3, 130.0, 129.6, 129.5, 129.4, 129.2, 128.93, 128.86, 
128.7, 128.3, 128.2, 127.4, 124.4, 124.3, 123.7, 122.4, 121.1, 120.0, 119.8, 118.2, 117.7, 117.3, 
117.0, 116.8, 116.6, 115.5, 115.1, 114.0, 113.8, 113.4, 112.7, 112.4, 111.9, 111.8, 111.4, 111.2, 
110.1, 109.9, 109.7, 109.4, 83.7, 75.9, 75.8, 74.2, 73.6, 73.3, 71.9, 70.4, 67.7, 67.0, 65.0, 64.3, 
55.9, 55.7, 55.5, 55.43, 55.35, 55.33, 55.30, 52.8, 52.7, 52.6, 49.7, 49.5, 49.2, 48.7, 48.6, 48.4, 
                                                 
* (CW106-082: procedure and proton NMR; CW090-079: carbon NMR; CW090-024: MS) 
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48.0, 45.2, 42.2, 40.9, 40.2, 39.4, 38.4, 37.8, 37.1, 36.8, 35.7, 34.9, 34.7, 34.6, 34.3, 33.8, 33.2, 
33.1, 32.8, 31.5, 31.4, 30.3, 30.03, 29.98, 29.9, 29.7, 25.5, 25.2, 25.02, 24.97, 24.9, 24.4, 23.6, 
19.0; HRMS (ESI) m/z calcd for C37H41NO7Na (M+Na) 634.2781, found 634.2772. 
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Preparation of 3-124.*  A solution of 3-121 (0.2176 g, 0.356 mmol) in THF (10.8 mL) at 
- 78 °C was treated with a solution of LDA (0.78 M in THF, 1.00 mL, 0.780 mmol, prepared 
freshly from diisopropylamine and nBuLi). The reaction mixture was stirred at room temperature 
for 10 min, quenched with water and extracted with EtOAc (3x). The combined organic layers 
were washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:THF = 2:1 to 1:1, all with 0.1% Et3N) 
afforded 0.2222 g of crude 3-124 as a mixture of diastereomers (ration = 1:1). The diastereomers 
were partially separated by chromatography (1st column with Hexanes:THF = 3:2 with 0.1% 
Et3N, 2nd column with DCM:Et2O = 10:1 to 2:1, 3rd column with DCM:Et2O = 10:1) to afford 
pure 3-124a: IR (neat) 2927, 2834, 1733, 1647, 1604, 1591 cm-1; 1H NMR 500 MHz (CDCl3)  
7.39 (d, 1 H, J = 8.0 Hz), 7.22 (d, 1 H, J = 8.0 Hz), 7.14 (d, 1 H, J = 8.0 Hz), 6.96 (d, 1 H, J = 7.0 
Hz), 6.91 (d, 1 H, J = 8.5 Hz), 6.84-6.77 (m, 2 H), 6.53 (d, 1 H, J = 2.5 Hz), 6.49 (d, 1 H, J = 8.0 
Hz), 6.36 (app s, 1 H), 5.48 (d, 1 H, J = 5.0 Hz), 4.46 (s, 1 H), 4.39 (d, 1 H, J = 4.5 Hz), 4.04-
3.97 (m, 1 H), 3.88 (s, 3 H), 3.76 (d, 1 H, J = 6.0 Hz), 3.71 (s, 3 H), 3.31 (s, 3 H), 3.17-3.08 (m, 
                                                 
* (CW106-091: procedure; CW106-095: resolving diastereomers, X-ray, mp, IR, NMRs and HRMS) 
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2 H), 3.08-2.99 (m, 1 H), 2.93 (dd, 1 H, 16.0, 4.0 Hz), 2.59-2.51 (m, 1 H), 2.46-2.35 (m, 2 H), 
2.34-2.27 (m, 1 H), 1.90-1.76 (m, 1 H); 13C NMR 150 MHz (CDCl3)  201.9, 168.6, 159.5, 
158.2, 156.6, 143.5, 138.1, 136.0, 133.6, 131.7, 129.6, 129.5, 129.2, 124.1, 121.6, 120.1, 118.9, 
115.7, 112.6, 112.5, 110.0, 75.2, 72.5, 67.6, 62.3, 55.7, 55.34, 55.28, 49.4, 46.0, 37.0, 33.9, 33.2, 
30.3, 30.2; HRMS (ESI) m/z calcd for C36H37NO6Na (M+Na) 602.2519, found 602.2540. 3-124a 
was recrystallized from DCM to yield x-ray quality yellow crystal: mp 219.4 °C (decomp.) 
(DCM). The crystal was collected and redissolved in CDCl3 to give a proton NMR spectrum that 
is identical to the sample before crystallization. 
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Preparation of 3-125.* Crude 3-124 (0.2222 g) in THF (8.7 mL) was treated with LiBH4 
(2 M in THF, 0.356 mL, 0.711 mmol) at room temperature. The reaction mixture was stirred for 
48 h, treated with additional LiBH4 (2 M in THF, 0.356 mL, 0.711 mmol) and stirred for 24 h. 
The reaction mixture was quenched with water and extracted with EtOAc (3x). The combined 
organic layers were washed with brine (1x), dried (Na2SO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes:THF = 1:1, all with 0.1% 
Et3N) followed by 2nd chromatography on SiO2 (DCM:Et2O = 10:1, with 0.1% Et3N) afforded 
97.2 mg  (47% over two steps) of 3-125 (mixture of diastereomers, ratio = 1:1) as a white solid, 
9.4 mg (4.5% over two steps) of 3-125a (single diastereomer) as a clear sticky solid and 16.2 mg 
                                                 
* (CW106-092: procedure, proton, carbon, COSY, HMQC, HMBC, HRMS and IR) 
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(7.8% over two steps) of 3-125b (single diastereomer) as a clear sticky solid. 3-125a: IR (neat) 
3419, 2924, 2849, 2832, 1638, 1602, 1436 cm-1; 1H NMR 500 MHz (CDCl3)  7.21 (d, 1 H, J = 
8.0 Hz), 7.19 (d, 1 H, J = 7.5 Hz), 7.08-7.03 (m, 2 H), 7.86 (d, 1 H, J = 8.0 Hz), 6.80-6.71 (m, 4 
H), 6.69 (d, 1 H, J = 8.0 Hz), 5.28 (dd, 1 H, J = 6.0, 3.0 Hz), 5.83 (d, 1 H, J = 3.5 Hz), 4.06 (s, 3 
H), 3.91 (d, 1 H, J = 6.0 Hz), 3.79 (s, 3 H), 3.75 (s, 3 H), 3.64 (app d, 1 H, 13.0 Hz), 3.52 (app t, 
1 H, J = 14.5 Hz), 3.33 (s, 3 H), 3.16 (d, 1 H, J = 16.5 Hz), 3.04 (t, 1 H, J = 13.0 Hz), 2.80 (dd, 1 
H, J = 16.0, 3.0 Hz), 2.53-2.37 (m, 3 H), 2.29 (app d, 1 H, J = 16.5 Hz), 1.85-1.69 (m, 3 H), 1.56 
(d, 1 H, J = 3.0 Hz); 13C NMR (CDCl3)  171.0, 159.6, 158.1, 156.7, 142.6, 142.3, 138.6, 135.9, 
133.5, 130.6, 130.2, 129.2, 127.2, 120.4, 118.9, 117.6, 115.2, 111.7, 111.5, 110.2, 75.2, 72.0, 
67.2, 62.2, 55.6, 55.4, 55.3, 52.8, 49.3, 47.1, 35.2, 34.6, 33.2, 30.7, 30.3; HRMS (ESI) m/z calcd 
for C36H39NO6Na (M+Na) 604.2675, found 604.2673. 3-125b: IR (neat) 3436, 2931, 2836, 1641, 
1602, 1477, 1436 cm-1; 1H NMR 500 MHz (CDCl3)  7.21-7.17 (m, 2 H), 7.10-7.06 (m, 2 H), 
6.95 (d, 1 H, J = 8.5 Hz), 6.86 (d, 1 H, J = 8.5 Hz), 6.79-6.72 (m, 3 H), 6.68 (d, 1 H, J = 2.5 Hz), 
5.37 (d, 1 H, J = 5.0 Hz), 5.11 (d, 1 H, J = 4.0 Hz), 4.99 (dd, 1 H, J = 6.0, 2.5 Hz), 4.43 (dd, 1 H, 
J = 15.0, 12.0 Hz), 4.04 (s, 3 H), 3.88 (d, 1 H, J = 6.0 Hz), 3.78 (s, 3 H), 3.74 (s, 3 H), 3.29 (s, 3 
H), 3.16 (d, 1 H, 16.0 Hz), 3.05 (dd, 1 H, J = 15.5, 6.5 Hz), 2.80 (dd, 1 H, J = 16.0, 4.0 Hz), 2.44 
(dd, 1 H, J = 17.0, 7.0 Hz), 2.28-2.12 (m, 4 H), 2.07-1.99 (m, 1 H), 1.95-1.87 (m, 2 H); 13C NMR 
(CDCl3)  172.8, 159.5, 158.2, 156.7, 143.0, 142.8, 138.0, 137.4, 136.7, 132.1, 130.6, 130.2, 
129.1, 126.1, 120.4, 119.0, 117.6, 115.2, 111.7, 111.5, 110.2, 77.7, 71.4, 63.1, 61.5, 55.5, 55.4, 
55.3, 53.6, 48.8, 38.1, 35.4, 34.9, 34.4, 33.4, 30.3; HRMS (ESI) m/z calcd for C36H39NO6Na 
(M+Na) 604.2675, found 604.2720. 
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Preparation of 3-123. *  A solution of 3-125 (3.2 mg, 0.00550 mmol, mixture of 
diastereomers, ratio = 5:1) in THF 0.1+0.1+0.1 mL was added to a suspension of KH 12.6 mg 
(35% in mineral oil, pre-washed with toluene three times to remove mineral oil) in THF 0.18 
mL. The reaction mixture was stirred for 1 h at 63 °C, cooled to 0 °C, quenched with saturated 
NH4Cl and extracted with EtOAc (1x). The organic layer was washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure. Purification of combined crude from 
three reactions by chromatography on SiO2 (Hexanes:EtOAc = 1:1) followed by supercritical 
fluid chromatography on cyano column with 20% MeOH in CO2 as eluent afforded 2.5 mg 
(23%) of 3-123 (mixture of diastereomers, ratio = 5:1) as a clear sticky solid: IR (neat) 2931, 
2834, 1669, 1630, 1600, 1477, 1464, 1433 cm-1; 1H NMR of major diastereomer 600 MHz 
(CDCl3)  7.25 (d, 1 H, J = 7.8 Hz), 7.20 (t, 1 H, J = 7.8 Hz), 7.06 (d, 1 H, J = 7.8 Hz), 6.89-6.76 
(m, 5 H), 6.68 (s, 1 H), 6.53 (app d, 1 H, J = 8.4 Hz), 6.47 (t, 1 H, J = 2.4 Hz), 5.58 (d, 1 H, J = 
6.6 Hz), 4.34 (d, 1 H, J = 4.8 Hz), 4.40-4.30 (m, 1 H), 3.811 (s, 3 H), 3.806 (s, 3 H), 3.71 (s, 3 
H), 3.27 (s, 3 H), 3.16-3.09 (m, 1 H), 3.12 (d, 1 H, J = 15.6 Hz), 2.99-2.91 (m, 2 H), 2.43 (dd, 1 
H, J = 16.8, 6.6 Hz), 2.38-2.26 (m, 3 H), 2.12-2.06 (m, 1 H), 2.02-1.96 (m, 2 H), 1.87-1.76 (m, 1 
H); 13C NMR of major diastereomer 150 MHz (CDCl3)  165.9, 160.0, 159.9, 158.8, 158.7, 
156.62, 156.55, 146.3, 146.2, 142.6, 142.2, 138.7, 138.1, 137.6, 136.8, 136.12, 136.06, 135.9, 
                                                 
* (CW182-010: procedure, proton, carbon, COSY, HMQC, HMBC, HRMS and IR) 
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133.6, 132.0, 130.2, 130.1, 129.8, 129.4, 128.2, 127.7, 127.5, 120.0, 119.8, 117.6, 117.5, 114.9, 
114.4, 114.2, 114.0, 112.8, 112.4, 112.1, 111.7, 110.4, 110.3, 75.6, 73.8, 57.0, 56.6, 55.6, 55.44, 
55.39, 55.33, 55.28, 49.5, 48.9, 46.0, 36.2, 35.7, 35.3, 33.9, 33.4, 29.4, 29.1, 27.4; ; HRMS (ESI) 
m/z calcd for C36H38NO5 (M+H) 564.2750, found 564.2700. 
OMe
OMe
N
HH
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(1R*,2S*)-Methyl 2-amino-7-methoxy-1-(3-methoxyphenyl)-2,3-dihydro-1H- 
indene-1-carboxylate (3-126141). *  3-111 (1.33 g, 2.63 mmol) in a solution of HCl (1 M, 
prepared from mixing MeOH and acetyl chloride) in MeOH (39 mL) was stirred at room 
temperature for 2.5 h, quenched with 5% aqueous K2CO3 and extracted with EtOAc (3x). The 
combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. The crude material was dissolved in THF (21.6 mL) and treated with 
LAH (2.00 g, 52.7 mmol) at room temperature. The reaction mixture was heated at reflux for 48 
h, cooled to 0 °C and quenched with a saturated solution of Rochelle’s salt and filtered. The 
filtrate was extracted with EtOAc (3x). The combined organic layers were washed with brine, 
dried (Na2SO4), filtered and concentrated under reduced pressure. The crude material and 2-(2-
bromo-5-methoxyphenyl)acetic acid169 (0.796 g, 3.25 mmol) in DCM (17.3 mL) was treated with 
EDCI (0.622 g, 3.25 mmol) at room temperature. The reaction mixture was stirred for 16 h, 
quenched with water and extracted with EtOAc (2x). The combined organic layers were washed 
with water (2x) and brine, dried (Na2SO4), filtered and concentrated under reduced pressure. 
                                                 
* (CW135-058, CW135-059, CW135-066: procedure and proton NMR; CW120-074: carbon NMR) 
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Purification by chromatography on SiO2 (Hexanes:EtOAc = 2:1) afforded 0.7522 g (53%) of 3-
126141 as a sticky clear solid: 1H NMR (CDCl3)  7.42 (d, 1 H, J = 9.0 Hz), 7.32 (t, 1 H, J = 7.8 
Hz), 7.27-7.22 (m, 1 H), 7.15 (t, 1 H, J = 8.1 Hz), 6.94 (d, 1 H, J = 7.5 Hz), 6.89 (d, 1 H, J = 3.0 
Hz), 6.85 (d, 1 H, J = 8.1 Hz), 6.72 (dd, 1 H, J = 8.4, 1.8 Hz), 6.69 (dd, 1 H, J = 9.0, 2.7 Hz), 
6.60 (app d, 1 H, J = 7.8 Hz), 6.48 (t, 1 H, J = 1.8 Hz), 4.92-4.84 (m, 1 H), 4.28-4.16 (m, 2 H), 
3.79 (s, 3 H), 3.77 (s, 3 H), 3.71 (s, 3 H), 3.65 (s, 2 H), 3.07 (dd, 1 H, J = 16.2, 6.0 Hz), 2.77 (app 
d, 1 H, J = 16.5 Hz), 2.42-2.32 (m, 1 H); 13C NMR (CDCl3)  170.0, 159.7, 159.3, 156.9, 145.5, 
144.3, 136.0, 133.6, 130.1, 129.53, 129.46, 119.2, 118.9, 117.2, 115.6, 115.2, 113.2, 111.8, 
109.4, 66.3, 62.6, 62.3, 55.7, 55.6, 55.3, 44.6, 39.0. 
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(4aS*,9aS*)-3-(2-bromo-5-methoxyphenyl)-5-methoxy-4a-(3-methoxyphenyl)-9,9a-
dihydro-1H-indeno[2,1-b]pyridin-2(4aH)-one (3-127141).* A solution of oxalyl chloride (0.405 
mL, 4.72 mmol) in DCM (3.6 mL) at -60 °C was treated with DMSO (0.722 mL, 10.2 mmol) in 
DCM (1.5 mL). The reaction mixture was stirred at -60 °C for 10 min and treated with 3-126 
(0.7522 g, 1.43 mmol) in DCM (1.5 mL). The resulting mixture was stirred for 0.5 h and treated 
with Et3N (2.98 mL, 21.2 mmol). The reaction mixture was stirred at -60 °C for 5 min then room 
temperature for 1 h, quenched with aqueous NaHCO3 and extracted with EtOAc (3x). The 
combined organic layers were washed with brine (1x), dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 2:1) 
                                                 
* (CW135-067, CW135-069: procedure and proton NMR; CW136-002: carbon NMR) 
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afforded 0.680 g (91%) of the aldehyde as a sticky clear solid, which was immediately dissolved 
in MeOH (79 mL) and treated with K2CO3 (1.79 g, 13.0 mmol) at room temperature. The 
reaction mixture was heated to 60 °C for 8 h. Concentration of the reaction mixture in vacuo 
gave a residue that was partitioned between brine and EtOAc. The aqueous layer was extracted 
with EtOAc (2x). The combined organic layers were dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 1:1 with 
0.1% TEA) afforded 0.4674 g (71%) of 3-127141 as a sticky clear solid: 1H NMR 500 MHz 
(CDCl3)  7.46 (d, 1 H, J = 7.7 Hz), 7.30 (t, 1 H, J = 8.0 Hz), 7.24 (t, 1 H, J = 8.0 Hz), 6.95 (d, 1 
H, J = 7.5 Hz), 6.92 (app s, 1 H), 6.82 (d, 1 H, J = 2.0 Hz), 6.83 - 6.78 (m, 3 H), 6.76 (dd, 1 H, J 
= 9.0, 3.0 Hz), 6.72 (br s , 1 H), 5.75 (app s, 1 H), 4.23 (app d, 1 H, J = 3.5 Hz), 3.80 (s, 3 H), 
3.77 (s, 3 H), 3.63 (s, 3 H), 3.37 (dd, 1 H, J = 15.5, 7.0 Hz), 3.18-3.09 (m, 1 H); 13C NMR 
125MHz (CDCl3)  163.9, 159.8, 158.9, 156.6, 145.0, 143.6, 140.9, 139.1, 133.1, 130.0, 129.8, 
129.4, 119.2, 117.5, 117.2, 115.1, 114.5, 113.1, 112.0, 110.0, 64.4, 55.6, 55.34, 55.31, 55.2, 40.8. 
Bpin
OMe
O OMe  
Methyl 2-(1-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3- 
enyl)acetate (3-130).* A solution of 3-114 (5.00 g, 16.65 mmol) in THF (139 mL) and water 
(5.3 mL) at 0 °C was treated with OsO4 (0.088 M in t-BuOH, 7.64 mL, 0.673 mmol) followed by 
NMO (60%wt in water, 4.54 mL, 20.2 mmol). The reaction mixture was stirred at room 
                                                 
* (CW135-077, CW135-080, CW135-086, CW157-001: procedure, IR, proton NMR and carbon NMR; 
note: the intermediates are either unstable or difficult to purify). 
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temperature for 14 h and treated with a suspension of NaIO4 (10.7 g, 50.0 mmol) in water (33.0 
mL). The resulting mixture was stirred at room temperature for 4 h. The reaction mixture was 
partitioned between ether and water, and the aqueous layer was extracted with ether (2x). The 
combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 5:1) 
afforded 3.76 g (75%) of the aldehyde as a black oil, which was immediately taken to the next 
step. A fraction of the aldehyde (1.63 g, 5.39 mmol) was dissolved in a mixture of t-BuOH (139 
mL) and water (58.3 mL). The mixture was then treated with 2-methyl-2-butene (40.0 mL, 378 
mmol), NaH2PO4 (5.95 g, 49.6 mmol) and NaClO2 (3.37 g, 37.2 mmol) at room temperature. 
The reaction mixture was stirred overnight and extracted with EtOAc (3x). The combined 
organic layers were washed with 5% aqueous KH2PO4 (2x), dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc 
= 2:1 to DCM:MeOH 10:1) afforded 1.78 g of the acid as a black oil. A fraction of the acid 
(0.626 g, 1.97 mmol) and K2CO3 (0.402 g, 2.91 mmol) in DMF (12.3 mL) at 0 °C was treated 
with MeI (0.230 mL, 3.70 mmol). The reaction mixture was stirred at the same temperature for 3 
h, diluted with water and extracted with EtOAc (3x). The combined organic layers were washed 
with saturated NaHCO3 (1x), water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:Et2O = 4:1) afforded 
0.3177 g (49% over two steps) of the ester as a clear oil. A fraction of the ester (0.2948 g, 0.926 
mmol) together with PdCl2(PPh3)2 (8.54 mg, 0.0278 mmol), Ph3P (3.61 mg, 0.0556 mmol), 
bis(pinacolato)diboron (0.261 g, 1.02 mmol) and KOPh (0.121 g, 1.39 mmol) were dissolved in 
toluene and heated to 50 °C for 3.5 h. The reaction mixture was partitioned between water and 
ether and the aqueous layer was extracted with ether (2x). The combined organic layers was 
 239 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by chromatography on SiO2 (Hexanes:Et2O = 8:1 to 6:1) afforded 0.1969 g (69%) of 3-130 as a 
clear oil: IR (neat) 2974, 2929, 2845, 2827, 1735, 1634, 1433 cm-1; 1H NMR (CDCl3)  6.39-
6.33 (m, 1 H), 3.60 (s, 3 H), 3.17 (s, 3 H), 2.50 (AB, 1 H, J = 13.5 Hz), 2.43 (AB, 1 H, J = 13.8 
Hz), 2.30-2.23 (m, 1 H), 2.23-2.05 (m, 2 H), 1.80-1.40 (m, 1 H), 1.80-1.60 (m, 1 H), 1.18 (s, 12 
H); 13C NMR (CDCl3)  171.2, 139.3, 83.2, 73.8, 53.5, 51.5, 49.1, 40.5, 36.7, 36.4, 30.1, 24.9, 
24.8, 24.1; MS (EI) m/z (rel intensity) 295 (8%), 278 (65%), 236 (25%), 205 (90%), 130 (65%), 
101 (100%); HRMS (EI) m/z calcd for C15H24BO5 (M-CH3) 295.1717, found 295.1717. 
Bpin
OMe
O OH  
2-(1-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enyl)acetic 
acid (3-131). *  A solution of 3-130 (0.1969 g, 0.635 mmol) in THF (10.4 mL) at room 
temperature was treated with LiOH (1 M in water, 1.90 mL, 1.90 mmol). The reaction mixture 
was stirred at room temperature for 1.5 h, acidified with 10% aqueous NaHSO4 and extracted 
with EtOAc (3x). The combined organic layers were washed with brine, dried (Na2SO4), filtered 
and concentrated under reduced pressure to afford 0.1732 g (92%) of 3-131 as a clear oil: IR 
(neat) 2974, 2931, 2830, 1729, 1705, 1636, 1386 cm-1; 1H NMR (CDCl3)  10.39 (br s, 1 H), 
6.41-6.34 (m, 1 H), 3.24 (s, 3 H), 2.53 (AB, 1 H, J = 13.8 Hz), 2.47 (AB, 1 H, J = 14.1 Hz), 
2.34-2.26 (m, 1 H), 2.26-2.05 (m, 2 H), 1.86-1.65 (m, 2 H), 1.20 (s, 12 H); 13C NMR (CDCl3)  
175.3, 139.0, 83.2, 74.1, 49.1, 40.3, 36.4, 35.9, 30.2, 29.9, 24.8, 24.7, 24.1; MS (EI) m/z (rel 
                                                 
* (CW157-002: procedure, IR, proton NMR and carbon NMR) 
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intensity) 281 (13%), 264 (80%), 236 (65%), 205 (90%), 165 (60%), 137 (60%), 116 (90%), 101 
(100%); HRMS (EI) m/z calcd for C14H22BO5 (M-CH3) 281.1560, found 281.1559. 
OMe
MeO
N Br
OMe
H
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MeO  
1-((4aS*,9aS*)-3-(2-Bromo-5-methoxyphenyl)-5-methoxy-4a-(3-methoxyphenyl)-
2,4a,9,9a-tetrahydro-1H-indeno[2,1-b]pyridin-1-yl)-2-(1-methoxy-4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)cyclohex-3-enyl)ethanone (3-132). *  A solution of 3-127 (0.4527 g, 
0.894 mmol) in THF (44 mL) at 0 °C was treated with LAH (0.407 g, 10.7 mmol) followed by 
ZnCl2 (0.5 M in THF, 10.7 mL, 5.35 mmol). The reaction mixture was stirred at room 
temperature for 1.5 h, cooled to 0 °C, quenched with a solution of saturated Rochelle’s salt and 
extracted with EtOAc (3x). The combined organic layers were dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford crude amine 3-128127 (0.4402 g) which was used 
without purification. An analytical sample was obtained after purification by chromatography on 
SiO2 (Hexanes:EtOAc = 1:1 with 0.2% Et3N): 1H NMR (CDCl3)  7.44 (d, 1 H, J = 8.7 Hz), 7.27 
(t, 1 H, J = 7.8 Hz), 7.19 (t, 1 H, J = 7.8 Hz), 6.96 (d, 1 H, J = 7.2 Hz), 6.84 (t, 1 H, J = 2.1 Hz), 
6.81-6.72 (m, 4 H), 6.69 (dd, 1 H, J = 8.7, 3.0 Hz), 6.37 (s, 1 H), 3.82 (dd, 1 H, J = 17.4, 1.8 Hz), 
3.769 (s, 3 H), 3.765 (s, 3 H), 3.68 (dd, 1 H, J = 6.9, 4.8 Hz), 3.63 (s, 3 H), 3.53 (d, 1 H, J = 17.4 
Hz), 3.18 (dd, 1 H, J = 16.2, 6.9 Hz), 2.94 (dd, 1 H, J = 16.2, 4.5 Hz); 13C NMR (CDCl3)  
159.7, 159.0, 157.6, 147.6, 143.9, 143.8, 139.6, 133.4, 132.6, 130.1, 129.2, 119.6, 118.0, 116.1, 
                                                 
* (CW135-073, CW157-003: procedure, NMRs, IR and MS; CW135-003: purification of 3-128) 
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114.3, 113.3, 113.0, 111.4, 109.7, 66.7, 55.7, 55.4, 55.3, 45.4, 36.3. A fraction of the crude 
amine (0.2057 g) and 3-131 (0.1732 g, 0.585 mmol) was dissolved in DMF (4.9 mL) and treated 
with DIPEA (0.145 mL, 0.835 mmol) followed by HATU (0.2223 g, 0.585 mmol) at room 
temperature. The reaction mixture was stirred at room temperature for 14 h, quenched with water 
and extracted with EtOAc (3x). The combined organic layers were washed with water (3x) and 
brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 3:1 to 2:1) afforded 0.2522 g (78% over two steps) 
of 3-132 (mixture of diastereomers, ratio = 1:1) as a sticky yellow solid: IR (neat) 2972, 2931, 
2832, 1815, 1733, 1632, 1589, 1477, 1462 cm-1; Representative 1H NMR of one diastereomer 
(CDCl3)  8.66 (dd, 1 H, J = 4.5, 1.2 Hz), 6.50-6.44 (m, 1 H), 5.82 (s, 1 H), 5.18 (dd, 1 H, J = 
9.3, 1.8 Hz), 4.72 (AB, 1 H, J = 8.4 Hz), 4.67 (AB, 1 H, J = 8.7 Hz), 3.73 (s, 3 H), 3.72 (s, 3 H), 
3.35 (s, 3 H), 3.01 (s, 3 H), 1.24 (s, 12 H); 13C NMR of a mixture of both diastereomers and 
rotamers (CDCl3)  170.3, 166.2, 159.53, 159.49, 158.8, 156.0, 151.8, 146.44, 146.37, 142.1, 
141.9, 140.5, 140.1, 139.5, 138.7, 135.9, 135.8, 134.9, 133.4, 131.6, 130.74, 130.66, 129.4, 
129.1, 126.5, 120.9, 119.0, 117.4, 116.3, 114.7, 113.1, 112.9, 112.7, 111.7, 111.6, 109.8, 83.3, 
83.1, 74.4, 74.3, 74.1, 66.1, 66.0, 55.7, 55.63, 55.55, 55.3, 55.0, 49.5, 49.2, 48.9, 48.8, 41.0, 38.8, 
38.1, 37.5, 36.7, 36.1, 35.3, 34.7, 33.9, 30.1, 29.6, 29.0, 24.8, 24.3, 23.8; MS (ESI) m/z 770.2 
(M+1), 1563 (2M+23); HRMS (ESI) m/z calcd for C42H49BNO7NaBr (M+Na) 792.2683, found 
792.2680. 
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Attempted preparation of 3-134. *  A mixture of 3-132 (15.2 mg, 0.0197 mmol) and 
K2CO3 (5.5 mg, 0.039 mmol) in DMSO (3.9 mL) was degassed by two freeze-pump-thaw cycles 
and treated with a solution of Pd(PPh3)4 (1.1 mg, 0. 99 µmol) in degassed DMSO (0.21 mL). The 
reaction mixture was heated to 85 °C for 24 h, treated with additional Pd(PPh3)4 (1.1 mg, 0.99 
µmol) in degassed DMSO (0.21 mL) and heated to 85 °C for another 24 h. After cooling to room 
temperature, the mixture was partitioned between saturated aqueous NH4Cl and EtOAc. The 
aqueous phase was extracted with EtOAc (2x). The combined organic layers were washed with 
water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes : EtOAc = 1:1) afforded 3.3 mg (30%) of 3-
134 (mixture of diastereomers) as a clear sticky solid: IR (neat) 2931, 2832, 1708, 1634, 1589, 
1462 cm-1; Representative 1H NMR of one diastereomer 600 MHz (CDCl3)  7.43 (d, 1 H, J = 
9.07 Hz), 7.22 (t, 1 H, J = 7.8 Hz), 5.85 (s, 1 H), 4.64 (t, 1 H, J = 8.4 Hz), 3.80 (s, 3 H), 3.77 (s, 3 
H), 3.55 (s, 3 H), 3.39 (dd, 1 H, J = 15.0, 10.2 Hz), 3.08 (s, 3 H), 2.49 (dt, 1 H, J = 13.8, 6.6 Hz), 
2.38 (dt, 1 H, J = 13.8, 6.6 Hz); 13C NMR of a mixture of both diastereomers and rotamers 150 
MHz (CDCl3) 211.6, 169.8, 169.7, 159.8, 159.5, 159.2, 159.1, 156.2, 146.9, 146.7, 142.4, 141.9, 
141.8, 141.7, 135.8, 133.9, 133.7, 131.7, 131.0, 130.8, 129.7, 129.5, 129.4, 129.0, 126.5, 126.4, 
119.3, 117.6, 117.5, 117.2, 116.7, 116.6, 115.1, 115.0, 114.8, 113.4, 113.3, 113.24, 113.18, 
                                                 
* (CW135-094: procedure and NMRs; CW157-004: HRMS) 
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111.8, 111.2, 110.2, 110.1, 74.5, 73.9, 66.4, 56.2, 56.0, 55.9, 55.8, 55.52, 55.48, 55.34, 55.25, 
55.2, 55.1, 55.0, 49.28, 49.26, 41.4, 41.3, 38.2, 38.1, 38.0, 36.8, 34.2, 33.1, 32.4, 29.9; MS (ESI) 
m/z 660.2 (M+H), 1342.8 (2M+Na); HRMS (ESI) m/z calcd for C36H38NO6NaBr (M+Na) 
682.1780, found 682.1804. 
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Attempted preparation of 3-133. * A mixture of 3-132 (5.0 mg, 0.0065 mmol), Pd(t-
Bu3P)2 (0.17 mg, 0.00032 mmol), K2CO3 (2.7 mg, 0.020 mmol) and DMSO (1.29 mL) in a glass 
tube was frozen in LN2 under vacuum. The tube was flame-sealed and heated to 150 °C for 3 h. 
The reaction mixture was partitioned between water and EtOAc and the aqueous phase was 
extracted with EtOAc (2x). The combined organic layers were washed with water (2x) and brine 
(1x), dried (MgSO4), filtered and concentrated under reduced pressure. Purification by PTLC 
(Hexanes:EtOAc = 1:1) afforded 1.2 mg (24%) of SM and 0.2 mg of by-PD 3-135: MS (ESI) m/z 
(M+H) 692.3. 
OMe
MeO
N
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H  
(4aS*,9aS*)-tert-Butyl 3-(2-bromo-5-methoxyphenyl)-5-methoxy-4a-(3- 
                                                 
* (CW161-022: procedure and MS) 
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methoxyphenyl)-2,4a,9,9a-tetrahydro-1H-indeno[2,1-b]pyridine-1-carboxylate (3-136). *  A 
solution of 3-128 (0.100 g, 0.203 mmol) in DCM (2.0 mL) at room temperature was treated with 
Boc2O (0.0532 g, 0.244 mmol). The reaction mixture was stirred at room temperature for 0.5 h 
and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes:Et2O = 4:1) afforded 0.0879 g (73%) of 3-136 as a sticky clear solid: IR (neat) 2998, 
2966, 2954, 2832, 1688, 1589, 1567, 1477 cm-1; 1H NMR of a mixture of both rotamers 600 
MHz (CDCl3)  7.48-7.40 (m, 1 H), 7.25 (t, 1 H, 7.8 Hz), 7.20 (t, 1 H, 7.8 Hz), 6.95-6.87 (m, 3 
H), 6.85-6.75 (m, 2 H), 6.75-6.68 (m, 2 H), 5.93-5.84 (m, 1 H), 5.09-5.02 (m, 0.3 H), 4.96 (t, 0.7 
H, J = 9.0 Hz), 4.87 (d, 0.7 H, J = 18.6 Hz), 4.67 (d, 0.3 H, J = 18.0 Hz), 3.91 (d, 1 H, J = 18.5 
Hz), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.53 (s, 3 H), 3.29 (t, 0.7 H, J = 13.8 Hz), 3.17 (br s, 0.7 H), 
3.07 (dd, 0.7 H, J = 15.0, 8.4 Hz), 1.15 (s, 9 H); 13C NMR of a mixture of both rotamers 150 
MHz (CDCl3)  159.5, 159.0, 156.3, 154.9, 147.3, 142.7, 142.3, 136.1, 135.2, 133.6, 131.8, 
131.5, 129.3, 128.9, 127.5, 127.2, 119.4, 118.0, 117.5, 117.0, 116.5, 114.9, 114.6, 113.4, 112.7, 
112.6, 111.8, 111.6, 110.0, 109.9, 80.1, 79.8, 63.5, 61.9, 55.8, 55.6, 55.5, 55.4, 55.3, 55.2, 43.0, 
41.9, 33.2, 33.0, 28.6, 28.5, 28.1; HRMS (ESI) m/z calcd for C32H34NO5NaBr (M+Na) 614.1518, 
found 614.1526. 
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(4aS*,9aS*)-tert-Butyl 5-methoxy-3-(5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2- 
                                                 
* (CW157-035: procedure, IR, HRMS and NMRs) 
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dioxaborolan-2-yl)phenyl)-4a-(3-methoxyphenyl)-2,4a,9,9a-tetrahydro-1H-indeno[2,1-
b]pyridine-1-carboxylate (3-137) (CW157-066: procedure, IR and NMRs). A solution of 3-136 
(0.0100 g, 0.0169 mmol) in ether (0.35 mL) at -78 °C was treated with butyllithium (1.38 M in 
hexane, 0.0245 mL, 0.0338 mmol) dropwise. The reaction mixture was stirred for 20 min and 
treated with 2-isopropoxy-4,4,5,5-tetramethyldioxaborolane. The reaction mixture was then 
warmed to -40 °C over 20 min and quenched with saturated aqueous NH4Cl. The mixture was 
extracted with EtOAc (2x). The organic layers were combined, dried (Na2SO4) and concentrated 
under reduced pressure. Purification by PTLC (Hexanes:EtOAc = 2:1) afforded 0.0081 g (75%) 
of 3-137 as a sticky clear solid: 1H NMR of a mixture of both rotamers 600 MHz (CDCl3)  
7.81-7.76 (m, 1 H), 7.44-7.41 (m, 0.3 H), 7.27-7.16 (m, 3.7 H), 7.06 (d, 0.3 H, 6.6 Hz), 6.98 (d, 
1.3 H, J = 7.2 Hz), 6.92-6.71 (m, 9 H), 6.69 (d, 1.4 H, J = 8.4 Hz), 6.31 (s, 0.3 H), 5.85-5.76 (m, 
1 H), 5.10-5.01 (m, 0.3 H), 5.00-4.88 (m, 1.4 H), 4.76 (d, 0.7 H, J = 18.0 Hz), 4.44 (d, 0.3 H, J = 
18.0 Hz), 4.08-3.97 (m, 1.3 H), 3.84 (s, 3 H), 3.83 (s, 1 H), 3.79 (m, 0.6 H), 3.77 (s, 0.7 H), 3.75 
(s, 3 H), 3.73 (s, 1 H), 3.59 (s, 1 H), 3.53 (s, 0.8 H), 3.52 (s, 3 H), 3.32-3.27 (m, 0.5 H), 3.18-3.02 
(m, 1 H), 2.98 (dd, 1 H, J = 14.4, 7.8 Hz), 1.27 (s, 8 H), 1.20 (s, 7 H), 1.13 (s, 9 H); 13C NMR of 
a mixture of both rotamers 150MHz (CDCl3)  161.9, 160.0, 159.5, 156.3, 154.9, 149.6, 148.2, 
143.2, 142.8, 142.7, 138.6, 138.1, 133.6, 132.2, 129.6, 129.3, 129.0, 128.9, 128.7, 124.5, 119.8, 
119.4, 118.0, 117.5, 115.9, 113.2, 112.9, 111.8, 111.4, 111.2, 110.0, 109.7, 83.7, 79.9, 79.4, 63.7, 
55.8, 55.6, 55.4, 55.32, 55.30, 55.2, 55.1, 43.5, 36.8, 33.4, 29.9, 28.7, 28.2, 24.9, 24.7, 23.5. 
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4-Methoxy-4-(2-((4aS*,9aS*)-5-methoxy-3-(5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)-4a-(3-methoxyphenyl)-2,4a,9,9a-tetrahydro-1H-indeno[2,1-
b]pyridin-1-yl)-2-oxoethyl)cyclohex-1-enyl trifluoromethanesulfonate (3-138). *  Compound 
3-137 (0.0081 g, 0.0127 mmol) was dissolved in DCM/TFA (10:1 v/v, 0.35 mL). The reaction 
mixture was stirred at room temperature for 0.5 h, cooled to 0 °C, quenched with 5% aqueous 
K2CO3 and extracted with EtOAc (3x). The combined organic layers were washed with brine, 
dried (Na2SO4), filtered and concentrated under reduced pressure to afford the crude amine, 
which was dissolved together with 2-(1-methoxy-4-(trifluoromethylsulfonyloxy)-cyclohex-3-
enyl)-acetic acid in DMF (0.15 mL) and treated with DIPEA (0.0044 mL, 0.025 mmol) followed 
by HATU (0.0067 g, 0.018 mmol) at room temperature. The reaction mixture was stirred for 14 
h, quenched with water and extracted with EtOAc (3x). The combined organic layers were 
washed with water (3x) and brine (1x), dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by PTLC (Hexanes:EtOAc = 1:1) afforded 0.0106 g (54%) of 3-138 
(mixture of diastereomers, ratio = 1:1) as a sticky clear solid: IR (neat) 2970, 2933, 2834, 1634, 
1593, 1479, 1412 cm-1; Representative 1H NMR of one diastereomer 600 MHz (CDCl3)  7.79 
                                                 
* (CW157-070, CW157-073: procedure and NMRs; CW157-057: IR, HRMS; CW135-011: MS) 
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(d, 1 H, J = 8.4 Hz), 5.79 (s, 1 H), 5.06 (dd, 1 H, J = 18.6, 6.6 Hz), 4.64 (d, 1 H, J = 8.4 Hz), 
3.97-3.91 (m, 1 H), 3.84 (s, 3 H), 3.76 (s, 3 H), 3.58 (dd, 1 H, J = 15.0, 10.8 Hz), 3.54 (s, 3 H), 
3.16 (d, 1 H, J = 16.2 Hz), 2.98 (s, 3 H), 1.26 (s, 12 H); 13C NMR of a mixture of both 
diastereomers 150 MHz (CDCl3)  169.8, 169.55, 169.53, 162.1, 161.9, 159.8, 156.2, 149.2, 
148.8, 148.7, 148.5, 148.4, 147.59, 147.56, 142.1, 138.6, 138.34, 138.31, 138.28, 138.26, 136.32, 
136.28, 131.6, 131.5, 129.4, 129.2, 128.7, 125.5, 123.74, 123.73, 119.8, 119.7, 119.5, 117.7, 
117.6, 117.5, 116.31, 116.26, 116.0, 115.5, 115.3, 115.2, 114.9, 113.6, 111.8, 111.7, 111.1, 
110.9, 110.7, 110.0, 109.8, 83.83, 83.79, 73.9, 73.8, 73.1, 73.0, 66.5, 66.4, 66.1, 60.3, 55.81, 
55.79, 55.47, 55.45, 55.3, 55.2, 49.83, 49.81, 49.39, 49.36, 46.9, 46.8, 43.03, 42.98, 40.2, 39.9, 
38.3, 38.2, 34.3, 33.1, 31.9, 31.8, 31.2, 30.54, 30.48, 30.2, 30.0, 29.9, 29.5, 25.2, 24.90, 24.86, 
24.7, 18.7, 15.5; MS (EI) m/z (rel intensity) 839 (25%), 706 (15%), 674 (10%), 621 (10%), 580 
(10%), 538 (10%), 451 (10%), 252 (100%); HRMS (EI) m/z calcd for C43H49B1N1O10F3S 
839.3122, found 839.3100. 
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Attempted cyclization of 3-133.* A mixture of Pd(Pt-Bu3)2 (0.6 mg, 0.00011 mmol), 3-
138 (1.9 mg, 0.0023 mmol) and Cs2CO3 (2.2 mg, 0.0068 mmol) in dioxane (0.44 ml) was heated 
                                                 
* (CW157-058: procedure, NMR and MS) 
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to 85 °C for 4 h. The reaction mixture was quenched with water and extracted with EtOAc (3x). 
The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes : EtOAc = 2:1) 
afforded 1.3 mg (80%) of by-product 3-139 (mixture of diastereomers) as a clear sticky solid: 
Representative 1H NMR of one diastereomer 300MHz (CDCl3)  6.28 (s, 1 H), 4.67 (t, 1 H, J = 
9.0 Hz), 3.82 (s, 3 H), 3.74 (s, 3 H), 3.61 (s, 3 H), 2.98 (s, 3 H); MS (ESI) m/z 713.9 (M+H), 
735.8 (M+Na). 
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(4aS*,9aS*)-tert-Butyl 5-methoxy-3-(5-methoxy-2-(4-methoxy-4-(2-methoxy-2- 
oxoethyl)cyclohex-1-enyl)phenyl)-4a-(3-methoxyphenyl)-2,4a,9,9a-tetrahydro-1H-
indeno[2,1-b]pyridine-1-carboxylate (3-140). *  A mixture of Pd(Pt-Bu3)2 (4.5 mg, 0.0088 
mmol), 3-136 (52.3 mg, 0.0883 mmol), 10 (68.5 mg, 0.221 mmol) and Cs2CO3 (86.3 mg, 0.265 
mmol) in dioxane (0.75 ml) was heated to 95 °C for 15 h. The reaction mixture was cooled to 
room temperature, passed through a pad of SiO2 and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes : EtOAc = 6:1 to 4:1) afforded 57.2 mg (93%) 
of 3-140 (mixture of diastereomers, ratio = 1:1) as a sticky clear solid: IR (neat) 2944, 2935, 
2832, 1735, 1688, 1599, 1585, 1477 cm-1; Representative 1H NMR of one diastereomer (CDCl3) 
 5.95 (s, 1 H), 5.39 (app s, 1 H), 5.02-4.78 (m, 2 H), 3.81 (s, 3 H), 3.74 (s, 3 H), 3.70 (s, 3 H), 
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3.52 (s, 3 H), 3.26 (s, 3 H), 3.15-2.96 (m, 2 H), 1.12 (s, 9 H); 13C NMR of a mixture of both 
diastereomers and rotamers 150 MHz (CDCl3)  171.4, 170.8, 159.5, 158.5, 158.4, 156.41, 
156.38, 155.0, 154.9, 148.0, 147.8, 142.6, 142.5, 139.9, 139.6, 138.0, 137.3, 136.2, 135.7, 
135.40, 135.36, 135.1, 135.0, 132.4, 132.2, 130.2, 129.8, 129.3, 128.8, 127.1, 126.8, 126.4, 
122.9, 122.8, 119.4, 118.8, 117.7, 117.6, 115.13, 115.06, 113.1, 112.9, 112.7, 112.6, 112.3, 
111.2, 111.0, 110.0, 92.2, 81.7, 80.1, 79.7, 79.6, 75.2, 74.1, 73.7, 73.6, 73.4, 63.42, 63.38, 61.9, 
55.6, 55.5, 55.3, 55.21, 55.20, 52.0, 51.7, 49.7, 49.5, 43.4, 42.0, 41.9, 41.6, 40.8, 40.7, 40.4, 36.8, 
36.7, 35.6, 35.5, 35.3, 34.9, 33.9, 33.8, 33.7, 33.23, 33.20, 30.5, 30.3, 30.1, 29.9, 29.2, 28.62, 
28.58, 28.5, 28.4, 28.1, 27.8, 25.0, 24.9, 23.6; MS (ESI) m/z 695.9 (M+H), 717.8 (M+Na); 
HRMS (ESI) m/z calcd for C42H49NO8 (M+H) 718.3356, found 718.3383. 
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(4aS*,9aS*)-tert-Butyl 5-methoxy-3-(5-methoxy-2-(4-methoxy-4-(2-methoxy-2- 
oxoethyl)cyclohex-1-enyl)phenyl)-4a-(3-methoxyphenyl)-2,4a,9,9a-tetrahydro-1H-
indeno[2,1-b]pyridine-1-carboxylate (3-141).* A solution of 3-140 (35.7 mg, 0.0513 mmol) in 
THF (0.70 mL) was treated with aqueous LiOH (1.0 M, 1.03 mL, 1.03 mmol) at room 
                                                 
* (CW161-010, CW161-019: procedure, NMRs, HRMS and IR; CW161-013: MS) 
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temperature. The reaction mixture was stirred for 4 days, acidified with 10% aqueous NaHSO4 
and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated under reduced pressure to afford 36.9 mg of the crude acid. 
A fraction of the crude acid (12.0 mg, 0.0176 mmol) was dissolved in DCM (0.23 mL) together 
with pentafluorophenol (6.5 mg, 0.0352 mmol). To this solution was added DCC (7.9 mg, 
0.0352 mmol) at room temperature. The reaction mixture was stirred for 20 h, filtered through 
Celite and concentrated under reduced pressure. Purification by chromatography on SiO2 
(Hexanes : EtOAc = 10:1) afforded 11.2 mg (75%) of 3-141 (mixture of diastereomers, ratio = 
1:1) as a clear oil: IR (neat) 2935, 2832, 1785, 1688, 1654, 1599, 1585, 1518, 1464 cm-1; 
Representative 1H NMR of one diastereomer 600 MHz (CDCl3)  5.97 (s, 1 H), 5.45 (app s, 1 
H), 3.82 (s, 3 H), 3.74 (s, 3 H), 3.53 (s, 3 H), 3.34 (s, 3 H), 2.92 (d, 1 H, J = 13.8 Hz), 2.75 (d, 1 
H, J = 13.8 Hz), 1.13 (s, 9 H); 13C NMR of a mixture of both diastereomers and rotamers 150 
MHz (CDCl3)  166.5, 159.6, 158.6, 158.5, 156.5, 156.4, 155.0, 147.9, 142.7, 142.6, 142.2, 
140.5, 140.0, 139.6, 138.9, 138.2, 137.3, 136.3, 135.7, 134.9, 134.7, 132.2, 130.3, 129.8, 129.3, 
128.9, 126.9, 126.5, 122.7, 122.6, 119.40, 119.37, 117.7, 117.6, 115.4, 115.2, 113.00, 112.95, 
112.7, 112.6, 111.1, 110.03, 109.99, 79.8, 79.7, 74.0, 63.5, 63.4, 55.6, 55.5, 55.3, 55.2, 49.7, 
42.1, 41.9, 40.1, 40.0, 36.8, 35.2, 34.6, 33.25, 33.18, 30.2, 30.1, 28.6, 28.4, 28.3, 28.1, 24.9, 
23.5; MS (ESI) m/z 848.4 (M+H); HRMS (ESI) m/z calcd for C47H46NO8F5Na (M+Na) 
870.3041, found 870.3055. 
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(1R*,2S*)-1-((tert-Butyldimethylsilyloxy)methyl)-7-methoxy-1-(3-methoxyphenyl)-
2,3-dihydro-1H-inden-2-amine (3-144141).* A solution of 3-113 (0.216 g, 0.427 mmol) and Pd 
(10% on carbon, 22.7 mg) in MeOH (3.1 mL) was exposed to H2 at 1 atm for 7 h at room 
temperature. The balloon was removed and the reaction mixture was treated with HCl (1 M in 
MeOH, 3.11 mL, 76.8 mmol) at room temperature. The reaction mixture was stirred for 2 h and 
filtered through a pad of Celite. The pad was washed with EtOAc. The combined filtrates were 
treated with 5% aqueous K2CO3 and extracted with EtOAc (3x). The combined organic layers 
were washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
A solution of the crude product in THF (1.0 mL) at room temperature was treated with LAH in 
Et2O (1 M, 0.853 mL, 0.853 mmol). The reaction mixture was stirred for 17 h, cooled to 0 °C 
and quenched with 10% aqueous H2SO4. The mixture was stirred for approximately 30 min until 
all of the solids had dissolved. The solution was basified with saturated aqueous NaHCO3 and 
Rochelle's salt. The mixture was extracted with EtOAc (3x). The combined organic layers were 
washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. A 
solution of the crude product in DMF/THF (2:3 v/v, 4.0 mL) was treated with imidazole (30.4 
mg, 0.446 mmol) and TBSCl (66.2 mg, 0.435 mmol) at room temperature. The reaction mixture 
was stirred for 15 h, quenched with water and extracted with Et2O (3x). The combined organic 
layers were washed with water (2x), brine (2x), dried (Na2SO4), filtered and concentrated under 
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reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 3:1 with 0.1% 
Et3N) afforded 0.0687 g (39%) of 3-144141 as a sticky clear solid: 1H NMR (CDCl3)  7.27-7.12 
(m, 2 H), 6.85 (d, 1 H, J = 7.5 Hz), 6.79-6.67 (m, 4 H), 4.58 (d, 1 H, J = 9.9 Hz), 4.22 (d, 1 H, J 
= 9.9 Hz), 3.75 (s, 3 H), 3.69 (t, 1 H, J = 7.8 Hz), 3.60 (s , 3 H), 3.18 (dd, 1 H, J = 15.3, 7.8 Hz), 
2.78 (dd, 1 H, J = 15.3, 7.8 Hz), 1.92 (br s, 2 H), 0.77 (s, 9 H), -0.08 (s, 3 H), -0.28 (s, 3 H); 13C 
NMR (CDCl3)  159.4, 157.0, 147.6, 145.4, 132.0, 128.9, 128.8, 118.9, 117.3, 112.9, 110.5, 
109.0, 65.2, 65.0, 60.5, 60.3, 55.2, 55.0, 42.1, 25.8, 18.1, -5.8, -6.0. 
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4-(2-(N-((1R*,2S*)-1-((tert-Butyldimethylsilyloxy)methyl)-7-methoxy-1-(3-
methoxyphenyl)-2,3-dihydro-1H-inden-2-yl)-2-(5-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetamido)ethyl)-4-methoxycyclohex-1-enyl 
trifluoromethanesulfonate (3-147).* A solution of 3-146 (66.9 mg, 0.162 mmol) and aldehyde 
3-115 (53.8 mg, 0.178 mmol) in MeOH (1.97 mL) was treated with NaBH(OAc)3 (0.108 g, 
0.485 mmol) at room temperature. The reaction mixture was stirred for 16 h, quenched with 5% 
aqueous K2CO3 and extracted with EtOAc (3x). The combined organic layers were washed with 
brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 3:1 to 1:1, with 1% Et3N) afforded 64.1 mg (57%) 
of product (mixture of diastereomers, ratio = 1:1) as a yellow oil. A fraction of the product (52.7 
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mg, 0.0753 mmol) and 3-119 (26.4 g, 0.0904 mmol) in DMF (0.88 mL) was treated with DIPEA 
(0.0262 mL, 0.151 mmol) followed by HATU (40.1 mg, 0.105 mmol) at room temperature. The 
reaction mixture was stirred for 17 h, quenched with water and extracted with EtOAc (3x). The 
combined organic layers were washed with water (3x) and brine (1x), dried (Na2SO4), filtered 
and concentrated under reduced pressure. Purification on SiO2 (Hexanes:EtOAc = 6:1 to 3:1) 
afforded 53.9 mg (73%) of 3-147 (mixture of diastereomers, ratio = 1:1) as a yellow oil: IR 
(neat) 2927, 2851, 1645, 1600, 1462, 1412 cm-1; Representative 1H NMR of one diastereomer 
500 MHz (CDCl3)  7.70 (d, 1 H, J = 8.5 Hz), 7.25 (t, 1 H, J = 8.0 Hz), 5.61-5.57 (m, 1 H), 4.74 
(t, 1 H, J = 8.5 Hz), 4.48 (d, 1 H, J = 10.5 Hz), 4.26 (d, 1 H, J = 10.5 Hz), 4.10 (dt, 1 H, J = 12.5, 
3.0 Hz), 3.80 (s, 3 H), 3.76 (s, 3 H), 3.60 (s, 3 H), 3.27 (s, 3 H), 1.27 (s, 12 H), 0.72 (s, 9 H), -
0.13 (s, 3 H), -0.25 (m, 3 H); 13C NMR of a mixture of both diastereomers and rotamers 125 
MHz (CDCl3)  173.5, 173.4, 161.7, 160.0, 156.3, 148.9, 148.8, 146.80, 146.76, 144.88, 144.86, 
143.9, 143.8, 137.9, 130.3, 128.5, 128.3, 119.1, 116.8, 116.32, 116.30, 115.2, 114.1, 111.70, 
111.66, 111.48, 111.46, 83.19, 83.17, 72.63, 72.56, 69.5, 64.0, 60.5, 55.4, 55.2, 54.8, 49.7, 39.5, 
38.6, 36.43, 36.36, 33.7, 33.6, 33.3, 30.7, 30.2, 26.0, 25.40, 25.38, 25.1, 24.9, 18.42, 18.38, -
5.48, -5.52, -5.76, -5.85; MS (EI) m/z (rel intensity) 973 (15%), 916 (90%), 841 (20%), 828 
(15%), 816 (10%), 784 (15%), 566 (15%), 397 (20%), 340 (95%), 265 (100%); HRMS (ESI) m/z 
calcd for C49H67NO11F3NaS (M+Na) 996.4439, found 996.4423. 
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Preparation of 3-148.* A mixture of 3-147 (10.0 mg, 0.0103 mmol) and K2CO3 (2.84 mg, 
0.0205 mmol) in DMSO (2.0 mL) and water (0.555 µL, 0.0308 mmol) was degassed by two 
freeze-pump-thaw cycles and treated with a solution of Pd(PPh3)4 (0.593 mg, 0.513 µmol) in 
degassed DMSO (0.11 mL). The reaction mixture was heated to 85 °C for 2 h, cooled to room 
temperature, quenched with water and extracted with EtOAc (3x). The combined organic layers 
were washed with water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 3:1) afforded 3.6 
mg (50%) of 3-148 (mixture of diastereomers, ratio = 1:1) as a clear oil: 1H NMR not provided 
due to the complex chemical shift pattern; 13C NMR of a mixture of both diastereomers 75 MHz 
(CDCl3) 176.4, 175.1, 160.1, 160.0, 158.3, 158.1, 156.1, 156.0, 147.1, 146.2, 143.9, 143.6, 
137.9, 136.2, 135.5, 135.3, 134.3, 133.7, 130.6, 130.2, 129.8, 129.6, 129.5, 129.3, 129.2, 129.1, 
128.8, 126.4, 124.4, 119.5, 118.6, 117.0, 116.8, 116.6, 116.4, 113.1, 112.9, 112.3, 112.0, 111.8, 
111.1, 110.9, 109.5, 109.4, 109.2, 75.7, 72.0, 70.6, 65.2, 64.2, 63.3, 62.3, 61.6, 60.6, 55.7, 55.6, 
55.3, 55.2, 54.94, 54.90, 50.0, 49.7, 49.2, 42.7, 42.1, 40.9, 39.4, 38.9, 37.1, 36.9, 35.5, 35.1, 32.9, 
32.4, 30.2, 30.0, 29.9, 29.2, 26.1, 25.7, 24.9, 23.6, 21.3, 18.0, 17.9, 14.4, -5.3, -5.7, -6.1, -6.2. 
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Preparation of 3-149 and 3-150. * 3-148 (13.9 mg, 0.0199 mmol) was dissolved in a 
solution of DMDO170 (0.0301 M in DCM, 1.32 mL, 0.0398 mmol) at room temperature. The 
reaction mixture was stirred for 20 min, quenched with 5% aqueous Na2S2O3  and extracted with 
DCM (2x). The combined organic layers were dried (MgSO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes : EtOAc = 4:1) afforded 6.3 
mg (44%) of 3-149 (single diastereomer) as a clear oil and 5.8 mg (41%) of 3-150 (single 
diastereomer) as a clear oil. 3-149: IR (neat) 2925, 2851, 1690, 1653, 1606, 1587, 1477, 1462 
cm-1; Representative 1H NMR of one rotamer (CDCl3)  7.36 (d, 1 H, J = 8.7 Hz), 7.23 (t, 1 H, J 
= 8.4 Hz), 6.02 (d, 1 H, J = 2.4 Hz), 5.19-5.05 (m, 1 H), 4.69 (dd, 1 H, J = 11.7, 7.8 Hz), 4.41 (d, 
1 H, J = 10.2 Hz), 4.22 (d, 1 H, J = 9.9 Hz), 3.75 (s, 3 H), 3.72 (s, 3 H), 3.19 (s, 3 H), 3.92 (d, 1 
H, J = 3.9 Hz), 2.49 (dd, 1 H, J = 16.2, 3.9 Hz), 2.14 (d, 1 H, J = 15.9 Hz), 0.67 (s, 9 H), -0.07 (s, 
3 H), -0.40 (s, 3 H); HRMS (ESI) m/z calcd for C42H55NO7NaSi (M+Na) 736.3646, found 
736.3606; 3-150: IR (neat) 2924, 2851, 1645, 1606, 1587, 1462, 1433 cm-1; Representative 1H 
NMR of one rotamer (CDCl3)  6.10 (d, 1 H, J = 2.7 Hz), 4.72 (dd, 1 H, J = 11.1, 8.7 Hz), 4.52 
(d, 1 H, J = 10.2 Hz), 4.22 (d, 1 H, J = 10.2 Hz), 3.76 (s, 3 H), 3.73 (s, 3 H), 3.57 (s, 3 H), 3.29 
(d, 1 H, J = 3.9 Hz), 2.69-2.58 (m, 1 H), 0.68 (s, 9 H), -0.10 (s, 3 H), -0.37 (s, 3 H); HRMS (ESI) 
m/z calcd for C42H55NO7NaSi (M+Na) 736.3646, found 736.3717; 13C NMR of a mixture of both 
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diastereomers (3-149+3-150) (CDCl3)  174.8, 173.7, 172.6, 160.3, 160.2, 159.4, 159.3, 158.8, 
158.6, 156.1, 156.0, 146.8, 146.0, 143.8, 143.2, 135.8, 134.9, 132.1, 131.14, 131.07, 130.2, 
130.0, 129.8, 129.7, 129.5, 129.4, 128.1, 119.59, 119.56, 118.1, 117.8, 117.1, 116.9, 116.7, 
113.4, 113.2, 112.1, 111.9, 111.8, 111.0, 109.7, 109.6, 109.2, 74.5, 73.7, 72.1, 70.8, 64.2, 63.4, 
62.6, 62.5, 61.2, 60.2, 59.8, 57.7, 55.73, 55.67, 55.6, 55.33, 55.26, 55.0, 54.9, 49.3, 48.7, 46.0, 
43.2, 39.7, 39.4, 37.4, 37.3, 35.3, 32.3, 31.9, 31.2, 30.3, 29.6, 29.4, 26.1, 25.7, 24.8, 18.0, 17.9, -
5.3, -5.7, -6.1, -6.2. 
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Preparation of 3-151.* A solution of 3-149 (12.3 mg, 0.0172 mmol) in THF 0.50 mL was 
treated with a solution of TBAF (1.0 M in THF, 0.172 mL, 0.172 mmol) at room temperature. 
The reaction mixture was stirred at 50 °C for 7.5 h, quenched with water and extracted with 
EtOAc (2x). The combined organic layers were washed with water (1x), brine (1x), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes : EtOAc = 3:2) afforded 5.3 mg (51%) of 3-151 as a clear sticky solid: IR (neat) 
3432, 2929, 2837, 1606, 1587, 1477, 1461 cm-1; (note the NMR data is not provided here due to 
the inherent low quality of spectras); HRMS (ESI) m/z calcd for C36H41NO7Na (M+Na) 
622.2781, found 622.2775.  
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Preparation of 3-152.* A solution of 3-150 (15.9 mg, 0.0223 mmol) in THF (0.64 mL) 
was treated with a solution of TBAF (1.0 M in THF, 0.223 mL, 0.223 mmol) at room 
temperature. The reaction mixture was stirred at 50 °C for 8.5 h, room temperature for 13 h then 
50 °C for 5 h. The reaction mixture was quenched with water and extracted with EtOAc (2x). 
The combined organic layers were washed with water (1x), brine (1x), dried (MgSO4), filtered 
and concentrated under reduced pressure. Purification by chromatography on SiO2 (Hexanes : 
EtOAc = 3:2) afforded 9.1 mg (68%) of 3-152 as a clear sticky solid: IR (neat) 3417, 2931, 2832, 
1619, 1606, 1589, 1505, 1477, 1457 cm-1; (note the NMR data is not provided here due to the 
inherent low quality of spectras); HRMS (ESI) m/z calcd for C36H41NO7Na (M+Na) 622.2781, 
found 622.2802.  
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Preparation of 3-142.* A solution of oxalyl chloride (4.7 µL, 0.0550 mmol) in DCM 
(0.20 mL) at -60 °C was treated with DMSO (8.4 µL, 0.119 mmol). The reaction mixture was 
stirred at -60 °C for 10 min and treated with 3-151 (2.5 mg, 4.17 µmol) in DCM (0.30 mL). The 
resulting mixture was stirred for 15 min and treated with Et3N (0.0348 mL, 0.248 mmol). The 
reaction mixture was stirred at -60 °C for 5 min then room temperature for 3 h, quenched with 
aqueous NaHCO3 and extracted with EtOAc (3x). The combined organic layers were washed 
with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification 
by chromatography on SiO2 (Hexanes:EtOAc = 3:2) afforded 1.6 mg (64%) of 3-142 as a sticky 
clear solid along with 0.5 mg (19%) chlorination product. 3-142: IR (neat) 2931, 2832, 1707, 
1628, 1602, 1578, 1505, 1477 cm-1; (note the NMR data is not provided here due to the inherent 
low quality of spectras); HRMS (ESI) m/z calcd for C36H39NO7Na (M+Na) 620.2624, found 
620.2584. 
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Preparation of 3-143.* A solution of oxalyl chloride (23.3 µL, 0.271 mmol) in DCM 
(0.60 mL) at -60 °C was treated with DMSO (41.4 µL, 0.583 mmol). The reaction mixture was 
stirred at -60 °C for 10 min and treated with 3-152 (12.3 mg, 20.5 µmol) in DCM (0.3 mL). The 
resulting mixture was stirred for 15 min and treated with Et3N (0.171 mL, 1.22 mmol). The 
reaction mixture was stirred at -60 °C for 5 min then room temperature for 20 min, quenched 
with aqueous NaHCO3 and extracted with EtOAc (3x). The combined organic layers were 
washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 3:2) afforded 10.9 mg (89%) of 3-
143 as a sticky clear solid: IR (neat) 2933, 2832, 1707, 1628, 1604, 1578, 1505, 1477 cm-1; (note 
the NMR data is not provided here due to the inherent low quality of spectras); HRMS (ESI) m/z 
calcd for C36H39NO7Na (M+Na) 620.2624, found 620.2599. 
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Preparation of 3-144.* A solution of 3-142 (1.7 mg, 2.84 µmol) in MeOH (0.35 mL) was 
treated with K2CO3 (3.93 mg, 0.0284 mmol) at room temperature. The reaction mixture was 
heated to 65 °C for 2 months in a sealed tube. Concentration of the reaction mixture in vacuo 
gave a residue that was partitioned between brine and EtOAc. The aqueous layer was extracted 
with EtOAc (2x). The combined organic layers were dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by PTLC on SiO2 (Hexanes:EtOAc = 1:2) afforded 1.3 mg 
(68%) of 3-144 as a sticky clear solid: IR (neat) 2927, 2832, 1667, 1623, 1602, 1479, 1462 cm-1; 
1H NMR 500 MHz (CDCl3)  7.45 (d, 1 H, J = 8.5 Hz), 7.30 (t, 1 H, J = 8.0 Hz), 7.22 (t, 1 H, J = 
8.0 Hz), 6.91 (d, 1 H, J = 7.5 Hz), 6.87 (s, 1 H), 6.86-6.78 (m, 4 H), 6.55 (dd, 1 H, J = 7.5, 0.5 
Hz), 6.47 (t, 1 H, J = 2.0 Hz), 4.98 (app t , 1 H, J = 14.0 Hz), 4.43 (d, 1 H, J = 4.5 Hz), 3.84 (s, 3 
H), 3.80 (s, 3 H), 3.71 (s, 3 H), 3.23-3.13 (m, 2 H), 3.18 (s, 3 H), 3.06 (d, 1 H, J = 4.0 Hz), 3.00 
(dd, 1 H, J = 16.5, 5.0 Hz), 2.71-2.63 (m, 1 H), 2.49 (ddd, 1 H, J = 16.0, 4.5, 1.0 Hz), 2.18-2.03 
(m, 4 H), 1.86 (dd, 1 H, J = 16.0, 5.0 Hz), 1.54-1.47 (m, 1 H); 13C NMR 150MHz (CDCl3)  
164.5, 160.0, 159.2, 156.5, 146.1, 142.6, 139.5, 137.2, 136.1, 131.9, 131.6, 130.3, 130.0, 126.8, 
119.8, 117.5, 114.7, 114.1, 112.5, 112.0, 110.4, 74.7, 67.7, 62.9, 59.9, 56.4, 55.6, 55.4, 55.3, 
48.6, 39.1, 38.5, 35.9, 31.7, 30.7, 24.7; MS (EI) m/z (rel intensity) 579 (30%), 264 (35%), 252 
(40%), 121 (90%); HRMS (EI) m/z calcd for C36H37NO6 579.2621, found 579.2620. 
                                                 
* (CW192-013: procedure and IR, HRMS, proton NMR, carbon NMR) 
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Preparation of 3-145.* A solution of 3-143 (3.4 mg, 5.69 µmol) in MeOH (3.1 mL) was 
treated with K2CO3 (7.86 mg, 0.0569 mmol) at room temperature. The reaction mixture was 
heated to 100 °C for 11 days in a sealed tube. Concentration of the reaction mixture in vacuo 
gave a residue that was partitioned between brine and EtOAc. The aqueous layer was extracted 
with EtOAc (2x). The combined organic layers were dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by PTLC on SiO2 (Hexanes:EtOAc = 1:2) afforded 1.5 mg 
(45%) of 3-145 as a sticky clear solid: IR (neat) 2994, 2957, 2942, 2832, 1666, 1625, 1602, 
1580, 1457 cm-1; 1H NMR 600 MHz (CDCl3)  7.45 (d, 1 H, J = 9.0 Hz), 7.29 (t, 1 H, J = 7.8 
Hz), 7.23 (t, 1 H, J = 7.8 Hz), 6.91-6.88 (m, 2 H), 6.83 (d, 1 H, J = 8.4 Hz), 6.79 (dd, 1 H, J = 
7.8, 2.4 Hz), 6.74 (d, 1 H, J = 2.4 Hz), 6.72 (s, 1 H), 6.57 (dd, 1 H, J = 8.4, 0.6 Hz), 6.39 (t , 1 H, 
J = 2.4 Hz), 4.30 (d, 1 H, J = 2.8 Hz), 3.83 (s, 3 H), 3.86-3.77 (m, 1 H), 3.79 (s, 3 H), 3.76 (d, 1 
H, J = 6.0 Hz), 3.71 (s, 3 H), 3.61-3.54 (m, 1 H), 3.21 (s, 3 H), 3.18 (d, 1 H, J = 16.2 Hz), 3.06 
(dd, 1 H, J = 16.2, 4.8 Hz), 2.96 (dt, 1 H, J = 13.2, 1.8 Hz), 2.45-2.38 (m, 1 H), 2.34 (dd, 1 H, J = 
16.2, 5.4 Hz), 2.27 (ddd, 1 H, J = 15.0, 5.4, 2.4 Hz), 2.05 (d, 1 H, J = 15.0 Hz), 1.72-1.67 (m, 1 
H), 1.46-1.41 (m, 1 H); 13C NMR 150MHz (CDCl3)  165.3, 160.0, 159.4, 156.4, 145.5, 141.9, 
138.2, 138.0, 137.3, 132.2, 130.7, 130.4, 130.1, 130.0, 120.0, 117.5, 114.5, 114.1, 113.8, 111.8, 
110.3, 73.7, 73.5, 60.8, 59.1, 57.1, 55.5, 55.38, 55.37, 49.2, 46.4, 36.4, 31.4, 30.6, 30.5, 28.0; MS 
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(EI) m/z (rel intensity) 252 (55%), 328 (10%), 368 (10%), 520 (10%), 548 (35%), 579 (90%), 
HRMS (EI) m/z calcd for C36H37NO6 579.2621, found 579.2615. 
OMe
MeO
N
OMe
H
OMe
O
 
Attempted Preparation of 3-123 by means of hydroxyl group elimination with 
K2CO3/MeOH.* A solution of 3-125 (5.5 mg, 9.46 µmol) in MeOH (0.38 mL) was treated with 
K2CO3 (13.1 mg, 0.0946 mmol) at room temperature. The reaction mixture was heated to 65 °C 
for 2 months in a sealed tube. Concentration of the reaction mixture in vacuo gave a residue that 
was partitioned between brine and EtOAc. The aqueous layer was extracted with EtOAc (2x). 
The combined organic layers were dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by PTLC on SiO2 (EtOAc 100%) afforded 2.6 mg (49%) of starting 
material. LC-MS analysis of the crude material revealed trace amount of product (m/z = 564). 
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Preparation of 3-157.† A solution of 3-124 (5.0 mg, 0.00863 mmol) in DCM (0.28 mL) 
and NaHCO3 buffer (0.5M, pH = 8.3, 0.10 mL) was treated with mCPBA (7.44 mg, 0.0431 
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† (CW135-008: procedure, NMRs and MS) 
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mmol) in small portions at room temperature. The reaction mixture was stirred at room 
temperature for 48 h, diluted with water and extracted with DCM (3x). The combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (DCM:Et2O = 10:1) afforded 1.6 mg (31%) of 3-157 (mixture of two 
diastereomers, ratio = 1.6:1) as a sticky clear solid: IR (neat) 2927, 2832, 1731, 1645, 1604, 1479 
cm-1; Representative 1H NMR of one diastereomer 600 MHz (CDCl3)  4.50 (d, 1 H, J = 4.8 Hz), 
3.96 (app d, 1 H, J = 13.8 Hz), 3.87 (s, 3 H), 3.76 (s, 3 H), 3.71 (s, 3 H), 3.31 (d, I H, J = 5.4 Hz), 
3.20 (s, 3 H); 13C NMR of a mixture of both diastereomers 150 MHz (CDCl3)  201.2, 200.7, 
169.0, 167.7, 159.58, 159.55, 158.9, 158.7, 156.5, 156.4, 143.9, 143.2, 138.2, 137.4, 133.5, 
133.4, 132.0, 131.91, 131.88, 131.4, 131.1, 129.7, 129.3, 129.0, 121.6, 121.4, 120.1, 120.0, 
119.6, 118.9, 115.8, 115.5, 113.4, 112.6, 112.4, 112.3, 110.2, 110.1, 74.0, 73.5, 73.3, 68.1, 67.8, 
67.4, 62.4, 61.9, 61.6, 60.3, 59.7, 57.2, 55.72, 55.66, 55.35, 55.33, 55.30, 55.26, 49.1, 48.8, 47.0, 
39.3, 39.0, 36.8, 36.6, 31.8, 31.2, 31.0, 30.9, 30.3, 29.9, 29.6, 26.8; HRMS (ESI) m/z calcd for 
C36H37NO7Na (M+Na) 618.2468, found 618.2450. 
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Preparation of 3-158 and 3-159. *  3-121 (0.136 g, 0.222 mmol) was dissolved in a 
solution of DMDO170 (0.0298 M in DCM, 14.9 mL, 0.445 mmol) at room temperature. The 
reaction mixture was stirred for 20 min, quenched with 5% aqueous Na2S2O3 and extracted with 
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DCM (2x). The combined organic layers were dried (MgSO4), filtered and concentrated under 
reduced pressure. Purification by chromatography on SiO2 (Hexanes : Et2O = 1:3) afforded 63.9 
mg (46%) of 3-158 (single diastereomer) as a sticky clear solid and 64.9 mg (47%) of 3-159 
(single diastereomer) as a sticky clear solid (note the NMR data is not provided here due to the 
low quality of spectra). 3-158: IR (neat) 2925, 2834, 1714, 1643, 1604, 1479, 1464 cm-1; LC-MS 
(ESI) m/z 628.1 (M+H) and 650.3 (M+Na); MS (EI) m/z (rel intensity) 117 (35%), 251 (20%), 
280 (25%), 310 (100%), 595 (5%), 627 (15%); HRMS (EI) m/z calcd for C37H41NO8 
627.283218, found 627.284410; 3-159: IR (neat) 2938, 2933, 2832, 1720, 1640, 1604, 1479 cm-
1; LC-MS (ESI) m/z 628.3 (M+H) and 650.2 (M+Na); MS (EI) m/z (rel intensity) 117 (40%), 252 
(20%), 280 (20%), 310 (100%), 627 (10%); HRMS (EI) m/z calcd for C37H41NO8 627.2832, 
found 627.2809.  
OMe
MeO
N
OMe
H O
O
OMe
OHH
 
Preparation of 3-161.* Stock solution of LiNEt2 was prepared as follows: a solution of 
diethylamine (0.200 mL, 1.93 mmol) in THF (1.0 mL) at -78 °C was treated with BuLi (1.6 M in 
hexane, 1.2 mL, 1.92 mmol). The mixture was warmed to 0 °C and titrated with 
Menthol/Fluorene in THF. A fraction of the stock solution (0.841 M, 0.0961 mL, 0.0808 mmol) 
was diluted with THF (0.98 mL) and treated at 0 °C with a solution of 3-159 (0.0203 g, 0.0323 
mmol) in THF (0.40 mL). The flask containing 3-159 was washed twice with THF (2 x 0.4 mL) 
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and the eluent was added to the reaction mixture. The reaction mixture was stirred at room 
temperature for 23 h, quenched with brine and extracted with EtOAc (1x). The organic layer was 
dried (Na2SO4) and concentrated under reduced pressure. Purification by chromatography on 
SiO2 (Hexanes:EtOAc = 3:2 to 1:2, all with 0.1% TEA) afforded 0.9 mg (4%) of starting 
material, 6.3 mg (33%) of 3-161 as a sticky clear solid: IR (neat) 3428, 2929, 2834, 1723, 1664, 
1602, 1587, 1479, 1464 cm-1; 1H NMR 600 MHz (CDCl3)  7.39 (t, 1 H, J = 8.4 Hz), 7.28 (d, 1 
H, J = 8.4 Hz), 7.21 (t, 1 H, J = 7.8 Hz), 6.97 (d, 1 H, 7.2 Hz), 6.92 (d, 1 H, J = 7.8 Hz), 6.87 
(dd, 1 H, J = 8.4, 2.4 Hz), 6.79 (dd, 1 H, J = 7.8, 2.4 Hz), 6.48-6.43 (m, 2 H), 6.26 (s, 1 H), 4.46 
(d, 1 H, J = 3.6 Hz), 3.83 (s, 3 H), 3.80-3.76 (m, 1 H), 3.74 (s, 3 H), 3.70 (s, 3 H), 3.29 (s, 3 H), 
3.25-3.23 (m, 1 H), 3.09 (dt, 1 H, J = 13.8, 3.6 Hz), 3.01 (d, 1 H, J = 15.6 Hz), 2.86 (dd, 1 H, J = 
16.2, 4.2 Hz), 2.72-2.65 (m, 1 H), 2.36-2.32 (m, 2 H), 1.98-1.93 (m, 1 H), 1.90 (s, 1 H), 1.88-
1.84 (m, 1 H), 1.84-1.80 (m, 1 H), 1.80-1.73 (m, 2 H), 1.62-1.60 (m, 1 H); 13C NMR 150 MHz 
(CDCl3)  207.5, 172.6, 160.3, 159.6, 157.8, 144.5, 142.1, 140.1, 140.0, 131.9, 129.5, 129.0, 
125.7, 123.3, 121.4, 119.3, 115.9, 114.1, 112.2, 112.0, 110.4, 78.3, 75.7, 72.6, 72.4, 71.0, 68.4, 
67.7, 60.6, 56.1, 55.7, 55.6, 55.4, 55.3, 53.7, 49.0, 45.7, 37.8, 34.1, 33.1, 32.9, 31.7, 29.5, 28.7; 
MS (EI) m/z (rel intensity) 198 (85%), 252 (100%), 567 (10%), 577 (15%), 595 (20%); HRMS 
(EI) m/z calcd for C36H37NO7 595.2570, found 595.2556. The product was recrystallized from 
DCM-toluene to give X-ray quality colorless crystals: m.p. 198.5-204.6 °C (lost solvent). The 
crystal was collected and redissolved in CDCl3 to give a proton NMR spectrum that is identical 
to the sample before crystallization. 
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Preparation of 3-162.* Stock solution of LiNEt2 was prepared as follows: a solution of 
diethylamine (0.200 mL, 1.93 mmol) in glyme (1.0 mL) at 0 °C was treated with BuLi (1.6 M in 
hexane, 1.2 mL, 1.92 mmol). The mixture was titrated with Menthol/Fluorene in THF. A 
solution of 3-158 (5.0 mg, 0.0080 mmol) in glyme (0.24 mL) was treated with the stock solution 
(0.817M, 0.0244 mL, 0.0199 mmol) at 0 °C. The reaction mixture was stirred at room 
temperature for 18 h, quenched with brine and extracted with EtOAc (1x). The organic layer was 
dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 1:1 to 1:2, all with 0.1% TEA) afforded 0.8 mg 
(16%) of starting material, 1.1 mg (23%) of 3-162 as a sticky clear solid: IR (neat) 3417, 2933, 
2832, 1636, 1571, 1479, 1435 cm-1; 1H NMR 600 MHz (CDCl3)  7.61 (d, 1 H, J = 9.0 Hz), 
7.28-7.26 (m, 1 H), 7.25 (d, 1 H, J = 7.8 Hz), 7.12 (t, 1 H, 7.8 Hz), 6.90 (d, 1 H, J = 7.8 Hz), 
6.82-6.78 (m, 2 H), 6.76 (dd, 1 H, J = 8.4, 2.4 Hz), 6.70 (d, 1 H, J = 7.2 Hz), 6.61 (s, 1 H), 4.60 
(app s, 1 H), 4.40 (t, 1 H, J = 5.4 Hz), 4.19 (dd, 1 H, J = 15.6, 10.2 Hz), 3.80 (s, 3 H), 3.71 (s, 3 
H), 3.65 (s, 3 H), 3.15 (s, 3 H), 3.17-3.13 (m, 1 H), 3.09 (dd, 2 H, J = 15.0, 5.4 Hz), 2.90-2.82 
(m, 1 H), 2.54 (d, 1 H, J = 14.4 Hz), 2.19 (dd, 1 H, J = 15.0, 3.6 Hz), 2.06-1.96 (m, 2 H), 1.60-
1.50 (m, 1 H), 1.48-1.43 (m, 1 H); 13C NMR 150 MHz (CDCl3)  188.8, 163.5, 159.6, 158.8, 
158.0, 143.0, 142.0, 134.2, 132.3, 131.5, 129.8, 129.1, 124.8, 117.1, 116.7, 115.5, 113.0, 111.5, 
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111.2, 105.9, 91.0, 74.7, 72.4, 71.3, 64.9, 56.0, 55.6, 55.5, 48.7, 46.4, 38.7, 36.8, 35.1, 34.5, 
30.4; MS (ESI) m/z 596.3 (M+H); MS (EI) m/z (rel intensity) 252 (100%), 577 (10%), 595 
(30%); HRMS (EI) m/z calcd for C36H37NO7 595.2570, found 595.2567. 
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Preparation of 3-163.* 3-158 (1.05 g, 1.68 mmol) was dissolved in a mixture of H2SO4 
(10% aqueous solution, 6.16 mL, 6.71 mmol) and DMSO (29.8 mL) at room temperature. The 
reaction mixture was stirred for 3 days at the same temperature, poured into cold saturated 
aqueous NaHCO3 and extracted with EtOAc (3x). The combined organic layers were washed 
with water (2x) and brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 1:1) afforded 0.828 g (78%) of 3-
163 as a white foam (mixture of diastereomers): IR (neat) 3488, 2927, 2849, 1714, 1636, 1604, 
1479, 1464, 1431 cm-1; 1H NMR of major diastereomer 500 MHz (CDCl3)  7.23 (t, 1 H, J = 8.0 
Hz), 7.15 (t, 1 H, J = 8.0 Hz), 7.13-7.10 (m, 2 H), 6.97 (app d, 1 H, J = 7.5 Hz), 6.90-6.84 (m, 1 
H), 6.82-6.72 (m, 3 H), 6.67 (d, 1 H, J = 8.5 Hz), 5.67 (d, 1 H, J = 5.0 Hz), 4.40 (t, 1 H, J = 8.5 
Hz), 4.32 (d, 1 H, J = 13.5 Hz), 4.25-4.18 (m, 1 H), 4.14-4.04 (m, 2 H), 3.78 (s, 3 H), 3.76 (s, 3 
H), 3.62 (s, 3 H), 3.49 (s, 3 H), 3.32-3.26 (m, 1 H), 3.24 (s, 3 H), 3.09 (dd, 1 H, J = 15.0, 9.0 Hz), 
2.88 (d, 1 H, J = 13.5 Hz), 2.62 (d, 1 H, J = 17.0 Hz), 2.24-2.15 (m, 2 H), 2.04-1.93 (m, 2 H), 
                                                 
* (CW210-024: procedure; CW192-040: IR, HRMS; CW182-048: proton and COSY, HMQC, HMBC; 
CW182-034; carbon NMR) 
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1.69 (dd, 1 H, J = 15.5, 6.0 Hz); 13C NMR (CDCl3)  173.5, 171.8, 159.4, 159.3, 156.8, 146.8, 
143.5, 140.8, 137.1, 131.9, 131.7, 130.2, 129.7, 129.0, 127.1, 119.8, 118.2, 116.9, 113.9, 112.3, 
111.3, 109.8, 73.4, 68.2, 64.2, 55.6, 55.5, 55.4, 52.8, 49.0, 48.5, 40.7, 39.8, 39.1, 35.5, 33.9; 
HRMS (ESI) m/z calcd for C37H41NO8Na (M+Na) 650.2730, found 650.2680. 
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Preparation of 3-165.* A mixture of 3-163 (0.828 g, 1.32 mmol), molecular sieves 4 Å 
(1.26 g) and NMO (0.637 g, 5.27 mmol) in DCM (34 mL) was treated with TPAP (92.7 mg, 
0.264 mmol) at room temperature. The reaction mixture was stirred for 17 h and directly purified 
by chromatography on SiO2 (Hexanes:EtOAc = 2:3) to afford 0.711 g (86%) of the enone as a 
clear oil. A fraction of the enone (0.131 g, 0.209 mmol) was dissolved in a mixture of DIPEA 
and trifluoroethanol (1.0 + 1.0 mL) and heated in the microwave at 100 C for 30 min. The 
reaction mixture was concentrated under reduced pressure and co-evaporated with acetone (2x). 
The residue was redissolved in acetone (2.0 mL) and treated with K2CO3 (0.289 g, 2.09 mmol) 
and Me2SO4 (0.120 mL, 1.26 mmol) at room temperature. The reaction mixture was heated at 
reflux for 15 h, cooled to room temperature, diluted with water and extracted with EtOAc (2x). 
The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (Hexanes:EtOAc = 3:2) 
                                                 
* (CW210-027, CW210-029, CW224-015: procedure; CW224-015: HRMS; CW192-060: IR; CW192-048: 
proton and carbon NMR) 
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afforded 0.1079 g (85%) of 3-165 as a sticky white foam: IR (neat) 2998, 2946, 1725, 1662, 
1591, 1567, 1479 cm-1; 1H NMR 500 MHz (CDCl3)  7.48 (d, 1 H, J = 8.0 Hz), 7.37 (t, 1 H, J = 
8.0 Hz), 7.18 (t, 1 H, J = 8.0 Hz), 7.01 (d, 1 H, J = 7.5 Hz), 6.96 (d, 1 H, J = 11.0 Hz), 6.89-6.76 
(m, 6 H), 6.56 (d, 1 H, J = 2.5 Hz), 4.76 (dd, 1 H, J = 7.0, 5.0 Hz), 4.22-4.14 (m, 1 H), 3.82 (s, 3 
H), 3.76 (d, 1 H, J = 4.5 Hz), 3.73 (s, 3 H), 3.70 (s, 3 H), 3.69 (s, 3 H), 3.52 (s, 3 H), 3.49 (d, 1 
H, J = 4.5 Hz), 3.33 (dd, 1 H, J = 16.0, 7.0 Hz), 2.84-2.67 (m, 3 H), 2.33 (d, 1 H, J = 16.0 Hz); 
13C NMR 150 MHz (CDCl3)  171.6, 171.5, 161.1, 159.5, 158.6, 156.8, 143.5, 143.0, 141.7, 
137.6, 131.3, 130.6, 130.44, 130.42, 129.7, 129.1, 126.1, 124.5, 120.9, 119.0, 116.7, 115.5, 
115.0, 112.2, 111.7, 110.2, 71.6, 68.0, 55.6, 55.5, 55.39, 55.37, 52.6, 44.1, 41.5, 38.3, 35.3; 
HRMS (ESI) m/z calcd for C37H37NO7Na (M+Na) 630.2468, found 630.2457. 
Alternatively, the microwave heating can be substituted by oil bath heating (CW224-
015): Enone 3-163 (336 mg, 0.537 mmol) was dissolved in a mixture of DIPEA and 
trifluoroethanol (3.4 + 3.4 mL) and heated at 78 C for 50 min. The reaction mixture was 
concentrated under reduced pressure. The residue was redissolved in acetone (3.4 mL) and 
treated with K2CO3 (0.742 g, 5.37 mmol) and Me2SO4 (0.308 mL, 3.22 mmol) at room 
temperature. The reaction mixture was heated at reflux for 13 h, cooled to room temperature, 
diluted with water and extracted with EtOAc (2x). The combined organic layers were washed 
with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 3:2) afforded 0.273 g (84%) of 3-165 as a sticky 
white foam with spectroscopy data identical to that of the microwave condition. 
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Preparation of 3-166.* A solution of 3-165 (0.103 g, 0.169 mmol) in boiling toluene 
1.0x5 mL was added to a suspension of KH (96.7 mg, 0.844 mmol, 35% in mineral oil, pre-
washed with toluene three times to remove mineral oil) in toluene 1.0 mL at room temperature. 
The reaction mixture was stirred for 1.5 h at 108 °C, cooled to 0 °C, quenched with saturated 
NH4Cl and extracted with DCM (2x). The combined organic layers were washed with brine, 
dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 1:1) afforded 75.2 mg (77%) of 3-166 as a white 
solid: IR (neat) 2929, 2849, 2834, 1733, 1647, 1593, 1464 cm-1; 1H NMR 600 MHz (CDCl3)  
7.55 (d, 1 H, J = 8.4 Hz), 7.32 (t, 1 H, J = 7.8 Hz), 7.25 (t, 1 H, J = 7.8 Hz), 7.03 (app s, 1 H), 
6.94 (dd, 1 H, J = 8.4, 3.0 Hz), 6.88 (d, 1 H, J = 7.2 Hz), 6.86 (app s, 1 H), 6.85-6.80 (m, 2 H), 
6.62 (d, 1 H, J = 7.8 Hz), 6.52 (app s, 1 H), 6.46 (d, 1 H, J = 2.4 Hz), 4.39 (app dt, 1 H, J = 13.2, 
5.4 Hz), 4.28 (s, 1 H), 4.11 (d, 1 H, J = 4.8 Hz), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.763 (s, 3 H), 3.758 
(s, 3 H), 3.02 (d, 1 H, J = 16.2 Hz), 2.97-2.91 (m, 2 H), 2.86-2.77 (m, 2 H); 13C NMR 150 MHz 
(CDCl3)  200.7, 166.5, 161.2, 159.5, 158.7. 156.3, 144.1, 143.4, 138.8, 136.1, 131.4, 131.1, 
130.6, 130.4, 130.2, 129.2, 125.8, 121.7, 121.5, 120.5, 118.6, 115.6, 114.4, 112.5, 112.2, 109.7, 
67.63, 67.55, 62.9, 55.6, 55.4, 55.30, 55.28, 45.8, 36.3, 33.3; HRMS (ESI) m/z calcd for 
C36H33NO6Na (M+Na) 598.2206, found 598.2181. A fraction of 3-166 was recrystallized from 
                                                 
* (CW210-040: procedure; CW192-063: mp, IR, HRMS, X-ray; CW192-028: proton NMR, CW192-050 
carbon NMR and COSY, HMQC, HMBC) 
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hot toluene to yield X-ray quality colorless crystal: mp 307.2-309.3 °C (toluene). The crystal was 
collected and redissolved in CDCl3 to give a proton NMR spectrum that is identical to the sample 
before crystallization. 
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Preparation of 3-167.* A solution of 3-166 (2.3 mg, 4.00 µmol) and LiH (1.6 mg, 0.200 
mmol) in diglyme 0.5 mL was stirred for 4 days at 140 °C. The reaction mixture was cooled to 
room temperature, quenched with saturated NH4Cl and extracted with DCM (2x). The combined 
organic layers were dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by PTLC (Hexanes:EtOAc = 1:2) afforded 1.7 mg (72%) of 3-167 as a clear sticky 
solid: IR (neat) 2916, 2847, 1708, 1701, 1602, 1477 cm-1; 1H NMR 500 MHz (CDCl3)  7.45 (d, 
1 H, J = 2.5 Hz), 7.34 (d, 1 H, J = 8.5 Hz), 7.20 (t, 1 H, J = 8.0 Hz), 7.10 (dd, 1 H, J = 8.04, 2.5 
Hz), 6.98 (t, 1 H, J = 8.0 Hz), 6.95-6.92 (m, 1 H), 6.92-6.89 (m, 2 H), 6.80 (t, 1 H, J = 2.0 Hz), 
6.78 (d, 1 H, J = 7.5 Hz), 6.75-6.71 (m, 2 H), 6.59 (ddd, 1 H, J = 5.5, 2.5, 0.5 Hz), 6.40 (s, 1 H), 
4.43-4.34 (m, 2 H), 3.88 (s, 3 H), 3.84 (s, 3 H), 3.76 (s, 3 H), 3.61 (s, 3 H), 3.24 (dd, 1 H, J = 
14.0, 7.0 Hz), 3.13 (dd, 1 H, J = 14.0, 6.0 Hz), 3.10-3.02 (m, 2 H), 2.82 (app dt, 1 H, J = 12.5, 
6.5 Hz); 13C NMR 75 MHz (CDCl3)  169.2, 166.3, 159.1, 158.6, 158.2, 157.5, 141.7, 138.9, 
138.6, 132.3, 131.8, 130.7, 130.0, 129.7, 129.4, 129.0, 128.7, 121.7, 120.4, 118.8, 118.4, 116.0, 
114.7, 112.6, 112.0, 110.0, 72.9, 66.8, 62.0, 55.7, 55.5, 55.3, 38.9, 33.7, 32.8; HRMS (ESI) m/z 
                                                 
*  (CW210-063: procedure; CW210-050: IR, HRMS, X-ray, proton NMR, carbon NMR and COSY, 
HMQC, HMBC) 
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calcd for C36H33NO7Na (M+Na) 614.2155, found 614.2149. A fraction of 3-167 was 
recrystallized from hot toluene to yield X-ray quality colorless crystal: mp 274.0-276.0 °C 
(toluene). 
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Preparation of 3-168. * 3-159 (28.2 mg, 0.0449 mmol) was dissolved in a mixture of 
Ti(OiPr)4 (0.0165 mL, 0.0539 mmol) and toluene (0.50 mL) at room temperature. The reaction 
mixture was stirred for 33 h at 100 ºC, poured into cold saturated aqueous NaHCO3 and extracted 
with EtOAc (3x). The combined organic layers were washed with water (1x) and brine (1x), 
dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 2:3) afforded 17.7 mg (63%) of 3-168 as a clear 
sticky solid (mixture of diastereomers): IR (neat) 3445, 3337, 2972, 2924, 1714, 1615, 1587, 
1550, 1541, 1531, 1425 cm-1; 1H NMR of major diastereomer 700 MHz (CDCl3)  7.23 (t, 1 H, J 
= 7.7 Hz), 7.16 (t, 1 H, J = 8.4 Hz), 7.06 (t, 1 H, J = 2.1 Hz), 7.02 (d, 1 H, J = 8.4 Hz), 6.94-6.92 
(m, 1 H), 6.82-6.79 (m, 2 H), 6.77-6.73 (m, 2 H), 6.67 (d, 1 H, J = 7.7 Hz), 5.55 (dd, 1 H, J = 
6.3, 1.4 Hz), 4.75 (t, 1 H, J = 8.4 Hz), 4.47 (dd, 1 H, J = 9.1, 7.7 Hz), 4.06 (d, 1 H, J = 14.0 Hz), 
3.99 (t, 1 H, J = 14.7 Hz), 3.78 (s, 3 H), 3.76 (s, 3 H), 3.63 (s, 3 H), 3.51 (s, 3 H), 3.31-3.27 (m, 1 
H), 3.26 (s, 3 H), 3.15 (dd, 1 H, J = 17.5, 9.1 Hz), 2.95 (d, 1 H, J = 14.7 Hz), 2.55 (d, 1 H, J = 
16.8 Hz), 2.41 (ddd, 1 H, J = 12.6, 7.0, 2.1 Hz), 2.17-2.12 (m, 1 H), 2.09-1.96 (m, 2 H), 1.82 (d, 
                                                 
* (CW192-088: procedure, IR, HRMS; CW192-081: proton and carbon NMR) 
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1 H, J = 3.5 Hz), 1.73-1.68 (m, 1 H); 13C NMR 175 MHz (CDCl3)  174.2, 172.0, 159.5, 159.4, 
156.6, 146.4, 144.2, 137.4, 136.1, 131.9, 131.4, 130.8, 129.7, 129.0, 120.0, 118.0, 116.8, 114.1, 
112.3, 111.4, 109.5, 72.0, 67.9, 65.0, 55.8, 55.6, 55.5, 55.4, 52.8, 48.8, 47.9, 40.5, 39.4, 38.0, 
35.7, 34.7; HRMS (ESI) m/z calcd for C37H41NO8Na (M+Na) 650.2730, found 650.2731. 
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Preparation of 3-170.* A mixture of 3-168 (17.7 mg, 0.0282 mmol), molecular sieves 4 Å 
(26.9 g) and NMO (13.6 mg, 0.113 mmol) in DCM (0.54 mL) was treated with TPAP (1.98 mg, 
0.00564 mmol) at room temperature. The reaction mixture was stirred for 4 h at the same 
temperature and directly purified by chromatography on SiO2 (Hexanes:EtOAc = 3:2) to afford 
17.0 mg (96%) of enone as a clear oil. A fraction of the enone (13.9 mg, 0.0222 mmol) was 
dissolved in a mixture of DIPEA and trifluoroethanol (0.6 + 0.6 mL) and heated in the 
microwave at 100 C for 30 min. The reaction mixture was concentrated under reduced pressure 
and co-evaporated with acetone (2x). The residue was redissolved in acetone (0.50 mL) and 
treated with K2CO3 (30.7 mg, 0.222 mmol) and Me2SO4 (0.0128 mL, 0.133 mmol) at room 
temperature. The reaction mixture was heated at reflux for 15 h, cooled to room temperature, 
diluted with water and extracted with EtOAc (2x). The combined organic layers were washed 
with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (Hexanes:EtOAc = 3:1) afforded 11.5 mg (85%) of 3-170 as a clear 
                                                 
* (CW192-094, CW210-006: procedure; CW192-091: IR, MS; CW192-096: proton and carbon NMR) 
 274 
sticky solid: IR (neat) 2994, 2944, 2832, 1725, 1664, 1591, 1569, 1479, 1429 cm-1; 1H NMR 700 
MHz (CDCl3)  7.44 (d, 1 H, J = 8.4 Hz), 7.38 (t, 1 H, J = 7.7 Hz), 7.20 (t, 1 H, J = 8.4 Hz), 7.07 
(dd, 1 H, J = 7.7, 1.4 Hz), 7.01 (d, 1 H, J = 7.7 Hz), 6.90-6.81 (m, 6 H), 6.66 (d, 1 H, J = 1.4 Hz), 
6.59 (d, 1 H, J = 2.8 Hz), 4.72 (dd, 1 H, J = 7.0, 4.2 Hz), 4.19-4.13 (m, 1 H), 3.82 (s, 3 H), 3.73 
(s, 3 H), 3.72 (s, 3 H), 3.71 (s, 3 H), 3.59 (d, 1 H, J = 16.8 Hz), 3.51 (s, 3 H), 3.52-3.48 (m, 1 H), 
3.33 (dd, 1 H, J = 16.1, 7.7 Hz), 2.79 (dd, 1 H, J = 11.9, 5.6 Hz), 2.75 (dd, 1 H, J = 14.7, 6.3 Hz), 
2.69 (dt, 1 H, J = 11.9, 5.6 Hz), 2.50 (d, 1 H, J = 16.1 Hz); 13C NMR 175 MHz (CDCl3)  171.6, 
170.9, 159.5, 158.7, 157.5, 156.9, 143.5, 142.6, 141.4, 137.2, 137.1, 132.9, 130.5, 130.3, 129.2, 
127.7, 127.4, 125.4, 120.9, 119.2, 118.8, 116.6, 115.0, 112.6, 112.5, 110.2, 71.4, 68.2, 57.8, 55.6, 
55.5, 55.4, 52.6, 44.3, 41.8, 38.3, 35.2; HRMS (ESI) m/z calcd for C37H37NO7Na (M+Na) 
630.2431, found 630.2468. 
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Preparation of 3-171.* A solution of 3-170 (3.8 mg, 6.25 µmol) in toluene 0.1+0.1+0.1 
mL was added to a suspension of KH (15.6 mg, 0.136 mmol, 35% in mineral oil, pre-washed 
with toluene three times to remove mineral oil) in toluene 0.2 mL at room temperature. The 
reaction mixture was stirred for 4 h at 106 °C, cooled to 0 °C, quenched with saturated NH4Cl 
and extracted with EtOAc (1x). The organic layer was washed with brine, dried (MgSO4), 
filtered and concentrated under reduced pressure. Purification by PTLC (Hexanes:EtOAc = 1:2) 
                                                 
* (CW210-005: procedure, proton NMR; CW210-065: IR, HRMS) 
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afforded 1.4 mg (39%) of 3-171 (mixture of diastereomers, ratio = 1.5:1) as a clear sticky solid: 
IR (neat) 3507, 2931, 2832, 1736, 1645, 1599, 1565, 1477 cm-1; Representative 1H NMR of one 
diastereomer 700 MHz (CDCl3)  4.48 (app dt, 1 H, J = 13.3, 4.9 Hz), 4.02 (d, 1 H, J = 4.2 Hz), 
3.85 (s, 3 H), 3.78 (s, 3 H), 3.77 (s, 3 H), 3.72 (s, 3 H); 13C NMR 150 MHz (CDCl3)  196.3, 
166.4, 161.1, 159.6, 158.71, 158.66, 157.8, 156.7, 156.5, 144.2, 143.5, 142.9, 142.1, 140.5, 
139.0, 138.9, 138.0, 137.2, 136.6, 133.6, 132.3, 131.3, 130.3, 130.08, 130.05, 129.6, 129.5, 
129.0, 127.6, 127.4, 124.8, 123.9, 123.2, 121.0, 120.9, 120.6, 118.5, 118.3, 117.9, 117.7, 115.1, 
114.2, 113.6, 113.0, 110.1, 109.9, 72.2, 70.8, 67.99, 67.95, 67.4, 62.6, 61.0, 60.4, 59.9, 59.3, 
55.63, 55.60, 55.5, 55.4, 55.3, 45.32, 45.25, 36.1, 34.9, 33.4, 33.3, 29.9; HRMS (ESI) m/z calcd 
for C36H34NO6 (M+H) 576.2386, found 576.2399. 
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Preparation of 3-172.* A solution of 3-165 (23.9 mg, 0.0393 mmol) in THF (0.50 mL) at 
room temperature was treated with LiBH4 (2 M in THF, 0.0983 mL, 0.197 mmol) at room 
temperature. The reaction mixture was stirred at 60 °C for 22 h, cooled to room temperature, 
quenched with water and extracted with EtOAc (2x). The combined organic layers were washed 
with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification 
by chromatography on SiO2 (Hexanes:EtOAc = 3:2 to 1:2) afforded 20.8 mg  (91%) of 3-172 as 
a clear sticky solid: IR (neat) 3488, 2996, 2931, 2832, 1653, 1645, 1587, 1569, 1476, 1462 cm-1; 
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1H NMR 500 MHz (CDCl3)  7.42 (d, 1 H, J = 8.5 Hz), 7.35 (t, 1 H, J = 8.0 Hz), 7.18 (t, 1 H, J = 
8.0 Hz), 7.06 (d, 1 H, J = 7.5 Hz), 6.89 (dd, 1 H, J = 8.0, 2.0 Hz), 6.86-6.78 (m, 4 H), 6.74 (dd, 1 
H, J = 8.0, 1.5 Hz), 6.65-6.63 (m, 1 H), 6.58 (t, 1 H, J = 2.0 Hz), 4.56 (ddd, 1 H, J = 14.0, 12.0, 
5.5 Hz), 4.33 (t, 1 H, J = 9.5 Hz), 4.18 (dd, 1 H, J = 11.0, 5.0 Hz), 4.06 (dd, 1 H, J = 10.5, 7.0 
Hz), 3.77 (s, 3 H), 3.70 (s, 3 H), 3.69 (s, 3 H), 3.57 (s, 3 H), 3.43 (d, 2 H, J = 9.5 Hz), 3.30 (dd, 1 
H, J = 14.0, 5.0 Hz), 3.20 (d, 1 H, J = 16.5 Hz), 2.95 (dd, 1 H, J = 12.5, 5.0 Hz), 2.71 (dt, 1 H, J 
= 12.5, 5.5 Hz), 1.88 (dd, 1 H, J = 7.0, 5.0 Hz), 0.68 (d, 1 H, J = 16.5 Hz); 13C NMR 125 MHz 
(CDCl3)  172.7, 161.1, 160.3, 158.4, 156.2, 145.8, 143.3, 143.1, 137.9, 131.5, 130.2, 130.0, 
129.9, 129.7, 126.0, 124.8, 119.8, 119.0, 117.7, 115.2, 113.4, 111.9, 111.1, 110.5, 70.2, 63.7, 
62.7, 55.6, 55.43, 55.36, 55.2, 44.6, 39.9, 38.0, 36.0; HRMS (ESI) m/z calcd for C36H37NO6Na 
(M+Na) 602.2519, found 602.2548. 
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Preparation of 3-173.* A solution of oxalyl chloride (20.3 µL, 0.237 mmol) in DCM 
(0.30 mL) at -60 °C was treated with DMSO (36.2 µL, 0.510 mmol). The reaction mixture was 
stirred at -60 °C for 10 min and treated with 3-172 (20.8 mg, 35.9 µmol) in DCM (0.6 mL). The 
resulting mixture was stirred for 15 min, treated with Et3N (0.150 mL, 1.07 mmol), stirred at -60 
°C for 5 min then room temperature for 10 min. The reaction was quenched with aqueous 
NaHCO3 and the mixture was extracted with EtOAc (3x). The combined organic layers were 
                                                 
* (CW210-054: procedure, proton NMR; CW210-048: carbon NMR, IR and HRMS) 
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washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (Hexanes:EtOAc = 2:1 to 1:1) afforded 17.2 mg (83%) 
of 3-173 as a sticky clear solid: IR (neat) 2924, 2849, 2834, 1718, 1662, 1589, 1567, 1479, 1464 
cm-1; 1H NMR 500 MHz (CDCl3)  9.92 (d, 1 H, J = 0.5 Hz), 7.47 (d, 1 H, J = 3.0 Hz), 7.40 (t, 1 
H, J = 7.5 Hz), 7.25 (t, 1 H, J = 8.0 Hz), 7.08 (d, 1 H, J = 7.5 Hz), 6.94 (app dd, 1 H, J = 7.5, 2.0 
Hz), 6.86-6.81 (m, 3 H), 6.79-6.77 (m, 1 H), 6.75 (dd, 1 H, J = 8.0, 1.0 Hz), 6.70-6.67 (m, 1 H), 
6.62 (t, 1 H, J = 2.5 Hz), 6.19 (d, 1 H, J = 3.0 Hz), 4.48-4.37 (m, 2 H), 3.79 (s, 3 H), 3.71 (s, 3 
H), 3.70 (s, 3 H), 3.60 (s, 3 H), 3.57-3.44 (m, 2 H), 3.40-3.30 (m, 2 H), 2.93 (dd, 1 H, J = 13.0, 
5.5 Hz), 2.73 (dt, 1 H, J = 12.0, 5.5 Hz), 1.04 (d, 1 H, J = 16.5 Hz); 13C NMR 125 MHz (CDCl3) 
 198.7, 172.5, 161.2, 160.3, 158.5, 156.6, 143.7, 143.0, 141.1, 137.6, 131.4, 131.0, 130.4, 130.0, 
129.9, 126.4, 125.9, 124.5, 120.5, 119.1, 117.6, 115.2, 113.9, 112.9, 111.1, 110.3, 71.7, 71.2, 
55.6, 55.4, 55.3, 45.5, 40.4, 37.9, 35.7; HRMS (ESI) m/z calcd for C36H35NO6Na (M+Na)  
600.2362, found 600.2368. 
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Preparation of 3-174.* A mixture of 3-173 (0.0203 g, 0.0351 mmol) and LiH (1.1 mg, 
0.141 mmol) in diglyme (1.0 mL) was heated to 140 °C for 4 h. The reaction mixture was cooled 
to 0 °C, quenched with saturated NH4Cl and extracted with DCM (3x). The combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by 
                                                 
*  (CW224-090: procedure; CW224-014: HRMS, IR; CW224-005: X-ray, melting point; CW210-089: 
proton, carbon and COSY, HMQC, HMBC) 
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chromatography on SiO2 (Hexanes:EtOAc = 1:1 to 1:2) afforded 11.5 mg (57%) of 3-174 as a 
clear sticky solid: IR (neat) 3499, 2933, 1686, 1602, 1582, 1464 cm-1; 1H NMR 600 MHz 
(CDCl3)  7.62 (d, 1 H, J = 8.4 Hz), 7.29-7.25 (m, 1 H), 7.25 (d, 1 H, J = 1.8 Hz), 7.19 (t, 1 H, J 
= 8.4 Hz), 7.14 (d, 1 H, J = 7.8 Hz), 7.00 (d, 1 H, J = 7.8 Hz), 6.94-6.90 (m, 2 H), 6.85-6.80 (m, 
2 H), 6.76 (app d, 1 H, J = 8.4 Hz), 6.57 (d, 1 H, J = 7.8 Hz), 6.36 (app s, 1 H), 4.95 (app s, 1 H), 
4.36 (app dt, 1 H, J = 13.2, 4.2 Hz), 4.29 (app s, 1 H), 4.16-4.11 (m, 2 H), 3.85 (s, 3 H), 3.82 (s, 
3 H), 3.777 (s, 3 H), 3.68 (s, 3 H), 3.14 (d, 1 H, J = 16.8 Hz), 3.09 (dd, 1 H, J = 15.0, 4.2 Hz), 
2.93 (dd, 1 H, J = 13.2, 4.8 Hz), 2.84 (dd, 1 H, J = 16.8, 5.4 Hz), 2.57 (dt, 1 H, J = 12.6, 4.2 Hz); 
13C NMR 150 MHz (CDCl3)  172.3, 163.0, 160.0, 159.2, 156.0, 145.4, 144.9, 142.9, 138.0, 
132.8, 131.6, 131.1, 130.2, 130.1, 125.2, 121.6, 118.6, 118.2, 116.7, 116.1, 113.3, 111.6, 110.6, 
110.2, 75.2, 68.7, 66.7, 55.8, 55.53, 55.52, 55.2, 51.0, 44.8, 34.7, 32.9; HRMS (ESI) m/z calcd 
for C36H35NO6Na (M+Na) 600.2362, found 600.2351. A fraction of 3-174 was recrystallized 
from hot toluene to yield X-ray quality colorless crystal: mp 116.3-118.0 °C (toluene). The 
crystal was collected and redissolved in CDCl3 to give a proton NMR spectrum that is identical 
to the sample before crystallization. 
OMe
MeO
N
OMe
H
OMe
 
Preparation of 3-175.* A solution of 3-174 (9.1 mg, 0.0158 mmol) in THF (0.65 mL) was 
treated with a solution of LAH (2.4 M in THF, 32.8 µL, 0.0788 mmol) at room temperature. The 
                                                 
*  CW224-045: procedure, HRMS, IR, X-ray ；, mp CW224-018 and CW224-001(combined): proton, 
carbon and COSY, HMQC, HMBC 
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reaction mixture was heated to 63 °C for 9 h, cooled to 0 °C, quenched with EtOAc followed by 
saturated aqueous Rochelle’s salt. The mixture was extracted with EtOAc (1x). The organic layer 
was washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by PTLC (Hexanes:EtOAc = 2:1  with 0.5% Et3N) afforded 4.3 mg (50%) of 3-175 
(mixture of N-inversion isomers) as a clear sticky solid: IR (neat) 2926, 1847, 1599, 1559, 1477 
cm-1; 1H NMR of both isomers 500 MHz (CDCl3)  7.35 (d, 1 H, J = 8.5 Hz), 7.21 (t, 1 H, J = 
7.5 Hz), 7.14 (t, 1 H, J = 7.5 Hz), 7.05 (t, 1 H, J = 8.0 Hz), 6.83 (dd, 1 H, J = 8.0, 2.5 Hz), 6.79 
(d, 2 H, J = 7.0 Hz), 6.77-6.73 (m, 1 H), 6.72 (s, 1 H), 6.67-6.53 (m, 4 H), 5.90-5.81 (m, 1 H), 
5.03-4.93 (m, 1 H), 3.82 (s, 3 H), 3.78-3.65 (m, 3 H), 3.59 (s, 3 H), 3.49-3.43 (m, 1 H), 3.80 (s, 3 
H), 2.93-2.80 (m, 3 H), 2.71-2.64 (m, 1 H), 2.53-2.46 (m, 2 H), 1.59 (s, 3 H); 13C NMR not 
provided due to its low quality; HRMS (ESI) m/z calcd for C36H38NO4 (M+H) 548.2801, found 
548.2769. X-ray quality crystal was obtained by dissolving the product in MeOH (~0.5 mL) and 
aqueous HCl (37%, 1 equivalent) and slowly evaprorate the solvent over 1 month: colorless 
crystal, mp 209.1 °C (decomp.) (MeOH-HCl). The crystal was dissolved in EtOAc and washed 
with 5% K2CO3 (2x), dried (Na2SO4), filtered and concentrated under reduced pressure. The 1H 
NMR of the residue is identical to that of the sample before crystallization. 
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Preparation of 3-176 and 3-177.* A solution of AlCl3 (10.5 mg, 0.0788 mmol) in THF 
(0.50 mL) was prepared by adding THF to AlCl3 at -78 °C then warming up to room 
temperature. This solution was treated with NaAlH4 (0.5 M in THF, 0.158 mL, 0.0788 mmol) at 
room temperature and stirred for 0.5 h. This reaction mixture was then treated with a solution of 
3-174 (9.1 mg, 0.0158 mmol) in THF (0.10x3 mL) at room temperature. The reaction mixture 
was stirred for 17 h, cooled to 0 °C, quenched with MeOH followed by saturated aqueous 
Rochelle’s salt. The mixture was extracted with EtOAc (2x). The combined organic layers were 
washed with brine (1x), dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by PTLC (Hexanes:EtOAc = 1:1  with 0.5% Et3N) afforded 1.3 mg (15%) of 3-177 
and 5.1 mg (57%) of 3-176 as clear sticky solids. 3-176: IR (neat) 3311, 2931, 2834, 1600, 1479 
cm-1; 1H NMR 500 MHz (CD2Cl2)  7.38 (d, 1 H, J = 8.0 Hz), 7.34 (t, 1 H, J = 7.5 Hz), 7.12-
7.06 (m, 2 H), 7.01 (d, 1 H, J = 2.5 Hz), 6.96 (d, 1 H, J = 7.0 Hz), 6.93-6.83 (m, 4 H), 6.71-6.62 
(m, 2 H), 6.57 (s, 1 H), 3.92 (app d, 1 H, J = 5.0 Hz), 3.78 (s, 3 H), 3.74 (s, 3 H), 3.67 (s, 3 H), 
3.62 (s, 3 H), 3.51 (d, 1 H, J = 6.0 Hz), 3.29-3.21 (m, 2 H), 3.11 (dd, 1 H, J = 11.5, 4.0 Hz), 3.05 
(dd, 1 H, J = 14.5, 6.5 Hz), 2.76-2.70 (m, 1 H), 2.66-2.58 (m, 1 H), 2.58-2.48 (m, 2 H), 2.32 (t, 1 
H, J = 13.0 Hz), 0.94-0.87 (m, 1 H), -0.56--0.64 (m, 1 H); 13C NMR 150 MHz (CD2Cl2)  159.7, 
                                                 
* (CW241-015: procedure and proton, carbon, COSY, HMQC and HMBC; CW241-014 and CW224-096: 
carbon and COSY, HMQC, HMBC; CW224-060: HRMS, IR; CW224-093: HRMS; CW241-023: X-ray; CW241-
033 and CW241-042: conversion of 3-176 to 3-177) 
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158.8, 158.2, 156.3, 148.2, 145.4, 144.4, 141.2, 133.6, 133.0, 131.8, 130.3, 129.0, 128.7, 127.8, 
125.4, 119.20, 119.15, 117.6, 113.5, 111.2, 111.1, 110.9, 73.8, 72.8, 64.6, 60.6, 58.6, 56.1, 56.0, 
55.5, 55.4, 49.1, 47.5, 37.5, 35.6; HRMS (ESI) m/z calcd for C36H40NO6 (M+H) 582.2856, found 
582.2873. 3-177: IR (neat) 3565, 2927, 2830, 1599, 1582, 1476, 1462 cm-1; 1H NMR 500 MHz 
(CD2Cl2)  7.53 (d, 1 H, J = 8.5 Hz), 7.25 (d, 1 H, J = 2.0 Hz), 7.22-7.14 (m, 2 H), 7.04 (d, 1 H, 
J = 7.5 Hz), 6.87 (d, 1 H, J = 7.5 Hz), 6.82 (dd, 1 H, J = 8.5, 2.5 Hz), 6.79-6.71 (m, 3 H), 6.69 (s, 
1 H), 6.65 (d, 1 H, J = 8.0 Hz), 6.30 (d, 1 H, J = 7.5 Hz), 4.99 (s, 1 H), 3.85-3.80 (m, 1 H), 3.77 
(s, 3 H), 3.73 (s, 3 H), 3.71 (s, 3 H), 3.45 (d, 1 H, J = 9.5 Hz), 3.37 (s, 3 H), 2.98 (dd, 1 H, J = 
9.0, 6.3 Hz), 2.78-2.62 (m, 3 H), 2.40-2.28 (m, 2 H), 2.21-2.13 (m, 1 H), 0.97 (s, 1 H), -0.07 (d, 1 
H, J = 12.0 Hz); 13C NMR 150 MHz (CD2Cl2)  161.8, 159.5, 159.4, 156.6, 150.2, 146.7, 145.9, 
144.4, 133.3, 132.9, 132.5, 130.4, 129.5, 128.4, 127.7, 126.0, 120.6, 118.3, 115.8, 115.3, 112.9, 
110.3, 109.8, 109.7, 75.7, 70.1, 60.1, 57.1, 55.8, 55.7, 55.6, 45.3, 42.0, 39.0, 30.5; HRMS (ESI) 
m/z calcd for C36H38NO5 (M+H) 564.2750, found 564.2795. 
Conversion of 3-176 to 3-177: A solution of 3-176 (11.3 mg, 0.0194 mmol) in pyridine 
(0.66 mL) was treated with MsCl (15.4 µL, 0.194 mmol) at room temperature. The reaction 
mixture was stirred for 2 h, quenched with saturated NaHCO3 and extracted with EtOAc (2x). 
The combined organic layers were washed with brine (1x), dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by PTLC (Hexanes:EtOAc = 1:2  with 0.5% 
Et3N) afforded 10.7 mg (83%) of the mesylate as a clear wticky solid. A fraction of this mesylate 
(7.5 mg, 0.0111 mmol) in a mixture of diglyme (1.3 mL) and DIPEA (0.68 mL) was heated to 
115 °C for 24 h, treated with additional DIPEA (0.20 mL) and heated to 115 °C for 6 h. The 
solvent was evaporated at room temperature. Purification by PTLC (Hexanes:EtOAc = 2:1  with 
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0.5% Et3N) afforded 3.0 mg (48%) of 3-177 as a clear sticky solid with 1H NMR identical to that 
of the sample from the reduction of 3-174 with AlH2Cl. 
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APPENDIX A  
PROPOSED MECHANISM FOR THE FORMATION OF 3-167 
Scheme 92 Proposed mechanism for the formation of 3-167 
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APPENDIX B 
X-RAY DATA 
Figure 46 X-ray structure of 3-102 
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Figure 47  X-ray structure of 3-109 
 
 296 
Figure 48 X-ray structure of 3-124a 
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Figure 49 X-ray structure of 3-161 
 
 298 
Figure 50 X-ray structure of 3-166 
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Figure 51 X-ray structure of 3-167 
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Figure 52 X-ray structure of 3-174 
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Figure 53 X-ray structure of 3-175 
 
 302 
Figure 54 X-ray structure of 3-177 
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APPENDIX C 
SELECTED NMR DATA 
 
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1 . 2 5 5
1 . 2 6 9
1 . 2 8 3
1 . 5 7 4
1 . 7 7 0
1 . 7 8 0
1 . 7 9 9
1 . 8 1 0
1 . 8 4 6
1 . 8 6 0
2 . 0 5 6
2 . 3 3 3
2 . 4 0 0
2 . 4 3 1
2 . 9 1 6
2 . 9 4 0
2 . 9 4 8
3 . 0 3 6
3 . 0 6 1
3 . 1 0 3
3 . 1 3 5
3 . 3 1 0
3 . 7 1 0
3 . 7 6 4
3 . 8 7 7
4 . 1 2 3
4 . 1 3 8
4 . 3 8 3
4 . 3 9 2
4 . 4 5 6
5 . 4 7 1
5 . 4 8 1
6 . 3 5 9
6 . 4 8 5
6 . 5 0 1
6 . 5 2 4
6 . 5 2 9
6 . 7 9 2
6 . 7 9 6
6 . 8 0 9
6 . 8 2 2
6 . 8 2 7
6 . 9 0 1
6 . 9 1 8
6 . 9 4 9
6 . 9 6 3
7 . 1 3 6
7 . 1 5 2
7 . 2 0 2
7 . 2 1 8
7 . 2 3 4
7 . 2 7 0
7 . 3 7 6
7 . 3 9 1
7 . 4 0 7
3 . 3 1
1 . 1 2
2 . 1 6
1 . 0 6
1 . 0 6
1 . 0 9
2 . 1 0
3 . 1 3
3 . 3 0
3 . 2 5
3 . 1 9
1 . 0 7
1 . 0 5
1 . 0 0
1 . 0 0
0 . 9 7
1 . 0 0
0 . 9 9
2 . 0 6
1 . 0 8
0 . 9 9
1 . 0 4
1 . 1 0
1 . 0 2
C
W106−095F1 LDA Suzuki DCK F1 PD CDCl3 500MHz post−X−ray
3
-
1
2
4
a
3 0 4
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 4 2
3 0 . 2 3
3 0 . 3 0
3 3 . 2 3
3 3 . 8 8
3 6 . 9 9
4 5 . 9 9
4 9 . 4 0
5 5 . 2 8
5 5 . 3 4
5 5 . 6 5
6 0 . 6 4
6 2 . 2 5
6 7 . 5 5
7 2 . 4 9
7 5 . 1 9
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
1 1 0 . 0 0
1 1 2 . 4 6
1 1 2 . 5 7
1 1 5 . 6 8
1 1 8 . 8 9
1 2 0 . 1 2
1 2 1 . 5 7
1 2 4 . 1 1
1 2 9 . 2 1
1 2 9 . 5 2
1 2 9 . 5 7
1 3 1 . 7 3
1 3 3 . 5 8
1 3 6 . 0 1
1 3 8 . 1 3
1 4 3 . 5 4
1 5 6 . 5 6
1 5 8 . 2 0
1 5 9 . 5 0
1 6 8 . 6 3
2 0 1 . 9 0
C
W106−095F1 LDA Suzuki DCK F1 150MHz
3
-
1
2
4
a
3 0 5
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1 . 5 8 3
1 . 9 8 5
1 . 9 9 8
2 . 2 9 1
2 . 9 3 8
2 . 9 4 6
2 . 9 6 4
2 . 9 7 3
3 . 1 0 2
3 . 1 2 0
3 . 1 2 8
3 . 2 6 8
3 . 2 9 9
3 . 7 0 9
3 . 7 1 3
3 . 8 0 3
3 . 8 0 6
3 . 8 1 1
3 . 8 2 4
4 . 3 3 8
4 . 3 4 6
5 . 5 7 0
5 . 5 8 1
6 . 4 6 9
6 . 4 7 2
6 . 4 7 6
6 . 5 2 7
6 . 5 4 1
6 . 6 6 7
6 . 6 8 7
6 . 7 7 8
6 . 7 8 2
6 . 7 9 2
6 . 7 9 9
6 . 8 0 2
6 . 8 0 7
6 . 8 1 3
6 . 8 2 0
6 . 8 2 9
6 . 8 3 3
6 . 8 4 9
6 . 8 5 2
6 . 8 5 8
6 . 8 7 1
6 . 8 7 8
7 . 0 5 0
7 . 0 6 3
7 . 1 5 8
7 . 1 8 7
7 . 2 0 0
7 . 2 1 1
7 . 2 1 3
7 . 2 4 5
7 . 2 5 8
7 . 2 7 0
0 . 2 9
0 . 4 9
0 . 7 0
2 . 2 8
1 . 3 5
0 . 6 3
2 . 3 0
0 . 6 1
1 . 2 1
0 . 3 5
0 . 4 0
2 . 8 6
2 . 4 4
3 . 0 3
1 . 0 1
3 . 2 0
0 . 8 7
0 . 2 3
0 . 3 2
3 . 9 6
3 . 1 6
1 . 1 0
0 . 4 0
2 . 0 8
1 . 0 0
0 . 3 3
0 . 3 3
0 . 9 9
1 . 3 7
0 . 3 3
0 . 9 8
4 . 9 0
1 . 8 9
0 . 9 9
0 . 6 2
1 . 1 1
1 . 1 1
Chenbo 0041809a CW182−010 KH LiBH4 DCK SFC RP 600MHz
3
-
1
2
3
3 0 6
200
180
160
140
120
100
80
60
40
20
0
ppm
2 7 . 4 0
2 9 . 1 3
2 9 . 4 4
3 3 . 3 7
3 3 . 8 9
3 5 . 3 0
3 5 . 7 3
3 6 . 2 0
4 5 . 9 8
4 8 . 8 8
4 9 . 5 1
5 5 . 2 8
5 5 . 3 3
5 5 . 3 9
5 5 . 4 4
5 5 . 6 3
5 6 . 5 5
5 6 . 9 6
7 3 . 7 8
7 5 . 6 2
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
1 1 0 . 2 8
1 1 0 . 3 5
1 1 1 . 7 4
1 1 2 . 0 8
1 1 2 . 4 3
1 1 2 . 8 0
1 1 3 . 9 9
1 1 4 . 1 8
1 1 4 . 3 7
1 1 4 . 9 1
1 1 7 . 5 3
1 1 7 . 5 8
1 1 9 . 8 4
1 2 0 . 0 1
1 2 7 . 5 4
1 2 7 . 7 3
1 2 8 . 1 8
1 2 9 . 4 3
1 2 9 . 8 0
1 3 0 . 0 8
1 3 0 . 1 6
1 3 2 . 0 2
1 3 3 . 5 7
1 3 5 . 8 8
1 3 6 . 0 6
1 3 6 . 1 2
1 3 6 . 8 2
1 3 7 . 5 7
1 3 8 . 1 4
1 3 8 . 6 9
1 4 2 . 2 2
1 4 2 . 6 0
1 4 6 . 2 1
1 4 6 . 2 8
1 5 6 . 5 5
1 5 6 . 6 2
1 5 8 . 6 9
1 5 8 . 7 5
1 5 9 . 9 0
1 5 9 . 9 4
1 6 5 . 9 0
Chenbo 0041809a CW182−010 KH LiBH4 DCK SFC RP 600MHz
3
-
1
2
3
3 0 7
11
10
9
8
7
6
5
4
3
2
1
0
ppm
0 . 8 8 9
1 . 1 4 8
1 . 2 2 3
1 . 2 5 4
1 . 2 6 2
1 . 2 6 9
1 . 2 8 3
1 . 4 0 4
1 . 5 6 6
1 . 5 9 0
2 . 0 5 6
2 . 1 8 3
3 . 1 4 9
3 . 3 5 2
3 . 3 6 6
3 . 3 8 3
3 . 3 9 7
3 . 6 3 0
3 . 6 4 7
3 . 7 6 3
3 . 7 7 1
3 . 7 9 1
3 . 8 0 3
3 . 9 0 3
4 . 1 2 3
4 . 1 3 8
4 . 2 3 1
4 . 2 3 8
5 . 3 1 0
5 . 7 4 7
6 . 7 2 4
6 . 7 4 7
6 . 7 5 3
6 . 7 6 5
6 . 7 7 1
6 . 7 8 6
6 . 7 9 4
6 . 7 9 7
6 . 8 0 5
6 . 8 0 9
6 . 8 2 1
6 . 8 2 5
6 . 9 2 0
6 . 9 4 6
6 . 9 6 1
7 . 2 2 7
7 . 2 4 3
7 . 2 5 9
7 . 2 7 0
7 . 2 8 7
7 . 3 0 3
7 . 3 1 9
7 . 4 5 3
7 . 4 7 1
7 . 4 7 7
1 . 0 0
1 . 0 9
3 . 1 7
3 . 1 5
3 . 0 0
1 . 0 0
0 . 9 6
0 . 7 2
1 . 0 5
2 . 7 4
1 . 0 0
0 . 7 9
0 . 9 8
1 . 0 5
0 . 9 8
0 . 9 0
Chenbo 110408a CW135−069 K2CO3 MeOh WDCK PD CDCl3 500MHz
3
-
1
2
8
3 0 8
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 3 1
2 1 . 1 6
4 0 . 7 8
5 5 . 2 3
5 5 . 3 1
5 5 . 3 4
5 5 . 6 1
6 0 . 5 1
6 4 . 3 6
7 6 . 9 8
7 7 . 2 3
7 7 . 4 9
1 1 0 . 0 3
1 1 2 . 0 1
1 1 3 . 0 6
1 1 4 . 4 7
1 1 5 . 0 5
1 1 7 . 1 8
1 1 7 . 5 3
1 1 9 . 2 0
1 2 9 . 4 4
1 2 9 . 8 4
1 3 0 . 0 0
1 3 3 . 1 1
1 3 9 . 0 7
1 4 0 . 9 1
1 4 3 . 5 9
1 4 4 . 9 9
1 5 6 . 5 6
1 5 8 . 8 5
1 5 9 . 7 8
1 6 3 . 8 7
Chenbo 090908a CW136−002 K2CO3 MeOH WDCK PD CDCl3 125MHz
3
-
1
2
8
3 0 9
11
10
9
8
7
6
5
4
3
2
1
0
ppm
0 . 8 6 7
1 . 2 4 1
1 . 2 6 4
1 . 2 8 8
1 . 3 6 8
2 . 0 5 0
2 . 9 1 0
2 . 9 2 4
2 . 9 6 3
2 . 9 7 8
3 . 1 3 9
3 . 1 6 2
3 . 1 9 3
3 . 2 1 6
3 . 5 0 3
3 . 5 6 1
3 . 6 3 2
3 . 6 6 3
3 . 6 7 9
3 . 6 8 6
3 . 7 0 2
3 . 7 6 5
3 . 7 6 9
3 . 7 8 4
3 . 7 9 1
3 . 8 4 3
3 . 8 4 9
4 . 0 9 1
4 . 1 1 5
4 . 1 3 9
4 . 1 6 2
5 . 2 8 5
6 . 3 6 6
6 . 6 7 1
6 . 6 8 1
6 . 7 0 0
6 . 7 1 0
6 . 7 3 2
6 . 7 4 1
6 . 7 4 7
6 . 7 5 7
6 . 7 8 4
6 . 8 3 7
6 . 8 4 4
6 . 8 5 1
6 . 9 4 4
6 . 9 6 8
7 . 1 5 9
7 . 1 8 6
7 . 2 1 2
7 . 2 4 4
7 . 2 6 9
7 . 2 9 5
7 . 4 2 1
7 . 4 5 0
0 . 9 5
1 . 0 0
1 . 0 0
2 . 9 2
0 . 8 4
6 . 0 4
0 . 4 6
0 . 8 2
1 . 0 2
3 . 5 0
0 . 9 2
0 . 9 3
0 . 9 7
1 . 0 2
0 . 8 6
Chenbo 091009a CW135−003 ZnCl2 LAH WDCK PD? CDCl3 300MHz
3 1 0
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 3 5
2 1 . 2 0
3 6 . 2 7
4 5 . 4 1
5 5 . 2 9
5 5 . 3 5
5 5 . 6 5
6 0 . 5 4
6 6 . 6 7
7 6 . 8 0
7 7 . 2 3
7 7 . 6 5
1 0 9 . 7 3
1 1 1 . 3 6
1 1 3 . 0 2
1 1 3 . 2 7
1 1 4 . 2 9
1 1 6 . 1 3
1 1 7 . 9 5
1 1 9 . 6 0
1 2 9 . 1 8
1 3 0 . 1 0
1 3 2 . 6 1
1 3 3 . 3 9
1 3 9 . 5 6
1 4 3 . 8 0
1 4 3 . 8 8
1 4 7 . 6 2
1 5 7 . 6 3
1 5 8 . 9 7
1 5 9 . 6 9
1 7 1 . 3 0
Chenbo 091009a CW135−003 ZnCl2 LAH WDCK PD? CDCl3 300MHz
3
-
1
2
8
3 1 1
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1 . 2 6 2
1 . 2 6 9
1 . 5 0 1
1 . 5 2 7
1 . 5 7 5
2 . 0 5 5
2 . 0 6 7
2 . 0 7 4
2 . 0 9 9
2 . 1 1 9
2 . 1 3 2
3 . 0 1 2
3 . 0 2 2
3 . 0 5 7
3 . 0 6 5
3 . 1 6 3
3 . 1 7 9
3 . 1 9 5
3 . 3 9 5
3 . 7 1 1
3 . 7 9 7
3 . 8 3 9
4 . 4 2 1
4 . 4 3 0
4 . 9 7 9
6 . 4 6 0
6 . 4 6 5
6 . 4 6 9
6 . 5 3 8
6 . 5 4 0
6 . 5 5 4
6 . 5 5 5
6 . 7 8 6
6 . 7 9 0
6 . 8 0 2
6 . 8 0 8
6 . 8 1 3
6 . 8 2 0
6 . 8 2 6
6 . 8 3 1
6 . 8 3 7
6 . 8 4 3
6 . 8 4 7
6 . 8 7 3
6 . 9 0 1
6 . 9 1 6
7 . 1 9 9
7 . 2 1 5
7 . 2 3 1
7 . 2 7 0
7 . 2 8 0
7 . 2 9 6
7 . 3 1 2
7 . 4 4 1
7 . 4 5 8
1 . 6 0
1 . 1 1
4 . 4 3
1 . 0 6
1 . 0 8
1 . 0 5
1 . 1 1
5 . 1 6
0 . 3 9
0 . 4 9
3 . 1 0
3 . 1 1
3 . 0 9
1 . 0 1
1 . 0 0
0 . 9 8
0 . 9 9
3 . 9 9
0 . 9 8
1 . 0 2
1 . 1 1
1 . 1 3
0 . 9 8
Chenbo 081709a CW192−013 K2CO3 MeOH TBS DCK F1 PD? CDCl3 500MHz
3
-
1
5
3
3 1 2
200
180
160
140
120
100
80
60
40
20
0
ppm
2 4 . 6 6
3 0 . 7 3
3 1 . 7 2
3 5 . 9 4
3 8 . 5 4
3 9 . 1 2
4 8 . 6 2
5 5 . 3 1
5 5 . 3 9
5 5 . 6 4
5 6 . 3 6
5 9 . 9 0
6 2 . 9 2
6 7 . 7 1
7 0 . 7 8
7 4 . 7 0
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
1 1 0 . 3 5
1 1 2 . 0 4
1 1 2 . 4 6
1 1 4 . 1 0
1 1 4 . 6 7
1 1 7 . 5 4
1 1 9 . 8 1
1 2 6 . 8 2
1 2 9 . 9 5
1 3 0 . 3 0
1 3 1 . 6 2
1 3 1 . 9 3
1 3 6 . 1 4
1 3 7 . 2 3
1 3 9 . 4 5
1 4 2 . 6 3
1 4 6 . 0 7
1 5 6 . 5 4
1 5 9 . 1 9
1 6 0 . 0 0
1 6 4 . 4 8
Chenbo 081809b CW192−013 K2CO3 MeOH DMDO TBS DCK (F1) PD? CDCl3 150MHz
3
-
1
5
3
3 1 3
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1 . 2 1 8
1 . 2 4 5
1 . 2 6 2
1 . 2 6 9
1 . 2 9 3
1 . 5 7 8
1 . 6 4 5
1 . 6 6 2
1 . 6 8 4
1 . 7 0 5
1 . 7 2 1
2 . 0 2 6
2 . 0 5 6
2 . 0 7 6
2 . 3 5 0
2 . 3 6 4
2 . 9 5 5
3 . 0 7 7
3 . 0 9 2
3 . 1 6 2
3 . 2 1 4
3 . 7 1 1
3 . 7 5 5
3 . 7 8 7
3 . 8 3 4
4 . 1 1 9
4 . 1 4 2
4 . 2 9 6
4 . 3 1 1
6 . 3 8 5
6 . 3 9 1
6 . 3 9 8
6 . 5 5 5
6 . 5 8 1
6 . 7 1 4
6 . 7 3 2
6 . 7 4 1
6 . 7 6 8
6 . 7 7 6
6 . 7 9 5
6 . 8 0 3
6 . 8 1 6
6 . 8 4 3
6 . 8 7 5
6 . 8 8 3
6 . 9 0 4
6 . 9 1 2
7 . 2 0 0
7 . 2 2 7
7 . 2 5 4
7 . 2 7 1
7 . 2 9 2
7 . 3 1 8
7 . 4 3 8
7 . 4 6 6
1 . 1 4
2 . 5 5
1 . 9 1
3 . 3 1
1 . 5 3
0 . 5 9
0 . 7 7
3 . 0 8
1 . 4 8
2 . 8 0
4 . 3 8
3 . 3 3
1 . 0 0
0 . 9 1
0 . 9 3
1 . 8 0
1 . 8 3
1 . 8 1
0 . 9 4
0 . 9 1
Chenbo 060109a CW192−009 K2CO3 MeOH TBS DCK (F2) 100C F3 ? CDCl3 300MHz
3
-
1
5
4
3 1 4
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 4 2
2 1 . 3 0
2 7 . 9 9
3 0 . 5 4
3 0 . 5 7
3 1 . 3 9
3 6 . 3 6
4 6 . 3 9
4 9 . 1 8
5 5 . 3 7
5 5 . 3 8
5 5 . 5 1
5 7 . 0 9
5 9 . 0 5
6 0 . 7 6
7 3 . 5 0
7 3 . 7 4
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
1 1 0 . 3 0
1 1 1 . 8 0
1 1 3 . 8 1
1 1 4 . 1 4
1 1 4 . 4 7
1 1 7 . 4 8
1 1 9 . 9 9
1 3 0 . 0 2
1 3 0 . 1 2
1 3 0 . 3 6
1 3 0 . 7 4
1 3 2 . 1 9
1 3 7 . 3 3
1 3 8 . 0 4
1 3 8 . 1 6
1 4 1 . 9 0
1 4 5 . 5 0
1 5 6 . 3 8
1 5 9 . 4 1
1 6 0 . 0 0
1 6 5 . 3 0
Chenbo 060109b CW192−009 K2CO3 MeOH TBS DCK (F2) F3 PD? CDCl3 150MHz
3
-
1
5
3
3 1 5
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1 . 7 7 4
1 . 8 5 7
1 . 8 8 8
1 . 9 4 7
2 . 3 4 1
2 . 3 5 0
2 . 3 6 5
2 . 8 7 7
2 . 8 8 4
2 . 9 9 4
3 . 0 2 6
3 . 0 8 6
3 . 0 9 2
3 . 2 4 0
3 . 2 8 8
3 . 7 0 5
3 . 7 3 1
3 . 7 4 5
3 . 7 7 0
3 . 7 7 7
3 . 8 1 4
3 . 8 2 7
4 . 4 5 5
4 . 4 6 2
6 . 2 6 1
6 . 4 5 3
6 . 4 6 6
6 . 4 7 0
6 . 7 8 2
6 . 7 8 6
6 . 7 9 8
6 . 8 0 2
6 . 8 5 7
6 . 8 6 1
6 . 8 7 3
6 . 8 7 8
6 . 9 1 1
6 . 9 2 8
6 . 9 6 7
6 . 9 8 1
7 . 1 6 9
7 . 1 7 9
7 . 1 9 5
7 . 2 1 2
7 . 2 2 8
7 . 2 5 1
7 . 2 7 0
7 . 2 9 3
7 . 3 7 1
7 . 3 8 7
7 . 4 0 3
2 . 4 9
1 . 5 1
1 . 2 1
2 . 0 1
2 . 0 9
0 . 9 8
0 . 9 7
0 . 9 6
1 . 0 2
1 . 1 1
2 . 9 6
3 . 3 2
2 . 8 4
1 . 0 7
3 . 1 8
1 . 0 0
0 . 8 5
1 . 7 7
1 . 0 7
1 . 0 2
1 . 0 0
0 . 9 6
2 . 6 8
1 . 0 4
C
w161−065F3 LDA DMDO DCK post−xray CDCl3 500MHz
3
-
1
6
1
3 1 6
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 4 2
2 1 . 2 9
2 8 . 7 5
3 1 . 7 0
3 2 . 9 1
3 3 . 1 3
3 7 . 7 8
4 5 . 6 9
4 8 . 9 6
5 5 . 2 8
5 5 . 6 2
5 5 . 6 7
6 0 . 6 3
6 7 . 7 2
7 0 . 9 7
7 2 . 4 0
7 2 . 5 7
7 5 . 7 4
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
7 8 . 2 5
1 1 0 . 4 4
1 1 2 . 0 4
1 1 2 . 2 5
1 1 4 . 0 6
1 1 5 . 9 2
1 1 9 . 3 1
1 2 1 . 4 3
1 2 3 . 2 7
1 2 5 . 7 3
1 2 9 . 5 4
1 3 1 . 9 0
1 3 9 . 9 9
1 4 0 . 0 6
1 4 2 . 0 8
1 4 4 . 4 7
1 5 7 . 8 1
1 5 9 . 6 2
1 6 0 . 3 2
1 7 2 . 5 7
2 0 7 . 5 1
Chenbo 022809a CW161−065 LDA DMDO (F1)  F3 PD 150MHz CDCl3
3
-
1
6
1
3 1 7
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1 . 2 5 5
1 . 2 7 0
1 . 2 8 4
1 . 5 7 2
2 . 0 5 5
2 . 3 1 5
2 . 3 4 7
2 . 7 1 8
2 . 7 4 4
2 . 7 7 2
2 . 7 8 3
2 . 7 9 8
2 . 8 1 0
3 . 3 4 1
3 . 3 5 5
3 . 4 8 9
3 . 4 9 8
3 . 5 2 2
3 . 6 9 3
3 . 7 0 3
3 . 7 2 6
3 . 7 5 1
3 . 7 5 4
3 . 7 6 6
3 . 8 2 0
4 . 1 2 5
4 . 1 3 9
4 . 7 5 4
4 . 7 5 8
6 . 5 6 2
6 . 5 6 7
6 . 7 6 6
6 . 7 8 1
6 . 7 9 7
6 . 8 0 8
6 . 8 1 2
6 . 8 2 9
6 . 8 3 5
6 . 8 5 7
6 . 8 6 1
6 . 8 7 8
6 . 8 8 3
6 . 9 3 4
6 . 9 4 9
7 . 0 0 4
7 . 0 1 9
7 . 1 6 6
7 . 1 8 2
7 . 1 9 8
7 . 2 7 0
7 . 3 5 3
7 . 3 6 8
7 . 3 8 4
7 . 4 7 3
7 . 4 8 9
1 . 0 0
3 . 1 1
1 . 0 2
0 . 6 9
3 . 1 6
3 . 4 0
2 . 6 3
3 . 5 3
0 . 8 6
3 . 2 4
1 . 5 7
1 . 0 0
1 . 0 0
6 . 9 1
1 . 0 5
1 . 0 4
1 . 0 5
1 . 0 3
0 . 9 4
Chenbo 061309d CW192-048II Aroma DCK (F2) Me2SO4x2 PD? CDCl3 500MHz
3
-
1
6
5
3 1 8
200
180
160
140
120
100
80
60
40
20
0
ppm
3 5 . 3 3
3 8 . 3 3
4 1 . 5 0
4 4 . 1 0
5 2 . 6 1
5 5 . 3 7
5 5 . 3 9
5 5 . 4 6
5 5 . 6 3
6 8 . 0 4
7 1 . 5 6
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
1 1 0 . 2 3
1 1 1 . 6 7
1 1 2 . 2 0
1 1 4 . 9 5
1 1 5 . 4 8
1 1 6 . 6 5
1 1 8 . 9 7
1 2 0 . 9 4
1 2 4 . 4 5
1 2 6 . 0 9
1 2 9 . 1 2
1 2 9 . 7 4
1 3 0 . 4 2
1 3 0 . 4 4
1 3 0 . 6 0
1 3 1 . 3 0
1 3 7 . 5 8
1 4 1 . 6 6
1 4 2 . 9 8
1 4 3 . 5 0
1 5 6 . 7 7
1 5 8 . 6 4
1 5 9 . 4 6
1 6 1 . 1 3
1 7 1 . 5 3
1 7 1 . 6 3
Chenbo 061409a CW192−048 Aroma DCK PD (F2) CDCl3 150MHz
3
-
1
6
5
3 1 9
11
10
9
8
7
6
5
4
3
2
1
0
ppm
0 . 0 7 7
1 . 2 6 0
1 . 5 7 8
2 . 1 8 4
2 . 8 0 5
2 . 8 1 3
2 . 8 2 2
2 . 8 3 4
2 . 8 4 1
2 . 8 4 9
2 . 9 1 3
2 . 9 2 2
2 . 9 3 5
2 . 9 4 2
2 . 9 5 3
2 . 9 6 1
3 . 0 0 8
3 . 0 3 5
3 . 7 5 8
3 . 7 6 3
3 . 7 7 7
3 . 7 9 1
4 . 1 0 1
4 . 1 0 9
4 . 2 8 4
4 . 3 6 4
4 . 3 8 6
4 . 3 9 5
5 . 3 1 1
6 . 4 5 3
6 . 4 5 7
6 . 5 1 5
6 . 6 1 4
6 . 6 2 7
6 . 8 1 2
6 . 8 1 9
6 . 8 2 4
6 . 8 3 3
6 . 8 3 7
6 . 8 5 8
6 . 8 6 9
6 . 8 8 1
6 . 9 3 0
6 . 9 3 5
6 . 9 4 4
6 . 9 4 9
7 . 0 3 0
7 . 2 4 1
7 . 2 5 4
7 . 2 7 0
7 . 3 0 7
7 . 3 2 0
7 . 3 3 3
7 . 5 3 8
7 . 5 5 2
3 . 2 9
0 . 8 4
0 . 1 5
2 . 0 4
2 . 0 1
1 . 0 5
3 . 1 3
2 . 8 6
2 . 9 6
2 . 9 9
1 . 0 7
0 . 9 9
1 . 0 0
0 . 2 0
0 . 9 6
0 . 9 3
0 . 9 6
2 . 0 1
1 . 0 2
0 . 9 1
0 . 9 9
1 . 9 8
0 . 9 0
1 . 1 1
0 . 1 2
0 . 9 2
Chenbo 052809a CW192−028 KH Aroma DCK ester PD? CDCl3 600MHz
3
-
1
6
6
3 2 0
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 4 2
3 3 . 3 0
3 6 . 3 4
4 5 . 7 6
5 5 . 2 8
5 5 . 3 0
5 5 . 4 3
5 5 . 5 8
6 2 . 9 2
6 7 . 5 5
6 7 . 6 3
1 0 9 . 7 1
1 1 2 . 2 2
1 1 2 . 5 4
1 1 4 . 3 7
1 1 5 . 5 7
1 1 8 . 6 1
1 2 0 . 4 9
1 2 1 . 4 5
1 2 1 . 6 8
1 2 5 . 8 0
1 2 9 . 1 8
1 3 0 . 1 8
1 3 0 . 3 5
1 3 0 . 5 9
1 3 1 . 0 7
1 3 1 . 4 2
1 3 6 . 0 9
1 3 8 . 8 2
1 4 3 . 4 3
1 4 4 . 0 6
1 5 6 . 2 5
1 5 8 . 6 7
1 5 9 . 4 6
1 6 1 . 1 9
1 6 6 . 5 0
2 0 0 . 7 2
Chenbo 061409b CW192−050 KH Aroma DCK PD (F2) CDCl3 150MHz
3
-
1
6
6
3 2 1
11
10
9
8
7
6
5
4
3
2
1
0
ppm
0 . 0 7 8
1 . 2 6 3
1 . 5 9 3
1 . 8 5 0
1 . 8 5 7
1 . 8 6 3
1 . 8 7 0
1 . 8 7 6
2 . 5 6 8
2 . 5 7 7
2 . 9 2 1
3 . 1 0 5
3 . 1 1 3
3 . 1 2 5
3 . 1 5 8
3 . 3 9 5
3 . 6 8 1
3 . 7 4 4
3 . 7 5 7
3 . 7 7 1
3 . 8 2 1
3 . 8 5 2
4 . 1 2 8
4 . 1 3 9
4 . 1 5 5
4 . 2 8 7
4 . 9 4 7
6 . 3 5 8
6 . 5 6 2
6 . 5 7 7
6 . 7 5 5
6 . 7 5 9
6 . 7 7 1
6 . 7 7 5
6 . 8 1 9
6 . 8 3 6
6 . 9 0 6
6 . 9 2 2
6 . 9 2 8
6 . 9 3 9
6 . 9 4 5
6 . 9 9 0
7 . 0 0 6
7 . 1 3 7
7 . 1 5 3
7 . 1 7 6
7 . 1 9 2
7 . 2 0 8
7 . 2 4 4
7 . 2 4 9
7 . 2 5 5
7 . 2 7 0
7 . 2 8 6
7 . 6 1 3
7 . 6 3 0
1 . 0 0
1 . 0 2
1 . 0 6
1 . 9 7
0 . 6 2
0 . 4 2
0 . 3 8
3 . 1 7
1 . 7 2
3 . 4 6
3 . 0 6
2 . 9 0
1 . 9 6
1 . 0 0
1 . 0 6
1 . 0 0
0 . 9 5
1 . 1 1
1 . 0 2
2 . 1 2
1 . 9 4
1 . 0 7
1 . 0 3
0 . 9 8
1 . 2 7
0 . 9 0
C
W224−090 LiH CHO Aroma CDCl3 500MHz
3
-
1
7
4
3 2 2
200
180
160
140
120
100
80
60
40
20
0
ppm
3 2 . 9 3
3 4 . 6 8
4 4 . 8 3
5 1 . 0 4
5 5 . 2 2
5 5 . 5 2
5 5 . 5 3
5 5 . 8 1
5 9 . 2 7
6 6 . 7 3
6 8 . 7 4
7 2 . 1 6
7 5 . 2 4
7 7 . 0 2
7 7 . 2 3
7 7 . 4 4
1 1 0 . 1 6
1 1 0 . 5 6
1 1 1 . 6 1
1 1 3 . 3 3
1 1 6 . 0 9
1 1 6 . 7 1
1 1 8 . 2 0
1 1 8 . 6 4
1 2 1 . 6 4
1 2 5 . 1 9
1 3 0 . 0 7
1 3 0 . 1 5
1 3 1 . 0 5
1 3 1 . 6 4
1 3 2 . 7 6
1 3 8 . 0 4
1 4 2 . 9 2
1 4 4 . 9 1
1 4 5 . 4 1
1 5 5 . 9 8
1 5 9 . 2 1
1 5 9 . 9 6
1 6 3 . 0 4
1 7 2 . 2 6
Chenbo 090409a CW210−089 LHMDS CHO Aroma DCK (F2) F1 PD ? CDCl3 150MHz
3
-
1
7
4
3 2 3
11
10
9
8
7
6
5
4
3
2
1
0
ppm
− 0 . 0 8 2
− 0 . 0 5 8
0 . 0 8 2
0 . 9 7 4
1 . 2 3 0
1 . 2 4 5
1 . 2 6 2
1 . 5 3 4
2 . 0 0 3
2 . 3 1 6
2 . 3 2 0
2 . 3 3 9
2 . 6 4 4
2 . 6 6 3
2 . 6 7 8
2 . 6 9 3
2 . 7 0 8
3 . 3 3 2
3 . 3 6 6
3 . 4 3 6
3 . 4 5 5
3 . 7 0 7
3 . 7 2 7
3 . 7 4 7
3 . 7 7 4
3 . 8 2 0
4 . 9 9 3
5 . 3 2 1
6 . 2 9 1
6 . 3 0 6
6 . 6 3 8
6 . 6 5 4
6 . 6 8 6
6 . 7 2 0
6 . 7 3 6
6 . 7 5 3
6 . 7 7 9
6 . 8 1 1
6 . 8 1 5
6 . 8 2 7
6 . 8 3 2
6 . 8 6 7
6 . 8 8 2
7 . 0 3 1
7 . 0 4 6
7 . 1 5 8
7 . 1 6 7
7 . 1 7 5
7 . 1 8 3
7 . 1 9 0
7 . 1 9 8
7 . 2 5 0
7 . 2 5 4
7 . 5 2 0
7 . 5 3 7
0 . 9 5
0 . 4 6
0 . 8 6
0 . 8 3
3 . 4 2
1 . 1 5
2 . 1 3
3 . 2 8
1 . 0 7
2 . 7 2
1 . 0 6
0 . 6 3
3 . 5 2
2 . 9 6
0 . 8 6
2 . 7 5
1 . 6 2
1 . 0 0
0 . 8 4
0 . 9 4
1 . 0 9
1 . 5 9
1 . 5 3
0 . 8 9
1 . 4 8
1 . 2 1
2 . 0 5
1 . 1 7
0 . 9 2
C
W241−015 AlH2Cl LiH F2 ? CD2Cl2 500MHZ
3
-
1
7
6
3 2 4
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 5 4
3 0 . 2 4
3 0 . 5 1
3 9 . 0 0
4 1 . 9 9
4 5 . 3 2
5 3 . 6 4
5 3 . 8 2
5 4 . 0 1
5 4 . 1 8
5 4 . 3 7
5 5 . 6 4
5 5 . 6 7
5 5 . 8 3
5 7 . 0 6
6 0 . 1 4
7 0 . 1 2
7 5 . 6 5
1 0 9 . 6 7
1 0 9 . 8 3
1 1 0 . 3 3
1 1 2 . 9 4
1 1 5 . 3 0
1 1 5 . 8 2
1 1 8 . 2 8
1 2 0 . 6 1
1 2 5 . 9 9
1 2 7 . 6 5
1 2 8 . 4 3
1 2 9 . 5 3
1 3 0 . 3 5
1 3 2 . 5 4
1 3 2 . 8 6
1 3 3 . 2 8
1 4 4 . 3 5
1 4 5 . 8 7
1 4 6 . 7 2
1 5 0 . 2 4
1 5 6 . 6 1
1 5 9 . 4 4
1 5 9 . 5 4
1 6 1 . 8 0
C
W241−015 F2 AlH2Cl PD CDCl3 150MHz
3
-
1
7
6
3 2 5
11
10
9
8
7
6
5
4
3
2
1
0
ppm
0 . 9 0 3
0 . 9 1 3
1 . 2 1 7
1 . 2 3 2
1 . 2 4 6
1 . 5 4 2
2 . 0 0 4
2 . 3 2 1
2 . 5 2 2
2 . 5 5 3
2 . 5 6 6
2 . 6 1 6
2 . 7 4 3
3 . 0 2 5
3 . 0 3 9
3 . 0 5 5
3 . 0 6 9
3 . 0 9 4
3 . 1 0 3
3 . 2 3 5
3 . 2 5 8
3 . 4 9 8
3 . 5 1 1
3 . 6 2 2
3 . 6 6 9
3 . 7 3 6
3 . 7 8 1
3 . 9 1 8
3 . 9 2 8
4 . 0 7 2
4 . 0 8 6
5 . 3 2 0
6 . 5 6 6
6 . 6 7 1
6 . 6 8 8
6 . 6 9 1
6 . 8 4 3
6 . 8 6 0
6 . 8 7 7
6 . 8 8 2
6 . 8 9 4
6 . 9 0 5
6 . 9 1 7
6 . 9 5 5
6 . 9 6 9
7 . 0 0 4
7 . 0 0 8
7 . 0 8 2
7 . 0 9 7
7 . 1 1 3
7 . 3 2 6
7 . 3 4 2
7 . 3 5 7
7 . 3 7 6
7 . 3 9 2
0 . 8 1
1 . 0 7
0 . 9 2
2 . 7 4
0 . 9 0
0 . 9 7
1 . 0 9
0 . 8 8
1 . 8 2
1 . 1 0
2 . 9 2
2 . 5 7
2 . 6 9
2 . 7 6
1 . 0 0
0 . 8 4
1 . 7 4
3 . 4 8
0 . 6 7
0 . 9 0
1 . 6 9
1 . 6 7
C
W241−015 AlH2Cl LiH F3 amino alcohol ? CD2Cl2 500MHZ
3
-
1
7
7
3 2 6
200
180
160
140
120
100
80
60
40
20
0
ppm
1 4 . 5 5
3 5 . 7 8
3 7 . 7 4
4 7 . 7 2
4 9 . 2 9
5 3 . 6 4
5 3 . 8 2
5 4 . 0 0
5 4 . 1 8
5 4 . 3 6
5 5 . 5 5
5 5 . 6 8
5 6 . 2 3
5 6 . 2 9
5 8 . 7 9
6 0 . 7 9
6 4 . 8 1
7 2 . 9 7
7 4 . 0 1
1 1 1 . 1 1
1 1 1 . 3 1
1 1 1 . 4 3
1 1 3 . 6 8
1 1 7 . 8 0
1 1 9 . 3 5
1 1 9 . 4 0
1 2 5 . 5 6
1 2 7 . 9 6
1 2 8 . 9 2
1 2 9 . 1 9
1 3 0 . 5 2
1 3 2 . 0 0
1 3 3 . 2 1
1 3 3 . 7 6
1 4 1 . 4 0
1 4 4 . 6 3
1 4 5 . 6 0
1 4 8 . 3 9
1 5 6 . 4 5
1 5 8 . 3 7
1 5 8 . 9 6
1 5 9 . 9 0
C
W224−096F2 amino alcohol  CD2Cl2 150MHz
3
-
1
7
6
3 2 7
